Robert G. Gish, MD CV - May 2014

Table of Contents
Page
PROFESSIONAL INFORMATION

A. LICENSURE & CERTIFICATIONS ............................................................................ 1
B EDUCATION ............................................................................................................. 2
C. POST GRADUATE EDUCATION .............................................................................. 2
D. HONORS ................................................................................................................... 2
E. NATIONAL FOUNDATION HONORS ........................................................................ 2
F. SOCIETY MEMBERSHIPS ........................................................................................ 2
G. LANGUAGES ............................................................................................................ 2

BIOGRAPHY ...........................................................................................................................3-6

A. PERSONAL STATEMENT ......................................................................................... 5
B. EXPANDED RESEARCH .......................................................................................... 5
C. PRESS RELEASE - HEPATITIS B FOUNDATION .................................................... 6
D. FACULTY APPOINTMENTS ..................................................................................7-8
E. EMPLOYMENT AND STAFF POSITIONS ............................................................ 8-10
F. STATE OF CALIFORNIA CONSULTANT POSITIONS ............................................ 10
G. CONSULTANT POSITIONS .................................................................................... 10
H. BUSINESS POSITIONS .......................................................................................... 11
I. RESEARCH SUPPORT...................................................................................... 12-30
J. UCSD RESEARCH / ADVISORY ....................................................................... 31-32
K. COINVESTIGATOR: GASTROINTESTINAL TRIALS ......................................... 32-33

TEACHING ACTIVITIES ...................................................................................................... 34-35

A. COMMITTEES .................................................................................................... 35-40
B. BOARD ACTIVITIES ........................................................................................... 41-43
C. EDITORIAL ACTIVITIES .......................................................................................... 44
D. MENTEE LIST .................................................................................................... 45-47
E. CLINICAL EXAM SESSIONS ................................................................................... 47

PUBLICATIONS

A. PEER REVIEW ORIGINAL PUBLICATIONS ...................................................... 48-62
B. SUBMITTED FOR PUBLICATION ........................................................................... 63
C. REVIEW ARTICLES ........................................................................................... 64-67
D. PUBLIC POLICY ORIGINAL MANUSCRIPT ............................................................ 67
E. NEWLETTERS......................................................................................................... 68
F. BOOK CHAPTER & EDITORIALS....................................................................... 68-72
G. CASE REPORTS & LETTER TO THE EDITORS .................................................... 72
H. EDITOR / REVIEWER ........................................................................................ 73-76
I. UCSD ...................................................................................................................... 77
J. ABSTRACTS ..................................................................................................... 78-108

i
............................................................................................................................................ Page

OTHER

CME PRESENTATIONS AND PUBLICATIONS ............................................................... 109-115
FEDERAL AND STATE HEARINGS ....................................................................................... 116
EDUCATIONAL EVENTS ....................................................................................................... 116
SPECIAL COURSES ATTENDED .......................................................................................... 117
COMMUNITY SERVICE and MEDIA APPEARANCES .................................................... 118-126
INTERNATIONAL COMMUNITY PROGRAMS ....................................................................... 127
INTERNET SITES AND PUBLICATIONS ............................................................................... 128
INVITED LECTURES: NATIONAL AND INTERNATIONAL .............................................. 129-139
INVITED LECTURES: REGIONAL ................................................................................... 140-191
AWARDS, CERTIFICATES, AND HONORS .................................................................... 192-193
CONSULTANT: ACKNOWLEDGEMENT AS A CONTRIBUTOR / CME ACTIVITIES ...... 194-213
HISTORICAL PRACTICE ADDRESSES AND OUTREACH SITES ................................. 214-215
RESEARCH SUMMARY .................................................................................................. 216-217
FORMER PRACTICE LEADERSHIP ...................................................................................... 218

DISCLOSURES ...................................................................................................................... 219
PHARMACEUTICAL COMPANY RELATIONSHIPS ............................................................... 219
SPEAKERS BUREAU ............................................................................................................. 219

ii

Curriculum Vitae

ROBERT G. GISH, M.D.

PROFESSIONAL INFORMATION

8/31/2013 Present
Robert G. Gish MD, Principal
Robert G. Gish, Consultants LLC
6022 La Jolla Mesa Drive
La Jolla, California 92037
Cell phone: 1 858 229 9865
Fax: 1 858 886 7093
Email: rgish@robertgish.com
Web address: robertgish.com

10/1/2013 Present
(Adjunct) Professor of Clinical Medicine
University of Nevada, Las Vegas

10/1/2013 Present
Senior Medical Director
St. Josephs Hospital and Medical Center
Phoenix, Arizona

1/31/2014 Present
Medical Director
Hepatitis B Foundation
http://hepb.org/index.html

5/1/2014 - Present
Clincial Professor of Medicine (Consultant)
Stanford Hospital and Medical Center
Stanford, California

PERSONAL INFORMATION

Date of Birth: September 18, 1955
SSN: Available upon request
Marital Status: Married
Home Address: San Diego, California
Birthplace: Chicago, Illinois
Citizenship: U.S.A.

LICENSURE

State of California, G-045632
State of Nevada, 772112
State of Arizona, 48551

BOARD CERTIFICATION

1984 Internal Medicine ABIM 90181
1987 Gastroenterology ABIM 90181 (MOC active)
2007 CAQ Liver Transplantation ABIM 90181
Curriculum Vitae
ROBERT G. GISH, M.D. 2

EDUCATION

9/1/1973 6/15/1977 Pharmaceutical Sciences
University of Kansas
Lawrence, Kansas

9/1/1977 6/15/1980 Medical Doctor
University of Kansas School of Medicine
Kansas City, Kansas

POSTGRADUATE EDUCATION

6/1/1980 5/30/1981 Internship in Internal Medicine
University of California, San Diego
San Diego, California

6/1/1981 6/30/1983 Residency in Internal Medicine
` University of California, San Diego

7/1/1984 5/30/1988 Fellowship in Gastroenterology and Hepatology
University of California, Los Angeles
Los Angeles, California

NATIONAL HONORS Alpha Omega Alpha

NATIONAL FOUNDATION HONORS

2002 Salute to Excellence: American Liver Foundation, 2/9/2002

SOCIETY MEMBERSHIPS

American Association for the Study of Liver Disease
American Gastroenterological Association
American Society of Transplant Physicians
American College of Physicians
Asia Pacific Association for the Study of the Liver
California Medical Association
European Association for the Study of the Liver
International Liver Cancer Association
American Liver Foundation
American Transplant Society
International Coalition of Hepatology Educators

LANGUAGES

English
Spanish
Vietnamese
French

Curriculum Vitae

BIOGRAPHY

Dr. Gish began his medical training in 1974 when he was enrolled into the Pharmacy School at
the University of Kansas. He transferred to the University of Kansas Medical School in 1977 and
finished his MD degree in 1980.

Dr. Gish went on to complete a 3 year Internal Medicine residency at the University of Califor-
nia, San Diego and a 4 year Gastroenterology and Hepatology fellowship at the University of
California Los Angeles during which time he was awarded the NIH Physician Scientist Award to
study calcium signaling in liver cells.

After completing his training, Dr. Gish moved to San Francisco and took a position at the
California Pacific Medical Center (formerly known as Pacific Presbyterian Hospital). He became
the Co- Medical Director of the Liver Transplant Program in 1988 and then the Medical Director
of the Liver Transplant Program in 1994. In that role he developed an outreach program that
eventually served over 35,000 patients in the Northern California and Nevada regions, and
made the CPMC a leading liver transplant center.

Dr. Gish has had and continues to have an active research program in viral hepatitis, liver
transplant, bio artificial liver, and public policy especially related to liver cancer, liver transplanta-
tion and viral hepatitis. Although his primary research focus is clinical research, he frequently
collaborates with basic scientists in his research activities. He has published more than 500
original articles, review articles, abstracts and book chapters.

Dr. Gish is also actively involved in numerous professional societies, and is a long-term member
of the American Association for the Study of Liver Disease, European Association for the Study
of Liver Disease, Asian Pacific Association for the Study of the Liver, and the American Society
of Transplant Physicians.

He is a fellow of both the American College of Physicians and a long-term member of the
American Association for the Study of Liver Disease. Dr. Gish has served on the editorial
boards of American Journal of Gastroenterology, Journal of Hepatology, Digestive Diseases
and Sciences, Gastroenterology, Hepatology, Liver Transplantation and Surgery, and Journal of
Viral Hepatitis. He has co-authored a public health policy for liver health in Vietnam and is also
assisting with the development of health care policies in Armenia and the Philippines.

In December 2010, Dr. Gish moved to San Diego to join the faculty of UCSD as a Clinical
Professor of Medicine, Section Chief of Hepatology, and Director of the Center of Excellence for
Hepatobiliary Disease and Abdominal Transplantation (C.H.A.T.).

In September of 2013, Dr. Gish left UCSD to form a consulting company, Robert G. Gish
Consultants LLC to provide consultative support to Hepatology Centers and Liver Transplant
Programs who wish to start or grow their programs through pathways of quality and optimal
patient care that is integrated with research and education. In September of 2013, Dr Gish
joined Dr Manch at St Josephs Hospital and Medical Center to start a liver and liver transplant
center which continues to be an ogoing venture. On April 1, 2014, Dr Gish joined the Stanford

Curriculum Vitae

BIOGRAPHY: Continued

Department of Medicine, Division of Gastroenterology and Hepatology and Liver Transplant
Service Line as a Staff Physician with major roles in inreach and outreach as well as program
development. Over the years of 2012 to 2014, Dr Gish has been and continues to be very active
with the National Viral Hepatitis Round Table (NVHR) a patient and community advocacy non-
profit organization. In February of 2014, Dr Gish joined the Hepatitis B Foundation, (HBF) as
their medical director to lend his policy, advocacy and clinical science skills to their armamentar-
ium,

Today, Dr. Gish is a Clinical Professor of Medicine (Adjunct) at the University of Nevada in Las
Vegas where he continues to teach and is a senior consultant at St Josephs Medical Center in
Phoenix. And Clinical Professor of Medicine at Stanford University (Consultant)

LIVER CENTERS AND LIVER TRANSPLANT PROGRAMS

Dr. Gish became the Co-Medical Director of the Liver Transplant Program at the California
Pacific Medical Center in 1988. He developed an outreach program that now serves over
35,000 patients in Northern California and Nevada, making CPMC a leading liver transplant
center. Dr. Gish joined the faculty of University of California San Diego in several capacities,
including Director of the Center for Hepatobiliary Disease and Abdominal Transplantation. He
also became Director of Clinical Hepatology at UCSD in 2010. His research on Regional Review
Boards may also change public policies on liver transplants in the United States. This research
supports the replacement of the current RRB system with a national review board that uses
clinical expertise to assign priorities. The goal of this system is to allocate organs equitably while
improving compliance with the HHS Final Rule. His appointment with the Liver Transplant
Program and Department of Medicine at Stanford University began on April 30, 2014.

RESEARCH

Dr. Gishs pharmaceutical research includes a 2011 Phase III study on the effects of BI
201335, pegylated interferon-a and ribavirin on patients infected with genotype 1 chronic
hepatitis C. He is also the principle investigator in an ongoing study on screening for viral
hepatitis and its economic effects on healthcare. Another study currently being conducted by Dr.
Gish involves the analysis of liver patients at UCSD.

Dr. Gish was the principle investigator in a study that was started in 2012 to investigate the
effects of PSI-352938, PSE-7977 and Ribavirin in patients with Chronic HCV. He is also
currently investigating the challenges of educating Asians in San Diego County on Hepatitis B in
a study that began in 2012.

Dr. Gish was an investigator in studies that led to the development of tests for HBV and HCV
and most recently a 2005 study on DNA HBV genotyping and molecular profiling in newly
recruited, HBV and HCV patients. He was also an investigator in a 2006 study that used
molecular signatures to predict interferon response in patients infected with Hepatitis C.

Curriculum Vitae

Dr Gishs research now includes co-leading a research program with Arrowhead Pharmaceuti-
cals on iRNA treatment of HBV infection.

Curriculum Vitae


HEALTH POLICY AND PATIENT ADVOCACY

Dr. Gish has been involved with patient care and patient advocacy groups dating back to 1988
when he became involved with the American Liver Foundation. Since that time, he has been
active with a number of organizations including the National Viral Hepatitis Roundtable, Viral
Hepatitis Action Coalition, the Fair Foundation, Center for Eradication of Viral Hepatitis/Asia
Pacific Organization, HEP- DART, World Health Organization, Centers for Disease Control,
Hepatitis B Free (San Francisco and San Diego), Hepatitis B Foundation, Hepatitis C Caring
Ambassadors, Viral Hepatitis Foundation, and Hepatitis Foundation for Vietnam.

Dr. Gishs international advocacy career focuses on public policy in Vietnam, Philippines, and
Armenia. His team wrote a white paper on Health Care and Liver Health in Vietnam that was
published in a peer-reviewed publication. Additional projects in Vietnam and the Philippines
include protocols that advance screening for viral hepatitis and linkage to care, as well as
global liver health issues including obesity, fatty liver, and alcohol induced liver disease. The
newest addition to Dr. Gishs global health policy work is in Armenia, where he is developing a
white paper for that countrys 5-year Liver Health Policy.

PERSONAL STATEMENT

My clinical research and studies focus on viral hepatitis, liver transplant, bioartificial liver, public
policy especially related to liver transplantation and viral hepatitis. Clinical trials for a variety of
antiviral therapies and new bioartificial livers systems will continue to be a major focus of my
practice. We will use databases to help uncover associations between liver cancer and certain
cancer biomarkers. In addition we will be building a multidisciplinary liver cancer program and
will integrate models of HCC signaling into our program. My background includes training in viral
hepatitis clinical trials and liver cancer trials. I plan to have a focus on biomarkers for liver
cancer to help guide treatment decisions and therapies. I have 25 years of experience as a
clinician and clinical investigator in the realm of liver disease, liver transplant and liver cancer. I
do a variety of educational programs for Pharma including promotional talks that are highly
regulated by the FDA and the Pharma Code: these funds are all recycled into research,
education, policy, philanthropy and supporting international health care.

EXPANDED RESEARCH

Dr. Gishs work focuses on the epidemiology of liver disease, biomarkers for liver disease and
multi-targeted therapies for liver cancer such as protein kinase inhibitors, fibroblast growth
factors and iRNA technologies to treat viral hepatitis. His research also includes the diagnosis
and treatment of liver failure, liver transplantation, and viral hepatitis, both B and C variants.
Recent clinical studies have focused on the Hepatitis B Virus within the Asian population at
large as well as exosomes, liver failure, bioartifical livers and international health policy.

Curriculum Vitae


PRESS RELEASE February 2014

Hepatitis B Foundation Welcomes Dr. Robert Gish as Medical Director

Renowned leader in the field of liver disease takes on new role leading advocacy and research

DOYLESTOWN, Pa. (February 2014) The Hepatitis B Foundation (www.hepb.org), the only
national nonprofit organization solely dedicated to finding a cure for hepatitis B, is pleased to
announce that Robert G. Gish, M.D., became the foundations medical director on Jan. 30,
2014. An internationally renowned medical researcher in the field of viral hepatitis, Dr. Gish has
made invaluable contributions to the understanding and treatment of hepatitis B, which is the
worlds leading cause of liver cancer. A longtime supporter of the foundations mission and a
member of the Scientific Advisory Board, Dr. Gishs new role will further strengthen its research
and advocacy efforts worldwide. We are delighted to welcome Dr. Gish to our board, said Dr.
W. Thomas London, senior member emeritus of Fox Chase Cancer Center and vice president
of the board of directors of the Hepatitis B Foundation. He has long been a leader in the field
and has extensive experience in the conduct of clinical trials of new drugs to combat chronic
hepatitis B. His leadership as medical director will help us advance the treatment and prevent
the severe consequences of this potentially deadly disease. After receiving his medical degree
in 1980, Dr. Gish quickly developed a keen interest in liver health, focusing his research on
investigation of viral hepatitis B and C. He went on to become medical director of the liver
transplant program at California Pacific Medical Center in 1994, developing an outreach
program that eventually served more than 35,000 patients in northern California and Nevada
and made the medical center a leading liver transplant center. Over the course of his career, Dr.
Gish has published more than 600 original articles, abstracts and book chapters and more than
120 peer-reviewed publications. Today, he is a clinical professor of Medicine at the University of
Nevada in Las Vegas, where he continues to teach, and is a senior consultant at St. Josephs
Medical Center in Phoenix. In 2013, he formed Robert G. Gish Consultants LLC to support liver
health and transplant programs with operations, outreach, compliance, financial planning and
program development in the U.S. and Asia. Dr. Gishs background is a perfect fit for the work
we do here at the Foundation and our Baruch S. Blumberg Institute, said Dr. Timothy Block,
president of the Hepatitis B Foundation and also a professor of Microbiology at Drexel Universi-
ty. We are honored that Dr. Gish has agreed to become our medical director and look forward
to many years of collaboration so we can finally put an end to this serious liver infection. To
learn more about Dr. Robert Gish, visit his website.

Curriculum Vitae

FACULTY APPOINTMENTS

*Please note: The following dates are best estimates due to lack of evidenced documentation:

7/1/1983 6/30/1984 Emergency Room Associate
Claremont Hospital
Claremont, California

6/1/1985 5/30/1988 Research Associate
Division of Gastroenterology

9/11988 6/1/1993 Research Associate
Medical Research Institute
California Pacific Medical Center
University of the Pacific
San Francisco, California

9/1/1991 7/2/1996 Assistant Clinical Professor of Medicine
University of California, Davis
Sacramento, California

7/1/1991 6/30/1996 Valley Children's Hospital
Liver Disease Program
Fresno, California

7/1/1993 6/30/1998 Merced Community Hospital
Family Medicine Program

University of Nevada, Reno
Reno, Nevada

7/1/1998 6/30/2005 Associate Clinical Professor of Medicine
University of Nevada, Reno
Reno, Nevada

7/1/2005 6/30/2006 Clinical Professor of Medicine
University of Nevada, Las Vegas, Nevada

8/1/1995 1/1/2010 Medical Director of Liver Transplant Program

University of California, San Francisco
Curriculum Vitae

FACULTY APPOINTMENTS: Continued

7/30/1999 6/30/2009 Associate Clinical Professor of Medicine


University of California, School of Medicine

1/1/2014 Present Clinical Professor,
Department of Internal Medicine, Adjucnt
University of Nevada School of Medicine,
Las Vegas, Nevada

EMPLOYMENT AND STAFF POSITIONS

1975 1977 Research Associate
McCollum Laboratories
University of Kansas
Lawrence, Kansas

1982 1983 Per diem Physician
Medicus Medical Group

Kaiser Permanente

1982 1983 On call MD: Life Flight-Critical Air Transport

Pioneer Memorial Hospital
Brawley, California

1983 1984 Emergency Clinic and Medical Doctor at Clarmmont Hospital
Industrial Medical Centers

Curriculum Vitae

EMPLOYMENT AND STAFF POSITIONS: Continued

1984 1986 Emergency Physician: Serra Memorial Hospital
Emergency Medicine
Sun Valley, California

1986 1988 Consultant
Sherman Oaks Community Hospital
Sherman Oaks, California

1987 Consultant
Phillip Edelman, M.D.
Occupational Medicine
Orange, California

1987 Consultant
Washington Medical Center
Culver City, California

Valley Presbyterian
Van Nuys, California

1988 Staff Physician
Oliveview Medical Center
Sylmar, California

1988 Consultant
West Hills Medical Center
Conoga Park, California

Mt. Zion Medical Center

Seton Medical Center
Daly City, California

Valley Children's Hospital
Fresno, California

Enloe Hospital,
Chico, California

Sunrise Hospital
Las Vegas, NV

Curriculum Vitae

EMPLOYMENT AND STAFF POSITIONS: Continued

1988 2010 Staff Physician

2009 2010 Physician
St. Lukes Hospital

Highland Hospital
Oakland, California

Medical Staff, Department of Medicine
John Muir Medical Center
Walnut Creek, California

Alta Bates Medical Center
Medicine and Family Practice
Berkeley, California

2003 2010 Physician
Saint Marys Medical Center

2010 2013 Medical Director of Center for Hepatobiliary Disease and Abdominal
Transplantation (CHAT)
Chief of Hepatology

2014 - Present Medical Director, Staff Physician
Stanford, CA

STATE OF CALIFORNIA CONSULTANT POSITIONS

1996 State of California
Department of Corrections
Infectious Disease Advisory Board

CONSULTANT POSITIONS

2010 Present Founding Member
CEVHAP (Coalition to Eradicate Viral Hepatitis in Asia Pacific).
Singapore
2012 2014 Advisory Board/Steering Committee,
National Viral Hepatitis Roundtable

2013 2014 Executive Committee Vice Chair, NVHR
Curriculum Vitae

BUSINESS POSITIONS

1999 2000 President and Treasurer
Pacific Hepatology and Gastroenterology Medical Group, P.C.

1999 2001 President and CEO
Hepahope Corporation

2000 2005 President
Pacific Hepatology and Gastroenterology Medical Group, P.C.

2009 Present President, Pacific Health Consortium LLC

1988 2010 Office address:
2340 Clay Street
San Francisco, California 94115

2010 2013 U.C. San Diego
Medical Director of Center for Hepatobiliary Disease and
Abdominal Transplantation (CHAT)
Chief of Hepatology
Professor of Medicine
350 Dickinson Street, Suite 342

8/31/2013 Robert G. Gish MD
Present Robert G. Gish Consultants, LLC
Business address:
San Diego, CA 92037
Cell phone: 1 858 229 9865
Website: robertgish.com

Curriculum Vitae

RESEARCH SUPPORT

1975 1977 Co-Investigator: NIH Grant #GM 22357. Ionization Kinetics of
Carbon Acids. University of Kansas. Grant award: $70,000.

1985 1988 Principle Investigator: National Institute of Environmental Health
Sciences Physician Scientist Award. Grant award: $210,000.

1993 1995 Co-Investigator: Amgen grant. A Phase III, Randomized, Double-
Blind Controlled Trial of Recombinant Methionyl Interferon
Consensus (r-tetIFN-Con1) in Patients with Chronic Hepatitis C
Virus (HCV) Infection. California Pacific Medical Center.
Grant award: $187,604.

1993 1994 Co-Investigator: Loewy Fund grant. Development and Validation
of a Standardized Interview for the Detection of Alcoholism in
Patients Referred for Liver Transplantation. California Pacific
Medical Center. Grant award: $6,487.

1993 1998 Co-Investigator: NIH grant. Cytokines and Human Autoimmune
Liver Disease. Grant award: $579,800.

1994 Principle Investigator: Syntex grant. Ganciclovir for the Treatment
of Hepatitis B after Organ Transplantation. Grant award: $10,000.

1994 Principle Investigator: Schering Corporation grant. Interferon alfa-
2b: Dose Escalation and Taper for the Treatment of Hepatitis C.

1995 Principle Investigator: PRI grant. Natural History of Hepatitis B.

1995 Co-Investigator: Chiron grant. Beta-Interferon for Retreatment of
Hepatitis C. Grant award: $30,000.

1995 1997 Principle Investigator: Schering-Plough grant. Hepatitis C
Treatment with Interferon with or without Phlebotomy.

1995 1997 Co-investigator: GlaxoWellcome grant. Study P110-008-
Tucaresol Dose Escalation Drug Study for Hepatitis B.

1996 1997 Co-Investigator: GlaxoWellcome grant. Study NUCA 3011- A
Placebo-Controlled Study of Lamivudine and Intron-A in Patients
with Chronic Hepatitis B Infection who are Interferon Non-
Responders. Grant award: $8,000.

Curriculum Vitae

RESEARCH SUPPORT: Continued

1996 1997 Co-Investigator: GlaxoWellcome grant. Study NUCA3010- A
Study of Lamivudine or Placebo in Patients with Chronic Hepatitis
B Infection who are Treatment Naive. Grant award: $10,000.

1996 1997 Co-Investigator: GlaxoWellcome grant. Study NUCA3005-
Lamivudine Open Label Program for Treatment of Patients with
Hepatitis B Viral Infection Post-Liver Transplantation.

1996 1997 Co-Investigator: GlaxoWellcome grant. Study NUCA2006- A Pilot
Study to Assess the Safety and Efficacy of Lamivudine During the
Course of Liver Transplantation for Patients with Chronic Hepatitis
B Infection (nave study). Grant award: $35,000.

1996 2001 Principle Investigator: GlaxoWellcome grant. Study NUCA3017- A
Study of Extended LamivudineTtreatment for Hepatitis B Patients
Previously Enrolled in Phase II or Phase III Lamivudine Trials.

1996 1997 Co-Investigator: Schering-Plough grant. Study C95-144- Interferon
with or without Ribavirin in Hepatitis C Patients with Relapse after
Interferon. Grant award: $158,000.

1996 1997 Co-Investigator: Schering-Plough grant. Study C95-132- IntronA
Monotherapy vs. IntronA + Ribavirin for Treatment of Chronic
Hepatitis C in Interferon-naive Patients. Grant award: $178,000.

1996 1998 Principle Investigator: Schering-Plough grant. Interferon with
Ribavirin for Interferon Failure in Hepatitis C Patients.

1996 1997 Principle Investigator: Ciba Corning grant. Lab study of Mx protein
as a Marker for Injection Therapy. Grant award: $5,000.

1996 1999 Principle Investigator: GlaxoWellcome grant. Study NUCA3021-
Lamivudine Compassionate Use Treatment Program for Subjects
of Three Life-Threatening Forms of Hepatitis B Infection.

1997 2000 Principle Investigator: Otsuka America Pharmaceutical Inc. Grant.
Study 156-96-203; Multicenter, Randomized, Double-Blind,
Placebo-Controlled, Dose-Ranging, Efficacy, Safety and
Pharmacokinetics Study of OPC 41061 in Hospitalized Patients
with Hyponatremia, Secondary to Liver Disease.

Curriculum Vitae


1997 2002 Co-investigator: Roche BioScience grant. Study MYCO 2642- A
Randomized, Double-Blind, Comparative Study of the Efficacy
and Safety of Intravenous and Oral Mycophenolate Mofetil and
Azathioprine, Each in Combination with Cyclosporine (Neoral) and
Corticosteroids in Liver Transplant Recipients.

1997 2002 Principle Investigator: GlaxoWellcome grant. Study NUCA 3016- A
Long-term Epidemiologic Study of Patients who have Evidence of
Possible Durable Response to Lamivudine in Phase II or Phase III
Trials of Lamivudine. Grant award: $21,000.

1998 2000 Principle Investigator: Triangle Pharmaceuticals grant. Phase I
Clinical Trial of FTC for Patients who have Chronic HBV Infection.

1998 2001 Principle Investigator: Triangle Pharmaceuticals grant. Phase II
Rollover Clinical Trial of FTC for Patients who have Chronic HBV
Infection. Grant award: $200,000.

1998 1999 Principle Investigator: Bristol-Myers Squibb grant. Lobucavir vs.
Interferon for patients who have not undergone previous
Treatment with Interferon Therapy. Grant award: $75,000.

1999 2000 Principle Investigator: Bristol-Myers Squibb grant.
200475 vs. Interferon for patients who have not undergone
previous treatment with Interferon therapy. Grant award: $85,000.

1998 1999 Co-investigator: Bristol-Myers Squibb grant. Lobucavir for Patients
who have Failed Previous Treatment with Interferon Therapy.

1997 1998 Co-investigator: Matrix Pharmaceuticals grant. Intratumoral
Injection of Cis-Platinum/Bovine Collagen for theTreatment of
Hepatocellular Carcinoma and Metastatic Colon Cancer.

1998 Present Principal Investigator: Schering-Plough grant. Interferon/Ribavirin
Treatment of Non-Responders and Relapsers. Grant award:
$750,000.

1998 2000 Principle Investigator: Schering-Plough grant. Study C98-169-
Comparison of Intron A Induction Therapy + Rebetol vs. Intron
A + Rebetol for the Treatment of Adult Naive Subjects with
Chronic Hepatitis C Infected with HCV Genotypes 1, 2, 3, or 2/3.

Curriculum Vitae


1998 2001 Principle Investigator: Hoffmann-LaRoche grant. Study
NV15496C- A Phase III Open-label, Randomized, Multicenter,
Parallel Dose Efficacy and Safety Study Comparing Pegylated-
Interferon -2a (RO 25-8310) to a Standard Regimen of Roferon
A in the Treatment of Patients with Chronic Hepatitis C. Grant
award: $148,000.

Treatment of Relapse in Patients with Chronic Hepatitis C
Comparing Intron A Monotherapy vs. IntronA + Ribavirin.

1998 2001 Principle Investigator: An open-label, single arm Study to Evaluate
the Combination of Zenapax (daclizumab) and CellCept
(mycophenolate mofetil) with Corticosteroids in the Prevention of
Acute Rejection in Primary Liver transplant Recipients. Roche
Pharmaceuticals. Grant award: $17,500.

Comparison of Peg-interferon vs. Intron A for Treatment of Adult
Subjects with Chronic Hepatitis C not Previously Treated with
Interferon: Dose-finding study. Grant award: $105,000.

1999 2002 Principle Investigator: Hoffmann-LaRoche grant. Study #
NV15801- A phase III,Rrandomized, Multicenter, Efficacy and
Safety Study Comparing the Combination of Pegylated-interferon
-2a (Ro 25-8310) and Ribavirin with Rebetron A in the
Treatment of Patients with Chronic Hepatitis C. Grant award:
$68,000.

1999 2002 Principle Investigator: Hoffmann-LaRoche grant. Study NR15994-
A randomized, open-label, multicenter, efficacy and safety Study
of Pegasys plus Ribavirin, Pegasys plus CellCept,
Pegasys plus Amantadine, or Pegasys plus Amantadine plus
Ribavirin in Patients with Chronic HCV Infection who have not
Responded to at least 12 Weeks of Treatment with Rebetron.

1999 2002 Principle Investigator: Gilead grant. Study GS98-437- A double-
blind, randomized, placebo-controlled Study of Adefovir Dipivoxil
for the Treatment of Patients with HBeAg+ Chronic Hepatitis B Vi-
rus Infection. Grant award: $106,000.

Curriculum Vitae


1999 2006 Principle Investigator: Gilead Pharmaceuticals grant. Phase III &
Rollover, Double-blind, randomized, placebo-controlled Study of
Adefovir Dipivoxil for Treatment of Patients with HBeAg+ Chronic
Hepatitis B Virus Infection with Open Label Long Term Follow Up
of Safety, Efficacy, and Resistance of Adefovir.

2000 2001 Principle Investigator: Gilead grant. Study 472- Pharmacokinetics
study (PK) of 48 weeks treatment with adefovir 10mg/day for HBV
infected, nucleoside treatment-nave patients with compensated
liver disease.

2000 Sub-Investigator: Bristol-Meyers Squibb grant. Long-Term
rollover, assessment of safety and antiviral activity of open-label
entecavir plus lamivudine in chronic hepatitis B patients who have
viremia on monotherapy in other entecavir trials.

2000 2005 Sub-Investigator: Bristol-Meyers Squibb grant. A phase III study of
the Safety and Antiviral Activity of Entecavir vs. Lamivudine in
Adults with Chronic Hepatitis B Infection who are Positive for
Hepatitis B E Antigen. Grant award: $75,867.

2000 2005 Sub-Investigator: Bristol-Meyers Squibb grant. A Phase III Study
of the Safety and Antiviral Activity of Entecavir vs. Lamivudine in
Adults with Chronic Hepatitis B Infection who are Negative for
Hepatitis B E-Antigen. Grant award: $29,911.

2000 2005 Sub-Investigator: Bristol-Meyers Squibb grant. A Phase III Study
of the Safety and Antiviral Activity of Entecavir vs. Lamivudine in
Adults with Chronic Hepatitis B Infection who are Negative for
Hepatitis B E-Antigen. Grant award: $40,048.

2000 2005 Sub-Investigator: Bristol-Meyers Squibb. Long-term Assessment
of Treatment Outcomes with Entecavir and Lamivudine for
Chronic Hepatitis B Infection in Patients who have Enrolled in
Phase III Entecavir Trials. Grant award: $3,524.

2000 2005 Principle Investigator: Bristol-Meyers Squibb. Decompensated,
Comparison of the Efficacy and Safety of Entecavir vs. Adefovir in
Subjects Chronically Infected with Hepatitis B virus with Evidence
of Lamivudine Resistance and Hepatic Decompensation.

2001 Principle Investigator: GlaxoSmithKline grant. Study Nuc2094 -
Lamivudine and Adefovir Combination for the Treatment of
Chronic HBV Infection.

Curriculum Vitae


2001 2002 Principle Investigator: Scripps Consortium grant. Hepatitis C
Registry. Grant award: $5,000.

2001 2002 Principle Investigator: Bayer Pharmaceuticals grant. HCV 3.0
assay development. Grant award: $6,000.

2001 2002 Co-Investigator: BioMeasure, Inc., grant. Lanreotide Study for the
Study of Acute GI Bleeding in Portal Hypertension.

2001 2002 Principle Investigator: Bristol-Meyers Squibb grant. Study 014-
020- Entecavir vs. Lamivudine (52 weeks therapy) in Adult
Patients with Chronic Hepatitis B who are Positive for Hepatitis B
e-Antigen and Nave to Previous Therapy.

2001 2002 Principle Investigator: Roceh Pharmaceuticals: 8 weeks of Peg-
Interferon +/- Ribavirin vs. Roferon 3 MU TIW + Ribavirin for
Patients with Chronic Hepatitis C Co-infected with HIV, Nave to
Interferon Therapy.

2001 2002 Sub-Investigator: Physician initiated study: Hepatitis Resource
Network. Peg-interferon -2b + Ribavirin for Treatment of Chronic
Hepatitis C Infection in HIV-infected Persons not Previously
Treated with Interferon.

2001 2002 Sub-Investigator: National Hemochromatosis Transplant Registry
grant. Prevalence of Hepatic Iron Overload and HFE Mutations
among Patients Undergoing Orthotopic Liver Transplantation
(OLT): Interim Results from the National Hemochromatosis
Transplant Registry (NHTR) NIH.

2001 2006 Sub-Investigator: SciClone Pharmaceuticals grant. A multicenter,
double-blinded study in patients with compensated non-cirrhosis
due to chronic hepatitis C who are non-responders to prior
interferon alfa + ribaviron therapy, comparing treatment with
thymosin + peg-interferon with peg-interferon + placebo.

2001 2008 Sub-Investigator: SciClone Pharmaceuticals grant. A multicenter,
double-blinded study in patients with compensated cirrhosis due
to chronic hepatitis C who are non-responders to prior interferon
alfa + ribaviron therapy, comparing treatment with thymosin + peg-
interferon with peg-interferon + placebo. Grant award: $240,869.

Curriculum Vitae


2001 2005 Sub-Investigator: Hoffman-LaRoche grant. A Phase III partially
double-blind study Evaluating the Efficacy and Safety of 40kD
Branched Pegylated Interferon Combined withPlacebo or Lamivu-
dine vs. Lamivudine in HBeAg- Positive Patients with Chronic
Hepatitis B. Grant award: $45,579.

2001 2006 Principle Investigator: Schering-Plough grant. Long term follow up
Protocol to Assess Subjects after Completing 24 weeks of
Schering-Plough Research Institute (SPRI) Clinical Trial for
Chronic Hepatitis C. Grant award: $19,200.

2001 2005 Principle Investigator: Schering-Plough grant. Comparison of peg-
interferon plus ribavirin given as a fixed dose or on a weight
optimized basis for treatment of chronic hepatitis C in previously
untreated adult subjects. Grant award: $41,950.

2002 2004 Principle Investigator: Roche Pharmaceuticals grant. A phase III
partially double-blinded Study Evaluating the Efficacy and Safety
of Pegasys with Placebo or Lamivudine Versus Lamivudine in
HBeAg-PositivePpatients with Chronic Hepatitis B.

2002 Principle Investigator: Ortho-Biotech grant. Procrit vs. Placebo
weekly to treat anemia for patients taking ribavirin + interferon or
peg-interferon.

2002 Principle Investigator: Akros Pharma grant. A randomized,
double-blind placebo-controlled, ascending dose Study of the
Safety, Tolerability, Pharmacokinetics, andPpharmacodynamics of
JTK-003 inPpatients with Chronic Hepatitis C Infection for Non-
responders to Previous Therapy.

2002 2003 Principle Investigator: ICN pharmaceuticals/Ribapharm grant. A
Phase I multiple-dose astudy to evaluate safety, tolerability, and
pharmacokinetics of viramidine for patients with compensated
HCV.

2002 Principle Investigator: Chiron grant. Randomized, placebo-
controlled study of the safety and efficacy of HBV/MF59 (vaccine)
alone or in combination with lamivudine.

2002 2003 Principle Investigator: Bristol-Meyers Squibb grant. Entecavir vs.
Lamivudine (52 weeks therapy) in Adult Patients with Chronic
Pepatitis B who have had an Incomplete Response to Lamivudine
Therapy.

Curriculum Vitae


2002 2005 Principle Investigator: SciClone Pharmaceuticals grant. Thymosin
for HCV Non-responders Comparing Treatment with Thymosin
Alpha 1 + Peg-interferon Alpha-2a with Peg-interferon Alpha-2a +
Placebo (Study 1: noncirrhotic; Study 2: cirrhotic).

2002 2005 Co-Investigator: NIH grant. Recurrent Hepatitis B after Liver
Transplant. Grant award: $32,705.

2002 2005 Sub-Investigator: Roche Pharmaceuticals. A randomized, open
label, multi-center, pilot study of Pegasys and Epivir-HBV as Initial
Treatment of HBeAg- Negative Chronic Hepatitis B Infection.

2002 2003 Principle Investigator: Intermune grant. Double-blind, randomized,
placebo-controlled Study of the Safety and Anti-fibrotic Efficacy of
Gamma Interferon in Patients with Severe Liver Fibrosis or
Cirrhosis due to HCV.

2002 2003 Sub-investigator: Schering Corp. Comparison of Peg-interferon
Alfa-2b plus Ribavirin Given as a Fixed Dose or on a Weight
Optimized Basis for Treatment of Chronic Hepatitis in Previously
Untreated Adult Patients.

2002 2004 Principle Investigator: SciClone Pharmaceuticals grant. Trial of
zadaxin with transarterial chemoembolization in patients with
unresectable hepatocellular chemoembolization with or without
zadaxin therapy for 6 months. Award $240,000

2002 2003 Principle Investigator: ICN pharmaceuticals/Ribapharm grant. A
Phase II randomized Study to Evaluate the Efficacy of Viramidine
for Patients with Compensated HCV.

2002 2003 Principle Investigator: Eximias Pharmaceuticals. Thymataq vs.
Doxorubicin for the Treatment of HCC. Grant award: $240,000

2002 2005 Principle Investigator: Valeant Pharmaceuticals grant. Phase II
dose-ranging Study of Viramidine in Combination with Pegasys in
Treatment-nave Subjects with Chronic Hepatitis C Infection.

2002 2005 Sub-Investigator: Idenix Pharmaceuticals grant. A randomized,
double-blind trial of Telbivudine vs.Llamivudine in Adults with
Compensated Chronic Hepatitis B. Grant award: $106,427.

Curriculum Vitae


2002 2009 Sub-Investigator: XTL Pharmaceuticals grant. A pilot phase II,
multi-center, randomized, double-blind, placebo-controlled, dose
escalation Study of the Safety and Efficacy of Human HCV-
antibody (HCV-AB 68) for Prevention of Hepatitis C Disease
Recurrence in Patients who have Received Hepatic Allografts for
Treatment of End-stage Liver Disease due to Hepatitis C Virus
Infection. Grant award: $10,000.

2003 2004 Principle Investigator: Bristol-Meyers Squibb. Entecavir vs. Lamiv-
udine (52 weeks therapy) in Adult patients with Chronic Hepatitis
B who have had an Incomplete Response to Lamivudine Therapy:
Rollover study.

2003 Sub-investigator: Medtronic grant. Interstim sacral nerve
stimulation therapy for bowel control: Fecal incontinence study.

2003 Principle Investigator: Roche Pharmaceuticals grant. Randomized,
open-label study of Pegasys and Epivir-HBV as initial treatment of
HBeAg negative HBV.

2003 Sub-investigator: Two-week randomized, double-blind, placebo-
controlled study of PRN, BID and fixed dosing regimens of
alosetron in female subjects with severe diarrhea-predominant
irritable bowel syndrome who have failed conventional therapy.

2003 Principle Investigator: Idun Pharmaceuticals grant. Caspase study
for the treatment of chronic liver disease including chronic HCV
infection.

2003 Principle Investigator: United Therapeutics grant. Phase II study of
UT 231, including PK assessment, in patients with chronic HCV
who were non-responders to previous interferon and ribavirin
therapy.

2003 Principle Investigator: Actelion Pharmaceuticals. Phase II Study
of tezosentan for the treatment of portal hypertension.

2003 SubInvestigator: Celera grant. Natural history of fibrosis in
patients who had undergone treatment for HCV.

2003 2004 Principle Investigator: Chiron grant. Evaluation of the Procleix
HIV-1/HCV RNA qualitative assay in detecting HCV RNA from
whole blood from HCV infected patients.

Curriculum Vitae


2003 2006 Sub-Investigator: Hoffman-LaRoche grant. Rrandomized, multi-
center, open-label, phase IV study evaluating efficacy and safety
of 16 week vs. 24 week treatment with Pegasys in combination
with Copegus in interferon-nave patients with chronic hepatitis C
genotype 2 or 3 virus infection. Grant award: $136,513.

2003 2006 Principle Investigator: Gilead Pharmaceuticals grant. Long-term
study of durability of seroconversion in patients with chronic
hepatitis B virus infection who have seroconverted while
participating in the previous Gilead-sponsored study of adefovir
dipivoxil. Grant award: $1,000.

2003 2005 Principle Investigator: Celera grant. DNA genotyping and mRNA profiling
of newly recruited, treatment-nave HCV patients.

2003 2004 Principle Investigator: XTL Pharmaceuticals grant. Phase II, multi-
center, randomized, open-label, dose ranging, parallel group study
of the antiviral effects, pharmacokinetics and safety of HepeX-B
as compared to hepatitis B immune globulin in patients who have
received hepatic allografts for hepatitis B virus infection.

2004 Principle investigator (CPMC): Amgen grant. Treatment of
ribavirin-induced anemia during the treatment of chronic HCV with
darbopoietin (ADHERENCE trial).

2004 Principle investigator: (CPMC) Ortho Biotech grant. Prospective
treatment trial using erythropoietin to treat anemia due to ribavirin
during interferon treatment for chronic HCV infection.

2004 Principle Investigator: Eximias Pharmaceutical Corp. grant.
Phase III Evaluation of THYMITAQ(R) nolatrexed dihydrochloride,
in unresectable hepatocellular carcinoma (ETHECC[C]) trial.

2004 Co-Principle Investigator: WEAVE (WEST EAST ANTIVIRAL
EFFICACY) protocol- Randomized trial of Pegasys/ribavirin vs.
Pegasys/ribavirin and CAM therapy.

2004 2005 Principle Investigator: Idun Pharmaceuticals grant. A phase III
dose-response study of caspase inhibitor in hepatitis C patients.

2004 2005 Sub-Investigator: Boehringer Ingleheim grant. A pharmacokinetic
study to assess nevirapine levels in HIV-infected patients with
impaired hepatic function. Grant award: $19,929.

Curriculum Vitae


2004 2006 Sub-Principle Investigator: Ortho Biotech grant. Procrit for the
treatment of post-transplant anemia. Grant award: $50,000.

2004 2006 Principle Investigator: eXagen Diagnostics grant. Identification of a
molecular signature from peripheral blood that predicts interferon
response in hepatitis C infection. Grant award: $30,000.

2004 2006 Sub-Investigator: Hoffman-LaRoche grant. Prospective,
randomized, multi-center, open-label, comparative safety and
efficacy study of prophylactically administered pegylated interferon
plus ribavirin vs. no prophylaxis following liver transplantation for
hepatitis C. Grant award: $246,608.

2004 2007 Principle Investigator: Valeant Pharmaceuticals grant. Phase II
randomized, double-blind, multi-center study to compare safety
and efficacy of viramidine to ribarivin in treatment-nave patients
with chronic hepatitis C. Grant award: $202,395.

2004 2007 Sub-Investigator: Vertex Pharmaceuticals grant. Phase 2b study
of merimepodib in combination with interferon and ribavirin in
subjects with chronic hepatitis C genotype 1 non-responsive to
prior therapy and interferon. Grant award: $96,740.

2004 2009 Co-Investigator: NIH grant. Early detection of liver cancer.

2005 2007 Principle Investigator: Stanford University grant. CPMC/Stanford
keratin study of liver disease in African Americans.

2005 2007 Sub-Investigator: Idenix Pharmaceuticals grant. A randomized,
double blind trial of telbivudine vs. adefovir dipivoxil in adults with
HBeAg-positive, compensated chronic hepatitis B.

2005 2008 Sub-Investigator: Idenix Pharmaceuticals grant. Open-label study
of telbivudine in adults with chronic hepatitis B previously treated
in Idenix-sponsored telbivudine studies. Grant award: $126,005.

2005 2007 Sub-Investigator: Idenix Pharmaceuticals grant. Randomized,
phase IIb clinical trial to evaluate the safety and antiviral activity of
NM283 and the combination of interferon plus NM283 in patients
with chronic hepatitis C who have previously failed to respond to
standard therapy. Grant award: $69,883.

Curriculum Vitae


2005 Sub-Investigator: Hemolife Medical grant. Continuous plasma
filtration with sorbent adsorbent detoxification utilizing the
HemoLife Medical Inc. HLM 100 column and the HLM-200 plasma
filter for the treatment of episodic type C hepatic encephalopathy
in subjects with decompensated cirrhosis. Grant award: $86,790.

2005 Sub-Investigator: Orphan Therapeutics grant. A double-blind,
randomized, placebo-controlled, multi-center phase III study of
intravenous terlipressin in patients with hepatorenal syndrome
Type 1. Grant award: $34,791.

2007 2008 Principle investigator: Nucleonics siRNA therapy for the treatment
of chronic hepatitis B. Grant award: $124,000.

2008 2010 PROTOCOL GS-US-174-0108 A Phase II, Double-Blind, Multi-
Center, Randomized Study Comparing Tenofovir Disoproxil
Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and
Entecavir In The Treatment Of Chronic Hepatitis B Subjects With
Decompensated Liver Disease And In The Prevention Of Hepatitis
B Recurrence Post-Transplantation. Budget $26,642

2010 Sub-Investigator: Study of the Antiviral Activity of Entecavir in
Patients Receiving Liver Transplant Due to Chronic Hepatitis B
Virus Infection.

2010 Sub-Investigator: Ph 2 rollover protocol of Telaprevir (VX-950) in
combination with Peginterferon Alfa-2a and Ribavirin in subjects
enrolled in the controlled group (Group A) of study VX06-950-106,
VX05-950-104 and VX05-650-104EU who did not achieve or
maintain an undetectable HCV RNA level through sustained viral
response.

2010 Sub-Investigator: A Randomized, Placebo-Controlled, Dose-
Escalation Study to Assess the Safety and Effect of Cidofovir in
Renal Transplant Recipients with BK Virus Nephropathy
(CASG209).

2010 Sub-Investigator: Multicenter, randomized, double-blind, placebo
controlled, multiple dose study of the safety, tolerability and
population pharmacokinetics of CMX001 in post transplant
subjects with BK virus viruria.

2010 Sub-Investigator: A Phase III randomized, double-blind, placebo-
controlled study of sorafenib as adjuvant treatment for
hepatocellular carcinoma after surgical resection or local ablation.

Curriculum Vitae


2010 Sub-Investigator: A Phase II randomized, double-blind, placebo-
controlled study of Sorafenib or Placebo in combination with
transarterial chemoembolization (TACE) performed with DC bead
and doxorubicin for intermediate stage hepatocellular carcimoma
(HCC).

2010 Principle-Investigator: A Randomized, Double-blind, Multi-center
Phase II Study of Brivanib plus Best Supportive Care (BCD)
versus Placebo plus BSC in Subjects with Advanced
Hepatocellular Carcinoma (HCC) who have Failed or are
Intolerant to Sorafenib. Budget amount $244,105.00

2010 Sub-Investigator: A Phase I, Open-Label, Multi-center, Dose-
escalation Study of the Safety, Tolerability, and Pharmacokinetics
of GC33 in Combination with Sorafenib (Nexavar) in Patients with
Advanced or Metastic Hepatocellular Carcinoma (HCC).

2010 Sub-Investigator: Global Investigation of Therapeutic Decisions in
Hepatocellular Carcinoma and of its Treatment with Sorafenib.

2010 Principle-Investigator: Randomized, Controlled Phase 2a/b Study
of the Efficacy and Safety of PEG-rIL-29 Administed in
Combination with Ribavirin to Treatment-Nave Subjects with
Chronic Hepatitis C Virus Infection. Budget $48,950.00

2010 Sub-Investigator: A Rollover Protocol to Provide Open-Label
Emtricitabine/Tenofovir Disoproxil Fumarate Combination Product
to Subjects Completing the GS-US-203-0107 Study.

2010 Principle-Investigator: A Phase 2, Randomized, Double-Blind
Study Exploring the Efficacy, Safety and Tolerability of Tenofovir
Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus
Tenofovir DF Fixed-Dose Combination Therapy in Subjects
Currently Being Treated with Adefovir Dipiivoxil for Chronic
Hepatitis B and having Persistent Viral Replication.

2010 Sub-Investigator: An Open Label Trial of Telbivudine (LdT) in
Adults with Chronic Hepatitis B Previously Treated in Idenix-
Sponsored Telbivudine Studies. NV-02B-022.

2010 Sub-Investigator: A Phase 2, Open-Label, Multi-Center,
Randomized Trial to Demonstrate the Pharmacokinetics of LCP-
TACRO Tablets Once Daily and Program Capsules Twice Daily in
Adult De Novo Liver Transplant Patients.

Curriculum Vitae


2010 Sub-Investigator: A Phase 2, Randomized, Double-Blind,
Multicenter, Dose and Duration Finding Study to Evaluate the
Sustained Virologic Response of the HCV Polymerase Inhibitor
Prodrug (RO5024048) in Combination with Pegasys and Copegus
versus the Currently Approved Combination of Pegasys and
Copegus in Treatment Nave Patients with Chronic Hepatitis C
Genotype 1 or 4 Virus Infection.

2010 Sub-Investigator: Salix Pharmaceuticals, Inc./A Multi-Center,
Open-Label, Trial to Evaluate the Long-Term Safety and
Tolerability of Rifaximin 550 BID in Subjects with a History of
Hepatic Encephalopathy.

2010 Sub-Investigator: Long-Term Follow-Up of Subjects in a Phase 2
or 3 Clinical Trial in which SCH 503034 was Administered for the
Treatment of Chronic Hepatitis C.

2010 Sub-Investigator: Ph2, Open label randomized study to evaluate
the efficacy and safety of the combination product,
Emtricitabine/Tenofovir (Truvada) in the presence of absence of
Hepatitis B immunoglobulin (CHB) post-orthotopic liver transplant
(OLT).

2010 Sub-Investigator: An open-level, single-arm, roll-over trial of
telaprevir in combination with pegylated interferon alfa-2a
(Pegasys) and ribavirin (Copegus) for subjects from the control
group of the VX-950-TiDP24-C216 trail who failed therapy for
virologic reasons.

2010 Sub-Investigator: Phase III, 24 dose regimens of Telaprevir in
combination with Peginterferon alfa 2a and Ribavirin in treatment
nave subjects with genotype 1 chronic hepatitis C.

2010 Sub-Investigator: Randomized study of stopping treatment at
24wks vs. continuing treatment to 48 weeks in treatment-nave
subjects with Genotype 1 CHC who achieve an extended RVR
while receiving Telaprevir, Peginterferon (Peasys) and Ribavirin
(Copegus).

2010 Sub-Investigator: A 3-Year, Virology Follow up Study in Subjects
Previously Treated WithTelaprevir in Select Clinical Studies.

2010 Sub-Investigator: Efficacy and Safety of the Extracorporeal Liver
Assist Device (ELAD) in Subjects with Fulminant Hepatic Failure
(FHF).

Curriculum Vitae


2010 Sub-Investigator: Efficacy and Safety of the Extravorporeal Liver
Assist Device (ELAD) in Subjects with Acute on Chronic Hepatitis
(AOCH).

2010 Sub-Investigator: A multi-center randomized, double-blind,
placebo-controlled trial to evaluate the efficacy, safety and
tolerability of Rifaximin 550 mg bid for 6 months in preventing
hepatic encephalopaty.

2010 ILCS Horizon Scanning Protocol International and National
Priorities for Liver Cancer Control. Johns Hopkins Bloomberg
School of Public Health IRB.

4/2010 8/2013 Co-Primary Investigator: NV20536. A Roche Study: A Random-
ized, Double-blinded, Multicenter, Dose and Duration Finding
Study to Evaluate the Sustained Virologic Response of the HCV
Polymerase Inhibitor Prodrug (RO5024048) in Combination with
Pegasys and Copegus versus the Currently Approved Combi-
nation of Pegasys and Copegus in Treatment-Naive Patients
with Chronic Hepatitis C Genotype 1 or 4 Virus Infection. Grant
Award: $214,336.60.

11/2010 8/2013 Co-Primary Investigator: NV22688. A Roche Study: A Long-Term
Monitoring Study To Evaluate The Persistence Of Direct Acting
Antiviral (DAA) Treatment-Resistant Mutations Or The Durability
Of Sustained Virological Response (SVR) In Patients Treated
With DAA-Containing Regimens For Chronic Hepatitis C Infection
(CHC). Grant Award: $21,273.00.

4/2011 8/2013 Co-Primary Investigator: P7977-0724. A Gilead Sciences &
Pharmasett study: A Multicenter, Open-label, Randomized, Dura-
tion Finding Study to Investigate the Safety, Tolerability, Pharma-
cokinetics and Pharmacodynamics following Oral Administration
of PSI-7977 in Combination with Pegylated Interferon and Ribavi-
rin in Treatment-Nave Patients with Chronic HCV Infection Geno-
type 1,4,5, or 6. Grant Award: $117,872.

2011 Co-Primary Investigator: WV21913C. A Roche Study: A Random-
ized, Open-Label, Multicenter Study to Evaluate the Sustained Vi-
rologic Response of the HCV Protease Inhibitor Danoprevir
Boosted with Low Dose Ritonavir (DNV/r) and Copegus, in Com-
bination with the HCV Polymerase Inhibitor Prodrug RO 5024048
and/or Pegasys in Chronic Hepatitis C Genotype 1 Patients who
have Failed a Previous Course of Peginterferon Alfa Plus Ribavi-
rin Combination Therapy. Grant Award: $141,986.

Curriculum Vitae


6/2011 8/2013 Co-Primary Investigator: GS-US-248-0120. A Gilead Sciences,
Inc. Study: A Phase 2 Randomized, Open-Label Study of GS-
5885 Administered Concomitantly with GS-9451, Tegobuvir and
Ribavirin (RBV) to Treatment-Naive Subjects with Chronic Geno-
type 1 HCV Infection. Grant Award: $213,102.

9/2011 8/2013 Co-Primary Investigator: GS-US-248-0121. A Gilead Sciences,
Inc. Study: A Phase 2 Randomized, Open-Label, Exploratory Trial
of GS-5885, GS-9451 with Peginterferon Alfa 2a (PEG) and Rib-
avirin (RBV) in Treatment-Nave Subjects with Chronic Genotype
1 Hepatitis C Virus Infection and IL28B CC Genotype. Grant
Award: $59,742.

2011 8/2013 Primary Investigator: BIPI 1220.48. A Boehringer Ingelheim
Study: A Phase III, open-label study of once daily BI 201335 240
mg for 24 weeks in combination with pegylated interferon-a
(PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic
hepatitis C infection who failed a prior PegIFN / RBV treatment
[Version 3.0] Grant Award: $89,739.

2011 8/2013 Co-Primary Investigator: AI444038. A Bristol-Myers Squibb Study:
Open-Label, Single Arm Evaluation of BMS-790052 in Combina-
tion with Peg-Interferon Alfa-2a and Ribavirin in Black-African
Americans, Latinos, and White-Caucasians with Chronic Hepatitis
C Genotype 1 Infection. Grant Award: $92,572.

2011 8/2013 Co-Primary Investigator: GS-US-248-0123. A Gilead Sciences,
Inc. Study: A Long Term Follow-up Registry Study of Subjects
Who Did Not Achieve Sustained Virologic Response in Gilead-
Sponsored Trials in Subjects with Chronic Hepatitis C Infection.
Grant Award: $33,491.

2011 8/2013 Co-Primary Investigator: GS-US-248-0122 . A Gilead Sciences,
Inc. Study: A Long Term Follow-up Registry for Subjects Who
Achieve a Sustained Virologic Response to Treatment in Gilead-
Sponsored Trials in Subjects with Chronic Hepatitis C Infection.

2011 8/2013 Co-Primary Investigator: NV27779. A Roche Study: A Phase II,
Randomized, Double-Blind, Multicenter, Parallel Group Study To
Evaluate The Sustained Virologic Response Of The HCV Poly-
merase Inhibitor Prodrug Ro5024048 In Combination With
Telaprevir And Pegasys/Copegus In Patients With Chronic
Hepatitis C Genotype 1 Virus Infection Who Were Prior Null Re-
sponders To Treatment With Pegylated Interferon/Ribavirin.

Curriculum Vitae


2011 8/2013 Primary Investigator: P2938-0721. A Gilead Sciences / Pharma-
sett, Inc. Study: An International, Multi-center, Blinded, Random-
ized Study to Investigate Safety, Tolerability, Pharmacokinetics
and Pharmacodynamics following Administration of Regimens
Containing PSI-352938, PSI-7977, and Ribavirin in Patients with
Chronic HCV Infection. Grant Award: $273,564.

2012 8/2013 Primary Investigator: BMS AI444-043. A Brstol-Myers Squib
Study: A Phase 3, Open Label Study of Safety and Efficacy with
BMS-790052 plus Peg- Interferon Alfa 2a and Ribavirin in Previ-
ously Untreated HCV Patients Coinfected with Human Immunode-
ficiency Virus (HIV) and Hepatitis C Virus (HCV). Grant Award:
$73,976.

2012 8/2013 Co-Primary Investigator: VX11-950-114. A Vertex Study: A Phase
3b Study of 2 Treatment Durations of Telaprevir, PEG-INF (Pega-
sys), and Ribavirin (Copegus) in Treatment-Naive and Prior
Relapser Subjects with Genotype 1 Chronic Hepatitis C and IL28B
CC Genotype [Version 2.0]. Grant Award: $58,092.

2012 8/2013 Co-Primary Investigator: P7977-2025. A Gilead Sciences / Phar-
masett, Inc. Study: An Open-Label Study to Explore the Clinical
Efficacy of GS-7977 with Ribavirin Administered Pre-Transplant in
Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant.

2012 8/2013 Co-Primary Investigator: GS-US-334-0107 . A Gilead Sciences,
Inc. Study: A Phase 3, Multicenter, Randomized, Double-Blind,
Placebo-Controlled Study to Investigate the Efficacy and Safety of
GS-7977 + Ribavirin for 12 Weeks in Subjects with Chronic Geno-
type 2 or 3 HCV Infection who are Interferon Intolerant, Interferon
Ineligible or Unwilling to Take Interferon. Grant Award: $102,037.

2012 8/2013 Co-Primary Investigator: GS-US-334-0109, A Gilead Sciences,
Inc. Study: An Open-Label Study of GS-7977+ Ribavirin with or
without Peginterferon Alfa-2a in Subjects with Chronic HCV Infec-
tion who Participated in Prior Gilead HCV Studies Grant Award:
$94,440.

2012 8/2013 Co-Primary Investigator: GS-US-334-0108, A Gilead Sciences,
Inc. Study: A Phase 3, Multicenter, Randomized, Double-Blind,
Study to Investigate the Efficacy and Safety of GS-7977 + Ribavi-
rin for 12 or 16 Weeks in Treatment Experienced Subjects with
Chronic Genotype 2 or 3 HCV Infection. Grant Award: $100,831.

Curriculum Vitae


2012 8/2013 Primary Investigator: P7977-1231, A Gilead Sciences / Pharma-
sett, Inc. Study: A Phase 3, Multicenter, Randomized, Active-
Controlled Study to Investigate the Safety and Efficacy of PSI-
7977 and Ribavirin for 12 Weeks Compared to Pegylated Interfer-
on and Ribavirin for 24 Weeks in Treatment-Nave Patients with
Chronic Genotype 2 or 3 HCV Infection. Grant Award: $43,041.

2012 8/2013 Primary Investigator: GS-US-283-0102, A Gilead Sciences, Inc.
Study: A Double-Blind, Randomized, Placebo-Controlled, Single
and Multiple-Dose Ranging, Study Evaluating the Safety, Tolera-
bility, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity
of GS-9620 in Virologically Suppressed Subjects with Chronic
Hepatitis B Virus Infection. Grant Award: $43,041.

2012 Primary Investigator: GS-US-283-0106, A Gilead Sciences, Inc.
and Multiple-Dose Ranging, Adaptive Study Evaluating the Safety,
Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral
Activity of GS-9620 in Treatment Naive Subjects with Chronic
Hepatitis B Virus Infection. Grant Award: $178,385. 6/1/12
8/2013.

2012 Primary Investigator: GS-US-243-0102., A Gilead Sciences, Inc.
and Multiple-Dose Ranging Study Evaluating the Safety, Tolerabil-
ity, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of
GS-9620 in Treatment Nave Subjects with Chronic Hepatitis C Vi-
rus Infection. Grant Award: $183,441. 6/1/12 8/2013.

2012 Primary Investigator: GS-US-283-0110, A Gilead Sciences, Inc.
Study: A Long Term Follow-up Registry Study of Subjects Who
Did Not Achieve Loss of S Antigen (HBsAg) and Sustained HBV
Viral Load Reduction Below the Limit of Quantitation (BLQ) in Gil-
ead-Sponsored Trials of GS-9620 in Subjects with Chronic Hepati-
tis B Infection. Grant Award: $139,400. 7/1/12 8/2013.

2012 Co-Primary Investigator: GS-US-334-0110, A Gilead Sciences,
Inc. Study: A Phase 3, Multicenter, Open-Label Study to Investi-
gate the Efficacy and Safety of GS-7977 with Peginterferon Alfa2a
and Ribavirin for 12 Weeks in Treatment-Naive Subjects with
Chronic Genotype 1, 4, 5, or 6 HCV Infection. Grant Award:
$102,411. 7/1/12 8/2013.

Curriculum Vitae


Inc. Study: A Phase 3, Multicenter, Randomized, Open-Label
Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-
5885 Fixed-Dose Combination Ribavirin for 12 and 24 Weeks in
Treatment-Experienced Subjects with Chronic Genotype 1 HCV
Infection. Gilead Sciences, Inc. Grant Award: $116,799. 1/1/13
8/2013.

2013 Co-Primary Investigator: GS M14-002. An AbbVie Study: A Ran-
domized, Double-Blind, Controlled Study to Evaluate the Efficacy
and Safety of the Combination of ABT-450/Ritonavir/ABT-267
(ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin
(RBV) in Treatment-Nave Adults with Genotype 1a Chronic Hepa-
titis C Virus (HCV) Infection (PEARL-IV). Grant Award:
$126,539.00. 3/1/13 8/2013.

Inc. Study: A Phase 3, Multicenter, Randomized, Open-Label
Study to Investigate the Efficacy and Safety of Sofosbuvir / Ledi-
pasvir Fixed-Dose Combination Ribavirin for 8 Weeks and
Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in
Treatment-Nave Subjects with Chronic Genotype 1 HCV Infec-
tion. Grant Award: $104,650. 5/1/13 8/2013.

2013 GS-US-342-0102, A Gilead Sciences, Inc. Study: A Phase 2, Mul-
ticenter, Randomized, Open-Label Study to Investigate the Safety
and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-
Nave Subjects with Chronic HCV Infection . Grant Award:
$46,551. 5/1/13 8/2013.

Curriculum Vitae

UCSD: RESEARCH / ADVISORY

2012 Co-Principal Investigator: Biological Markers and Outcomes in
Hepatitis C and Other Liver Diseases. All UCSD Health Systems.
Other Co-Principal Investigator: Julio Gutierrez, MD.

2013 Co-Principal Investigator: STOPC Biobank Genetics Consortium
(UCSD Unit). Other Co-Principal Investigator: Alexander Kuo,
MD.

2012 Principal Investigator: Retrospective Analysis of UCSD Liver Pa-
tient Population, UCSD Medical Center, 5-Year Study. UCSD
Liver Center.

2011 Principal Investigator: POC Hepatitis B and Hepatitis C:
Screening for Viral Hepatitis, Its Role in Linkage to Care and
Economic Ramification in Healthcare, Asian Pacific Health
Foundation (APHF) Community Outreach Events. In Process.

2011 Principal Investigator: Retrospective Analysis of UCSD Liver
Patient Population. UCSD Human Research Protections
Program. UCSD Medical Center. Study is for 5 years,
In Process.

2011 2013 Principal Investigator: UCSD Liver Research Biorepository.
UCSD Health Systems.

2012 Principal Investigator: An International Multi-Center, Blinded,
Randomized Study to Investigate Safety, Tolerability, PK and PD
Following Administration of Regimens Containing PSI-352938,
PSE-7977, and Ribavirin in Patients with Chronic HCV, AVRC at
UCSD.

2012 2013 Principal Investigator: Barriers to Hepatitis B Screening and
Hepatitis B Knowledge Among Asian Population in San Diego
County. All UCSD Health Systems.

2012 2013 Study to Improve Early Identification of Hepatitis B (HBV) and C
(HCV) Infections in Clinical and Community Settings and to En-
hance Linkage to Care, Treatment, and Preventive Services for In-
fected Persons. Grant submitted by Hepatitis Free San Diego in
collaboration with the Antiviral Research Center, University of
California, San Diego. Approved by Centers for Disease Control
and Prevention (CDC), September 2012 for 1 year.

2013 Present Co-investigator: A University of California, San Diego Skaggs
School of Pharmacy and Pharmaceutical Sciences study; Cost-
Effectiveness of Hepatitis C Screening: Point of Care (POC) vs.
Standard of Care Tests.
Curriculum Vitae

UCSD: RESEARCH / ADVISORY: Continued

2012 Present Co-investigator: A University of California, San Diego Skaggs
School of Pharmacy and Pharmaceutical Sciences study. Cost Ef-
ficiency Analysis of Point-of-Care versus Standard of Care Tests
for Hepatitis B in Asian Americans in San Diego County.

8/31/2013 Robert G. Gish MD
Present Robert G. Gish Consultants, LLC
Business address:
San Diego, CA 92037
Cell phone: 1 858 229 9865
Website: robertgish.com

COINVESTIGATOR: GASTROINTESTINAL TRIALS

2002 Tegaserod vs. Placebo, for functional dyspepsia with documented
delayed gastric emptying. (Novartis).

2002 A phase III, double-blind, multicenter, randomized, placebo-
controlled study of the effects of a somatostatin analogue -
lanreotide as an adjuvant to endoscopic band ligation of patients
with acute bleeding from oesophageal varies secondary to
cirrhosis and portal hypertension (Biomeasure).

2002 Performance evaluation of the given diagnostic imaging system in
the upper gastrointestinal tract (given imaging).

2002 An efficacy and safety study of intravenous pantoprazole in the
prevention of recurrent peptic ulcer bleeding after successful
hemostasis (Wyeth-Ayerst).

2002 Prospective comparison of air contrast barium enema (ACBE)
computed tomographic colonography (virtual colonoscopy) and
colonoscopy for evaluation of the colon.

2002 Evaluation of investigational sclerotherapy-type needle for tissue
identification (Enterics).

2002 A pilot Phase II, muliticenter, randomized, double-blind, placebo-
controlled, dose escalation study of the safety and efficacy of
human HCV-antibody (HCV-Ab XTL 68) for prevention of hepatitis
C disease recurrence in patients who have received hepatic
allografts for treatment of end-stage liver disease due to hepatitis
C virus infection.

Curriculum Vitae

COINVESTIGATOR: GASTROINTESTINAL TRIALS: Continued

2010 Moving towards comprehensive liver cancer control: A qualitative
study.

2010 Applying conjoint analysis to develop a comprehensive liver
cancer control plan in Asia.

2011 Predicting the future impact of emerging technologies on
Hepatocellular carcinoma (HCC): Measuring stakeholders
preferences with best-worst scaling.

2011 Stakeholder involvement in priority setting of strategies to improve
hepatocellular carcinoma policy (EU data).

Hepatocellular carcinoma (HCC): Measuring stakeholders
preferences with best-worst scaling.

hepatocellular carcinoma (HCC): Using best-worst scaling to
explore clinicians views.

2011 Controlling liver cancer internationally: A qualitative study of
clinicians perceptions of current public policy needs.

2011 Stakeholder involvement in priority setting of strategies to improve
liver cancer control policy in Asia.

2011 Focus will be all Asian data results vs. USA - performance needs
and discussion around country-level differences (possible
publication in special supplement of ONCOLOGY, tbc).

2011 Evaluation of the Merits of the Evidence Regarding the
Identification of Hepatitis C Virus (HCV) and HCV-Related Chronic
Disease Among Persons Born from 1945 to 1965.

2012 Associate Member, Moores UCSD Cancer Center.

2013 Editorial Advisory Board, Gastroenterology & Hepatology Journal,
Digestive Disease Week Breakfast, Orlando, FL.; May 19, 2013.

2011 2013 STOPSC Genetics Recruitment; Studies of Primary Sclerosing
Cholangitis (STOPSC) is a multi-center joining effort to
understand the possible causes and treatment of Primary
Slerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) as
well as the effects of the disease on the liver over time
Curriculum Vitae

TEACHING ACTIVITIES

19871988 Consult Attending
Gastroenterology and Liver Services
Wadsworth Veterans Hospital

19871988 Clinical Toxicology
UCLA School of Medicine

19891991 UC Davis Liver Conference
Martinez VA, University of California, Davis
Martinez, California

19911995 Gastroenterology and Liver Clinic

1994 Visiting Professor
University of Florida
Gainesville, Florida

University of Iowa
Iowa

1996, 1997 & 2003 Visiting Professor
Los Angeles, CA

University of Colorado
Denver, Colorado

University of Southern California
1988 2010 Gastroenterology Teaching Service
Highland General Hospital, Alameda County Medical Center
Oakland, California

1988 2010 Gastroenterology and Liver Teaching Service

1993 1999 Merced Community Hospital
Teaching Faculty
Family Medicine Program
Merced, California
Curriculum Vitae

TEACHING ACTIVITIES: Continued

1996 2010 Department of Medicine
OSCE 1995-2002
Medicine Teaching Service at CPMC
Housestaff Teaching Service at Highland Hospital
50 hours per year of teaching service (minimum)

Medicine Teaching Service
(a total of 88 hours of preceptorship)


2013 Consultant to Hepatitis Free San Diego Elective Course,
UCSD Skaggs School of Pharmacy and Pharmaceutical
Sciences, San Diego, California

2013 Developed and Funded New Graduate Training Program
Committee approval for Transplant Hepatology fellow for one
year, Dr. Heather Patton,
Department of Medicine, University of California, San Diego

June 2013 Review of Dr. Tami Daugherty for Clinical Associate Professor
Department of Medicine, Stanford University School of Medicine,
Division of Gastroenterology and Hepatology
Stanford, California

COMMITTEES

1989 1992 Member, Human Liver Cell Culture Facility
SRI International
Menlo Park, California

1989 1992 Member, Executive Committee
Pacific Transplant Institute

1990 1992 Executive Vice President, S.F. Bay Area Chapter
Curriculum Vitae

COMMITTEES: Continued

1990 1992 Chairman, Fundraising Committee
S.F. Bay Area Chapter

1991 1993 Member, Scientific Exhibits Committee
American Society for Gastrointestinal Endoscopy

1992 1993 Chairman, Nominating committee

1992 1993 Chairman, Public Education Committee

1993 Member, Committee for Test Question Development
American Board of Internal Medicine

1993 1996 Chairman, Medical Advisory Committee

1994 1997 Member, Committee on Liver and Intra-abdominal Organ
Transplantation

1996 Member, Abstract Review Committee

1997 1998 Member, Hepatitis Task Force
State of California Public Awareness and Department of
Corrections, under direction of Senator Polanco

1997 2001 Member, Clinical Research Committee
American Association for the Study of Liver Diseases

1999 Secretary
Hepatitis Resource Network

1999 2000 Chairman, Search Committee
California Pacific Medical Center Pathologist
San Francisco, CA

Curriculum Vitae


1999 2013 Member, Governing Council
Abstract Reviewer
American Association for the Study of Liver Diseases (AASLD)

1999 2001 Co-Chair, Membership Committee
American Society of Transplantation

2001 2002 Medical Adivsory Committee

2001 2002 Member, HCV Advocate Medical Writers Circle

2002 2004 Member, Abstract Review Committee
AASLD

2003 Chair
AASLD Topic Forum

2003 Faculty Member
AASLD Expert Consensus Conference

2003 Task Force Member
Santa Barbara County HCV Strategic Plan

2003 2006 Member, Liver and Intestinal Transplantation Committee
Organ Procurement and Transplantation Network (OPTN)/UNOS

2004 Member, Health Liver Alert Screening Committee

2004 Expert Council Member
Advancing Clinical Treatment of Hepatitis B Virus (ACT-HBV) Ini-
tiative

2004 2006 Member, Fund Development Committee
AASLD

2005 2007 Member, Public Policy Committee
AASLD

2004 2010 Member, Research Development Committee

2006 Present Member, Scientific Committee
Hep Dart Conference

Curriculum Vitae


1994 2007 Director, Department of Transplantation
Serum and Tissue Bank

1995 2007 Liver Center Member

1996 1998 Member, National Scientific Review Committee

1997 2000 Member, Membership Committee

1997 2003 Medical Review Subcommittee

1997 Member, Southern China Hepatitis Study Group
Guangzhou, China and Hong Kong

1998 2010 Member, Committee on Information Technology

2004 2005 Member, Hepatitis Plan Workgroup
State of Nevada

2007 Member, Fund Raising Study Task Force
AASLD

2007 Abstract Reviewer
American Transplant Congress

2007 2008 Member, Organizing Committee
Hong Kong-Shanghai International Liver Congress

2007 2010 San Francisco Hep B Free Campaign

2008 2010 Board Member, American Liver Foundation, San Francisco
Chapter

2008 2010 Advisor, LASH
Local Area Support for Hepatitis, Inc. (L.A.S.H.)

2008 Present Board Member, FAIR Foundation

2008 Present Scientific Advisory Committee, Global Antiviral Journal

Curriculum Vitae


2009 Program of comprehensive research actions: Hepatocellular car-
cinoma. French National Cancer Institute. Grant Review. 2009

2009 2010 Member at large, Nominating Committee
American Society of Transplantation (AST)

2009 Present Board Member
Hepatitis C Oversight Partnership (HepCop)

2009 Present Group Membership, AASLD
Special Interest Group on Hepatitis B (SIG)

2010 Present Scientific Board Member
Asian Pacific Association for the Study of Liver Disease (APASL)

2010 Abstract Reviewer
Asian Pacific Association for the Study of Liver Disease
(ASPASL), Beijing, China

2009 2013 Co-Chair of and Memberof Steering Committee
AASLD Hepatitis B Special Interest Group (SIG)

2010 Nomination Committee
San Francisco Medical Society

2010 Present Member, Hepatitis D International Network

2011 Present LI-RADS
(Liver Imaging Reporting and Data System)

2011 Abstract review panel: AASLD Fall meeting

2011 Present San Diego County Medical Society

2011 Present Member, Philippines Viral Hepatitis Project

2012 2013 Graduate Medical Education Enrollment Committee, Transplant
Hepatology Program University of California, San Diego.

2012 Present Member, International Coalition of Hepatology Educators

Curriculum Vitae


2012 Abstract Review Committee, American Association for the Study
of Liver Disease

2012 2013 Vice President, Steering committee of the National Viral Hepatitis
Round Table

2012 2015 Member, National Viral Hepatitis Round Table

2012 Present Member, Coalition to Eradicate Viral Hepatitis in Asia Pacific
(CEVHAP)

2011 & 2012 Faculty Interviewer Committee, Internal Medicine Residency Ap-
plicants, University of California, San Diego Department of Internal
Medicine.

2013 AASLD Abstract Review Committee

2013 Member, Editorial Advisory Board, Gastroenterology & Hepatology
Journal, Digestive Disease Week Breakfast, Orlando, FL.,
May 19, 2013.

2011 2013 EMR Provider Optimization Group (POG) EPIC Commitee

2013 Planning and Steering Committee Member for Imaging and
Surveillance, Liver Cancer Roundtable

2013 Executive Vice-Chair, National Viral Hepatitis Roundtable
Committee

2013 Present Founding Member, Liver Cancer Roundtable

2010 Co-Chair, the 2
nd
Biannual International Conference of Armenian
Hepatological Forum.

2013 Finance Review Committee, American Association for the Study
of Liver Diseases (AASLD), Annual Business Meeting

2014 Committee Member Nominee, Centers for Disease Control and
Prevention (CDC)/HRSA Advisory Committee on HIV, Viral
Hepatitis and STD Prevention and Treatment (CHACHSPT).

2014 Present Medical Director
Hepatitis B Foundation, Doylestown, PA

2014 Present Member
Global Hepatitis Community, www.hepcomm.com
Curriculum Vitae

BOARD ACTIVITIES

1999 2002 Member, Medical Advisory Board
Schering-Plough
InforMed Hepatology

1999 2002 Cheng Si Yaun, Hong Kong and Beijing, Research and Education
in Liver Disease, Board Member, Peoples Republic of China

2001 2003 Member, Data Safety Monitoring Board
Department of Health and Human Services, National Institutes of
Health Civacir HCV immunoglobulin protocol

2002 2010 Chair, U.S. Hepatitis B Advisory Board
Bristol-Meyers Squibb Corporation

2002 2006 At-large Member, Region 5
Organ Allocation Listing Committee
Regional Review Board
United Network for Organ Sharing (UNOS)

2003 2004 Member, Data Safety Monitoring Board
Civicir Research protocol to prevent recurrent HCV after liver
transplantation

1999 Present Board Member, Hepatitis C Caring Ambassadors

2007 Editorial Board, Antiviral Therapy Manuscript Central

2003 2006 Member, Advisory Board
Liver Institute for Education and Research (L.I.F.E.R.) Foundation

2004 Present Member, Editorial Board
Liver Transplantation

2005 Present Member, Editorial Advisory Board
Gastroenterology & Hepatology

2007 Present Hepatitis B Foundation Medical and Scientific Advisory

2009 Present Member, Board of Directors
HepaHope

2009 Member, International Advisory Board
Egyptian Society of Liver Cancer (ESLC)

2011 Member, Advisory Board, Pharmasset
Curriculum Vitae

BOARD ACTIVITIES: Continued

1992 Member, Academic Review Board
University of Florida
Gainesville, Florida

1992 1994 Member, Advisory Board
Hepatitis B Demonstration Project
City of San Francisco, Children's Immunization

1999 2002 Medical Director, Board of Directors
HCV Global Foundation

1999 2000 Editorial Board
The Practical Hepatitis Newsletter (PHN)

2011 Present Member, Philippines Viral Hepatitis Project

2011 Southern Nevada Health District (SNHD)
21
st
Holoaulea Festival (Pure Aloha Festival). (September 2011)
hosted by Las Vegas Hawaiian Civic Club Leadership

2012 Present Member, Liver Imaging Radiology Committee (LI-RADS)
University of California, San Diego.

2012 Present Member, Abstract Review Committee
American Transplant Congress (ATC), Review Program Live.

2012 At Large, Board Nominations
Nominee, American Association for the Study of Liver Diseases,
Governing Board, May 2012.

2013 At Large, Nominee, American Association for the Study of Liver
Diseases, Governing Board, and Treasurer, May 2013.

2013 Present National Hepatitis B Task Force, Advisory Board.

2013 Present Advisory Board Member
North American Journal of Medicine and Science (NAJMS).

2013 Present Member, Gastroenterology & Hepatology Editorial Advisory Board.

2013 Present Advisor, National Viral Hepatitis Task Force (NVHTF)

2013 Present Advisor, Viral Hepatitis Foundation (VHF)

2013 Present Advisor, Hepatology Society of the Philippines

Curriculum Vitae

BOARD ACTIVITIES: Continued

2013 Advisor, Abstract Review Committee, American Association for
the Study of Liver Disease Annual Conference Committee, Wash-
ington, D.C., November 1-5, 2013

2013 Advisory Board Member, Tan Tao School of Medicine, Ho Chi
Minh City, Vietnam

2013 Academic Peer Review Surakit Pungpapong, M.D., Associate
Professor of Medicine, College of Medicine, Mayo Clinic, October
8, 2013.

2014 2015 Member, Drug Safety Monitoring Board, Isis Pharmaceuticals
HBV Phase 2 Drug Development

Curriculum Vitae

EDITORIAL ACTIVITIES

Alimentary Pharmacology & Therapeutics
Archives of Medical Research
ASTP Abstract Review Committee
American Journal of Gastroenterology
Biodrugs
Diabetes Care
Digestive Diseases and Sciences
European Journal of Gastroenterology & Hepatology
Gastroenterology
Gastrointestinal Endoscopy
Gut
Hepatology
Journal of Clinical Investigation
Journal of Gastrointestinal Endoscopy
Journal of Hepatology
Journal of Infectious Disease
Liver Transplantation and Surgery
Liver International
Mayo Clinic Proceedings
Obstetrics and Gynecology
Transplantation Proceedings
Transplantation
Journal of AIDS
Section Editor, Current Hepatitis Reports, Vol. 1, No. 1, November 2007
Peer View/in Focus
Gastroenterology Clinics of North America
Journal of Virology Review 2005 Edition
European Journal of Gastroenterology & Hepatology

Associate Editor:
Chinese Hepatology 2005

Thesis Advisor: PhD in Psychology
Louise I. Bertman, 1999
Compliance, noncompliance and comparative MMPI-2 profiles of alcohol-dependent and
non-alcohol-dependent patients evaluated for orthotopic liver transplantation

Curriculum Vitae

MENTEE LIST

NAME ETHNICITY MENTOR RELATIONSHIP POSITION NOW
(Dates, How mentored)

Debbie Hana-Yi Korean
2008-2010 research
associate
NYU Residency
Michael Mangahas Filipino
2008-2010 research
associate
Med student; UCSF/UC
Berkeley
Sumbella F. Baqai,
MD
Pakistani
2008-2010 research
associate
Resident and Chief
Resident
Department of Internal
Medicine; Alameda
County Medical Center,
Oakland, CA
Javaheri Shahram Persian 1999-2000: GI Fellow Fellowship mentor
Aris Mendiola Pilipino 2000-2001: GI Fellow Fellowship mentor
Sheila Savur Indonesian 2001-2001: GI Fellow Fellowship mentor
Tammy Daugherty Caucasian 2000-2003: GI Fellow Fellowship mentor
Linda Nguyen Vietnamese 2000-2003: GI Fellow Fellowship mentor
Daniel Rengstorff Caucasian 2001-2004: GI Fellow Fellowship mentor
Ann Chen Chinese 2003-2004: GI Fellow Fellowship mentor
Christine Pizzute Caucasian 2004-2005: GI Fellow Fellowship mentor
Jessie Liu Chinese 2005-2006: GI Fellow Fellowship mentor
Katerina Shetler Russian/Ukrainian 2005-2006: GI Fellow Fellowship mentor
Mimi Lin Chinese 2006-2007: GI Fellow Fellowship mentor
Liz Clark Chinese/Hawaiian 2007-2008: GI Fellow Fellowship mentor
Michele Tana Chinese 2008-2009: GI Fellow Fellowship mentor
Cathy Cabansag Filapina 2008-2009: GI Fellow Fellowship mentor
Edward Holt Caucasian 2009-2010: GI Fellow Fellowship mentor
Curriculum Vitae

MENTEE LIST: Continued


Irene Vodkin Caucasian
2007-2008: Preceptor for
students Longitudinal
Clinical Experience (LCE)
UCSF Med Student
Iris Ma Chinese
UCSF Med Student
Arlene Vazquez Hispanic
UCSF Med Student
Patricia Zheng Chinese
UCSF Med Student
Steve Kane Caucasian 2010-2013
Premed student,
research associate
Margaret Clark Caucasian 2010-2013
Premed student,
research associate

Erica Boettcher Caucasian 2010 2013 GI Fellow
Brigid Boland Caucasian 2010 2013 GI Fellow
Imad Elkhatib Middle Eastern 2010 2013 GI Fellow
Wilson Kwong Asian 2011 2013 GI Fellow
Michael McTigue Caucasian 2011 2013 GI Fellow
Mazen Nourredin Caucasian 2010 2013 GI Fellow
Suresh Pola Asian Indian 2010 2013 GI Fellow
Ashish Shah Asian Indian 2011 2013 GI Fellow
Amir Zarrinpar Persian 2011 2013 GI Fellow
Ingrid Gonzalez Hispanic 2011 2013 GI Fellow
Thuy Anh Le Asian 2010 2013 GI Fellow
Julio Guttierrez Hispanic 2010 2013 GI Fellow
Fred Park Asian 2011 2013 GI Fellow
Toritsesan Boyo
(Tosan)
Nigerian 2011-2013 Business Resident
Curriculum Vitae

MENTEE LIST: Continued


Lilly Nguyen Vietnamese 2013 2013 Pharmacy Student
Thuy Nguyen Vietnamese 2013 Pharmacy Student
Xuan Phan Vietnamese 2013 Pharmacy Student
Laura Stinton Caucasian June 2013 Fellowship mentor

CLINICAL EXAM SESSIONS

Participant / Proctor, GI Focused clinical exam session, UCSD, November 2011
Participant, Clinical Exam Sessions, University of California, San Diego School of Internal
Medicine, November 21, 2011.
Curriculum Vitae
PUBLICATIONS: PEER REVIEW ORIGINAL PUBLICATIONS

1979 1994

1. Stella VJ, Gish RG. Ionization kinetics of the carbon acid phenindione. J Pharm Sci.
August 1979; 68(8):1042-1047.
2. Stella VJ, Gish RG. Kinetics and mechanism of ionization of the carbon acids 4-
substituted 2-phenyl-1, 3-indanediones. J Pharm Sci. August 1979; 68(8):1047-1049.
3. Gish RG, Garcia C, Reedy T, Kaplowitz N, Langer GA. Calcium compartmentation and
exchange rates in primary hepatocyte culture. Anal Biochem. May 1990; 187(1):187-
196.
4. Zeldis JB, Depner TA, Kuramoto RK, Gish RG, Holland PV. The prevalence of hepatitis
C virus antibodies among hemodialysis patients. Ann Intern Med. Jun 1990;112(12):958-
960.
5. Linton MF, Gish RG, Hubl ST, Butler E, Esquivel CO, Boyles JK, Wardell MR, Young
SG. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J
Clin Invest. Jul 1991;88(1):270-281.
6. Nakazato P, Cox K, Concepcion W, Gish RG, Berquist W, Imperial J, Esquivel C. Early
experience with FK506 induction immunosuppression suggestion for using oral FK506.
Transplant Proc. Dec 1991;23(6):3019-3020.
7. Gish RG, Warmerdam M, Zeldis J, Keeffe EB, Nakazato P, Lim J, Cox K, Kuramoto IK,
Fry KE, Yarbough P, Moeckli R, Yun-cho K, Reyes G. Variation in antibody reactivity to
the hepatitis C virus by comparative immunoscreening and enzyme immunoassay. Viral
Immunology. Spring 1993;6(1):49-54.
8. Gish RG, Lee AH, Keeffe EB, Rome H, Concepcion W, Esquivel CO. Liver transplanta-
tion for patients with alcoholism and end-stage liver disease. Am J Gastroenterol. Sep
1993;88(9):1337-1342.
9. Gonzalez-Peralta RP, Fang JW, Davis GL, Gish RG, Tsukiyama-Kohara K, Kohara M,
Mondelli MU, Lesniewski R, Phillips MI, Mizokami M, et al. Optimization for the detection
of viral hepatitis C (HCV) antigens in liver. J Hepatology. Jan 1994;20(1):143-147.
10. Lang T, Berquist W, Rich E, Cox K, De Vries P, Cahill J, Baker E, Gish R. Treatment of
recurrent pancreatitis by endoscopic drainage of a duodenal duplication. J Pediatr Gas-
troenterol Nutr. May 1994;18(4):494-496.
1995

11. Martinez OM, Villanueva JC, Lawrence-Miyasaki L, Quinn MB, Gish RG, Cox K, So S,
Esquivel CO, Krams SM. Molecular markers of Epstein-Barr virus infection in the circula-
tion of transplant recipients. Transplant Proc. Feb 1995;27(1):1211-1212.
12. Gish RG, Krams S, Martinez OM. Interleukin 12 (IL-12): A possible cytotoxic T-
lymphocyte (CTL) differentiation factor in allograft recipients. Transplant Proceed. Feb
1995;27(1):459-460.

Curriculum Vitae

PUBLICATIONS PEER REVIEW ORIGINAL PUBLICATIONS: Continued

13. Lau JY, Mizokami M, Kolberg JA, Davis GL, Prescott LE, Ohno T, Perrill RP, Lindsay
KL, Gish RG, Qian KP, Kohara M, Simmonds P, and Urdea MS. Application of six hepa-
titis C virus genotyping systems to sera from chronic hepatitis C patients in the United
States. J Inf Dis. Feb 1995;171(2):281-289.
14. Gish RG, Keeffe EB, Lim J, Brooks LJ, Esquivel CO. Survival after liver transplantation
for chronic hepatitis B using reduced immunosuppression. J Hepatol. Mar
1995;22(3):257-262.
15. Gonzalez-Peralta RP, Fang JW, Davis GL, Gish RG, Kohara M, Mondelli MU, Urdea
MS, Mizokami M, Lau JY. Significance of hepatic expression of hepatitis C viral (HCV)
antigens in chronic hepatitis C. Dig Dis Sci. Dec 1995;40(12):2595-2601.
1996
16. Gish RG, Lau JY, Brooks L, Fang JW, Steady SL, Imperial JC, Garcia-Kennedy R,
Esquivel CO, Keeffe EB. Ganciclovir treatment of hepatitis B virus infection in liver
transplant recipients. Hepatology. Jan 1996;23(1):1-7.
17. Lau GK, Davis GL, Wu SP, Gish RG, Balart LA, Lau JY. Hepatic expression of hepatitis
C virus RNA in chronic hepatitis C: a study by in situ reverse-transcription polymerase
chain reaction. Hepatology. Jun 1996;23(6):1318-1323.
18. Cacciarelli T, Martinez OM, Gish RG, Villaneuva JC, Krams SM. Immunoregulatory
cytokines in chronic hepatitis C virus infection: pre- and post-treatment with interferon al-
fa. Hepatology. Jul 1996;24(1):6-9.
19. Lau JY, Davis GL, Prescott LE, Maertens G, Lindsay KL, Qian K, Mizokami M, Sim-
monds P; Hepatitis Interventional Therapy Group (Gish RG). Distribution of hepatitis C
virus genotypes determined by line probe assay in patients with chronic hepatitis C seen
at tertiary referral centers in the United States. Ann Intern Med. May 1996;124(10):868-
876.
1997
20. Gish RG, Qian KP, Quan S, Xu YL, Pike I, Polito A, DiNello R, Lau JY. Concordance
between hepatitis C virus serotyping assays. J Viral Hepat. 1997;4(6):421-422.
21. Ku NO, Wright TL, Terrault NA, Gish RG, Omary MB. Mutation of human keratin 18 in
association with cryptogenic cirrhosis. J Clin Invest. Jan 1997;99(1):19-23.
22. Gish RG. Hepatitis C virus: Seven years old. Viral Hepatitis Reviews. 1997;3(1):17-
37.Gish RG, Lau JYN. Hepatitis C Virus: Eight Years Old. Viral Hepatitis Reviews. Mar
1997;3(1):17-37.
23. Gish RG and Olden K. Alcohol and liver disease should transplantation be of-
fered? Practical Gastroenterology. December 1997.
Curriculum Vitae

PUBLICATIONS PEER REVIEW ORIGINAL PUBLICATIONS: Continued

24. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish RG, Keeffe EB, Kneteman NM, Lake
JR, Martin P, McDiarmid SV, Rakela J, Shiffman ML, So SK, Wiesner RH. Minimal crite-
ria for placement of adults on the liver transplant waiting list: a report of a national con-
ference organized by the American Society of Transplant Physicians and the American
Association for the Study of Liver Diseases. Liver Transpl Surg. Nov 1997;3(6):628-637.
25. Gish RG. Review of computer program "A simplified approach to the management of
patients with chronic hepatitis B and C infections." Gastroenterology. Dec1997.
1998

26. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS. Hepatitis B
virus S mutants in liver transplant recipients who were reinfected despite hepatitis B im-
mune globulin prophylaxis. Hepatology. Jan 1998;27(1):213-222.
27. Xiang J, Klinzman D, McLinden J, Schmidt WN, LaBrecque DR, Gish RG, Stapleton JT.
Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid
and expression of sequences upstream of the E1 protein. J Virol. Apr 1998;72(4):2738-
2744.
28. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keefe EB, Kneteman NM, Lake
JR, Martin P, Rakela J, Shiffman ML, So S, Wiesner RH. Minimal criteria for placement
of adults on the liver transplant waiting list: a report of a national conference organized
by the American Society of Transplant Physicians and the American Association for the
Study of Liver Diseases. Transplantation. Oct 1998;66(7):956-962.
29. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML,
Zeuzem S, Craxi A, Ling MH, Albrecht J; International Hepatitis Interventional Therapy
Group (Gish RG). Interferon alfa-2b alone or in combination with ribavirin for the treat-
ment of relapse of chronic hepatitis C. N Engl J Med. Nov 1998;339(21):1493-1499
30. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman
ZD, Ling MH, Cort S, Albrecht JK; Hepatitis Interventional Therapy Group (Gish RG). In-
terferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hep-
atitis C. N Engl J Med. Nov 1998;339(21):1485-1492.
31. Gish RG. Longer, Longer, Longer. Advances in Gastroenterology, Hepatology and
Clinical Nutrition. 1998;3:83-85.
1999

32. Poordad FF, Gish RG. Evolving therapies for the treatment of viral hepatitis. Expert
Opinion on Emerging Drugs. Jan 1999;4(1):15-34.
33. Fischer L, Sterneck M, Muller-Ruchholtz C, Gish R, Will H. Hepatitis B virus variants
associated with clinically severe recurrence after liver transplantation. Transplant Proc.
Feb-Mar 1999;31(1-2):492-493.
Curriculum Vitae

PUBLICATIONS: PEER REVIEW ORIGINAL PUBLICATIONS: Continued

34. Gish RG, Qian K, Brooks L, Leung J, Xu Y, Pike I, Lau JY. Characterization of anti-
hepatitis C virus-positive sera not genotyped by restriction fragment length polymor-
phism or serology. J Gastroenterol Hepatol. Apr 1999;14(4):339-344.
35. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, Caldwell S, Schiff E,
Gish R, Villeneuve JP, Farr G, Anschuetz G, Crowther L, Brown N. Multicenter study of
lamivudine therapy for hepatitis B after liver transplantation, Lamivudine Transplant
Group. Hepatology. May 1999;29(5):1581-1586.
36. Elkayam O, Hassoba HM, Ferrell LD, Garcia-Kennedy R, Gish RG, Wright TL, Laffler T,
Traylor D, Hunt G, Rosenthal P. GB virus C (GBV-C/HGV) and E2 antibodies in children
preliver and postliver transplant. Pediatr Res. Jun 1999;45(6):795-798.
37. Tung BY, Farrell FJ, McCashland TM, Gish RG, Bacon BR, Keeffe EB, Kowdley KV.
Long-term follow-up after liver transplantation in patients with hepatic iron overload. Liver
Transpl Surg. Sep 1999;5(5):369-374.
38. Ware JE Jr., Bayliss MS, Mannocchia M, Davis GL; The Interventional Therapy Group
(Gish RG). Health-related quality of life in chronic hepatitis C: impact of disease and
treatment response. Hepatology. Aug 1999;30(2):550-555.
39. Nalbandian G, Van de Water J, Gish R, Manns M, Coppel RL, Rudich SM, Prindiville T,
Gershwin ME. Is there a serological difference between men and women with primary
biliary cirrhosis? Am J Gastroenterol. Sep 1999;94(9):2482-2486.
40. Tanaka A, Prindiville TP, Gish R, Solnick JV, Coppel RL, Keeffe EB, Ansari A, Gershwin
ME. Are infectious agents involved in primary biliary cirrhosis? A PCR approach. J
Hepatol. Oct 1999;31(4):664-671.
41. Tanaka A, Lindor K, Gish R, Batts K, Shiratori Y, Omata M, Omata M, Nelson JL, Ansari
A, Coppel R, Newsome M, Gershwin ME. Fetal microchimerism alone does not contrib-
ute to the induction of primary biliary cirrhosis. Hepatology. Oct 1999;30(4):833-38.
42. Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R, Gish
RG. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis
against hepatitis B recurrence after liver transplantation. Liver Transpl and Surg. Nov
1999;5(6):491-496.
43. Gish, RG, Wakil AE. Combination interferon-alfa 2B plus ribavirin for treatment of
chronic hepatitis C. Current Practice of Medicine. 1999;2(4-10).
2000

44. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T,
Yao R, Albrecht; International Hepatitis Interventional Therapy Group (Gish RG). The
Impact of Interferon Plus Ribavirin on Response to Therapy in Black Patients With
Chronic Hepatitis C. Gastroenterology. Nov 2000;119(5):1317-1323.

Curriculum Vitae


2001

45. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish RG, Martin P, Dienstag J, Adams
P, Dickson R, Anschuetz G, Bell S, Condreay L, Brown N; Lamivudine North American
Transplant Group. A multicenter United States-Canadian trial to assess lamivudine
monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology.
Feb 2001;33(2):424-432.
46. Ku NO, Gish R, Omary M, Wright TL. Keratin 8 mutations in patients with cryptogenic
liver disease. N Engl J Med. May 2001;344(21):1580-1587.
47. Gish RG, Lee A, Brooks L, Leung J, Lau JY, Moore DH. Long-term follow-up of patients
diagnosed with alcohol dependence or alcohol abuse who were evaluated for liver
transplantation. Liver Transpl. Jul 2001;7(7):581-87.
48. Hadlock KG, Gish RG, Rowe J, Rajyaguru SS, Newsom M, Warford A, Foung SK.
Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second
envelope glycoprotein (E2). J Med Virol. Sep 2001;65(1):23-29.
49. Kato H, Orito E, Sugauchi F, Ueda R, Gish RG, Usuada S, Miyakawa Y, Mizokami M.
Determination of hepatitis B genotype by polymerase chain reaction with hemi-nested
primers. J Med Virol Methods. Nov 2001;98(2):153-159.
2002

50. Kato H, Orito E, Gish RG, Bzowej N, Newsom M, Sugauchi F, Suzuki S, Ueda R,
Miyakawa Y, Mizokami M. Hepatitis B e antigen in sera from individuals infected with
hepatitis B virus of genotype G. Hepatology. Apr 2002;35(4):922-9.
51. Kato H, Orito E, Gish RG, et al. Characteristics of hepatitis B virus isolates of genotype
G and their phylogenetic differences from the other six genotypes (A through F). Journal
of Virology. Jun 2002;76(12):6313-6137.
52. Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH,
Delehanty J, Rigney A, Mondou E, Snow A, Rousseau F. Dose range study of pharma-
cokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis
B virus infection. Antimicrob Agents Chemother. Jun 2002;46(6):1734-40.
53. Shakil AO, McGuire B, Crippin J, Teperman L, Demetris AJ, Conjeevaram H, Gish R,
Kwo P, Balan V, Wright TL, Brass C, Rakela J. A pilot study of interferon alfa and ribavi-
rin combination in liver transplant recipients with recurrent hepatitis C. Hepatology. Nov
2002;36(5):1253-8.
54. Mao TK, Kimura Y, Kenny TP, Branchi A, Gish RG, Van de Water J, Kung HJ, Friedman
SL, Gershwin ME. Elevated expression of tyrosine kinase DDR2 in primary biliary cirrho-
sis. Autoimmunity. Dec 2002;35(8):521-529.
55. Kato H, Orito E, Sugauchi F, Ueda R, Koshizaka T, Yanaka S, Gish RG, Mizokami M.
New hepatitis B virus genotyping system that allows for identification of mixed genotype
infection. Submitted 2002.
Curriculum Vitae


2003

56. Hann HW, Fontana RJ, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anschuetz G,
Gardner SD, Brown N, Griffiths D; United States Lamivudine Compassionate Use Study
Group (Gish RG). A United States compassionate use study of lamivudine treatment in
nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis.
Liver Transpl. Jan 2003;9(1):49-56.
57. Marcellin P, Chang TT, Lim SG, Tong M, Sievert W, Shiffman, M, Jeffers L, Goodman Z,
Wulfsohn MS, Xion S, Fry J, Brosgart C, for the Adefovir Dipivoxil 437 Study Group
(Gish RG). Adefovir Dipivoxil for the treatment of hepatitis B e antigen-positive chronic
hepatitis B. N Engl J Med. Feb 2003;348(9):808-816.
58. Zarski JP, Mc Hutchison J, Bronowicki JP, Sturm N, Garcia-Kennedy R, Hodaj E, Truta
B, Wright T, Gish R. Rate of natural disease progression in patients with chronic hepati-
tis C. J Hepatol. Mar 2003;38(3):307-314.
59. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A,
Lai CL, Gish RG, Ueda R, Miyakawa Y, Mizokami M. Epidemiological and virological
characteristics of hepatitis B virus genotype B having the recombination with genotype
C. Gastroenterology. Apr 2003;124(4):925-932.
60. Kato H, Orito E, Sugauchi F, Ueda R, Koshizaka T, Yanaka S, Gish RG, Kurbanov F,
Ruzibakiev R, Kramvis A, Kew MC, Ahmad N, Khan M, Usuda S, Miyakawa Y, Mizokami
M. Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by
hybridization with type-specific probes immobilized on a solid-phase support. J Virol
Methods. Jun 2003;110(1):29-35.
61. Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, Alonzo J, Garcia-Kennedy
R, Rayon JM, Wright TL. A model to predict severe HCV-related disease following liver
transplantation. Hepatology. Jul 2003;38(1):34-41.
62. Westland C, Delaney W 4th, Yang H, Chen SS, Marcellin P, Hadziyannis S, Gish R, Fry
J, Brosgart C, Gibbs C, Miller M, Xiong S. Hepatitis B virus genotypes and virologic re-
sponse in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology. Jul
2003;125(1):107-116.
63. Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, Lok AS, Hussain
KB, Gish R, Van Thiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J,
Flamm S, Blei A, Befeler AS; Liver Cancer Network. Hepatitis C-related hepatocellular
carcinoma in the United States: influence of ethnic status. Am J Gastroenterol, Sep
2003;98(9):2060-2063.
64. Poordad F, Gish R, Wakil A, Garcia-Kennedy R, Martin P, Yao FY. De novo non-
alcoholic fatty liver disease following orthotopic liver transplantation. Am J Transplant.
Nov 2003;3(11):1413-1417.

Curriculum Vitae


2004

65. Sugauchi F, Kumada H, Acharya SA, Shrestha SM, Gamutan MT, Khan M, Gish RG,
Tanaka Y, Kato T, Orito E, Ueda R, Miyakawa Y, Mizokami M. Epidemiological and se-
quence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. J
Gen Virol. Apr 2004;85(Pt 4):811-820.
66. Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during
interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus
infection. J Viral Hepat. May 2004;11(3):243-250.
67. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T,
Younossi Z, Goon BL, Tang KL, Bowers PJ; Proactive Study Group (Gish RG). Epoetin
alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, ran-
domized controlled study. Gastroenterology. May 2004;126(5):1302-1311.
68. Kato H, Gish RG, Bzowej N, Newsom M, Sugauchi F, Tanaka Y, Kato T, Orito E, Usuda
S, Ueda R, Miyakawa Y, Mizokami M. Eight genotypes (A-H) of hepatitis B virus infect-
ing patients from San Francisco and their demographic, clinical, and virological charac-
teristics. J Med Virol. Aug 2004;73(4):516-21.
69. Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, Gordon SC, Wright HI,
Zweiban B, Podda M, Gershwin ME. Primary biliary cirrhosis in monozygotic and dizy-
gotic twins: genetics, epigenetics, and environment. Gastroenterology. Aug
2004;127(2):485-92.
70. Tanaka Y, Hasegawa I, Kato T, Orito E, Hirashima N, Acharya SK, Gish RG, Kramvis A,
Kew MC, Yoshihara N, Shrestha SM, Khan M, Miyakawa Y, Mizokami M. A case-control
study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and
Ae) and D. Hepatology. Sep 2004;40(3):747-55.
71. Jazayeri M, Basuni AA, Sran N, Gish R, Cooksley G, Locarnini S, Carman WF. HBV
core sequence: definition of genotype-specific variability and correlation with geograph-
ical origin. J Viral Hepat. Nov 2004;11(6):488-501.
2005
72. Aora S, Xu C, Teng A, Peterson J, Yeh LT, Gish R, Lau D, Rossi S, Lin CC. Ascending
multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects
with compensated hepatitis C infection. J Clin Pharmacol. Mar 2005;45(3):275-285.
73. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, Wakeford
C, Shaw A, Quinn J, Gish RG, Rousseau F. Severe hepatotoxicity associated with nevi-
rapine use in HIV-infected subjects. J Infect Dis. Mar 2005;191(6):825-829.

Curriculum Vitae


74. Savur S, Bonacini M, Bzowej N, Gish R, Wakil A, Osorio R. Erythropoietin is approved
for the treatment of anemia associated with renal failure, chemotherapy, preoperative
anemia, and human immunodeficiency virus disease.. Liver Transpl. Mar
2005;11(3):366.
75. Gish RG, Trinh H, Leung N, Chan FK, Fried MW, Wright TL, Wang C, Anderson J,
Mondou E, Snow A, Sorbel J, Rousseau F, Corey L. Safety and antiviral activity of
emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J
Hepatol. Jul 2005;43(1):60-66..
76. Kowdley KV, Brandhagen DJ, Gish RG, Bass NM, Weinstein J, Schilsky ML, Fontana
RJ, McCashland T, Cotler SJ, Bacon BR, Keeffe EB, Gordon F, Polissar N; National
Hemochromatosis Transplant Registry. Survival after liver transplantation in patients with
hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterolo-
gy. Aug 2005;129(2):494-503.
77. Terrault NA, Pawlotsky JM, McHutchison J, Anderson F, Krajden M, Gordon S, Zitron I,
Perrillo R, Gish R, Holodniy M, Friesenhahn M. Clinical utility of viral load measure-
ments in individuals with chronic hepatitis C infection on antiviral therapy. J Viral Hepat.
Sep 2005;12(5):465-472.
78. Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, Pastore G,
Bacon BR, Poynard T, Joshi S, Klesczewski KS, Thiry A, Rose RE, Colonno RJ, Hindes
RG; BEHoLD Study Group. A dose-ranging study of the efficacy and tolerability of
entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology. Oct
2005;129(4):1198-1209.
79. Kato H, Fujiwara K, Gish RG, Sakugawa H, Yoshizawa H, Sugauchi F, Orito E, Ueda R,
Tanaka Y, Kato T, Miyakawa Y, Mizokami M. Classifying genotype F of hepatitis B virus
into F1 and F2 subtypes. World J Gastroenterol. Oct 2005;11(40):6295-6304.
80. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, Kaplan MM,
Vierling JM; USA PBC Epidemiology Group (Gish RG). Risk factors and comorbidities in
primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology.
Nov 2005;42(5):1194-1202.
81. Colquhoun S, Gish R, Runyon B. MELD Exception Guidelines for Candidates with
Ascites. www.unos.org November 21, 2005.
82. Washburn K, Gish R, Kamath P. MELD Exception Guidelines for Candidates with
Budd-Chiari Syndrome. www.unos.org November 21, 2005.
83. Gores G, Gish R, Sudan D. MELD Exception Guidelines for Candidates with Cholangi-
ocarcinoma. www.unos.org November 21, 2005.
84. Horseln S, Sweet S, Gish R, Shepherd R. MELD Exception Guidelines for Candidates
with Cystic Fibrosis and Coexistent Chronic Liver Disease. www.unos.org November
21, 2005.
85. Ham J, Gish R, Mullen K. MELD Exception Guidelines for Candidates with Hepatic
Encephalopathy. www.unos.org November 21, 2005.
Curriculum Vitae


86. Pomfret E, Gish R, Brandhagen D. MELD Exception Guidelines for Candidates with
Familial Amyloidotic Polyneuropathy (FAP). www.unos.org November 21, 2005.
87. Mulligan DC, Gish RG, Krowka MJ. MELD Exception Guidelines for Candidates with
Hepato-pulmonary Syndrome. www.unos.org November 21, 2005.
88. Garcia-Tsao G, Gish RG, Punch J. MELD Exception Guidelines for Candidates with
Hereditary Hemorrhagic Telangiectasia. www.unos.org November 21, 2005
89. Horslen S, Gish RG, McDonald R. MELD Exception Guidelines for Candidates with
Primary Hyperoxaluria. www.unos.org November 21, 2005.
90. Arrazola L, Gish RG, Everson GT. MELD Exception Guidelines for Candidates with
Polycystic Liver Disease. www.unos.org November 21, 2005.
91. Mulligan DC, Gish R, Krowka MJ. MELD Exception Guidelines for Candidates with
Portopulmonary Hypertension. www.unos.org November 21, 2005.
92. Washburn WK, Gish R. MELD Exception Guidelines for Candidates with Severe
Pruritus. www.unos.org November 21, 2005.
93. Gores G, Gish R, Roshan Shrestha, MELD Exception Guidelines for Candidates with
Recurrent Bacterial Cholangitis associated with Structural Biliary
ease. www.unos.org November 21, 2005.
94. Sheiner P, Gish R, Sunyal A. MELD Exception Guidelines for Candidates with Portal
Hypertensive GI Bleeding. www.unos.org November 21, 2005.
95. Sheiner P, Gish R, Miller C. MELD Exception Guidelines for Candidates with Small for
Size Syndrome after Liver Transplantation. www.unos.org November 21, 2005.
96. Punch J, Gish R.MELD Exception Guidelines for Candidates with Uncommon Hepatic
Tumors. www.unos.org November 21, 2005.
97. McDiarmid S, Gish R, Horslen S. MELD Exception Guidelines for Candidates with
Unusual Metabolic Liver Diseases That Would be Cured by Liver.
tion. www.unos.org November 21, 2005.
2006

98. Ito K, Tanaka Y, Orito E, Sugiyama M, Fujiwara K, Sugauchi F, Kato T, Tokita H, Izumi
N, Kato M, Yuen MF, Lai CL, Gish RG, Ueda R, Mizokami M. T1653 mutation in the box
alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B
virus genotype C infection. Clin Infect Dis. Jan 2006;42(1):1-7. Epub 2005 Nov 29.
99. Perrillo RP, Gish RG, Peters M, Keeffe EB, Alberti A, Buti M, Cooksley WG, Fried MW,
Hadziyannis SJ, Liaw YF, Naoumov NV, Schiff ER, Thio CL, Tsai N, Schalm S. Chronic
hepatitis B: a critical appraisal of current approaches to therapy. Clin Gastroenterol
Hepatol. Feb 2006;4(2):233-248.

Curriculum Vitae


100. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH,
Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD
AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive
chronic hepatitis B. N Engl J Med. Mar 2006;354(10):1001-1010.
101. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber
R, Zink RC, Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group (Gish
RG). Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
N Engl J Med. Mar 2006;354(10):1011-1020.
102. Morice Y, Cantaloube JF, Beaucourt S, Barbotte L, De Gendt S, Goncales FL, Butter-
worth L, Cooksley G, Gish RG, Beaugrand M, Fay F, Fay O, Gonzalez JE, Martins RM,
Dhumeaux D, Vanderborght B, Stuyver L, Sablon E, de Lamballerie X, Pawlotsky JM.
Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. J Med Vi-
rol. Oct 2006;78(10):1296-1303.
103. Sugiyama M, Tanaka Y, Kato T, Orito E, Ito K, Acharya SK, Gish RG, Kramvis A,
Shimada T, Izumi N, Kaito M, Miyakawa Y, Mizokami M. Influence of hepatitis B virus
genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatol-
ogy. Oct 2006;44(4):915-924.
104. Arrazola L, Moonka D, Gish RG, Everson GT. Model for end-stage liver disease (MELD)
exception for polycystic liver disease. Liver Transpl 2006; 12 Suppl 3:S110-S111.
105. Biggins SW, Colquhoun S, Gish RG, Runyon BA. Model for end-stage liver disease
(MELD) exception for ascites. Liver Transpl 2006; 12 Suppl 3:S88-S90.
106. Freeman RB, Jr., Gish RG, Harper A, Davis GL, Vierling J, Lieblein L et al. Model for
end-stage liver disease (MELD) exception guidelines: Results and recommendations
from the MELD exception study group and conference (MESSAGE) for the approval of
patients who need liver transplantation with diseases not considered by the standard
MELD formula. Liver Transpl 2006; 12 Suppl 3:S128-S136.
107. Garcia-Tsao G, Gish RG, Punch J. Model for end-stage liver disease (MELD) exception
for hereditary hemorrhagic telangiectasia. Liver Transpl 2006; 12 Suppl 3:S108-S109.
108. Gores GJ, Gish RG, Shrestha R, Wiesner RH. Model for end-stage liver disease
(MELD) exception for bacterial cholangitis. Liver Transpl 2006; 12 Suppl 3:S91-S92.
109. Gores GJ, Gish RG, Sudan D, Rosen CB. Model for end-stage liver disease (MELD)
exception for cholangiocarcinoma or biliary dysplasia. Liver Transpl 2006; 12 Suppl
3:S95-S97.
110. Ham J, Gish RG, Mullen K. Model for end-stage liver disease (MELD) exception for
hepatic encephalopathy. Liver Transpl 2006; 12 Suppl 3:S102-S104.
111. Horslen S, Sweet S, Gish RG, Shepherd R. Model for end-stage liver disease (MELD)
exception for cystic fibrosis. Liver Transpl 2006; 12 Suppl 3:S98-S99.
112. Horslen S, Gish RG, McDonald R. Model for end-stage liver disease (MELD) exception
for primary hyperoxaluria. Liver Transpl 2006; 12 Suppl 3:S117-S118.
Curriculum Vitae


113. Krowka MJ, Fallon MB, Mulligan DC, Gish RG. Model for end-stage liver disease
(MELD) exception for portopulmonary hypertension. Liver Transpl 2006; 12 Suppl
3:S114-S116.
114. McDiarmid S, Gish RG, Horslen S, Mazariegos GV. Model for end-stage liver disease
(MELD) exception for unusual metabolic liver diseases. Liver Transpl 2006; 12 Suppl
3:S124-S127.
115. Pomfret E, Gish RG, Brandhagen D. Model for end-stage liver disease (MELD)
exception for familial amyloidotic polyneuropathy. Liver Transpl 2006; 12 Suppl 3:S100-
S101.
116. Punch J, Gish RG. Model for end-stage liver disease (MELD) exception for uncommon
hepatic tumors. Liver Transpl 2006; 12 Suppl 3:S122-S123.
117. Sheiner P, Gish RG, Sanyal A. Model for end-stage liver disease (MELD) exception for
portal hypertensive gastrointestinal bleeding. Liver Transpl 2006; 12 Suppl 3:S112-S113.
118. Sheiner P, Belghiti J, Gish RG, Miller C. Model for end-stage liver disease (MELD)
exception small-for-size syndrome. Liver Transpl 2006; 12 Suppl 3:S120-S121.
119. Washburn WK, Gish RG, Kamath PS. Model for end-stage liver disease (MELD)
exception for Budd-Chiari syndrome. Liver Transpl 2006; 12 Suppl 3:S93-S94.
120. Washburn WK, Gish RG. Model for end-stage liver disease (MELD) exception for
severe pruritus. Liver Transpl 2006; 12 Suppl 3:S119.
121. Wiesner R, Lake JR, Freeman RB, Gish RG. Model for end-stage liver disease (MELD)
exception guidelines. Liver Transpl 2006; 12 Suppl 3:S85-S87.
2007

122. Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV,
Gish RG. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in
HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2007;25(11):963-977.
123. Pockros PJ, Jeffers L, Afdhal N, Goodman ZD, Nelson D, Gish RG, Reddy KR,
Reindollar R, Rodriguez-Torres M, Sullivan S, Blatt LM, Faris-Young S. Final results of a
double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in
chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology. Mar
2007;45(3):569-578.
124. Gish RG. Do we need to MEND the MELD? Liver Transpl. Apr 2007;13(4):486-487.
125. Gish RG, Arora S, Rajender Reddy K, Nelson DR, O'Brien C, Xu Y, Murphy B.
Virological response and safety outcomes in therapy-naive patients treated for chronic
hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a
randomized, phase 2 study. J Hepatol. Jul 2007;47(1):51-59. Epub 2007 Mar 12.

Curriculum Vitae


126. Inductivo-Yu I, Adams A, Gish RG, Wakil A, Bzowej NH, Frederick RT, Bonacini M.
Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to
standard immunosuppressive therapy. Clin Gastroenterol Hepatol. Jul 2007;5(7):799-
802.
127. Veenstra DL, Spackman DE, Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral
drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-
effectiveness analysis. Aliment Pharmacol Ther. 2008; Epub 2007 Mar 27.
128. Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J,
Gallo J, Kennealey GT. Phase III randomized controlled trial comparing the survival of
patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubi-
cin. J Clin Oncol. Jul 2007;25(21):3069-3075.
129. Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Ma-
khviladze M, Huyghe M, Hecht D, Oltersdorf T, Shapiro DA. Oral IDN-6556, an antiapop-
totic caspase inhibitor, may lower aminotransferase activity in patients with chronic
hepatitis C. Hepatology. Aug 2007;46(2):324-329.
130. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee
SD, Harris M, Yang J, Colonno R, Brett-Smith H. Entecavir therapy for up to 96 weeks in
patients with HBeAg-positive chronic hepatitis B. Gastroenterology. Nov
2007;133(5):1437-1444. Epub 2007 Aug 14.
131. Carr C, Blaine Hollinger F, Yoffe B, Wakil A, Phillips J, Bzowej N, Leung J, Mirro K,
Poordad F, Moore DH, Gish RG. Efficacy of interferon alpha-2b induction therapy before
retreatment for chronic hepatitis C. Liver Int. Oct 2007;27(8):1111-1118.
132. Ko C, Siddaiah N, Berger J, Gish R, Brandhagen D, Sterling RK, Cotler SJ, Fontana RJ,
McCashland TM, Han SH, Gordon FD, Schilsky ML, Kowdley KV. Prevalence of hepatic
iron overload and association with hepatocellular cancer in end-stage liver disease: re-
sults from the National Hemochromatosis Transplant Registry. Liver Int. Dec
2007;27(10):1394-1401.
133. Gish RG, Lau DT, Schmid P, Perrillo R. A pilot study of extended duration peginterferon
alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastro-
enterol. Dec 2007;102(12):2718-23. Epub 2007 Jul 27.
134. Selmi C, Gershwin ME, Lindor KD, Worman HJ, Gold EB, Watnik M, Utts J, Invernizzi P,
Kaplan MM, Vierling JM, Bowlus CL, Silveira MG, Bossi I; USA PBC Epidemiology
Group (Gish RG). Quality of life and everyday activities in patients with primary biliary
cirrhosis. Hepatology. 2007 Dec;46(6):1836-43.
135. Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, Bzowej N, Briggs AH.
The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities
from Infected and Uninfected Persons. Value Health. 2007; Epub 2007 Dec 17.

Curriculum Vitae


2008

136. Gish RG, Jacobson I, Pockros P. Improving HBV Treatment: Early Screening and
Sustained Control for Improved Outcomes. Clinical Roundtable Monograph. Gastroen-
terology and Hepatology. January 2008.
137. Gish RG. Comment: Entecavir therapy provides long-term benefit for chronic hepatitis B.
Contemporary Dental Assisting. Reuters Health, 2008.
138. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC; Public Policy Committee of the
American Association for the Study of Liver Disease (Gish RG). Serum activity of ala-
nine aminotransferase (ALT) as an indicator of health and disease. Hepatology. Apr
2008;47(4):1363-1370.
139. Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, Bzowej N, Briggs AH.
The impact of chronic hepatitis B on quality of life: a multinational study of utilities from
infected and uninfected persons. Value Health. May-Jun 2008;11(3):527-38.
140. Veenstra DL, Spackman DE, Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral
effectiveness analysis. Aliment Pharmacol Ther. Jun 2008;27(12):1240-1252.
2009

141. Xu L, Guo L, Shen Z, Loss G, Gish R, Wasilenko S, Mason AL. Duplication of MER115
on chromosome 4 in patients with primary biliary cirrhosis. Liver Int. Mar
2009;29(3):375-383.
142. Gish RG, Gordon SC, Nelson D, Rustgi V, Rios I. A randomized controlled trial of
thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carci-
noma. Hepatol Int. Sept 2009; 3(3):480-489.
143. Chang TT, Chao YC, Gorbakov VV, Han KH, Gish RG, de Man R, Cheinquer H,
Bessone F, Brett-Smith H, Tamez R. Results of up to 2 years of entecavir vs lamivudine
therapy in nucleoside-nave HBeAg-positive patients with chronic hepatitis B. J Viral
Hepat. Nov 2009;16(11):784-789.
144. Marcellin P, Gish RG, Gitlin N, Heise J, Halliman DG, Chun E et al. Safety and efficacy
of viramidine versus ribavirin in ViSER2: Randomized, double-blind study in therapy-
naive hepatitis C patients. J Hepatol 2009.
2010

145. Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H,
Tamez R. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucle-
oside-nave HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. Jan
2010;17(1):16-22.

Curriculum Vitae


146. Marcellin P, Gish RG, Gitlin N, Heise J, Halliman DG, Chun E, Rodriguez-Torees M.
Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind
study in therapy-naive hepatitis C patients. J Hepatol. Jan 2010;52(1):32-38.
147. Gish RG, Cooper SL. Hepatitis B in the greater San Francisco bay area: an integrated
program to respond to a diverse local epidemic. Aug. 2010: J Viral Hep.
148. Gish R, Novel changes in glycosylation of serum Apo-J in patients with hepatocellular
carcinoma, Cancer Epidemiology, Biomarkers & Prevention, Dec 2010

2011

149. Gish RG, Satishchandran C, Young M, Pachuk C. RNA Interference and its Potential
Applications to Chronic HBV Treatment: Results Of A Phase 1 Safety And Tolerability
Study. Antivir Ther. 2011;16(4):547-554.
150. Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. Development of Hepatocellular
Carcinoma in Autoimmune Hepatitis Patients. A Case Series. Dig Dis Sci. 2011
Feb:56(2): 578-585.

151. Wong RJ, Gish R, Schilsky M, Frenette C. A Clinical Assessment of Wilson Disease in
Patients with Concurrent Liver Disease. J Clin Gastroenterol. 2011 Mar;45(3):267-273.

152. Frei R, Gish R, Boceprevir Studies Suggest Addition to Hepatitis-C Cocktail Increases
Efficacy in Genotype 1 Individuals, NEJM, March 2011

153. Gish RG, Cooper SL, Hepatitis B in the Greater San Francisco Bay Area: An Integrated
Programme to Respond to a Diverse Local Epidemic, Journal of Viral Hepa Apr; 18(4):
e40-51, April 2011.

154. Han SH, Reddy KR, Keefe EB, Soldevila-Pico C, Gish R, Chung RT, Degertekin B, Lok
A and the NIH HBV OLT study group. Clinical Outcomes Of Liver Transplantation For
Hbv-Related Hepatocellular Carcinoma: Data From The NIH HBV OLT Study. Clin
Transplant. 2011 Mar-Apr;25(2):E152-E162.

155. Comunale MA, Wang M, Rodemich-Betesh L, Hafner J, Lamontagne A, Klein A, Marrero
J, Di Bisceglie AM, Gish R, Block T, Mehta A. Novel Changes in Glycosylation of Serum
Apo-J in Patients with Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev.
2011 Jun;20(6):1222-1229.

156. Cohen C, Holmberg SD, McMahon Bi, Block JM, Brosgart CL, Gish RG, London WT,
Block TM, Is Chronic Hepatitis B Being Undertreated in the United States?, Journal of
Viral Hepatitis, Jun;18(6):377-83. June 18, 2011.

157. Cachey ER, Wyles DL, Goiceochea M, Torriani FJ, Ballard C, Colwell B, Gish RG,
Mathews WC. Reliability And Predictive Validity Of A Hepatitis-Related Symptom Inven-
tory In HIV-Infected Individuals Referred for Hepatitis C Treatment. AIDS Res & Ther.
2011 Aug 10;8:29.

Curriculum Vitae


158. Gish, RG, Kaveh H. HBV screening in asians and pacific islanders: interim cost-
effectiveness analysis of a single-enter San Francisco program; Journal of Epide and
Com Health. 2011 Sept (1).

2012

159. Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. The Impact of Race/Ethnicity on
the Clinical Epidemiology of Autoimmune Hepatitis. J Clin Gastroenterol. 2012
Feb;46(2):155-161.

160. Patton H, Misel M, Gish RG. Acute Liver Failure in Adults: An Evidence-based
Management Protocol for Clinicians. Gastroenterol Hepatol. 2012 Mar;8(3):161-212.

161. Kuo A, Gish R. Chronic Hepatitis B Infection. Clin Liver Dis. 2012 May;16(2):347-369.

162. Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Similar Risk of Renal
Events among Patients Treated with Tenofovir or Entecavir for Chronic Hepatitis B. Clin
Gastroenterol Hepatol. 2012 Aug; 10(8):941-946.

2013

163. Gish RG, Chang, Lai CL, Ade Man R. Quantitative Hepatitis B surface antigen analysis i
Hepatitis B E-antigen in positive, nucleoside-nave patients treated with encantavir, an-
tiviral therapy, AVT-12-OA-2806.R1, 2013 Mar(6):

164. Gish RG, Hana YD, Kane S, Clark M, Mangahas M, Baqai S, Winters M, Proudfoot, J,
Glenn JS,. Coinfection with Hepatitis B and D: epidemiology, prevalence and disease in
patients in northern California.

165. Gish RG, et al, One-Step Real-Time PCR Assay for Detection and Quantitation of
Hepatitis D Virus RNA"; Journal of Virological Methods, # VIRMET-D-13-00111R1

2014

166. Kim S, Syed G, Khan M , Chiu W, Sohail M, Gish R, Siddiqui A, "Hepatitis C Virus
Triggers Mitochondrial Fission and Attenuates Apoptosis to Promote Viral Persistence
Proc Natl Acad Sc,#:2013-21114RR 19Mar-2014.

167. Wong RJ, Gish RG; Implementing Best Practices When Initiating Hepatitis B Virus
Therapy, Clin in Liv Dis, Apr-2014.
Curriculum Vitae

SUBMITTED FOR PUBLICATION

1. Gish RG. Successful domino liver transplantation from a patient with methylmalonic
acidemia: first ever report. American Association for the Study of Liver Dis
ease, Liver Transplantation, Manuscript ID LT-12-522.R1; 2013 Mar(6):

2. Gish RG, Gutierrez J, Navarro-Cazarez N, Giang K, Adler, D, Tran B, Locarnini S,
Hammond R, Bowden D. A simple and inexpensive point-of-care test for hepatitis B sur-
face antigen detection: serological and molecular evaluation. Submitted for publication.
Journal of Vir Hep; 2013 Dec, JVH-00600-2013.

3. Gish, RG, Mendler M, Kono Y, Joshi K, Loomba R, Kuo A, Patton H. HCC Surveil-
lance: An Inquiry into Current Practices in the United States: National Survey of HCC
Surveillance Practices. Am Journ of Gastrentrol; Dec 2013. Submitted for publication.

4. Joshi K, Mendler M, Gish R, Loomba R, Kuo A, Patton H, Kono Y. HCC: Surveillance:
An Inquiry into Current Practices in the United States, American Journ of Gastroentrol,
Submitted for publication; 18 Dec-2013. Manuscript ID: AJG-13-2307.

5. Wong RF, Gish RG, Aijza, A: Hepatic Encephalopathy is Associated with Significantly
Increased Mortality Among Patients Awaiting Liver Transplantation, 5 Mar-2014. sub-
mitted for publication.

6. Baqai SF, Hana D, Zeng L, Gish RG. Entecavir Effective for Both Treatment-
Experienced and Treatment-Nave Chronic Hepatitis B Patients in Real Life Settings,
Lark Scientific, Mar-2014.

7. Mitchell, DG, Bruix, J, Sherman, M, Sirlin, CB. Gish, RG. RADS (Liver Imaging Report-
ing and Data System): Summary, Discussion, Consensus of the LI-RADS Management
Working Group and Future Directions. Journ of Hep: 30 Mar-2014.

Curriculum Vitae

PUBLICATIONS: REVIEW ARTICLES

1. Glassman P, Wong C, Gish R. A review of liver transplantation for the dentist and
guidelines for dental management. Spec Care Dentist. Mar-Apr 1993;13(2):74-80. Re-
view.

2. Gish RG, Ascher NL. Transmission of hepatitis B virus through allotransplantation. Liver
Transpl Surg. Mar 1996;2(2):161-164.
3. Gish RG. Standards of treatment in chronic hepatitis C. Semin Liver Dis. 1999;19 Supl
1:35-47. Review.
4. Gish RG. Future directions in the treatment of patients with chronic hepatitis C virus
infection. Can J Gastroenterol. Jan-Feb 1999;13(1):57-62. Review.
5. Yao F, Gish RG. Treatment of chronic hepatitis B: new antiviral therapies. Curr
Gastroenterol Rep. Feb-Mar 1999;1(1):20-26. Review.
6. Gish RG, Mason A. Autoimmune liver disease. Current standards, future directions. Clin
Liver Dis. May 2001;5(2):287-314. Review.
7. Gish RG. Treating hepatitis C: the state of the art. Gastroenterol Clin North Am. Mar
2004;33(1 Suppl):S1-9.
8. Gish RG. Clinical trial results of new therapies for HBV: implications for treatment
guidelines. Semin Liver Dis. 2005;25 Suppl 1:29-39. Review.
9. Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in
special populations: patient and treatment considerations. Clin Gastroenterol Hepatol.
Apr 2005;3(4):311-8. Review.
10. Gish RG. Current treatment and future directions in the management of chronic hepatitis
B viral infection. Clin Liver Dis. Nov 2005;9(4):541-65, v. Review.
11. Gish RG. Treating HCV with ribavirin analogues and ribavirin-like molecules. J
Antimicrob Chemother. Jan 2006;57(1):8-13. Epub 2005 Nov 17. Review.
12. Pawlotsky JM, Gish RG. Future therapies for hepatitis C. Antivir Ther. 2006;11(4):397-
408. Review.
13. Gish RG. Hepatocellular carcinoma: overcoming challenges in disease management.
Clin Gastroenterol Hepatol. Mar 2006;4(3):252-61. Review.
14. Chang TT, Gish R, de Man R, Gadano A, Sollano J, Han KH, et al. Management of
chronic hepatitis B virus infection: Current perspectives for the nurse practitioner. Jour-
nal of the American Academy of Nurse Practitioners. May 2006;18(5):203-215. Review.
15. Gish RG. Entecavir: A Viewpoint by Robert G. Gish. Drugs. 2006;66(12):1623-1624.
Review.
16. Gish RG. Setting Up an Outreach Clinic and Tertiary-Quaternary Medical Care Program.
Gastroenterology and Hepatology. May 2006;2(5): 384-385. Review.

Curriculum Vitae

PUBLICATIONS REVIEW ARTICLES: Continued

17. Gish RG, Locarnini SA. Chronic hepatitis B: current testing strategies. Clin Gastroenter-
ol Hepatol. Jun 2006;4(6):666-676. Review.
18. Gish RG. Current developments in the treatment of hepatitis and hepatobiliary disease.
Clin Adv Hematol Oncol. Jul 2006;4(7):511-512.
19. Gish RG, McCashland T. Hepatitis B in liver transplant recipients. Liver Transpl. Nov
2006;12(11 Suppl 2):S54-64. Review.
20. Gish RG, Gadano AC. Chronic hepatitis B: current epidemiology in the Americas and
implications for management. J Viral Hepat. Dec 2006;13(12):787-798. Review.

21. Gish RG. Improving outcomes for patients with chronic hepatitis B. Curr Gastroenterol
Rep. Mar 2007;9(1):14-22. Review.
22. Gish RG. Improving outcomes for patients with chronic hepatitis B. Hepatol Res. Jul
2007;37(s1):S67-78.
23. Gish RG, Perrillo RP, Jacobson IM. Customizing the management of chronic hepatitis B
virus infection. Semin Liver Dis. Aug 2007;27 Suppl 1:9-17. Review.
24. Gish RG, Locarnini S. Genotyping and genomic sequencing in clinical practice. Clin
Liver Dis. Nov 200711(4):761-95, viii. Review.
25. Gish RG, Baron A. Hepatocellular carcinoma (HCC): Current and evolving therapies.
IDrugs. Mar 2008;11(3):198-203.
26. Block TM, Marrero J, Gish RG, Sherman M, London WT, Srivastava S, Wagner PD. The
degree of readiness of selected biomarkers for the early detection of hepatocellular car-
cinoma: notes from a recent workshop. Cancer Biomark. 2008;4(1):19-33.
27. Gish RG, Hisatake G. Improving clinical trial design for hepatocellular carcinoma
treatments. Oncology Reviews. May 2007;1(1):45-52.
28. Gish R, Marrero JB, Tong MJ. Medical therapies to extend survival in hepatocellular
carcinoma. Clin Adv Hematol Oncol. Aug 2008;6(8):1-14.
29. Gish RG, Miyashita L. Sorafenib offers a new treatment for liver cancer new
medication shown to improve survival in clinical trials. Liver and GI Review. Winter
2008, No.24.
30. Gish RG. Diagnosis of chronic hepatitis B and the implications of viral variants and
mutations. Am J Med. Dec 2008;121(12 Suppl):S12-21.
31. Gish RG, Benson AB, Sherman M, Morgan BS. Cases in point: risk factors, surveillance
strategies and treatment options for HCC. Gastroenterol Hepatol. Jan 2009;5(1)Suppl
3:1-16.
32. Gish RG. Hepatitis B treatment: current best practices, avoiding resistance. Cleve Clin J
Med. May 2009;76(Suppl 3):S14-19.
Curriculum Vitae


33. Gish RG, Gholam PM. Monotherapy vs multiple-drug therapy: the experts debate. Cleve
Clin J Med. May 2009;76(Suppl3):S20-24.
34. Gish RG. Therapy for hepatitis B: la nouvelle vague. Can J Gastroenterol. June
2009;23(6):407-409.
35. Frenette CT, Gish RG. To be or not to be that is the question. Am Gastroenterol. Aug
2009;104(8):1948-1952.
36. Drug Effectiveness Review Project (DERP) team, Oregon Health & Science University,
Grant Funding from Attorney General Consumer, Prescriber Grant Program, and Con-
sumer Reports. Consumer Reports Best Buy Drugs. Consumer Reports. 2010.
37. Gish RG, Marrero JA, Benson AB. A multidisciplinary to the management of hepatocel-
lular carcinoma. Gastroenterol Hepatol 2010 Mar:6(3 Suppl 6):1-16. Clinical Roundtable
Monograph
38. Gish RG, Abou-Alfa GK, Tong MG. Integrating recent data in managing adverse events
in the treatment of hepatocellular carcinoma. Clin Adv Hematol Oncol. 2010 Sep;8(9):2p
preceding 4-15. Clinical Roundtable Monograph
39. Frenette C, Gish RG. Hepatocellular Carcinoma: Molecular and Genomic Guide for the
Clinician.Clin Liv Dis. 2011 May;15(2):307-321. Review
40. Gish RG, Meanwell NA. The NS5A replication complex inhibitors: difference makers?
Clin Liv Dis. 2011 Aug;15(3):627-639. Review
41. Wong R, Frenette C, Gish R. Hepatocellular carcinoma: locoregional and targeted
therapies. Gastroenterol Clin North Am. 2011 Sept;40(3):599-610. Review
42. Frenette CT, Frederick RT, Gish RG. Clinical Management and Case Reports for the
Treatment of Hepatocellular Carcinoma with Sorafenib. J Clin Gastroenterol. 2011
Sept;45(8):733-737 Case report
43. Frenette C, Gish R. Targeted Systemic Therapies for Hepatocellular Carcinoma:
Clinical Perspectives, Challenges And Implications. World J Gastroenterol. 2012 Feb
14;18(6):498-506. Review.
44. Gish RG, Society of interventional radiology critique and commentary on the cochrane
report on transarterial (chemo)embolization. American Association for the Study of Liver
Disease, Hepatology, HEP-12-0552; March 22, 2012.
45. Gish RG, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with
high barrier to resistance. Lancet Infect Dis. 2012 Apr;12(4):341-353. Review
46. Gish RG, Lencioni R, Di Bisceglie AM, Raoul JL, Mazzaferro V. Role of the multidisci-
plinary team in the diagnosis and treatment of hepatocellular carcinoms. Expert Rev
Gastroenterol Hepatol. 2012 Apr;6(2):173-185. Review.

Curriculum Vitae


47. Gish, RG, Marrero, J., Finn R. Extending survival with the use of targeted therapy for the
treatment of hepatocellular carcinoma. CAHO/G&H roundtable monograph, Clinical Ad-
vances in Hematol/Oncol, Millennium Medical Publishing, Inc. 2013 Feb;4: page num-
bers. Review.
48. Gish RG. Strategies for hepatocellular carcinoma surveillance and diagnosis. Gastroen-
terol Hepatol. 2013 Apr;V9(4): page numbers. Review.
49. Noureddin M, Gish RG. Hepatitis Delta: Epidemiology, Diagnosis and Management: 36
Years After Discovery. Curr Gastroenterol Rep (2014) 16:365; Springerlink.com, 30 Nov
2013. Review.

PUBLIC POLICY: ORIGINAL MANUSCRIPT

1. Gish RG, Bui TD, Nguyen CT, Nguyen DT, Tran HV, Tran DM, Trinh HN; International
Group for Liver Health in Viet Nam. Liver Disease In Viet Nam: Screening, Surveillance,
Management And Education: A 5-Year Plan And Call To Action. J Gastroenterol Hepa-
tol. 2012 Feb;27(2):238-247.
Curriculum Vitae

NEWSLETTERS

1. Gish RG, Osorio R. New Techniques and Devices are Revolutionizing Liver Transplan-
tation and Therapy. Pacific Currents, May 2000. Available at:
http://www.cpmc.org/professionals/research/currents/2000LiverTX.html.
2. Gish RG. The Future of Western Treatment for Hepatitis C. HCV Advocate Medical
Writers Circle. March 2002. Available at: http://www.hcvadvocate.org/hcsp/board.asp.
3. Gish RG. Overview of Treatment of Hepatitis B. HCV Advocate Medical Writers Circle.
April 2003. Available at: http://www.hcvadvocate.org/hcsp/board.asp.
4. Gish RG. Minimizing the Impact of Neuropsychiatric Effects During Chronic HCV
Disease and Treatment. HCV Advocate Medical Writers Circle. April 2004. Available
at: http://www.hcvadvocate.org/hcsp/board.asp.
5. Hassanein TI, (Gish RG steering committee). Managing HCV: Nonresponders to
Pegylated Interferon and Ribavirin Therapy. PHOENIX Perspectives in Hepatitis C
Outcomes: An Educational Network for Improving Options in Treatment Failures. 2005.
6. Gish RG, comment in: LoBuono C. New drug marks advance in treatment of hepatitis
B. Drug Topics: The News Magazines for Pharmacists. May 2, 2005.
7. Gish RG. Future Therapies for Hepatits C. HCV Advocate Medical Writers Circle. Feb
2006. Available at: http://www.hcvadvocate.org/hcsp/board.asp.
8. Gish RG, Miyashita L. Indicators of Hepatitis B Virsus (HBV) Infection Screening
Panel Advocated for At-Risk Populations. California Pacific Liver & GI
view. Spring/Summer 2006; Issue 20:2. www.cpmc.org/liver.
9. Gish RG. Multimodality Approach to the Treatment of HCC: The Emerging Paradigm.
Newsletter from 58th Annual AASLD, Boston, MA, November 2007.

PUBLICATIONS: BOOK CHAPTER & EDITORIALS

1. Gish RG. Ischemic and Congestive Liver Disease. In: Gitnick, G, ed. Principles and
Practice of Gastroenterology and Hepatology. New York: Elsevier Science Publishing
Co., 1988: 1346-1352.

2. Gish RG. Ischemic and Congestive Liver Disease. In: Gitnick, G, ed. Principles and
Practice of Gastroenterology and Hepatology. New York: Elsevier Science Publishing
Co., 1988: 1346-1352.
3. Gish RG, Keeffe EB. The Short Bowel Syndrome. In: Snape, W, ed. Consultations in
Gastroenterology. Cambridge, Mass: W.B. Saunders Company, 1995.
4. Gish RG, Keeffe EB. The Short Bowel Syndrome. In: Snape, W, ed. Consultations in
Gastroenterology. Cambridge, Mass: W.B. Saunders Company, 1995.
5. Gish RG, Keeffe EB. Recent developments in the treatment of chronic hepatitis B virus
infection. Expert Opinion on Investigational Drugs. Feb 1995;4(2):95-115.
Curriculum Vitae

PUBLICATIONS: BOOK CHAPTER & EDITORIALS: Continued

6. Gish RG, Keeffe EB. Recent developments in the treatment of chronic hepatitis B virus
infection. Expert Opinion on Investigational Drugs. Feb 1995;4(2):95-115.
7. Gish RG. Evolving therapies for the treatment of viral hepatitis. Ed. W. C. Bowman, J.
D. Fitzgerald and J. B. Taylor. Emerging Drugs: The prospect for improved medicines
annual executive briefing. Vol 1. London: Ashley Publications Ltd, 1996.
8. Gish RG, Cox KL, Mizokami M, Ohno T, Lau JY. Vertical transmission of hepatitis C.
(letter) J Pediatr Gastroenterol Nutrition. Jan 1996;22(1):118-119.
9. Gish RG. Evolving therapies for the treatment of viral hepatitis. Ed. W. C. Bowman, J.
D. Fitzgerald and J. B. Taylor. Emerging Drugs: The prospect for improved medicines
annual executive briefing. Vol 1. London: Ashley Publications Ltd, 1996.
10. Gish RG. Hepatitis C virus: Seven years old. Viral Hepatitis Reviews. 1997;3(1):17-37.
11. Gish RG, Lau JYN. Hepatitis C Virus: Eight Years Old. Viral Hepatitis Reviews. Mar
1997;3(1):17-37.
12. Gish RG. Liver physiology and pathology. Chapter 20, "Liver." Gastroenterology
Nursing: A Core Curriculum. 2nd ed. St.Louis, Missouri: Mosby-Year Book, Inc., Apr
1997.
13. Gish RG. Liver physiology and pathology. Chapter 20, "Liver." Gastroenterology
Nursing: A Core Curriculum. 2nd ed. St.Louis, Missouri: Mosby-Year Book, Inc., April
1997.
14. Gish RG and Olden K. Alcohol and liver disease should transplantation be of-
fered? Practical Gastroenterology. Dec1997.
15. Gish RG. Review of computer program "A simplified approach to the management of
patients with chronic hepatitis B and C infections." Gastroenterology. Dec 1997.
16. Gish RG, Locarnini S. Chronic Hepatitis B Viral Infection. In: Yamada and Alpers, eds.
Textbook of Gastroenterology. Vol. 2.;107:2309-2327. Lippincott Williams & Wilkins,
1998.
17. Gish RG, Locarnini S. Chronic Hepatitis B Viral Infection. In: Yamada and Alpers, eds.
Textbook of Gastroenterology. Vol. 2.;107:2309-2327. Lippincott Williams & Wilkins,
1998.
18. Gish RG. Longer, Longer, Longer. Advances in Gastroenterology, Hepatology and
Clinical Nutrition. 1998;3:83-85.
19. Gish, RG, Wakil AE. Combination interferon-alfa 2B plus ribavirin for treatment of
chronic hepatitis C. Current Practice of Medicine. 1999;2(4-10).
20. Gish RG, Baker EL. Imaging Before and After Liver Transplantation. Imaging in
Hepatobiliary and Pancreatic Disease, 1999.
Curriculum Vitae


21. Gish RG, Baker EL. Imaging Before and After Liver Transplantation. Imaging in
Hepatobiliary and Pancreatic Disease, 1999.
22. Gish RG. Treatment of Chronic Hepatitis B Transplant Recipients. Management of
Chronic Viral Hepatitis, 1999.
23. Gish RG. Counseling the Patient with Chronic Hepatitis C. Practical Hepatitis Update,
1999.
24. Poordad FF, Gish RG. Development in hepatitis C during 1997 1999. Expert Opinion
on Therapeutic Patents. Sep 1999;9(9):1249-1262.
25. Cohen MR, Gish RG and Doner K. The hepatitis C help book: a groundbreaking
treatment program combining Western and Eastern medicine for maximum wellness and
healing. 1st ed. New York: St. Martins Press, 2000.
26. Gish RG. Current Treatment Options in Gastroenterology. Current Science, 2000.
27. Gish RG. Treatment of Chronic HBV in Transplant recipients. In: Stuart Gordon, MD,
ed. Management of Chronic Viral Hepatitis. Marcel Dekker, 2001.
28. Gish RG. HCV: Molecular Tools for Measuring Treatment Responses. In: American
College of Gastroenterology Clinical Guidelines. ACG, 2001.
29. Gish RG. Prevention and treatment of hepatitis B in liver transplant recipients. In:
Arroyo, Bosch, Bruix, Gines, Navasa, and Rodes, eds. Therapy in Hepatology. Barcelo-
na: Ars Medica, 2001:183-191.
30. Lok AS, Heathcote EJ, Hoofnagle JH, Gish RG (subauthor). Management of hepatitis B:
2000 summary of a workshop. Gastroenterology. Jun 2001;120(7):1828-1853.
31. Gish RG. Approach to the Patient With Hepatomegaly. In: David Rossman, MD, ed.
Best Practice of Medicine. Praxis Press, 2002.
32. Lau G, Gish R, Liang R. Hepatitis B Infection and Immunosuppression. Chapter 12. In:
Locarnini S and Lai L, eds. Hepatitis B Virus Guide. London: International Medical
Press, 2002.
33. Gish RG, Wakil A. Hepatitis B in liver transplant recipients as a special model of antiviral
drug development. Methods Mol Med, Hepatitis B and D Protocols II. 2004;96:319-341.
34. Gish RG, Locarnini S. Studying the treatment of chronic hepatitis B viral infection in
special populations. Methods Mol Med, Hepatitis B and D Protocols III. 2004;96:465-
498.
35. Gish RG, Lau J, Fang J, Mizokam M, Wright T. Hepatitis C. In: J. Larry Jameson, ed.
Principles of Molecular Medicine. Humana Press, March 2004.
36. Gish RG. Maximizing the benefits of antiviral therapy for HCV: the advantages of
treating side effects. [editorial] Gastroenterol Clin North Am. Mar 2004;33(1 Suppl):xxiii-
xxiv.
Curriculum Vitae


37. Gish RG. Overview of Hepatitis C. St. John and Sandt, eds. Hepatitis C Choices. 3rd
Edition. Hepatitis C Caring Ambassadors Program, 2004:1-6.
38. Gish RG. Future of Allopathic Hepatitis C Treatment. St. John and Sandt, eds.
Hepatitis C Choices. 3rd Edition. Hepatitis C Caring Ambassadors Program, 2004:125-
134.
39. Gish RG. Flamm S, Fried M, Pockros P. Supporting Patients With Chronic Hepattis C
During Therapy. Special Report. January 1, 2005.
40. Gish RG, Briceno J. Factors Affecting Liver Transplantation for Hepatocellular
Carcinoma Associated with Hepatitis C Virus Cirrhosis. Transplant International. Manu-
script ID TRI-0A-06-0112.
41. Gish RG. Hepatitis C: Current Standards of Care and Future Perspectives. HCV
Advocate Medical Writers Circle. May 2006. Available at:
http://www.hcvadvocate.org/hcsp/board.asp.
42. Gish RG. Principles of Molecular Medicine. 2nd Ed. Totowa, NJ: Humana Press,
2006. ISBN: 1-58829-202-9.
43. Gish RG. Risk Factors and Treatment for Hepatocellular Carcinoma. Advances in
Hepatology. Gastroenterology & Hepatology. Volumne 2, Issue 7. July 2006.
44. Block TM, Marrero J, Gish RG, Sherman M, London WT, Srivastava S, Wagner PD. The
degree of readiness of selected biomarkers for the early detection of hepatocellular car-
cinoma: Notes from a recent workshop. Cancer Biomark. 2008;4(1):19-33.
45. Gish RG, Locarnini S. Chronic hepatitis B viral infection. Chapter 81. In: Yamada T,
Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, Powell DW. (Eds) Textbook of Gastroen-
terology. Oxford, England. Blackwell Publishing, 2009: 2112-2138.
46. Raymond T. Chung, Robert G. Gish, Stephen A. Harrison. Jounal Options Hepatitis.
Clinical Care Options. Volume 4, Issue 1. 2010.
47. Gish R, Martinez A, Western (Allopathic) Medicine: The Future of Allopathic Treatment
for Hepatitis C, Hep C Choices.

48. Gish RG, Tam D. Bui MD, PhD, Chuc T.K. Nguyen, Pharm PhD, Duc T. Nguyen, MS,
PhD, Huy V. Tran, MD, PhD, Diem M.T. Tran, Huy N. Trinh, MD, AGAF, International
Group for Liver Health in Vietnam (ILFVN), Liver Disease in Viet Nam: Screening, Sur-
veillance, Management and Education A Five Year Plan and Call To Action, Septem-
ber, 2011.

49. Gish, RG, HBV Screening in Asians and Pacific Islanders: Interim Cost-effectiveness
Analysis of a Single-center San Francisco Program, Journal of Epidemiology & Com-
munity Health, January 2012.

Curriculum Vitae


50. Guitierrez JA, Gish, RG. Efficacy of combination treatment modalities for intermediate
and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel
small molecules .Transl Cancer Res. 25 Nov 2013. Manuscript ID: TCR-13-113 DOI:
10.3978/j.issn.2218-676X.2013.10.01. Pioneer Bioscience Publishing Company.
www.thetcr.org

CASE REPORTS & LETTERS TO THE EDITOR

1. Huibregtse K, Gish RG, Tytgat GN. A frightening event during endoscopic papillotomy.
[letter] Gastrointes Endosc. Jan-Feb 1988;34(1):67-68.

2. Gish RG, Cox KL, Mizokami M, Ohno T, Lau JY. Vertical transmission of hepatitis C.
(letter) J Pediatr Gastroenterol Nutrition. Jan 1996;22(1):118-119.

3. Savur S, Bonacini M, Bzowej N, Gish R, Wakil A, Osorio R. Erythropoietin is approved
for the treatment of anemia associated with renal failure, chemotherapy, preoperative
anemia, and human immunodeficiency virus disease. (letter) Liver Transpl. Mar
2005;11(3):366.

4. Gish RG. Do we need to MEND the MELD? [comment] Liver Transpl. Apr
2007;13(4):486-487.

Curriculum Vitae

PUBLICATIONS: EDITOR / REVIEWER

1. Gish RG. Section Editor, Hepatitis B: Epidemiology, Natural History, Treatment, and
Transplantation. Current Hepatitis Reports. May 2003;2(2):49-59, 63-87.
2. Schreibman IR, Schiff ER. Entecavir: A Novel Treatment for Chronic Hepatitis B
Infection. Gish RG, ed. Future Virology. Sep 2006;1(5):541-552.
3. Gish RG, Reviewer/Editor. Entecavir Drug Evaluation. July 4, 2006.
4. Reviewer, The American Journal of Clinical Oncology, 2006.

5. Gish RG, Veenstra D, Iioeje U, Sullivan S, Tafesse E, Clarke L, Di Bisceglie A, Kowdley
K. Cost-Effectiveness of Entecavir versus Lamivudine in HBe-Ag-Positive Chronic Hep-
atitis B Based on a 2 Year Clinical Trial. Editorial Manger for Gastroenteroly. Manuscript
Draft.
6. Gish RG, Section Editor. Treatment and Antiviral Drug Resistance. Current Hepatitis B
Reports. Aug 2007;1(1).
7. Hou J, Schilling R, Janssen HL, Hansen BE, Heijtink R, Sablon E, Williams R, Lau GK,
Schalm SW, Naoumov NV. Genetic characteristics of hepatitis B virus genotypes as a
factor for interferon-induced HBeAg clearance. Gish RG, journal editor. J Med Virol. Aug
2007;79(8):1055-63.
8. Gish RG, Locarnini S. Genotyping and genomic sequencing in clinical practice. Clin
Liver Dis 2007; 11(4):761-95, viii.
9. Gish RG, Reviewer/Editor. Gankang Granula Therapy showed Potent Antiviral Activity
in Chronic Hepatitis B. 2007.
10. Gish RG, Reviewer/Editor. The treatment of chronic hepatitis B focus on adefovir like
antivirals. 2007.
11. Gish RG, journal reviewer/editor. Manuscript SGAS-2007-0057. Predicition of virologic
response in difficult-to-treat chronic hepatitis C patients during high dose interferon in-
duction therapy. Scandinavian Journal of Gastroenterology. March 3, 2008.
12. Gish RG, Reviewer/Editor. Impact of antiviral treatment on noninvasive predictors of
liver fibrosis in HIV/HCV co-infected patients: the Fibrovic 2 Study-ANRS HC02. Journal
of Acquired Immune Deficiency Syndromes. May 2008.
13. Ting-Tsung Chang, You-Chen Chao, Vladimir V. Gorbakov, Kwang-hyub Han, Gish RG,
Robert de Man, Hugo Cheinquer, Fernando Bessone, Helena Brett-Smith, Ricardo
Tamez. Summary of an International Study of Entecavir for the Management of Nucle-
oside-Nave HBeAg-positive Patients With Chronic Hepatitis B. Manuscript AJG-08-
1370. American Journal of Gastroenterology. Submitted August 2008.

14. Gish, RG, Expert Reviewer, French National Cancer Institute, "Program of comprehen-
sive research actions: Hepatocellular Carcinoma." 2008.

15. Gish, RG, Expert Reviewer. Wong, WS and Chan, Henry LY, HCC: Prevention and
Control in Low and Middle Income Countries, October 2011.
Curriculum Vitae

PUBLICATIONS EDITOR / REVIEWER: Continued

16. Gish, RG, Reviewer. Higher baseline transaminases predict cirrhosis while longer time
of adherence to antiretroviral therapy is linked to favorable virological outcome in HIV-
HBV-co-infected patients. Manuscript for HIV Clincal Trials. 2008.

17. James Fung, Ching-Lung Lai, Yasuhito Tanaka, Masashi Mizokami, John Yuen, Danny
Wong, Ting-Kin Cheung, Man-Fung Yuen. The duration of lamivudine therapy for chron-
ic hepatitis B: Cessation versus continuation of treatment after HBeAg seroconversion.
Gish R, reviewer. GUT Journal. 2008.
18. Reviewer for Grant Application, Deutsche Forschungsgemeinschaft (DFG).
19. Reviewer for Grant Application, National Research Foundation South Africa (NRF).
20. Gish RG, Reviewer. Abstract Session: Clinical: Allocaton MELD. 2008.
21. Gish RG, Reviewer. Cancer Chemotherapy and Pharmacology. CCP-08-0223. 2008.

22. Gish RG, Section Editor. Epidemiology and Natural History of Hepatitis B in Vietnam.
2008.

23. Gish RG, Section Editor. HBV Prevalence, Natural History, and Treatment in Eastern
Europe, Turkey, and Turkish-Speaking Countries in Central Asia. 2008.

24. Gish RG, Section Editor. Hepatitis B Virus Prevalence, Natural History, and Treatment
in Africans in Africa and the United States. 2008.

25. Gish RG, Section Editor. HBV Prevalence, Natural History, Treatment, and Resistance:
a 2008 Update with a Special Perspective on Individuals from the Indian Subcontinent.
2008.

26. Gish RG, Section Editor. Epidemiology, Presentation, and Treatment of Chronic HBV
Infection in Mainland China, in Taiwan, and in Chinese Americans in the United States.
2008.
27. Gish RG, Section Editor. HBV Prevalence, Natural History, and Treatment in Korea and
the United States. 2008.

28. Gish RG, Medical Reviewer. Understanding HCV A Patient Pocket Guide. 2009.

29. Gish Robert G. Hepatitis B in the Greater San Francisco Area: An Integrated Program
to Respond to a Diverse Local Epidemic. Clinical Gastroenterology and Hepatotolgy.
Submitted for publication. 2009.

30. Gish, Robert G. The Molecular and Functional Characterization of Hepatitis B Virus
(HBV) Genotypes Isolated from Human Immunodeficiency Virus (HIV) Infected Southern
Africans: Part II. The Medical Research Council (MRC). 2010.
31. Gish R., Reviewer. Hepatitus:Treatment and Clinical Trials The Governing Board of
the American Association for the Study of Liver Diseases (AASLD), 2011

32. Gish, R., Reviewer. BenhGan.org- Learn About Hepatitusand Liver Diseases
Curriculum Vitae


33. Gish, R., Reviewer. Evaluation of the merits of the evidence regarding the identification
of hepatitis C virus (HCV) and HCV-Related Chronic Disease Among {ersons Born from
1945 to 1965, Division of Viral Hepatitis at the Centers for Disease Control and
Prevention.

34. Gish, R., Reviewer. Management of a Case of Obscure Lower-GI Bleeding by
Transjugular Intrahepatic Portosystemic Shunt (TIPS): A Case Report, October 2011.

35. Gish, R., Reviewer. Rationale For Selecting Chronic Hepatitis B Therapy With a High
Barrier to Resistance, The Lancet Infectious Diseases. Elsevier Ltd., THELANCETID-D-
10-00628R1;October 2011.

36. Gish, R., Reviewer. Hepatitis B: Treatment and Clinical Trials, AASLD, San Francisco,
CA. October 2011.

37. Gish, R., Reviewer. American Journal of Tropical Medicine & Hygiene

38. Gish, R, Reviewer and Consultant, Screening for Hepatitis C Virus Infection in Adults,
Agency for Healthcare Research and Quality (AHRQ) HCV, December 2011.

39. Gish, R, Reviewer, HBV Abstract submissions, Digestive Disease Week, American
Association for the Study of Liver Disease, May 2012.

40. Assessment of Professor Jun Yu, Chinese University of Hong Kong; January 13, 2013.

41. Member, Hepatitis B: Treatment and Clinical Trials abstract review committee, American
Association for the Study of Liver Diseases (AASLD) Digestive Disease Week (DDW).
January 4, 2013.

42. MD Thesis (Professor Chan See Ching). External Reviewer / Examiner, The University
of Hong Kong. May 31, 2013.

43. American Gastroenterological Association (AGA) Technical Review Author for AGA
Guidelines for Antiviral Therapy for HBV Reactivation in Setting of Immunosuppressive
Therapy, June 2013.

44. Public Library of Science, Manuscript #: PONE-D-13-28265; High Prevalence and
Significance of Hepatitis D Virus Infection among Treatment-nave HBsAg-Positive Pa-
tients in Northern Vietnam ; 2013.

45. Digestive Diseases and Sciences, (DDSJ-D-13-01088); Primary Surgical Resection
versus Liver Transplantation for Transplant-Eligible Hepatocellular Carcinoma Patients",
2013.
46. Department of Health & Human Services, Agency for Healthcare Research and Quality
(AHRQ) Evidence-based Practice Center (EPC) Program, Peer Reviewer, 2012 2013.

47. High Prevalence and Significance of Hepatitis D Virus Infection among Treatment-nave
HBsAg-Positive Patients in Northern Vietnam, Public Library of Science (PLOS ONE),
PONE-D-13-28265R1, August 2013.

Curriculum Vitae


48. "Zinc Monotherapy is Effective in Wilsons Disease Patients with Mild Liver Disease
Diagnosed in Childhood: A Retrospective Study," Alimentary Pharmacology & Therapeu-
tics - APT-0841-2013, August 2013. 2013: Abstract Reviewer, Primary Surgical Resec-
tion versus Liver Transplantation for Transplant-Eligible Hepatocellular Carcinoma Pa-
tients" (DDSJ-D-13-01088R); Digestive Diseases and Sciences, 2013.

49. 2014: Peer Abstract Reviewer, Digestive Disease Week 2014, American Association
for the Study of Liver Disease, McCormack Place, Chicago, IL

50. Digestive Disease Week 2014: American Association for the Study of Liver Disease
(AASLD) Abstract Reviewer, Jan-2014.

51. Reviewer, Chronic hepatitis B prevalence among children and mothers: results from a
nationwide, population-based survey in Lao People's Democratic Republic, Open Ac-
cess Public Library of Science, PONE-D-13-44773R1, EMID:ccb2186b7e4e406c,
15Jan-2014.

52. Reviewer, Hepatitis B virus and Hepatitis C Virus Infections in United States-bound
Refugees from Asia and Africa, American Journal of Tropical Medicine and Hygiene,
AJTMH-14-0068, 5Feb-2014.

53. Seetharam A, Perrillo R, Gish RG. Immunosuppression in patients with chronic
Hepatitis B,3 Mar-2014

Curriculum Vitae

UCSD

2011 2012
UCSD DOM Residents Rotation Overview: Hepatology, HC

2010 2013
U.C. San Diego
Medical Director of Center for Hepatobiliary Disease and Abdominal Transplantation
(CHAT)
Chief of Hepatology
Professor of Medicine
350 Dickinson Street, Suite 342

Curriculum Vitae

PUBLICATIONS: ABSTRACTS

1. Gish RG, Kaplowitz N, Langer AB. Calcium compartmentation and exchange rates in
rat hepatocyte monolayers. Hepatology. 1987;7:1128. Presented at the American As-
sociation for the Study of Liver Diseases (AASLD) Liver Meeting, 1987.
2. Gish RG, Fernandez C, Kaplowitz N, Langer GA. Isotopic identification of calcium
compartmentation in hepatocyte monolayers. Hepatology. 1988;8:1309. Presented at
the AASLD Liver Meeting, 1998.
3. Young SG, Linton MF, Hubl ST, Gish RG, Esquivel CO, Wardell M, Concepcion W,
Nakazato P, Hardiman M. APO-E and APO-B phenotypes following liver transplanta-
tion. Clin Res. 1990;38:483A. Presented at the American Federation for Clinical Re-
search Meeting, 1990.
4. Gish RG, Nakazato P, Concepcion W, Garcia-Kennedy R, Imperial J, Esquivel C. Liver
transplantation for hepatitis B-induced cirrhosis using HBIG prophtyaxis. Presented at
the International Symposium on Viral Hepatitis and Liver Disease, 1990.
5. Nakazato P, Gish RG, Cox K, Berquist W, Concepcion W, Imperial J, Burns W, Garcia-
Kennedy R, Esquivel CO. Incidence of incidental hepatocellular carcinoma in endstage
liver disease patients undergoing liver transplantation with pre-transplant hepatitis C an-
tibody reactivity. Hepatology. 1991;14:60A. Presented at the AASLD Liver Meeting,
1991.
6. Fry KE, Gish RG, Nakazato P, Reyes GR, Kuramoto RK, Lim J, Yarbough PO, Zeldis
JB, Warmerdam M, Moeckli R, Yun-Chae K. Hepatitis C antibody testing in patients with
chronic liver disease. Gastroenterology. 1991;100:A742. Presented at the AASLD Liver
Meeting, 1991.
7. Gish RG, Fry KE, Concepcion W, Reyes GR, Kuramoto RK, Lim J, Yarbough PO, Zeldis
JB, Warmerdam M, Moeckli R, Yun-Chae K. Hepatitis C infections in patients with or-
thotopic liver transplantation. Presented at the American Gastroenterology Association
(AGA) Meeting, 1991.
8. Gish RG, Fry KE, Concepcion W, Reyes GR, Kuramoto RK, Lim J, Yarbough PO, Zeldis
JB, Warmerdam M, Moeckli R, Yun-Chae K. Early seroconversion to non-C100-3 anti-
gens in acute HCV hepatitis. Gastroenterology. 1991;100:A747. Presented at the AGA
Meeting, 1991.
9. Cox K, Berquist W, Gish RG, Imperial J, Rich E, Baker E. Endoscopic retrograde
cholangiopancreatography in children (ERCP). Gastrointest Endosc. 1992;38:266-267.
10. Cox K, Berquist W, Gish RG, Imperial J, Baker E. Biliary manometry in children.
Gastroenterology. 1992;102:A309. Presented at the AGA Meeting, 1992.
11. Gish RG, Lee AH, Rome H, Concepcion W, Esquivel CO, Keeffe EB. Liver transplanta-
tion (OLTx) for patients with alcoholism and endstage liver disease. Hepatology. Octo-
ber 1992:A941. Presented at the AASLD Liver Meeting, 1992.
12. Gish RG, Imperial JI, Esquivel CO, Keeffe EB. Ganciclovir treatment of severe hepatitis
B virus infection. Gastroenterology. April 1993;104:A908. Presented at the AGA Meet-
ing, 1993
Curriculum Vitae

PUBLICATIONS ABSTRACTS: Continued

13. Gish RG, Concepcion W, So SKS, Esquivel CO, Keeffe EB. Orthotopic liver transplan-
tation for hepatitis B virus cirrhosis; potential efficacy of therapy with HBIG. Gastroen-
terology. April 1993;104:A908. Presented at the AGA Meeting, 1993.
14. Gonzales-Peralta RP, Fang JWS, Davis GL, Gish RG, Mizokami M, Kohara M, Mondelli
M, Lesniewski R, Phillips I, Lau JYN. Optimization for the detection of viral hepatitis C
(HCV) antigens in liver. Gastroenterology. April 1993;104:A909. Presented at the AGA
Meeting, 1993.
15. Twu JS, Sherker AH, Fung K, Fernandez J, Yarbough PO, Gish RG, Bradley DW,
Robinson WS, Reyes GR. Hepatitis E virus infection of primary human hepatocytes and
identification of neutralizing antibodies. Presented at the International Symposium on Vi-
ral Hepatitis and Liver Disease, Eighth Triennial Congress, Tokyo, Japan, May 1993.
16. Twu JS, Sherker AH, Fung K, Fernandez J, Gish RG, Bradley DW, Robinson WS,
Reyes GR. Inhibition of hepatitis E virus replication by Ribavirin, iron and human alpha-
Interferon in primary human hepatocyte culture. Presented at the International Symposi-
um on Viral Hepatitis and Liver Disease, Eighth Triennial Congress, Tokyo, Japan, May
1993.
17. Lau JYN, Davis GL, Ohno T, Nakano T, Mizoguchi N, Perrillo R, Lindsay K, Gish RG,
Wilber JC, Urdea MS, Tsukiyama-Kohara K, Kohara M, Mizokami M. Application of hep-
atitis C virus (HCV) subtyping in chronic hepatitis C in the United States. Hepatology.
October 1993;18. Presented at the AASLD Liver Meeting, 1993.
18. Gonzalez-Peralta RP, Fang JWS, Davis GL, Gish RG, Lau GKK, Wu PC, Lau JYN.
Hepatic Response in chronic hepatitis C virus (HCV) infection. Hepatology. October
1993; 18. Presented at the AASLD Liver Meeting, 1993.
19. Fang JWS, Lau GKK, Marousus C, Gonzalez-Peralta RP, Davis GL, Gish RG, Moyer
RW, Kao KJ, Lesniewski R, Mizokami M, Houghton M, Lau JYN. Failure to detect cell
surface expression of hepatitis C virus (HCV) structural proteins using a vaccinia ex-
pression system. Gastroenterology. April 1994;106:A890. Presented at the AGA Meet-
ing, 1994.
20. Lau GKK, Fang JWS, Davis GL, Gish RG, Wu PC, Lau JYN. Detection of hepatitis C
virus (HCV) genome in liver by in-situ reverse transcription polymerase chain reaction (I-
RT-PCR). Gastroenterology. April 1994;106:A925. Presented at the AGA Meeting, 1994.
21. Gonzalez-Peralta RP, Fang JWS, Davis GL, Gish RG, Kohara M, Mondelli MU,
Mizokami M, Lau JYN. Significance of hepatic expression of hepatitis C viral (HCV) an-
tigens in chronic HCV infection. Gastroenterology. April 1994;106:A899. Presented at
the AGA Meeting, 1994.
22. Gish RG, Keeffe EB, Fang JWS, Garcia-Kennedy R, Lau JYN. Ganciclovir treatment of
recurrent hepatitis B virus (HBV) infection in orthotopic liver transplant (OLT) recipients.
Gastroenterology. April 1994;106:A899. Presented at the AGA Meeting, 1994.
23. Gish RG, Krams S, Martinez OM. Interleukin 12 (IL-12): A possible cytotoxic t-
lymphocyte (CTL) differentiation factor in allograft recipients. International Transplanta-
tion Meeting, Kyoto, Japan, August 1994.
Curriculum Vitae


24. Fang JWS, Gonzalez-Peralta RP, Gottschall JA, Davis GL, Gish RG, Mizokami M, Lau
JYN. Hepatic expression of c-FAS and apoptosis in chronic hepatitis C virus (HCV) in-
fection. Hepatology. October 1994;20:251A. Presented at the AASLD Liver Meeting,
1994.
25. Gonzalez-Peralta RP, Fang JWS, Davis GL, Gish RG, Mizokami M, Lau JYN.
Immunopathobiology of chronic hepatitis C virus infection. Hepatology. October
1994;20:232A. Presented at the AASLD Liver Meeting, 1994.
26. Burns W, Gish RG, Berquist W, Severson E, Esquivel C. Glutathione s-transferase as a
marker in the diagnosis of rejection in liver transplant recipients: A preliminary report.
Hepatology. October 1994;20:335A. Presented at the AASLD Liver Meeting, 1994.
27. Cacciarelli T, Martinez OM, Villaneuva JC, Lau JYN, Gish RG, Krams SM. Immunoreg-
ulatory cytokines in hepatitis C virus (HCV) infection pre- and posttreatment with alpha-
Interferon. Gastroenterology. April 1995;108:A1042. Presented at the AGA Meeting,
1995.
28. Ghany MG, Ayola B, Villamil FG, Gish RG, Roiter S, Vierling JM, Lok ASF. S Gene
escape mutants as a cause of HBV reinfection in patients who received HBIG post-OLT.
Hepatology. October 1995;22:174. Presented at the AASLD Liver Meeting, 1995.
29. Gish RG, Xu YL, Brooks L, Leung J, Qian KP, Pike I, Lau JYN. Application of a simple
serology based genotyping assay in a prospective cohort of patients with chronic hepati-
tis C. Hepatology. October 1995;22(4):1258. Presented at the AASLD Liver Meeting,
1995.
30. Ghany MG, Villamil FG, Gish RG, Roiter S, Vierling, JM, Lok ASF. Survival after liver
transplantation for HBV-liver failure is unrelated to pre-core stop codon mutation. Hepa-
tology. October 1995;22(4):1255. Presented at the AASLD Liver Meeting, 1995.
31. Bhardwai G, Ohno T, Mizokami M, Gish RG, Lau JYN. Host immune response in liver
in chronic hepatitis C: Both perforin and FAS-ligard are activated. Presented at the AGA
Meeting, May 1996.
32. Ghany MG, Ayola B, Villamil FG, Gish RG, Roiter S, Vierling JM, Lok ASF. HBV
reinfection in liver transplant (LT) patients (PTS) who remained HBsAG negative post-
LT. Presented at the AASLD Liver Meeting, 1996. Chicago, Illinois.
33. Ayola B, Ghany MG, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok ASF. HBIG-
induced gene mutations in liver transplant recipients can revert after withdrawal of HBIG.
Presented at the AASLD Liver Meeting, 1996. Chicago, Illinois.
34. Perrillo R, Rakela J, Martin P, Levy G, Schiff E, Wright T, Dienstag J, Gish RG,
Villeneuve J, Caldwell S, Brown N, Self P. Lamivudine for hepatitis B after liver trans-
plantation. Presented at the AASLD Liver Meeting, 1996. Chicago, Illinois.
35. Gish RG, Xu YL, Brooks L, Leung J, Pike I, Qian KP, Lau JYN. Anti-HCV positive sera
that were not genotypeable or serologically genotypablewhat does it mean? Present-
ed at the AASLD Liver Meeting, 1996. Chicago, Illinois.

Curriculum Vitae


36. Ghardwai G, Ohno T, Gish RG, Lau JYN. In vivo activated of cytotoxic t-lymphocyte
pathways in HCV-related cirrhosisimplications on immunopathogenesis. Presented at
the AASLD Liver Meeting, 1996. Chicago, Illinois.
Villeneuva J, Caldwell S, Brown N, Self P. Lamivudine for hepatitis B after liver trans-
plantation Presented at the AASLD Liver Meeting, 1996. Chicago, Illinois.
38. Bhardwai G, Ohno T, Gish RG, Lau JYN, In vivo activation of cytotoxic t-lymphocyte
(CTL) pathways in HCV-related cirrhosisimplications on immunopathogenesis Pre-
sented at the AASLD Liver Meeting, 1996. Chicago, Illinois.
39. Gish RG, Lee A, Brooks L, Leung J, Block GD. Long-term follow-up of patients
evaluated for liver transplantation using a method of risk stratification for estimating re-
cidivism. Presented at the American Society for Transplantation Physicians (ASTP) 15th
Annual Scientific Meeting, May 1997.
40. Gish RG. Assessment of an immunoblot hepatitis C virus serologic genotyping assay in
a large cohort of US patients. Presented at Digestive Diseases Week (DDW), 1997.
Washington, DC.
41. Xiang J, Klinzman D, Schmidt WN, Labrecque DR, Gish RG, Stapleton JT. Biophysical
characterization of hepatitis G virus. Presented at the 97th American Society for Micro-
biology Meeting (ASM), May 1997. Miami Beach, Florida.
42. Xing J, Ghany M, Ayola B, Villamil F, Gish RG, Rojter S, Vierling J, Lok, ASF. HBIG
induces mutations in the HBV S but not pre-S gene in liver transplant patients. Present-
ed at the AGA Annual Meeting, May 1997.
43. Elkayam O, Hassoba HM, Ferrell LD, Garcia-Kennedy R, Gish RG, Wright TL, Rosen-
thal P. Hepatitis GBV-C infection in children pre- and post-liver transplantation. Hepa-
tology. October 1997; 94. Presented at the AASLD Liver Meeting, 1997. Chicago, Illi-
nois.
44. Terrault NA, Pessoa MG, Singleton S, Kim E, Martin P, Crippin J, Gish RG, Keeffe E,
Lake J, Ascher N, Wright TL. Improved survival of hepatitis B patients undergoing liver
transplantation: Effects independent of therapeutic interventions. Presented at the
AASLD Liver Meeting, October 1997. Chicago, Illinois.
Villeneuva JP, Caldwell S, Brown N, Self P, and the Lamivudine Transplant Group.
Long term Lamivudine therapy of patients with recurrent hepatitis B post-liver transplan-
tation. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.
46. Xing J, Ghany M, Villamil F, Roiter S, Gish RG, Vierling J, Lok ASF. Different patterns
of HBV S gene mutations in liver transplant (OLT) patients (PTS) with and without HBV
reinfection. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.

Curriculum Vitae


47. Xing J, Hussain M, Roiter S, Gish RG, Villamil F, Vierling J, Lok ASF. Mutations in the
HBV pre-S regions are associated with more severe liver disease. Presented at the
AASLD Liver Meeting, 1997. Chicago, Illinois.
48. Perrillo R, Rakela J, Martin P, Wright T, Levy G, Schiff E, Dienstag J, Gish RG, Dickson
R, Adams P, Brown N, Self P, and the Lamivudine Transplant Group. Lamivudine for
suppression and/or prevention of hepatitis B when given pre/post liver transplantation
(OLT). Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.
49. Tung BY, Tabasco-Minguillan J, Bacon BR, Farrell FJ, Gish RG, McCashland TM,
Kowdley KV. Long-term follow-up after liver transplantation for hereditary hemochroma-
tosis. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.
50. Gish RG, Lee A, Brooks L, Leung J, Block GD. Long-term follow-up of patients
evaluated for liver transplantation using psychiatric risk factors for estimating recidivism.
Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.
51. Fischer L, Mller-Ruchholtz C, Gnther S, Gish RG, Will H, Sterneck M. Serial analysis
of the complete hepatitis B virus nucleotide sequences in patients with fibrosing choles-
tatic hepatitis after liver transplantation. Presented at the AASLD Liver Meeting, 1997.
Chicago, Illinois.
Villeneuva, JP, Caldwell S, Brown N, Self P, and the Lamivudine Transplant Group.
Long term Lamivudine therapy of patients with recurrent hepatitis B post-liver transplan-
tation. Presented at the AASLD Annual Meeting, 1997. Chicago, Illinois.
53. Xing J, Ghany M, Villamil F, Rojter S, Gish RG, Vierling J, Lok ASF. Different patterns of
HBV S gene mutations in liver transplant patients with and without NBV reinfection. Pre-
54. Xing J, Hussain M, Rojter S, Gish RG, Villamil F, Vierling J, Lok ASF. Mutations in the
HBV pre-S regions are associated with more severe liver disease. Presented at the
55. Perrillo R, Rakela J, Martin P, Wright T, Levy G, Schiff E, Dienstag J, Gish RG, Dickson
R, Adams P, Brown N, Self P, and the Lamivudine Transplant Group. Lamivudine for
suppression and/or prevention of hepatitis B when given pre/post-liver transplantation
(OLT). Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.
56. Terrault NA, Pessoa MG, Singleton S, Kim E, Martin P, Crippin J, Gish RG, Keeffe E,
Lake J, Ascher N, Wright TL. Improved survival of hepatitis B patients undergoing liver
transplantation: Effects independent of therapeutic interventions. Presented at the
57. Tung BY, Tabasco-Minguillan J, Bacon BR, Farrell RJ, Gish RG, McCashland TM,
Kowdley KV. Long-term follow-up after liver transplantation for hereditary hemochroma-
tosis. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.

Curriculum Vitae


58. Elkayam O, Hassoba HM, Ferrell LD, Garcia-Kennedy R, Gish RG, Wright TL, Rosen-
thal P. Hepatitis GBV-C infection in children pre- and post-liver transplantation. Pre-
59. Pessoa MG, Kim E, Martin P, Crippin J, Keeffe E, Gish RG, Ascher N, Wright TL,
Terrault NA. Dual effects of hepatitis B (HBV) infection and hepatitis B immunoglobulin
(HBIG) in educing the incidence of acute rejection post-transplantation. Presented at the
60. Dienstag J, Schiff E, Wright T, Perrillo R, Hann H-W, Crowther L, Woessner M, Rubin M,
Brown N, and the U.S. Lamivudine Investigator Group (Gish RG). Lamivudine treatment
for one year in previously untreated U.S. hepatitis B patients : histologic improvement
and hepatitis Be-antigen (HBeAg) seroconversion. Presented at the AGA Meeting, May
1998.
61. Pawlotsky JM, De Gendt S, Beaucourt, S, Lopes Gozclaes F, Butterworth LA, Cooksley
WGE, Gish RG, Ganne-Carrie N, Beuaugrand M, Fay O, Gonzalez JE, Brngel Martine
RM, Dhumeuax D, Vanderborght B, Stuyver L. Worldwide spread of hepatitis C virus
genotype 3a among intravenous drug users. Presented at the AASLD Liver Meeting,
1998.
62. McHutchison J, Gordon S, Schiff E, Shiffman M, Lee W, Rustgi V, Albrecht J for the
Hepatitis Interventional Therapy Group (Gish RG). Interferon alpha-2b alone or in com-
bination with Ribavirin in naive chronic HCV patients: A US multicenter randomized trial.
Presented at the AASLD Liver Meeting, 1998.
63. Cahoon-Young B, Gish RG, Livermore T, Clanon K. Prevalence of hepatitis C anti-body
and HIV co-infection in a high-risk female population. Presented at the AASLD Liver
Meeting, 1998.
64. Xu I, Guo L, Gish RG, Mason AL. A human endogenous retrovirus as a candidate
autoimmune gene in primary biliary cirrhosis. Presented at the AASLD Liver Meeting,
1998.
65. Poordad F, Yao F, Gish RG, Steady S, Osorio R, Roberts J. Post-orthotopic liver
transplantation antiviral therapy and immunoprophylaxis against recurrent hepatitis B.
Presented at the AASLD Liver Meeting, 1998.
66. Gish RG, Yao F, Brooks L, Poordad F, Cain-Schulze G and the North American
RibaHep study group. A randomized trial of interferon alfa-2b, daily vs. three times a
week for one month, followed by three times a week for one year in combination with
ribavirin in patients who have failed a previous course of interferon. Presented at the
AASLD Liver Meeting, 1998.
67. Yao F, Gish RG, Poordad F, Rodvien R. Hepatocellular carcinoma: data from the
California Cancer Registry. Presented at the AASLD Liver Meeting, 1998.
68. Gish RG, Cahoon-Young B, Clanon K, Livermore T, and Wakil A. Epidemiology,
diagnosis and management of hepatitis C in high-risk populations: A community-based
approach to developing coordinated services and harm reduction strategies. Journal
Substance Abuse, 1999. The American Society of Addiction Medicine, 1999.
Curriculum Vitae


69. Gish RG, Leung NWY, Schooley RT, Sykes A, Turner F, Shi H, Wakeford C, Delehanty
H, Rousseau F. Emtricitabin (FTC): Activity Against Hepatitis B Virus in a Phase I/II
Clinical Study. ICAAC for TRCB-101. May 1999.
70. Gish RG. Lamivudine for Prevention of Recurrent Hepatitis B After Liver Transplanta-
tion: Final Result of U.S./Canadian Multicenter Trial. A2006 Study AASLD 1999.
71. Tanaka A, Prindiville T, Solnick J, Coppel RL, Lake J, Keeffe E, Gish R, Gershwin ME.
Molecular identification of infectious agents in primary biliary cirrhosis. Presented at the
AASLD Liver Meeting, 1998.
72. Gish R, Leung NWY, Schooley R, Sykes A, Turner F, Shi H, Wakeford C, Delehanty J,
Rousseau F, California Pacific Medical Center, San Francisco, CA; Prince of Wales
Hospital, Hong Kong China; University of Colorado, Denver, CO; Triangle Pharmaceuti-
cals, Durham, NC. Emtricitabine (FTC): Activity against Hepatitis B Virus in a Phase
1/11 Clinical Study. Presented at ASMs 39th Interscience Conference on Antimicrobial
Agents and Chemotherapy, September 29-29, 1999.
73. Crippin J, Gish R, Prieto M, Bass T, Baker C, Watson J, Hillygus J, Netto G, Alonzo J,
Garcia R, Wright TL. Marked Increase In Post-Transplantation (OLT) HCV-Related Fi-
brosis Progression in Recent Years. November AASLD 1999.
74. Perrillo R, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, Dienstag J, Adams P,
Dickson R, Anschuetz G, Bell S, Brown N and the Lamivudine Transplant Group. A Mul-
ticenter U.S.- Canadian Trial to Assess Lamivudine Monotherapy Before and After Liver
Transplantation for Chronic Hepatitis B. DDW AASLD 2000.
75. Renz J, Osorio R, Horan S, Diaz G, Venook A, Gish R, Ascher N, Lake J, Roberts J,
Chemo-Embolization for Treatment of Hepatocellular Carcinoma Discovered While
Awaiting Liver Transplantation: A Multicenter Experience. Presented at the AGA Annu-
al Meeting, May 2000.
76. Durr R, Gish R, Brooks L, Williams R, Naoumov NV. Functional Characterization Of Full
Length Hepatitis B Virus (Hbv) Genomes From Liver And Serum Of Patients With Fi-
brosing Cholestatic Hepatitis. Presented at DDW, 2000.
77. Wright T, Gish R, Teverson G, Mcquire B, Crippin J, Batts K, Brass, C, Ullemeyer V,
Interferon-Alfa2B and Ribavirin Combination Therapy in Liver Transplant Recipients with
Recurrent Hepatitis C. Division of Gastroenterology & Hepatology. AASLD 2000.
78. Gish R, Hepatitis C Virus: Evaluation and management. Presented at the Family
Practice Re-Certification Meeting, June 2000.
79. Kowdley K, Tung B, Han S, Bass A, Gish R, Brandhagen D, Sterling R, Cotler S,
Fontana R, McCashland T, Emond M, National Hemochromatosis Transplant Registry
Investigators. Prevalence of Hepatic Iron Overload and HFE Mutations among orthotop-
ic Liver Transplant Recipients: Preliminary Results from the National Hemochromatosis
Transplant Registry. Presented at the AASLD Liver Meeting, October 2000.

Curriculum Vitae


80. Gish R, Wright T, Leung NWY, Trinh A, Robertson T, Delehanty J, Rousseau F, and
Delehanty J. Emtricitabine (FTC): Results from a 24-week dose-selection trial in pa-
tients with chronic HBV infection (FTCB-102). Presented at the AASLD Liver Meeting,
October 2000.
81. Jazayeri M, Sran N, Gish R, Basuni A, Cooksley G, Locarnini S, Carman WF. HBV Core
Sequence: Definition of Subtype-Specific Variability and Correlation With Geographic
Origin. Presented at the AASLD Liver Meeting, October 2000.
82. Gish R, Wakil A, Brooks L, Schulze G, Leung J. A Randomized Trial of Daily Interferon
Alfa-2B in Combination With Ribavirin, vs. Three Times a Week For One Month, Fol-
lowed by Three Times a Week for One Year in Relapse or Nonresponder Patients.
AASLD 2000.
83. Aschara G, Sadovsky R, Gish R, Paulotsky JM, Sulkowski M. Hepatitis C Virus:
Establishing the Standards of Diagnosis and Treatment. Presented at the Family Prac-
tice Re-certification Meeting, July 2000.
84. Hadlock K, Gish R, Rowe J, Rajyaguru S, Newsom M, Foung S, Cross Reactivity and
Clinical Impact of the Antibody Response to Hepatitis C Virus (HCV) Second Envelope
Glycoprotein (E2). AASLD 2000.
85. Hadlock K, Gish R, Rajyagura S, Row J, Newsom M, Dagan S, Foung S. High Levels of
Antibodies that can neutralize HCV Infection in the HCV-Trimera Model are rare in HCV
infected individuals. AASLD 2000.
86. Berenguer M, Watson J, Crippin R, Gish R, Netto G, Alonzo J, Garcia R, Wright T, Dept.
of Medicine VAMC/UCSF, Baylor University (Dallas), California Pacific Medical Center
(SF), La Fe-Hosp. (Valencia, Spain). HCV Related Fibrosis Progression Following Liver
Transplantation (OLT). AALSD 2000.
87. Shakil A, McGuire B, Crippin J, Conjeevaram H, Teperman L, Gish R, Kwo P, Wright T,
Demetris J, Rakela J, Division of Gastroenterology. Hepatology & Nutrition, University of
Pittsburgh, PA 15213 and MIRTH Study Group. Interferon-Alpa2B and Ribavirin Combi-
nation Therapy in Liver Transplant Recipients with Recurrent Hepatitis C AASLD 2000.
88. Kowdley, Brandhagen, Crippin, Gish RG, Bacon, Keeffe, Sterling, Fontana, Cotler,
Emond, NHTR Investigators. Survival after Orthotopic Liver Transplantation Among Pa-
tients with Hepatic Iron Overload: Preliminary Results from the National Hemochroma-
tosis Transplant Registry. Presented at the AASLD Liver Meeting, October 2000.
89. Kowdley, Tung, Han, Bass, Gish RG, Brandhagen, Sterling, Cotler, Fontana, McCash-
land, NHTR Investigators. Prevalence of Hepatic Iron Overload and HFE Mutations
Among Orthotophic Liver Transplant Recipients: Preliminary Results from the National
Hemochromatosis Transplant Registry. Presented at the AASLD Liver Meeting, October
2000.
90. Sanne I, Gish RG. FTC-302 Study Investigators and the FTC-302 Clinical Steering
Committee. Severe Liver Toxicity in Patients Receiving Two Nucleoside Analogues and a
Non Nucleoside Reverse Transcriptase Inhibitor. Presented at the AIDS and Retroviral
meeting, December 2000, Glasgow, Scotland, and DDW, May 2001, Atlanta, Georgia.
Curriculum Vitae


91. Hadlock, Gish RG, Rowe, Rajyaguru, Newsom, Warford, Foung. Cross Reactivity and
Clinical Impact of the Antibody Response to Hepatitis C virus (HCV) Second Envelope
Glycoprotein. DDW 2001.
92. Gish RG, Pawlostky JM, Gendt, Beaucourt S, Lopes F, Goncales, Butterworth,
Cooksley WGE, Ganne-Carrie N, Beaugrand M, Fay F, Fay O, Gonzalez JE, Martins
RM, Dhumeaux D, Vanderborght B, Stuyver J. Molecular Epidemiology of Hepatitis C Vi-
rus Genotype 3a In Intravenous Drug Users (IVDUs). 1999. AASLD
93. Gish RG. Severe Liver Toxicity In Patients Receiving Two Nucleoside Analogues and a
Non-Nucleoside Reverse Transcriptase Inhibitor. Presented at the AGA Meeting, May
2001.
94. Gish RG, Kowdley, Brandhagen, Bass, Weinstein, Schilsky, Fontana, McCashand,
Cotler, Bacon, Keefe and Nayak. Survival after Orthopedic Liver Transplant (OLT)
Among Patients With Hepatic Iron Overload: Interim Results from the National Hemo-
chromatosis Transplant Registry (NHTR). Presented at the AASLD Liver Meeting, 2001.
Dallas, Texas.
95. McHutchison J, Yoffe B, Brown R, Schiff E, Reddy R, Shiffman M, Carrithers R, Wright
T, Fried M, Gish RG, Younossi Z, Poulios N. Preliminary Report of the Development of a
Hepatitis C Web-based Patient Registry at 11 US Hepatology Units. Presented at the
AASLD Liver Meeting, 2001. Dallas, Texas.
96. Gish RG, Larry Corey, Nancy Leung, Amy Rigney, Lei Fang, Elsa Mondou, John
Dillberger, Antiviral Activity of 48 Weeks of Emtricitabine Treatment in Patients with
HbeAg Negative DNA Positive Chronic Hepatitis B (CHB). Hepatology 2001; 34: 323A.
Presented at the AASLD Liver Meeting, 2001. Dallas, Texas.
97. Gish RG, Leung NEWY, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH,
Delehanty J, Rigney A, Mondou E, Sykes A, and Rousseau F. A Dose Ranging Study of
the Pharmacokinetics, Safety, and Preliminary Antiviral Activity of Emtricitabine in Adults
with HBV Infection. 2001.
98. Gish RG, Fuminaka S, Etsuro O, et al. Recombination of HBV Genotypes. Nagoya City
University Medical School, December, 6, 2001.
99. Jazayer M, Basuni A, Sran N, Gish R, Cooklesy G, Locarnini S, Carman WF. HBV Core
Sequence: Definition of Genotype-Specific Variability and Correlation with Geographic
Origin. Journal of General Virology. 2001.
100. Kato H, Orito E, Sugauchi F, Gish R, Ueda R, Miyakawa Y, Mizokami M. New Detection
System for Hepatitis B Virus (HBV) of Genotype G and its Surveillance in Japanese Pa-
tients with HBV Infection. Journal of Medical Virology. 2001.
101. Gish R, Wright T, Wang C, Corey L, Leung N, Sykes A, Mondou E, Fang, L, Rousseau
F. HBeAg profile in patients with Chronic HBeAg+ hepatitis BV (CHB) treated with
emtricitabine (FTC) for 1 year. Presented at the AASLD Liver Meeting, 2001. Dallas,
Texas.

Curriculum Vitae


102. McHutchison J and the IHIG Study group (Gish RG). Durability of sustained virologic
response in patients with chronic hepatitis C after treatment with interferon alfa-b alone
or in combination with ribavirin. Abstract 281. Presented at the AASLD Liver Meeting,
2001. Dallas, Texas.

103. Sulkowski M, Wasserman R, Brooks L, Ball L, Gish R. Hemoglobin Changes During
Interferon/Riboviran Treatment. July 23, 2002.

104. Tong M, Shiffman M, Heathcote J, Gish RG, et al. Long-term safety beyond 48 weeks of
adefovir dipivoxil (ADV) 10 mg once daily for chronic hepatitis B (CHB): an integrated
analysis of two phase III studies. 2002.
105. Javaheri S, Bzowej N, Wakil A, Gish RG, et al. A new clue in HBV fibrosis progression:
negative HBV DNA levels in treatment nave patients are associated with cirrhosis re-
gardless of duration of disease. 2002.
106. Bzowej N, Gish RG, Wakil AE, Brooks l, Shaffer M, et al. Comparison of peginterferon
Alfa-2B and ribavirin with or without induction therapy for the treatment of chronic hepati-
tis C (HCV) nonresponders. 2002.
107. Terrault N, Friesenhahn M, Gish RG, et al. Decline in HCV viral load in chronically-
infected patients during the first eight weeks of therapy with standard interferon/ribavirin
is highly predictive of virologic outcome. Presented at the National Institutes of Health
Management of Hepatitis C Meeting, June 10-12 2002.
108. Selmi C, Mayo M, Gish RG, et al. Occurrence of primary biliary cirrhosis in identical
twins. 2002.
109. Afdahl N, Flamm S, Gish RG, et al. Analysis of 40 KDA peginterferon Alfa-2A
(PEGASYS) in combination with ribavirin, mycophenolate mofetil, amantadine, or
amantadine plus ribavirin in patients that relapsed or did not respond to Rebetron
therapy: a report of two randomized, multicenter, efficacy and safety studies. Abstract
41184. Presented at the AASLD Liver Meeting, 2001. Dallas, Texas.
110. Zarski J, McHutchison J, Bronowicki J, Gish RG, et al. Rate of natural disease progres-
sion in patients with chronic hepatitis C. 2002.
111. Kato H, Orito, E, Sugauchi, F, Ueda, R, Gish RG, Usuada, S, Miyakawa, Y, Mizokami,
M. . Recombination of HBV genotypes. 2002.
112. Elbeik T, Friesenhahn M, Gish RG, et al. Decline in HCV viral load in chronically-
infected patients during the first eight weeks of therapy with standard interferon/ribavirin
is highly predictive of virologic outcome. Presented at the AASLD Liver Meeting, 2002.
113. Kato H, Orito, E, Sugauchi, F, Ueda, R, Gish RG, Usuada, S, Miyakawa, Y, Mizokami,
M. Molecular analysis of hepatisi B virus of genotype G (HBV/G) and development of a
new method for detecting HBV/G. APASL J Gastro Hepatology. 2003;17;suppl. abs PI-2-
0:A44.
114. Shiffman ML, Angelino A, Gish RG. Side Effects Associated with the Treatment of
Hepatitis C, Infection: Recommendations for Improved Management. 2002.
Curriculum Vitae


115. Gish RG, TT Chang, S Hadziyannis, J Cianciara, M Rizzeto, E Schiff, G Pastore, K
Klesczewski, G Denisky J Zhu, D DeHertogh, R Hindes. Sustained Vral Load and ALT
Reduction following 48 weeks of Entecavir Treatments in HBeAg Negative and Positive
patients with Chronic Hepatitis B Who Have Failed Prior Lamivudine Therapy. Present-
ed at the European Association for the Study of the Liver (EASL) Meeting, 2003..
116. Gish RG. Clinical Significance of Nucleoside Resistance in HBV Antiviral Therapy.
Presented at Strategic Implications International, April, 2003.
117. Gish RG. Neuroendocrine Tumor Case Review. Presented at Williams Labadie
Communications for Healthcare Conference, January, 2003.
118. Gish RG. HCV side-effect management. Presented at DVC Healthcare Communications
Conference, March, 2003.
Conference, April, 2003.
120. Gish RG. SGNA Controversies in Hepatitis C Therapy Presented at Medical Education
Collaborative, Inc. (MEC) Conference, May 2003.
121. Gish RG. HCV The Case for Selective Treatment. Nurses CE Symposium, Contro-
versies in Hepatitis C Therapy, Does the Patient Really Need Treatment? Does the Pa-
tient Really Need a Liver Biopsy? Presented at Medical Education Collaborative Con-
ference, May 18, 2003. Atlanta, GA.
Conference, October, 2003.
Conference, October, 2003.
124. Gish RG, Sulkowski M, Wasserman R, Brooks L, Ball L. Changes in Hemoglobin During
Interferon alfa-2b Ribavirin Combination Therapy for Chronic Hepatitis C Virus Infection.
October, 2003.
125. Pockros P, Schiff E, Shiffman M, McHutchison J, Muir A, Beth A, Gish RG, Huyghe T,
Oltersdorf T, and Shapiro I. The First Caspase Inhibitor of Apoptosis, IDN-6556, Given
Orally Lowers Liver Enzymes in HCV Patients. October 2003.
126. Afdhal NH, Gish RG. New Data on Managing Anemia with Growth Factors for Patients
on Anti-HCV Therapy: A Case Based Series. October 2002.
127. Study Group 435 International Investigators Group (Gish, RG). Adefovir Dipivoxil
Therapy for Lamivudine-Resistant Hepatitis B in Pre- and Post- Liver Transplantation
Patients. Presented at the AASLD Liver Meeting, 2003.
128. Bzowej N, Gish RG, Newsom, M. Eight Genotypes (A-H) for Hepatits B Virus Infecting
Patients from San Francisco and their Demographic Clinical and Virological Characteris-
tics. Presented at the AGA Meeting. 2003.

Curriculum Vitae


129. Gish RG. Treating hepatitis C: the state of the art. Gastroenterol Clin North Am.
December 2003.
130. Gish RG, Selmi C, Mayo M, Bach N, Ishibashi H, Invernizzi P, Gordon S, Wright H,
Podda M, Stastny P, Gershwin E. Primary Biliary Cirrhosis in Monozygotic and Dizygotic
Twins, Genetics, Epigenetics and Environment. March 2004.
131. Gish RG, Tanaka Y, Hasegawa I, Kato T, Orito E, Hirashima N, Archarya S, Shrestha S,
Khan M, Miyakawa Y, Mizokami M. A Case-control Study for Differences among Hepati-
tis B Virus Infections of Genotypes A (Subtypes Aa and Ae)and D. March 2004.
132. Gish RG, Sugauchi F, Kumada H, Acharya S, Shrestha S, Gamutan T, Khan M, Tanaka
Y, Kato T, Orito E, Ueda R, Miyakawa Y, Mizokam, M. Epidemiological and virological
differences between two subtypes (Ae and Aa) of the hepatitis B virus genotype A. Jour-
nal of General Virology. March 2004.
133. Gish RG, Westland W, Delaney W, Huiling Y, Chen S, Marcellin P, Hadziyannis S, Fry
J, Brosgart C, Gibbs C, Miller M, Xiong, S. Hepatitis B Virus Genotypes and Virologic
Response in 694 Patients in Phase III Studies of Adefovir Dipivoxil. Presented at the
AGA Meeting, 2004.
134. Gish RG. Maximizing the Benefits of Antiviral Therapy for HCV: The Advantages of
Treating Side Effects, Treating Hepatitis C: State of the Art, March 2004.
135. Gish RG. Hepatitis C Combination Therapy with Virmadine and Peginterferon Alfa-2a
Reduces Potential for Ribavirin-Related Hemolytic Anemia. DDW AASLD, 2004.
136. Gish RG, Sanne I, Marin H, Hinkle J, Bartlett J, Lederman M, Maarteens G, Wakeford
C, Shaw A, Quinn J, Rousseau F. Severe Hepatotoxicity Associated with Nevirapine
Use in HIV-infected Patients, ICAAC 2004.
137. Gish RG. HCV in San Francisco and their demographic, clinical and virologic character-
istics. Journal of Medical Virology. March 2004.
138. Gish RG, Chang TT, Hadziyannis S, Cianciara J, Rizzetto M, Schiff E, Pastore G,
Jackson R, Thiry A, Hindes, R. Lamivudine-refactory Hepatitis B can be safely switched
directly to Entecavir 1.0mg daily therapy. Presented at the 39th Annual EASL Meeting,
2004.
139. Gish RG, Arora S, Nelson D, Fernandez H, Lamon K. Safety and efficacy of Viramidine
in combination with pegylated interferon alfa-2a for treatment of hepatitis C in therapy-
nave patients. Presented at the 39th Annual EASL Meeting, 2004.
140. Gish RG, Patt Y, Garcia-Vargas J, Gallo J, Suplick G. Demographics from the ETHECC
trial: A randomized comparison between Thymitaq and doxorubician for the treatment of
unresectable hepatocellular carcinoma (HCC) in terms of survival. 2004.
141. Gish RG, Bzowej N, Phung Y, Bonacini M, Wakil A, Lubliner G, Hassoun A, Rabkin J,
Hisatake G, Osorio R. Transplantation of HCV-positive livers in HCV-positive patients:
Interaction between donor and recipient virus. 2004.

Curriculum Vitae


142. Lok A, Regev A, Keeffe E, Han SH, Emre, S, Ishitani, M, Luketic V, Brown R, Fung SK,
Hussain M, HBV-OLT Study Group (Gish RG). Relation between HBV genotypes and
HBV variants and indications for liver transplant (LT) in hepatitis B patients in the US.
2004.
143. Patt Y, Gish RG, Garcia-Vargas J, Gallo J, Suplick G, Senico P. Thymitaq (nolatrexed
diihydrochloride) in unresectable HCC. Update of the ETHECC trial, a pivotal random-
ized phase III study comparing Thymitaq vs. doxorubicin in terms of survival. Gastroin-
testinal Oncology. 2004.
144. Chang T, Gish RG, de Man R, Gadano A, Sollano J, Han KH, Goodman Z, Cross Z,
Dehertogh D, Apelian D and the Entecavir study group. Entecavir is Superior to Lamivu-
dine for the treatment of HBeAg(+) chronic hepatitis B: results of phase III study ETV-
022 in nucleoside-nave patients. Presented at the AASLD Liver Meeting, 2004. Boston,
Massachusetts.
145. Terrault N, Godofsky E, Gish RG. New Hepatitis C Drugs: Can Safety, Efficacy be
Improved. Gastroenterology and Endoscopy News. 2004.
146. Snow A, Lim SG, Gish R, Sorbel J, Anderson J, Rousseau F. Correlation between
baseline genotype and antiviral response to Emtricitabine 200mg QD among HBeAg
positive patients with chronic hepatitis B infection. Presented at the AASLD Liver Meet-
ing, 2004. Boston, Massachusetts.
147. Gish RG, et al. ETV Efficacy across Disease-Related Baseline Subgroups. Presented at
the EASL Meeting, April 2004. Berlin, Germany.
148. Gish RG, Arora S, Nelson D, Fried M, Reddy KR, Xu Y, Peterson J, Murphy, B. End-of-
Treatment (EOT) Response in Therapy-Nave Patients Treated for Chronic Hepatitis C
with Viramidine in Combination with Pegylated Interferon. Presented at the AASLD Liver
Meeting, 2004. Boston, Massachusetts.
149. Gish RG, de Man RA, Pedersen C, et al. Sustained response off-treatment to entecavir
and lamivudine after 48 weeks of treatment in nucleoside-nave, HBeAg+ patients: 24-
week follow-up results of phase 3 study ETV-022. J Hepatol. 2005; 42(suppl 2):177.
Presented at the EASL Meeting, April 2005.
150. Gish RG, Trinh H, Leung N, Chan FKL, Fried MW, Wright TL, Wang C, Anderson J,
Mondou E, Snow A, Sorbel J, Rousseau F, Corey L., from Journal of Hepatology. JHE-
2004-00980.R1. Safety and Antiviral Activity of Emtricitabine (FTC) for the treatment of
Chronic Hepatitis B Infection: A Two Year Study. CAB Abstracts. 2005.
151. Porta C, Gish RG, Patt Y, Suplick G, Garcia-Vargas J, Gallo J. Demographics from the
ETHECC (Evaluation of THYMITAQ [nolatrexed dihydrochloride] in the Hepatocellu-
lar Carcinoma [HCC]) trial population. June 2005.
152. Porta C, Gish RG, Patt Y, Suplick G, Garcia-Vargas J, Gallo J. Improved safety profile
of nolatrexed dihydrochloride (THYMITAQ) IN THE Phase III Hepatocellular Carcinoma
(HCC) trial when compared to the safety of the Phase II program.

Curriculum Vitae


153. Nguyen T, Tong M, Brown R, Columbia, Gish R, Grant G, Viridae, Pico CS, Joshi S,
Siegal S, Lin C. Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Remo-
fovir in Chronic HBV Patients in US and Canada Following Daily Dosing for 28 days.
Presented at the EASLMeeting, April 2005. Paris, France.
154. Gish R, N Bzowej N, Brooks L, Brass C, Weng W. Treatment with Pegylated Interferon
ALFA-2B in Combination with Ribavirin Improved Health-Related Quality of Life Com-
pared with Interferon ALFA-2B Plus Ribavirin in Chronic Hepatitis C. 2005.
155. Sanne I, Marin H, Hinkle J, Bartlett J, Lederman M, Maarteens G, Wakeford C, Shaw A,
Quinn J, Gish RG, Rousseau F. Severe Hepatotoxicity Associated with Nevirapine Use
in HIV-Infected Subjects. 2005.
156. Yurdaydin C, Ciancara J, Gish RG, Chang TT, Sherman M, Apelian D, Fernandes L,
Hindes R, Thiry A, Cross A, Wilber R. Alanine Aminotransferase (ALT) Flares are Un-
common both On- and Post-treatment in Entecavir-Treated HBeAg-positive Patients.
Presented at the 40th Annual EASL Meeting, April 2005.
157. Lurie Y, Manns MP, Gish RG, Chang TT, Yurdaydin C, Lai CL, Shouval D, Brown RS,
Jr., Apelian D, Kiescziwski K, Cross A, Wilber R. The Efficacy of Entecavir is Similar Re-
gardless of Disease-Related Baseline Subgroups in Treatment of Nucleoside-Nave,
HBeAg(+) Patients with Chronic Hepatitis B. Presented at the 40th Annual EASL Meet-
ing, April 2005.
158. Shouval D, Senturk H, Gish RG, Chang TT, Yurdaydin C, Lai CL, Lok A, Brown RS, Jr.,
Apelian D, Fernandes L, Kiesczewski K, Cross A, Wilber R. Entecavir Demonstrates
Consistent Responses Throughout Baseline, Demographic Subgroups for the Treatment
of Nucleoside-Nave, HBeAg(+) and HBeAg(-) Patients, with Chronic Hepatitis B. Pre-
sented at the 40th Annual EASL Meeting, April 2005.
159. Gish RG, De Man RA, Pedersen C, Bialkowska J, Chang TT, Apelian D, Fernandes L,
Zhu J, Cross A, Wilber R, and the BEHoLd Study Group. Sustained Response Off-
treatment to ntecavir and lamivaudine After 48 Weeks of Treatment in Nucleoside-nave,
HBeAg(+) Patients: 24-week Follow-Up Results of Phase 3 Study ETV-022. Presented
at the 40th Annual EASL Meeting, April 2005.
160. Manns MP, Raptopoulou-Gigi M, Soliano J, Gish RG, Chang TT, Sherman M, Yurdaydin
C, Shouval D, Lok A, Cooney E, Hindes R, Yang J, Cross A, Wilber R. Entecavir is Well-
tolerated for the Treatment of Nucleoside-Nave and Lamivudine-Refractory Chronic
Hepatitis B Viral Infection: Phase II/III Safety Results. Presented at the 40th Annual
EASL Meeting, April 2005.
161. Cianclara J, Yurdaydin K, Gish RG, Chang TT, Sherman M, Goodman Z, Brett-Smith H,
Hindes R, Thiry A, Cross A, Wilber R. Alanine Aminotransferase (ALT) Flare are Un-
common both On- and Post-treatment in Entecavir (ETV)-treated HBeAg(+) Patients.
Presented at the 13th World Congress of Gastroenterology, September 10-14, 2005.
Montreal, Canada.

Curriculum Vitae


162. Gish R, Chang TT, de Man R, Dadano A, Sollano J, Han KH, Goodman Z, Zhu J, Cross
A, Brett-Smith H, the BEHoLD Study Group. Entecavir is Superior to Lamivudine for the
Treatment of HBeAg(+) Chronic Hepatitis B: Results of Phase III Study ETV-022 in Nu-
cleoside-nave Patients. Presented at the 13th World Congress of Gastroenterology,
September 10-14, 2005. Montreal, Canada.
163. Hillebrand DJ, Pfeifle J, Roberts C, Lo T, Hay K, Bull B, Frederick RT, Gish
RG. Anticoagulation for an artificial liver support device, the I.M.P.A.C.T. system (In-
termittent Modular Plasma Adsorption of Cytokines and Toxins). ASAIO Journal.
March/April 2006;52(2):10A. Presented at the American Society for Artificial Internal Or-
gans (ASAIO) Meeting, 2006.
164. Behrsing HP, Tam J, Gray B, Do A, Zhao D, Jung J, Bundey R, Gish RG, McGuire BM,
Suh D-J, Park S-S. Characterization of a novel porcine liver slice-filled bioartificial liver
(BAL) for treatment of liver failure patients. ASAIO Journal. March/April 2006;52(2):10A.
Presented at the ASAIO Meeting, 2006.
165. Hillebrand DJ, Pfeifle J, Roberts C, Lo T, Federick T, Gish RG. Intermittent modular
plasma adsorption of cytokines and toxins (IMPACT System) in subjects with cirrhosis
hepatic encephalopathy. ASAIO Journal. March/April 2006;52(2):10A. Presented at the
ASAIO Meeting, 2006.
166. Hillebrand DJ, Pfeifle J, Roberts C, Lo T, Frederick T, Gish RG. Improvement in
systemic hemodynamics with the I.M.P.A.C.T. System artificial liver support device.
ASAIO Journal. March/April 2006;52(2):10A. Presented at the ASAIO Meeting, 2006.
167. Veenstra DL, Iloeje UH, Tafesse E, Sullivan SD, Cross A, Di Bisceglie A, Gish RG.
Cost-effectiveness of Antivirals in HBeAg-positive Chronice Hepatitis B: Impact of Sero-
conversion and Viral Suppression. Presented at DDW, May 20-25, 2006. Los Angeles,
California.
168. Gish R, Behrsing HP, Tam J, Gray B, Do A, Park Y, Yun H, Zhao D, Gropper C, Jung J,
McGuire BM, Panoskaltsis-Mortari A, Lau GK, Lim Y-S, Lee HC, Suh D-J, Park S-S. In
vivo characterization of a novel procine liver slice-filled bioartificial liver (BAL) for treat-
ment of liver failure patients. HepaHope Inc. Presented at the World Tranplant Con-
gress, 2006.
169. Gish R, Fischer L, Will H, Sterneck M. Severe Recurrent Hepatitis B: Comparative
Analysis of Complete Genomic Sequences Isolated Before and After Liver Transplanta-
tion. Presented at the World Transplant Congress, August 2006. Boston, MA.
170. Gish R. Anticoagulation for an Artificial Liver Support Device, The I. M. P. A. C. T.
System [Trade] (Intermittent Modualr Plasma Adsorption of Cytokines and Toxins). Pre-
sented at the Blood Substitutes and Hematology Meeting., June 10, 2006.
171. Gish R, Porta C, Ruff P, Feld R, Feun L, Jeziorski K, Leighton J, Kennealey G. Results
of a Phase III randomized controlled study comparing the survival of patients with unre-
sectable hepatocellular carcinoma (HCC) treated with nolatrexed (NOL) or doxorubicin
(DOX). Presented at the Shanghai-Hong Kong Liver Congress, March 2006. Shanghai,
China.

Curriculum Vitae


172. Gish R. A Trial of Zdaxin? (thymalfasin) with Trans Arterial Chemoembolization (TACE)
in the treatment of adult patients with unresectable hepatocellular carcinoma: A Phase II
trial. Presented at the Shanghai-Hong Kong Liver Congress, March 2006. Shanghai,
China.
173. DeMan RA, Mutimer D, Gish RG, Chang T-T, Zhu J, Cross A, Brett-Smith H. Entecavir
(ETV) treatment through 96 weeks results in substantial virologic and biochemical im-
provement and HBeAg seroconversion in HBeAg(+) chronic patients (Study ETV-022).
Presented at the International Association for the Study of the Liver (IASL) Meeting,
2006.
174. Gish R. This Study Compared the Efficacy and Safety of Zadaxin plus TACE with TACE
alone in Patients with Unresectable HCC. Final Abstract. EASL 2006.
175. Gish R, Park S-S, Jung J, Zhao D, Yun H, Tam J, Park Y, Gropper C, McGuire B,
Panoskaltsis-Mortari A, Han JJ, Lim Y-S, Lee HC, Suh D-J. Assessment of a Novel Po-
cine Liver Slice-filled Bio-artificial Liver (BAL) for Dialysis of Liver Failure Patients. Pre-
sented at the AASLD Liver Meeting, October 27-31, 2006. Boston, MA.
176. Gish RG, TT Chang, CL Lai, R de Man, A Gadano, F Poordad, J Zhu, H Brett-Smith, R
Wilber. Hepatitis B Surface Antigen Loss in Antiviral-Treated Patients with HBeAG(+)
Chronic Hepatitis B (CHB) Infection: Observations from Antiviral-Nave Patients Treated
with Entecavir (ETV) or Lamivudine (LVD). Presented at the AASLD Liver Meeting, Oc-
tober 27-31, 2006. Boston, MA.
177. Gish RG, TT Chang, YC Chao, J Kuydowicz, S Kaymacoglu, H Cheinquer, M Pessoa, F
Poordad, J Yang, H Brett-Smith, R Hindes. Entecavir Maintained Virologic Suppression
Through 3 Years of Treatment in Antiviral-Nave HBeAg(+) Patients (ETV 022/901). Pre-
sented at the AASLD Liver Meeting, October 27-31, 2006. Boston, MA.
178. Gish R, Schiff E, Di Bisceglie A, Raptopulou-Gigi M, Hadzyannis S, Kaymakoglu S,
Chang TT, Sollano J, Lai CL, Young J, Hindes R, Lopez-Talavera JC. Entecavir is well
tolerated for the treatment of nucleoside-nave and lamivudine-refractory chronic hepati-
tis B: safety data through 2 years. 2006. Boston, MA.
179. Hoffman JC, Gish RG. Hepatitis C Associated Systemic Cryoglobulinemia: Successful
Treatment with Plasma Exchange. Presented at the AASLD Liver Meeting, November 2-
6, 2007. Boston, MA.
180. Carr C, Hollinger FB Yoffe B, Wakil A, Phillips J, Bzowej N, Leung J, Mirro K, Poordad F,
Moore DH, Gish RG. Efficacy of Interferon Alpha-2b Introduction Therapy before Re-
treatment for Chronic Hepatitis C. Presented at the AASLD Liver Meeting, November 2-
181. Schiff ER, Everson GT, Tsai N, Bzowei NH, Gish RG, McHutchison JG, Jacobson IM,
Tong MJ, Jensen DM, Lauer GM, Cruickshank S, Ferraro J, Haller A, Duke R, Rodell T,
Apelian D. HCV-Specific Cellular Immunity, RNA Reductions, and Normalization of ALT
in Chronic HCV Subjects after Treatment with GI-5005, a Yeast-Based Immunotherapy
Targeting NS3 and Core: A Randomized, Double-blind, Pacebo Controlled Phase 1b
Study. Presented at the AASLD Liver Meeting, November 2-6, 2007. Boston, MA.
Curriculum Vitae


182. Gish RG, McGuire M. Acute Liver Failure and Artificial Liver Support. Presented at the
AASLD Liver Meeting, November 2-6, 2007. Boston, MA.
183. Han S, Chang TT, Chao Y, Yoon S, Gish RG, Cheinquer H, Carrillho F, Zhang H, Brett-
Smith H, Hindes R. Four-Year Entecavir Treatment in Nucleoside-Nave HBeAg (+) Pa-
tients: Results from Studies ETV-022 and -901. Presented at the AASLD Liver Meeting,
November 2-6, 2007. Boston, MA.
184. Gish R, Hofmann J. Hepatitis C Associated Systemic Cryoglobulinemia: Successful
Treatment with Plasma Exchange. Presented at the AASLD Liver Meeting, November 2-
185. Chang TT, Caho YC, Lai CL, Yoon SK, Han KH, Tan CK, Gish RG, Cheinquer H, Han
S, Zhang H, Smith HB, Hindes R. Four-Year Treatment with Entecavir Results in High
Proportions of Nucleoside-Nave HBeAg-Positive Patients with Undetectable HBV DNA:
Results from Studies ETV-022 and -901. Presented at the AASLD Liver Meeting, No-
vember 2-6, 2007. Boston, MA.
186. Pachuk C, Gish R. Preclinical and Clinical Development of NUCB1000 An Expressed
Interfering RNA-Based Hepatitis B Antiviral. Presented at HEP DART, December 2007.
187. Schiff E, Everson G, Tsai N, Bzowej N, Gish R, McHutchison J, Jacobson I, Tong M,
Jensen D, Lauer G, Cruickshank S, Ferraro J, Haller A, Duke R, Rodell T, Apellian D.
HCV-Specfic Cellular Immunity, RNA Reductions, and Normalization of ALT in Chronic
HCV Subjects After Treatment with GI-5005, A Yeast-Based Immunotherapy Targeting
NS3 And Core: A Randomized, Double-Blind, Placebo Controlled Phase 1B Study. Pre-
sented at the AASLD Liver Meeting, November 2-6, 2007. Boston, MA.
188. Park S-S, Yang Y-K, Lee Y-I, Jung J, Zhao D, Park Y, Yoon H, Tam J, Ganda C, Lee H-
T, Park J, Yang S, Groupper C, Gish RG, McGuire BM, Panoskaltsis-Mortair A, Lim Y-S,
Lee HC, Suh D-J, Ferguson J. Preclinical Assessment of HepaHope Bioartificial Liver
System. Presented at the AASLD Liver Meeting, November 2-6, 2007. Boston, MA.
189. Gish RG, Satishchandran C. Polyamine-Complexed Plasmid DNA Nanoparticle
Delivery of RNAi to Hepatocytes. Meeting on Drug Delivery Boston. 2007.
190. Gish RG. Epidemiology Of Chronic Hepatitis B Patients. Presented at DDW, May 17-22,
2008. San Diego, CA.
191. Frederick RT, Zagorski J, Gish RG, Hofmann JC. Treatment of Hepatitis C Associated
Severe Mixed Cryoglobulinemic Syndrome With Plasma Exchange Improves Tolerability
and Response to Interferon-Based Therapy. Presented at DDW, May 17-22, 2008. San
Diego, CA.
192. Gish R, Frederick T, Hoffman J. Treatment of Hepatitis C Associated Severe Mixed
Cryoglobulinemic Syndrome With Plasma Exchange Improves Tolerability and Re-
sponse to Interferon-Based Therapy. Poster. DDW, San Diego, CA, May 17-22, 2008.

Curriculum Vitae


193. Sung-Soo Park, Jaeho Jung, Sunny Yang, Sunnie Kim, Sam Lee, Young Park, Hyoung
Yoon, Nercy Fernandez, Paul Hernandez, Nick Haman, Daren Cox, Robert Gish, Bren-
dan McGuire, Dong-Jin Suh, Han Chu Lee. How to Improve Bioartificial Liver (BAL)
System for Clinical Trials? Poster. ILC/ASAIO 2008.
194. Sung-Soo Park, Jaeho Jung, Delai Zhao, Sunny Yang, Sunnie Kim, Sam Lee, Hyoung
Yoon, Young Park, Nercy Fernandez, Robert G. Gish, Brendan M. McGuire, Angela
Panoskaltsis-Mortari, Han chu Lee, Dong-Jin Suh. Assessment of HepaHope bioartifi-
cial liver (BAL) system for treating liver failure patients. Hong Kong, China. ILC 2008.
195. Park S-S, Jung J, Yang S, Kim S, Lee S, Yoon H, Park Y, Fernandez N, Fernandez P,
Haman N, Cox D, Gish R, McGuire B, Suh D-J, Lee HC. How to Improve Bioartificial
Liver (BAL) System for Clinical Trials. Presented at the 54th Annual ASAIO Conference,
2008.
Smith H, Hindes R. Four-Year Treatment with Entecavir Results in High Proportions of
Nucleoside-Nave HBeAg-Positive Patients with Undetectable HBV DNA: Results from
Studies ETV-022 and ETV-901. Presented at the 18
th
Conference of the Asian Pacific
Association for the Study of Liver (APASL), March 2008. Seoul, Korea.
197. Levy AR, Kowdley KV, Iloege U, Tafesse E, Mukherjee J, Gish R, Bzowej N, et al. The
impact of chronic hepatitis B on quality of life: a multinational study of utilities from in-
fected and uninfected persons. Value Health. 2008 May-Jun; 11(3) :527-38.
198. RT Frederick, J Zagorski, R Courville, Gish RG. Negative tissue PCR does not confer
reduced risk of relapse after treatment of HCV in patients. Presented at the European
Association for the Study of Liver Disease (EASL), April 2008. Milan, Italy.
Smith H, Hindes R. Four-Year Treatment with Entecavir Results in High Proportions of
Nucleoside-Nave HBeAg-Positive Patients with Undetectable HBV DNA: Results from
Studies ETV-022 and ETV-901. Presented at the Hong Kong-Shanghai ILC Meeting,
June 2008. Hong Kong, China.
200. Morris Sherman, Cihan Yurdaydin, Halis Simsek, Marcelo Silva, Yun-Fan Liaw, Vinod K.
Rustgi, Hoel Sette, Naoky Tsai, Daniel J. Tenney, James Vaughan, Bruce Kreter, Robert
Hindes, AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study
Group. Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved viro-
logic, biochemical, and serology outcomes through 96 weeks. RG Gish included in
BEHoLD Study Group. Hepatology. July 1, 2008.
201. Gish R, Marrero JB, Tong MJ. Medical therapties to extend survival in hepatocellular
carcinoma. Clin Adv Hematol Oncol. 2008 Aug;6(8) :1-14; quiz 5.
202. S.Han, TT Chang, YC Chao, SK Yoon, RG Gish, H Cheinquer, G Kitis, H Zhang, U
IIoeje. Five Years of Continuous Entecavir for Nucleoside-Nave HBeAg(+) Chronic
Hepatitis B: Results from Study ETV-901. Journal of Hepatology. AASLD, November
2008. San Francisco, CA.

Curriculum Vitae


203. Sung-Soo Park, RG Gish, Brendan Martin McGuire, Angela Panoskaltsis-Mortari, Chris
Stevens. A Novel Acute Liver Failure Large Animal Model Suitable for Testing Extracorpo-
real Bioartificial Liver Systems. Poster. AASLD, November 2008. San Francisco, CA.
204. Steven Han, Rajender Reddy, Emmet B. Keeffe, Consuelo Soldevila-Pico, Robert Gish,
Raymond Chung, Bulent Degertekin, Anna Lok. Hepatocellular Carcinoma (HCC) is the
Main Inidcation for the Liver Transplantation (OLT) among HBV Patients in the Era of
Nucleos/Tide Analogue Therapies.
205. Paul Gaglio, Sundeep Singh, Bulent Degertekin, Michael Ishitani, Munira Hussain,
Robert Perrillo, Anna S Lok, and the NIH HBV OLT Study Group. Impact of HBV Geno-
type on Pre- and Post- Liver Transplantation Outcomes.
206. Debbie Hana Yi, Sumbella Baqai, Robert Gish. Characteristics of Hepatitis Delta in
Northern CA.
207. Ting-Tsung Chang, You-Chen Chao, Vladimir V. Gorbakov, Kwang-hyub Han, Robert
G. Gish, Robert de Man, Hugo Cheinquer, Fernando Bessone, Helena Brett-Smith, Ri-
cardo Tamez. Summary of an International Study of Entecavir for the Management of
Nucleoside-Nave HBeAg-positive Patients With Chronic Hepatitis B. 2008.
208. Debbie Hanna Yi, Sumbella Baqai, Robert G. Gish. Characteristics of Delta Hepatitis
in Northern California. Poster presented at AASLD. October 2008.
209. Xu L, Guo L, Shen Z, Loss G, Gish R, Wasilenko S, et al. Duplication of MER115 on
Chromosome 4 in Patients with Primary Biliary Cirrhosis. Liver Int. 2008 Oct 10.
210. Steven-Huy B. Han, Ting-Tsung Chang, You-Chen Chao, Seung Kew Yoon, Robert G.
Gish, Hugo Cheinquer, George E. Kitis, Hui Zhang, Uchenna LLoeje. Five Years of
Continuous Entecavir for Nucleoside-nave HBeAg(+) chronic hepatitis B: Results from
study ETV-901. 2008.
211. Robert G. Gish, Catherine Frenette. Hepatitis B: Advances in Screening, Diagnosis,
and Clinical Management Volume 4. Medscape Gastroenterology 2008.
212. Patrick Marcellin, Robert G. Gish, Norman Gitlin, Jamie Heise, Deanine G. Halliman,
Eric Chun, Maribel Rodriguez-Torres. Randomized, Double-Blind, Multicenter Study
Comparing the Safety and Efficacy of Viramidine and Ribavirin in Treatment-Nave Pa-
tients With Chronic Hepatitis C: Results of ViSER2. Manuscript Submitted for Publica-
tion. 2008.
213. Robert G. Gish. Diagnosis of Chronic Hepatitis B and the Implications of Viral Variants
and Mutations. The American Journal of Medicine. September 2008.
214. Maribel Rodriguez-Torres, Robert Gish, Norman Gitlin. Randomized, Double-Blind,
Multicenter Study Comparing the Safety and Efficacy of Viramidine and Ribavirin in
Treatment-Nave Patients with Chronic Hepatitis C: Results of ViSER2. Poster pre-
sented at AASLD. San Francisco, CA. October 2008.

Curriculum Vitae


215. Steven-Huy B. Han, Ting-Tsung Chang, You-Chen Chao, Seung Kew Yoon, Robert G.
Gish, Hugo Cheinque, George E. Kitis, Hui Zhang, Uchenna IIoeje. Five Years of Con-
tinuous Entecavir for Nucleoside-nave HBeAg (+) Chronic Hepatitis B: Results from
Studies ETV-022/-901. Poster presented at AASLD. San Francisco, CA. October
2008.
216. Catherine T. Frenette, Robert G. Gish. Screening At-Risk Individuals for Hepatitis B:
What do the Guidelines Say? Medscape, Expert Column. 2008.
217. Robert Gish. Hepatitis B: Advances in Screening, Diagnosis, and Clinical Manage-
ment. Medscape Volume 4. November 2008.
http://www.medscape.com/viewprogram/17750
218. Catherine T. Frenette, Robert G. Gish. Review of Selected Liver Cancer Abstracts
from the AASLD Meeting in San Francisco 2008 for NATAP Proteomics, Genomics
and Biomarkers. 2008.
from the AASLD Meeting in San Francisco 2008 for NATAP Hepatitis C and Hepato-
cellular Carcinoma. 2008.
from the AASLD Meeting in San Francisco 2008 for NATAP Hepatitis B and risk for
Hepatocellular Carcinoma. 2008.
from the AASLD Meeting in San Francisco 2008 for NATAP HCC Screening and Sur-
veillance. 2008.
from the AASLD Meeting in San Francisco 2008 for NATAP Risk Factors for Hepato-
cellular Carcinoma. 2008.
from the AASLD Meeting in San Francisco 2008 for NATAP Treatment of Hepatocellu-
lar Carcinoma, Treatment Access. 2008.
from the AASLD Meeting in San Francisco 2008 for NATAP TACE, Radiofrequency
Ablation and Other Ablative Therapies. 2008.
from the AASLD Meeting in San Francisco 2008 for NATAP Multi-Kinase Inhibitor, Oral
Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma. 2008.
from the AASLD Meeting in San Francisco 2008 for NATAP Liver Transplant Patients
and Hepatocellular Carcinoma. 2008.

Curriculum Vitae


227. Robert Gish, Catherine Frenette, Michael Schilsky, Dr Wong. Clinical epidemiology of
Wilson Disease in patients with concurrent liver disease. Hepatology Manuscript ID
HEP-08-1912. 2008.
228. Robert G. Gish. Diagnosis of Chronic Hepatitis B and the Implications of Viral Variants
and Mutations. The American Journal of Medicine. 121,S12-S21.
229. Robert Gish, Robert Osorio, Kenneth Binmoeller. New Strategies for Hard-to-Treat
Gastrointestinal Cancer. California Pacific Medical Center Research Institute Cur-
rents 2008.
230. Robert G. Gish. Chronic Hepatitis B Viral Infection. Atlas of Gastroenterology,
4
th
Edition. Page 636-641. 2009.
231. Robert G. Gish, Stephen Locarnini. Chronic Hepatitis B Viral Infection. Textbook of
Gastroenterology, 5
th
Edition. Volume 2, Page 2112-2138. 2009.
232. Sumbella Baqai, Robert G. Gish. High Rate of Core and Precore Mutations in a
Patient Population with Chronic Hepatitis B at a Tertiary Referral Center. 19
th
Confer-
ence of the APASL. Hong Kong Convention and Exhibition Centre. February 13-16,
2009.
233. Sumbella Baqai, Debbie Hanna Yi, Robert G. Gish. Characteristics of Hepatitis Delta
in Northern California. 19
th
Conference of the APASL. Hong Kong Convention and Ex-
hibition Centre. February 13-16, 2009
234. Robert G. Gish. What do we know about the Difficult-to-Treat Patient with Chronic
Hepatitis C Infection. 19
th
Conference of the APASL. Hong Kong Convention and Ex-
hibition Centre. February 13-16, 2009.
235. Robert G. Gish, Stuart C. Gordon, David Nelson, Vinod Rustgi, Isreal Rios. A
Randomized Controlled Trial of Thymalfasin plus Transartierial Chemoembolization
(TACE) for Unresectable Hepatocellular Carcinoma. Hepatology International. In
press. 2009.
236. Robert G. Gish, Ting-Tsung Chang, ching-Lung Lai, Robert de Man, Adrian Gadano,
Fred Poordad, Joanna Yang, Ricardo Tamez, Helena Brett-Smith. Loss of HBsAg Anti-
gen During Treatment With Entecavir or Lamivudine in Nucleoside-Nave HBeAg-
Positive Patients With Chronic Hepatitis B. Journal of Viral Hepatology. Submitted for
publication. 2009.
237. Adrian M. Di Bisceglie, Robert G. Gish, Steven-Huy B. Han, W. Ray Kim, Naoky C.S.
Tsai. HBV Advanced Certificate Program IV Launches with First Course. Projects In
Knowledge. 2009.
238. Robert G. Gish, Catherine Frenette. To Be or Not to Be: That is the Question.
American Journal of Gastroenterology. Submitted for publication. 2009.
239. Robert G. Gish, Steven Locarnini. Chronic Hepatitis B Viral Infcction. Gastroenterol-
ogy Textbook. 2009.
Curriculum Vitae


240. Adrian Di Bisceglie, Robert G. Gish, Patty Peterson, Elaine Rudell. HBV Management:
Gaps in Clinical Competence and Practice Performance US Survey Findings. Ab-
stract for EASL 2009.
241. Robert G. Gish. Update New Therapies for Hepatitis B and Hepatitis C. 16
th
Annual
Alimentary Update. South Lake Tahoe. March 27, 2009.
242. Robert G. Gish. Using a new palette of treatment options to paint the portrait of cure for
patients infected with hepatitis C on our clinical canvas. NATAP/EASL: New HCV
Drugs Report. EASL 2009. April 23-26, 2009.
243. Robert G. Gish. HBV Poster. DDW poster. May 2009.
244. Adrian Di Bisceglie, Robert G. Gish, Patty Peterson, Elaine Rudell. HBV Management
Among US Clinicians: Gaps in Clinical Competence and Practive Performance-Survey
Findings. DDW Poster. May 2009.
245. Robert G. Gish. Wilsons Disease Symposium. California Pacific Medical Center. San
Francisco, CA. May 2, 2009.
246. Michele Tana, Kaveh Hoda, Jackson Wong, Yiqiu Wei, Wylie Liu, Nanette Hinojales,
Paula Lykins, Germaine Andrews, David Stone, Doug Wong, Grace Estevez, Eddie
Cheung, Judy Li, Robert Gish, Stewart Cooper. DDW 2009 HBV Abstract. DDW
poster. May 30, 2009 June 3, 2009.
247. Adrian Di Bisceglie, Robert Gish. Hepatitis B Combined. DDW poster. May 30,
2009 June 3, 2009.
248. Robert Gish. Advanced Certificate Program IV: Bridging Cultural Differences to
Imporve HBV Treatment in Asian and Other Diverse Communities Course Title: Case
Study: HBeAg-Positive Vietnamese Patient. Tx Reporter. 2009.
249. Terry Conway, Vernon Smith, Gaylee Morgan, Jack Meyer, Dennis Roberts, Esther
Reagan. Robert Gish, Member of Expert Working Group. Early Medicaid Coverage
of Chronic Hepatitis B May Reduce Medicaid Spending and is Associated with Positive
Health Outcomes. JAMA. 2009.
250. Robert Gish. Loss of HBsAG antigen during treatment with entecavir or lamivudine in
nucleoside-nave HBeAg-positive patients with chronic hepatitis B. Journal of Viral
Hepatitis. 2009.
251. Edward L. Baker, Robert G. Gish. Imaging in Hepatobiliary and Pancreatic Disease: A
Practical Clinical Guide. 2009.
252. Robert Wong, Robert Gish, Michael Schilsky, Catherine Frenette. Clinical Epidemiolo-
gy of Wilson Disease in Patients With Concurrent Liver Disease. Poster. APASL 2010.
April 2009.
253. Robert Gish. Hepatitis B treatment: Current best practices, avaoiding resistance.
Cleveland Clinic Jouranal of Medicine. Supplement to Cleveland Clinic Journal of Medi-
cine. Supplement 3, Volume 76. May 2009.
Curriculum Vitae


gy of Wilson Disease in Patients With Concurrent Liver Disease. Poster. Wilson Dis-
ease Meeting. San Francisco, CA. May 2, 2009.
255. R.G. Gish, T.T. Chang, C.L. Lai, R. de Man, A. Gadano, F. Poordad, J. Yang, H. Brett-
Smith, R. Tamez. Loss of HBsAg antigen during treatment with entecavir or lamivudine
in nucleoside-nave HbeAg-positive patients with chronic hepatitis B. Journal of Viral
Hepatitis, 2009.
256. T.T. Chang, Y.C. Chao, V.V. Gorbakov, K.h. Han, R.G. Gish, R. de Man, H. Cheinquer,
F. Bessone, H. Brett-Smith, R. Tamez. Results of up to 2 years of entecavir vs lamivu-
dine therapy in nucleoside-nave HBeAg-positive patients with chronic hepatitis B.
Journal of Viral Hepatitis, 2009.
257. Michele Tana, Kaveh Hoda, David Hutton, Jackson Wong, Yiqiu Wei, Wylie Liu, Nanette
Hinojales, Paula Lykins, Germaine Andres, David Stone, Doug Wong, Grace Estevez,
Eddie Cheung, Judy Li, Robert Gish, Stewart Cooper. HBV Screening in Asians and
Pacific Islanders: An interim cost effectiveness analysis of a single center San Francisco
program. 2009.
258. Adrian M. Di Bisceglie, Robert G. Gish, Steven-Huy B. Han, W. Ray Kim, Nancy C.S.
Tsai. Bridging Cultural Differneces to Improve HBV Treatment in Asian and Other Di-
verse Communities. Advanced Certificate Program IV. Projects in Knowledge. 2009.
259. Adrian M. Di Bisceglie, Robert G. Gish,. Case Study: HBsAg-Positive, Anti-HBe-
Negative Black Immigrant from Somalia. Bridging Cultural Differneces to Improve HBV
Treatment in Asian and Other Diverse Communities. Advanced Certificate Program IV.
Projects in Knowledge. 2009
260. Adrian M. Di Bisceglie, Robert G. Gish, Case Study: HBsAg-Positive, Anti-HBe-
Negative Black Immigrant from Somalia. Bridging Cultural Differneces to Improve HBV
Treatment in Asian and Other Diverse Communities. Advanced Certificate Program IV.
Volume 4, Issue 5. Projects in Knowledge. 2009
gy of Wilson Disease in Patients With Concurrent Liver Disease. Liver International
Journal. Submission. November 2009.
262. Robert Wong, Todd Frederick, Natalie Bzowej, Robert Gish, Catherine Frenette.
Clinical Profile of Autoimmune Hepatitis Patients withConcurrent Development of Hepa-
tocellular Carcinoma. Submitted EASL abstract. November 2009.
263. Robert Gish. A Retrospective Analysis of Tenofovir DF and Entecavir Combination
Therapy in Patients with Chronic Hepatitis B (CHB) and Previouse Treatment Failure
(PTF). Submitted EASL Asbstract. November 2009.
264. Robert Gish. United network for Organ Sharing regional Review Analysis: Heterogenei-
ty of MELD Upgrade Scores for MELD Exceptions. Abstract Submission to American
Transplant Congress. December 2009.

Curriculum Vitae


265. Steven-Huy Han, K. Rajender Reddy, Emmet B. Keeffe, Consuelo Soldevila-Pico,
Robert Gish, Raymond Chung, Bulent Degertekin, Anna Lok, NIH-HBV OLT Study
Group. Clinical Outcomes of Liver Transplantation for HBV-Related Hepatocellular
Carcinoma: Data from the NIH HBV-OLT Study Group. Submitted for publication.
266. Adrian M. Di Bisceglie, Robert G. Gish,. Expert Insight Into: Hepatitis B Testing and
Vaccination Among Vietnamese-andCambodian-Americans (Part 2 of Series). Bridging
Cultural Differneces to Improve HBV Treatment in Asian and Other Diverse Communi-
ties. Advanced Certificate Program V. Projects in Knowledge. 2010.
267. Adrian M. Di Bisceglie, Robert G. Gish,. Expert Insight Into: Prevalence of Hepatitis B
Surface Antigen Among Refugees Entering the United States Between 2006 and 2008
(Part 3 of Series). Bridging Cultural Differneces to Improve HBV Treatment in Asian
and Other Diverse Communities. Advanced Certificate Program V. Projects in
Knowledge. 2010.
268. Adrian M. Di Bisceglie, Robert G. Gish,. Expert Insight Into: Decreased Incidence of
Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-Up Study (Part 4
of Series). Bridging Cultural Differneces to Improve HBV Treatment in Asian and Other
Diverse Communities. Advanced Certificate Program V. Projects in Knowledge. 2010.
269. Adrian M. Di Bisceglie, Robert G. Gish,. Expert Insight Into: Perinatal Transmission of
Hepatitis B Virus: An Australian Experience (Part 6 of Series). Bridging Cultural Differ-
neces to Improve HBV Treatment in Asian and Other Diverse Communities. Advanced
Certificate Program V. Projects in Knowledge. 2010.
270. Adrian M. Di Bisceglie, Robert G. Gish. Expert Insight Into: Incidence and Risk Factors
of Progression to Cirrhosis in Inactive Carriers of Hepatitis B Virus (part 5 of Series)
Bridging Cultural Differneces to Improve HBV Treatment in Asian and Other Diverse
Communities. Projects In Knowledge. 2010.
271. Robert Gish, Ji-Dong Jia, Stephen Locarnini, Fabien Zoulim. Principles for Selecting
Chronic Hepatitis B Therapy with a High Barrier to Resistance. Submitted for publica-
tion. 2010.
272. Robert Wong, Robert Gish, Michael Schilsky, Catherine Frenette. A Clinical Assess-
ment of Wilson Disease in Patients With Concurrent Liver Disease. Journal of Clinical
Hepatology. 2010.
273. Norah A. Terrault, Jennifer L. Dodge, Edward L. Murphy, John E. Tavis, T.R. Levin,
Robert Gish, Michael busch, Miriam J. Alter. Sexual Transmission of HCV Among Mo-
nogamous Heterosexual Couples: The HCV Partners Study. New England Journal of
Medicine. 2010.
274. Robert G. Gish. International and National Priorities for Liver Cancer Control. John
Hopkins Bloomberg School of Public Health IRB. February 2010.
275. Robert G. Gish, Jorge A. Marrero, Al B. Benson. A Muiltidisciplinary Approach to the
Management of Hepatocellular Carcinoma. Clinical Roundtable Monograph. March
2010.
Curriculum Vitae


276. R.Wong, R.Gish, T.Frederick, N.Bzowej, C.Frenette. Epidemiology, Staging and
Prognosis. Submission for ILCA 2010.
277. Chari Cohen, Scott Holmberg, Joan Block, Carol Brosgart, Brian McMahon, W.T.
London, Robert G. Gish, Timothy Block. Is Chronic Hepatitis B Being Under Treated in
the United States? JVH. Submitted 6/2010, Published 4/2011
278. Robert Wong, Robert Gish, Todd Frederick, Natalie Bzowej, Catherine Frenette.
Development of Hepatocellular Carcinoma in Autoimmune Hepatitis. ILCA Poster.
September 10-12, 2010.
279. Heiner Wedemeyer, Robert Gish, Tuan Nguyen, Ching-Lung Lai, Cyril Llamoso, Ting-
Tsung Chang. Efficacy and Safety of Entecavir in the Older Patient (>50 years of age).
Submitted to AASLD November 2010 Boston Meeting.
280. Sung-Soo Park, Jaeho Jung, Hong Bock Lee, Delai Zhao, Young Park, Hyoung Yoon,
Jason Lee, Sunny Yang, Jun Choi, David Goldberg, Vickie Sheckler, Robert G. Gish,
Todd Frederick, Brendan M. McGuire, Norman L. Sussman, Angela Panoskaltsis-
Mortari, Han Chu Lee, Dong Jin Suh. Acute Liver Failure and Artificial Liver. Poster.
AASLD November 2010 Boston Meeting.
281. Sung-Soo Park, Jaeho Jung, Hong Bock Lee, Delai Zhao, Young Park, Hyoung Yoon,
Jason Lee, Sunny Yang, Jun Choi, David Goldberg, Vickie Sheckler, Robert G. Gish,
Todd Frederick, Brendan M. McGuire, Norman L. Sussman, Angela Panoskaltsis-
Mortari, Han Chu Lee, Dong Jin Suh. Development of a Canine Acute Liver Failure
Model that is Suitable for Evaluating Safety and Efficacy of Bioartificial Liver Systems.
Poster. AASLD November 2010 Boston Meeting.
282. Catherine Frenette, Robert Gish. Clinical Management and Case Reports for the
Treatment of Hepatocellular Carcinoma with Sorafenib. Journal of Clinical Gastroenter-
ology. Submitted for publication. 2010.
283. Robert G. Gish, Norman Sussman. The Current Status of Artificial Liver Support
(ALS). The Gastroenterology Exchange. 2010.
284. Robert Gish. Is Chronic Hepatitis B Being Undertreated in the United States, Journal
of Viral Hepatitis. August 2010.
285. Adrian M. Di Bisceglie, Robert G. Gish. Severe Lactic Acidosis During Treatment of
Chronic Hepatitis B with a Nucleoside Analog in Patients with Impaired Liver Function
(Part 8 of Series) Bridging Cultural Differneces to Improve HBV Treatment in Asian and
Other Diverse Communities. Advanced Certificate Program V. Projects in Knowledge.
2010.
286. Adrian M. Di Bisceglie, Robert G. Gish, Case Study: Focus on Reactivation Projects
in Knowledge. 2010.
287. Robert Gish. UNOS Researchers Contribute to ATC Abstracts. UNOS Magazine.
2010.

Curriculum Vitae


288. Steven Huy Han, K. Rajender Reddy, Emmet B. Keeffe, Consuelo Soldevila-Pico, Robert
Gish, Raymond T. Chung, Bulent Degertekin, anna Lok, NIH-HBV OLT Study Group. Clin-
ical Outcomes of Liver Transplantation for HBV-Related Hepatocellular Carcinoma: Data
from the NIH HBV-OLT Study. Clinical Transplantation. 2010. CLTX-10-OA-0087.R1.
289. Robert Gish. HCC Treatment Options and Their Associated Adverse Events.
Integrating Recent Data in Managing Adverse Events in the Treatment of Hepatocellular
Carcinoma. Clinical Roundtable Monograph. September 2010.
290. Myron J. Tong, Robert Gish, Ghassan K. Abou-Alfa. Multidisciplinary Treatment of
Patients With HCC. Integrating Recent Data in Managing Adverse Events in the Treat-
ment of Hepatocellular Carcinoma. Clinical Roundtable Monograph. September 2010.
291. Mary Ann Cmunale, Mengjun Wang, Lucy Rodemich-Betesh, Julie Hafner, Anne
Lamontagne, Andrew Klein, Jorge Marrero, Adrian M. Di Bisceglie, Robert Gish, Timo-
thy Block, Anand Mehta. Novel Changes in Glycosylation of Serum Apo-J in Patients
with Hepatocellular Carcinoma. 2010.
292. R.G. Gish, S.L. Cooper. Hepatitis b in the greater san francisco bay area: an integrated
programme to respond to a diverse local epidemic. Journal of Viral Hepatitis. 2010.
293. Heiner Wedemeyer, Robert Gish, Tuan Nguyen, Ching-Lung Lai, Cyril Llamoso, Ting-
Tsung Chang. Efficacy and Safety of Entecavir in the Older Patient (50 years of age).
APASL 2010.
294. Robert Gish, Naoki Tsai, Calvin Pan, Kris Kowdley, Ke-Qing Hu, Lai CL, Ting-Tsung
Chang, Kwang-Hyub Han, David Coehn, Hong Tang, Myron Tong. Efficacy and Safety
of Entecavir in Nucleos(t)ide Nave Asians with HBeAg Positive and Negative Chronic
Hepatitis B: Results from Studies ETV-022/027. APASL 2011 - Thailand.
295. Catherine T. Frenette, Richard Todd Frederick, Robert Gish. Clinical Management and
Case Reports for the Treatment of Hepatocellular Carcinoma With Sorafenib. Journal of
Clinical Gastroenterology. 2010.
296. Robert Gish, Pamela Norton, Hongyan Liang, Timothy Block, Mengjun Wang, Ronald
Long. Hepatocellular Carcinoma Biomarker GP73: Effects of IL-6 Family Cytokines and
Interferon- in Human Hepatocytic Cells and in People with Liver Disease (lower case
alpha). Cancer Epidemiology, Biomarkers & Prevention. 2010.
297. Kohla M, El-Warraky M, Gish R, Management of a Case of Obscure Lower GI Bleeding
by Transjugular Intrahepatic Portosystemic Shunt (TIPS): A Case Report, EUGW2011,
Stockholm.

298. Gish R, Sussman N, Park S, McGuire, An In Vitro Demonstration of the HepaPheresis
TM

System that can Metabolize
15
N-Ammonia and Lidocaine using a Porcine Liver Slice-
Filled Bioartificial Liver

299. Gish R, Bu Y, Fang J, Lau J, Hanguar D, KX01, A Dual-Mechanism Src/Pretubulin
inhibitor, Is Synergistic With Sorafenib But Not with Doxorubicin Against Liver Cancer
Cells, AASLD
Curriculum Vitae


300. Gish R, DiBisceglie A, Nguyen M, Te H, Tran T, Testing and Interpretation of Hepatitis
B Serologic Markers and Other Markers of Disease Activity

301. Gish, R, Kohla M, Spontaneous Regression of HCC: A Case Report, accepted for
Poster Presentation, International Liver Cancer Association, September 2011.

302. Gish, R, Kohla M, Predictive Factors for Hepatic Decompensation after TACE for
Hepatocellular Carcinoma (HCC): A Single Center Experience, accepted for Poster
Presentation, International Liver Cancer Association, September 2011.

303. Robert G. Gish MD, Alexander, Colleen Tu BS, Kuo MD, Cyndy Collins NP, Shirley M.
Tsunoda, Pharm.D. Effect of Sirolimus on Immune Cell Function Assay in Liver Trans-
plant Recipients, September 2011.

304. R. Gish, W.Sievert
1
, H.Wedemeyer
2
, T.Nguyen
4
, C.L.Lai
5
, C.Llamoso
6
, T.T.Chang
7
,
Entecavir Efficacy and safety in patients 50 Years Of Age, Australian Gastroenterolo-
gy Week, Brisbane, Australia, 12-15 September 2011.

305. Gish, Robert G., HCV In At Risk Populations: Who Can Be Treated And How?,
Current Hepatitis Reports, September 2011.

306. Gish, Robert G., Hepatitis B Surface Antigen Quantification, Armenia Journal:
BLOOD. September 2011.

307. Gish, Robert G., Drug-Induced Liver Disease (DILI) and Acute Liver Failure, Armenia
Journal: BLOOD. September 2011.

308. Gish, Robert G., Autoimmune Hepatitis and Acute Liver Failure, Armenia Journal:
BLOOD. September 2011.

309. Gish, Robert G., Serologic and Virologic Tools For the Workup and Management of
Hepatitis B, Armenia Journal: BLOOD. September 2011.

310. Gish, Robert G., Wilson Disease, Armenia Journal: BLOOD. September 2011.

311. Gish, Robert G., Liver Cancer Biomarkers, Armenia Journal: BLOOD. September
2011.

312. Gish, Robert G., Current Management of Liver Cancer, Armenia Journal: BLOOD.
September 2011.

313. Gish, Robert G., Liver Transplantation in 2011, Armenia Journal: BLOOD. Septem-
ber 2011.

314. Gish, Robert G., Chronic HBV Infection Outside Treatment Guidelines: Is Treatment
Needed? Journal of Viral Hepatitis, (Submitted for Publication), December, 2011.

Curriculum Vitae


315. Robert G. Gish MD, Heather Patton MD, Michael Misel PharmD., Acute Liver Failure:
An Evidence-Based Management Protocol for Clinicians, Gastroenterology & Hepatolo-
gy, January 2012.

316. Gish, Robert G., Shirley Tsunoda, Pharm D, Effect of Sirolimus on Immune cell
function assay in liver transplant recipients, January, 2012.
317. Gish, Robert G., Binh Tran, PharmD, Barriers to Hepatitis B screening and Hepatitis B
knowledge among Asian populations in San Diego County, January 2012.

318. Gish, Robert G., Serum Albumin and AFP Levels as Predictors of Hepatic Decompen-
sation After TACE for Hepatocellular Carcinoma (HCC), Presented at: APASL, Taipei,
Taiwan. February 2012.

319. Gish, Robert G., Frenette, Catherine, Targeted Systemic Therapies for Hepatocellular
Carcinoma: Clinical Perspectives, Challenges and Implications, World Journal of Gas-
troenterology, February, 2012.

320. Gish, Robert G., Martinez, Anthony D, HCV In At-Risk Populations: Who Can Be
Treated and How? Current Hepatitis Reports, Volume 8, Number 1, February 2012.

321. Sumbella F. Baqai MD, Debbie H. Yi MD, Michael Mangahas, Robert G. Gish MD, High
Rate of Core Promoter and Precore Mutations in Patients with Chronic Hepatitis B and
Their Impact on Liver Disease, Journal of Viral Hepatitis, (Submitted for Publication),
2012.

322. Norah A. Terrault, Jennifer L. Dodge, Edward L. Murphy, John E. Tavis, Alexi Kiss, T.R.
Levin, Robert Gish, Michael Busch, Arthur L. Reingold, Miriam J. Alter: Sexual Trans-
mission of HCV Among Monogamous Heterosexual Couples: The HCV Partners Study,
study was supported by a cooperative agreement with the Centers for Disease Control
and Prevention, U50 CCU915651, U01 DK60345 (J.E.T), Accepted Article, doi:
10.1002/hep.26164; November 25, 2012.

323. Maja Kodani, Alyssa Martin, Tonya Mixson-Hayden, Jan Drobeniuc, Robert Gish, and
Saleem Kamili, One-Step Real-Time PCR Assay for Detection and Quantification of
Hepatitis D Virus RNA by Short-Form Paper, Journal of Clinical Microbiology, Virology
Section, Control number JCM00554-13; February 26, 2013

324. Robert G. Gish, Ting-Tsung Chang, Ching-Lung Lai, Robert A de Man, Adrian Gadano,
Cyril Llamoso, Hong Tang: Quantitative Hepatitis B Surface Antigen Analysis in Hepati-
tis B e Antigen-Positive, Nucleoside-Naive Patients Treated With Entecavir, Antiviral
Therapy, Manuscript ID AVT-12-OA-2806.R1, doi: 10.3851/IMP2559, International Med-
ical Press Ltd., http://www.intmedpress.com/journals/avt/abstract.cfm?id=2559&pid=48;
February 28, 2013.

325. Maja Kodani, Alyssa Martin, Tonya Mixson-Hayden, Jan Drobeniuc, Robert Gish,
Saleem Kamili, One-Step Real-Time PCR Assay for Detection and Quantification of
Hepatitis D Virus RNA One-Step qRT-PCR for HDV Detection, Journal of Clinical Mi-
crobiology, Virology Section, JCM0054-13, March 2013.
Curriculum Vitae


326. Robert B. Gish, Strategies for Hepatocellular Carcinoma Surveillance and Diagnosis,
Gastroenterology & Hepatology, April 2013 Volume 9, Issue 4.

327. Impact of Entecavir Versus Lamivudine on Hepatic HBV Covalently Closed-Circular
DNA and Total Hepatic HBV DNA in Nucleoside-Nave HBeAg Positive Chronic Hepati-
tis B Patients, Robert G. Gish, Scott Bowden, Stephen Locarnini, Ting-Tsung Chang,
You-Chen Chao, Kwang-hyub Han, Robert de Man, Cyril Llamoso, Hong Tang, DDW,
Orlando Florida oral presentation , Funded by Bristol-Myers Squibb; May 2013.

328. Shirley M. Tsunoda, Stephanie Wang, Linda Awdishu, Nina Phak, Alicia Somers, Robert
G. Gish, Utilizing Intracellular ATP Activity as a Biomarker for Predicting Rejection in
Hepatitis C Liver Transplant, submitted to 2013 ATC Conference; May 2013.

329. Robert G. Gish, Shirley M. Tsunoda, Jonathan Hu et al, Effect of Hepatitis C Therapy
on Immune Cell Function Assay in Liver Transplant Recipients, submitted to 2013 ATC
Conference; May 2013.

330. Scott Bowden, Stephen Locarnini, Ting-Tsung Chang, You-Chen Chao, Kwang-hyub
Han, Robert G. Gish, Robert de Man, Cyril Llamoso7, Hong Tang, Impact of Entecavir
Versus Lamivudine on Hepatic HBV Covalently Closed-Circular DNA and Total Hepatic
HBV DNA in Nucleoside-Nave HBeAg Positive Chronic Hepatitis B Patients, e-Poster,
Lecture collateral, Digestive Disease Week, Orlando, FL.; May 1921, 2013.

331. Speaker, Current Insights in to the Management of Hepatic Encephalopathy, Hepatology
Centers of Educational Expertise, San Diego, CA; May 28, 2013.

332. Session Chairman, Transforming Science to Clinical Practice, APASL Liver Week 2013
Singapore: Session Chairman, Singapore; June 6-10, 2013.

333. Dr. Robert Gish, Dr. Lynn Huang, Hec1 as a Novel Approach to Liver Cancer, submitted
for publication, June 24, 2013.

334. Maja Kodania, Alyssa Martina, Tonya Mixson-Haydena, Jan Drobeniuca, Robert R.
Gish, Saleem Kamilia; One-Step Real-Time PCR Assay for Detection and Quantitation
of Hepatitis D Virus RNA, Journal of Virological Methods 193 (2013), pp. 531-535, Au-
gust 2013.

335. Wyles D, Nelson D, Swain M, Gish RG, Ma J, McNally J, Brainard D, Symonds W,
McHutchison J, Bernstein D, Thompson A, Mangia A, Jacobson I. On Treatment HCV
RNA as a Predictor of Virologic Response in Sofosbuvir-Containing Regimens for Geno-
type 2/3 HCV Infection: Analysis of the FISSION, POSITRON, and FUSION Studies.
American Association for the Study of Liver Disease, The Liver Meeting. Washington
DC. November 1-5, 2013.

336. Scott Bowden, Stephen Locarnini, Ting-Tsung Chang, You-Chen Chao, Kwang-hyub
Han, Gish RG, Robert de Man, Cyril Llamoso, Hong Tang. Impact of Entecavir Versus
Lamivudine on Hepatic HBV Covalently Closed-Circular DNA and Total Hepatic HBV
DNA in Nucleoside-Nave HBeAg Positive Chronic Hepatitis B Patients. Australian
Gastroenterology Week 2013. Melbourne, Australia. October 7-9, 2013.
Curriculum Vitae


337. Gish RG et al; Hepatocellular Carcinoma Surveillance: An Inquiry Into Current
Practices, Abstract #ILCA2013-1080, International Liver Cancer Association Seventh
Annual Conference, Washington D.C., September 13-15, 2013.

338. Luke Huang; Simon Shih-Hsien Chuang, KJ Kao, Diana Wu; Jinn Wu, Gish, Robert;
Johnson Lau; Inhibition of Hec1 as a Novel Approach to the Treatment of Primary Liver
Cancer, Taivex Therapeutics, 2013.

339. Gish RG, VIRGIL ((Vigilance Against Viral Resistance) Study Establishes Clinical
Benefit of Virologic Suppression With Entecavir, Commentary, Clinical Care Options, Vi-
rology, September, 2013.

340. Gish RG, Delta Virus Infection: Epidemiology and Initiatives to Intercept It, Commen-
tary, Gastroenterology & Hepatology, September 2013

341. Gish RG, Global Hepatitis Overview and How to Respond to the Epidemic, Armenia
Liver Conference 2013, September 6-8, 2013.

342. Gish RG, Current Therapy of Hepatitis B: Planning for 2013 and Beyond, Armenia
Liver Conference 2013, September 6-8, 2013.

343. Gish RG, Hepatitis E, Armenia Liver Conference 2013, September 6-8, 2013.

344. Gish RG, Hepatitis C Virus: The Basics, Current Status and the Future, Armenia Liver
Conference 2013, September 6-8, 2013.

345. Gish RG et al; Utility of On-Treatment HCV RNA as a Predictor of Response, American
Association for the Treatment of Liver Disease, The Liver Meeting, Washington D.C.,
November 1-5, 2013.

346. Gish RG, et al, On Treatment HCV RNA as a Predictor of Virologic Response in
Sofosbuvir-Containing Regimens for Genotype 2/3 HCV Infection, The Liver Meeting,
AASLD 2013, Washington DC, November 1-5, 2013.

347. Gish RG et al, Impact of Entecavir Versus Lamivudine on Hepatic HBV Covalently
Closed-Circular DNA and Total Hepatic HBV DNA in Nucleoside-Nave HBeAg Positive
Chronic Hepatitis B Patients. ISGCON 2013 - Indian Society of Gastroenterology Con-
ference, Gujarat, Ahmedabad , India; November 28 December 2013.

348. Sandy Chong et al, Collaborative Efforts to Screen at-risk Populations for Hepatitis B
and C in San Diego County, abstract approved for HepDart 2013, Kohala, Hawaii, De-
cember 10, 2013.

349. Nguyen CT, Gish RG, et al; POC Testing for Hepatitis C Screening at Community-
Based-Organizations Facilitates Disease Control, abstract approved for HepDart 2013,
Kohala, Hawaii, December 10, 2013.

Curriculum Vitae


350. Julio Gutierrez, et al, Efficacy of Screening for Hepatitis B Infection and Immunity in Low
Resource Settings with an Inexpensive Point of Care Immunoassay, abstract approved
for HepDart 2013, Kohala, Hawaii, December 10, 2013.

351. Lillian Nguyen, et al, Cost-Effectiveness Analysis of Point of Care versus Standard of
Care Tests for Hepatitis B in Asian and Pacific Islanders in San Diego County, abstract
approved for HepDart 2013, Kohala, Hawaii, December 10, 2013.

352. Xuan Phan, et al, Targeting Populations At-Risk for Hepatitis B Using the Research
Electronic Data Capture (RED Cap) Program, abstract approved for HepDart 2013, Ko-
hala, Hawaii, December 10, 2013.

353. Lillian Nguyen, et al, Cost-Effectiveness Analysis of Point of Care versus Standard of
Care Tests for Hepatitis B in Asian and Pacific Islanders in San Diego County, poster
submitted to European Association for the Study of Liver Diseases (EASLD); Spring
2014

354. Sandy Chong et al, Collaborative Efforts to Screen at-risk Populations for Hepatitis B
and C in San Diego County, poster submitted to European Association for the Study of
Liver Diseases (EASLD), Spring 2014.

355. Julio Gutierrez, et al, Efficacy of Screening for Hepatitis B Infection and Immunity in Low
Resource Settings with an Inexpensive Point of Care Immunoassay, poster submitted
to European Association for the Study of Liver Diseases (EASLD), Spring 2014.

356. Xuan Phan, et al, Targeting Populations At-Risk for Hepatitis B Using the Research
Electronic Data Capture (RED Cap) Program, poster submitted to European Associa-
tion for the Study of Liver Diseases (EASLD), Spring 2014.

357. Christina Thuy Nguyen, et al; POC Testing for Hepatitis C Screening at Community
Based Organizations Facilitates Disease Control, poster submitted to European Associ-
ation for the Study of Liver Diseases (EASLD), Spring 2014.

358. Kono Y, Gish RG. HCC Surveillance: An Inquiry into Current Practices in the United
States . Poster submitted for Digestive Disease Week 2014. CID: 1901686. McCormick
Place Convention Center, Chicago, IL., 5 May-2014.

359. Chong SI, Gish RG, Nguyen C, Tran BN, Tsunoda S, Navarro-Cazarez N, Gutierrez J, P
Taylor P: Collaborative Efforts to Screen At-Risk Populations for Hepatitis B and C in
San Diego County: Singapore Hepatitis Conference, 6-7 June-2014.

360. Nguyen L.T., Tran BN, Fontanesi J, Gish RG; Cost-Effectiveness Analysis of Point-of
Care versus Standard of Care Tests for Hepatitis B in Asian and Pacific Islanders: Sin-
gapore Hepatitis Conference, 6-7 June-2014.
Curriculum Vitae

CME PRESENTATIONS AND PUBLICATIONS

1. Gish RG et al. The Clinicians Companion: Expert Perspectives on Contemporary
Clinical Issues in Hepatitis C. 1997.
2. Gish RG. Interferon alfa-2b/Ribavirin Combination Therapy: A Promising Step Toward
the Treatment of Chronic Hepatitis C: A CME monograph. Presented at a DDW Sympo-
sium. May 12, 1997.
3. Gish RG. Highlights of DDW 1997. Liver Disease Digest 1997.
4. Gish RG. Treating Chronic Hepatitis C: New Strategies for non-responders and
relapsers. AALSD Meeting Highlights. A CME monograph. Presented at an AALSD
Symposium. November 8, 1998.
5. Gish RG. Management of End-Stage Liver Disease from Viral Hepatitis. Placerville CA.
April 25, 199.
6. Gish RG. Liver Assist Device. Presented at a California Pacific Specialty Services
Continuing Medical Education. February 3, 2000.
7. Gish RG. The Medical/Surgical Aspects of Gastrointestinal Disease. Presented at Sutter
Roseville Medical Center. April 1, 2000.
8. Gish RG. Objective Structured Clinical Exercise (OSE). Presented at the University of
California, San Francisco. April 15, 2000.
9. Gish RG. Plenary I & Presidential Address I. Presented at the American Society of
Transplantation (AST) Meeting. May 13, 2000.
10. Gish RG. Clinical Science Symposium: Transplantation Tolerance. Presented at the
AST Meeting. May 13, 2000.
11. Gish RG. Concurrent Communications. Presented at the AST Meeting. May 13, 2000
12. Gish RG. Transplantation Immunobiology Symposium. Presented at the AST Meeting.
May 13, 2000.
13. Gish, RG. Concurrent Communications III. Presented at the AST Meeting. May 13,
2000.
14. Gish RG. Clinical Science Symposium: Practice Guidelines. Presented at the AST
Meeting. May 13, 2000.
15. Gish RG. Application of Epidmeology and Biostatistics to Clinical Research. Presented
at the AASLD symposium. May 20, 2000.
16. Gish RG. Physicians on the Attack against Hepatitis C. Office.com. December 21,
2000.

Curriculum Vitae

CME PRESENTATIONS AND PUBLICATIONS: Continued

17. Gish RG. Hepatitis C: Building a Response to the North State Crisis. Sacramento April
28, 2000.
18. Gish RG. Department of Transplantation: Transplant Tolerance, Living Donor Liver
Transplant. December 21, 2000.
19. Gish RG. What is the natural history of Hepatitis C? Treatment Reporter:
Gastroenterology. 2002.

20. Gish RG, Afdhal N. New data on managing anemia with growth factors for patients on
anti-HCV therapy: a case-based series. Treatment Reporter: Gastroenterology.
September 2002.

21. Gish RG. Optimizing Treatment Response in HCV Infection by Anemia Management.
Presented at the Foundation for better health and DVC. January 24, 2003.
22. Gish RG. Managing Liver Related Challenges. Presented at the AASLD Expert
Consensus. 2003
23. Gish RG. Autoimmune Liver Disease. Presented at a Special CME Conference. March
18, 2003
24. Gish RG. Hepatitis B. Presented at Sunrise Hospital, April, 2003. Las Vegas, NV.
25. Gish, RG. Optimal Clinical Outcomes: Managing Hepatitis Related Challenges.
University of Wisconsin. November 2004.

26. Gish RG, Chronic Hepatitis C, Hepatitis Magazine, May 2004.

27. Gish RG, Surveying the Hepatitis C Landscape: Current Treatment and a Look at New
Options on the Horizon. Medical Media Communications. May 2004.
28. Gish RG. Implications & Management of Anemia in Liver Disease. CME Monograph
Series, Volume 2, Issue 2, October 2004.
29. Gish RG. Prevalence and Characterization of HCV-Associated Cognitive Impairment.
DDW May 21, 2004.
30. Gish RG. Plan for Success: Effective Side Effect Management in Anti-HCV Therapy.
DDW May 16, 2004.
31. Gish RG. Concepts and Controversies in the Management of Hepatitis B A Debate
Among the Experts. DDW May 2004.
32. Gish RG. HBV Infection in Clinical Practice. Tx Reporter: Gastroenterology. March 22,
2005.
33. Gish RG. Phoenix Educational Initiative. Presented at The France Foundation, 2005.
34. Gish RG. New Data on Emerging Therapies for the Treatment of Chronic Hepatitis B
Virus. PVI and University of Florida, January 2005.
Curriculum Vitae


35. Gish RG. Implications & Management of Anemia in Liver Disease: Pre-Management of
HCV-Infected Patients Before & After Liver Transplantation. CME Monograph Series, V
2, Issue 3, March 2005.
36. Gish RG. Clinical Case Consults in Chronic Hepatitis B: An Interactive Teleconference
Program. Bristol-Meyers Squibb. 2005.
37. Gish RG, Benhamou Y, Forns X, Marcellin P. Ribavirin Analogues and Ribavirin-like
Molecules: New Directions in Antiviral Therapy. An update on Ribavirin Analogues:
Meeting the challenge of anemia in Hepatitis C treatment. April 14, 2005. CME Module
for Clinical Care Options.
38. Gish RG. Practical Pathways Towards Improved Management of HCV Treatment
Failures. Presented at DDW, May 15, 2005.
39. Gish RG. Therapies for Hepatocellular Carcinoma. Informed, The Newsletter of the
Hepatitis B Foundation. No. 43:Spring, 2005.
40. Gish RG. Controversies in Management of HBV: Lessons from Case Studies. October
12, 2005. CME-CD-ROM for Projects In Knowledge.
http://www.projectsinknowledge.com/Init/G/1718/
41. Gish RG. Part I: Diagnosing HBV: Signs, Symptoms, and Diagnostic Tests for Chronic
Infection. December 7, 2005.
42. Gish RG. Part 6 of 9: Management of Cirrhosis and Decompensation. HBV Infection in
Clinical Practice. The Treatment Reporter: Gastroenterology. September 23, 2005.
CME for Projects in Knowledge.
43. Gish RG. Immediately Useful Strategies for Improving Patient Outcomes. The
Treatment Reporter: Gastroenterology. Volume 1, Issue 6 2006.
44. Gish RG. Part 7 of 9: Management of the HBV Coinfected Patient. The Treatment
Reporter: Gastroenterology. 2006.
45. Gish RG. Part 8 of 9: A Steady Advance: Latest Findings from Anti-HBV Clinical
Trials. The Treatment Reporter: Gastroenterology. February 17, 2006.
46. Gish RG. Part 9 of 9: Viral Resistance. The Treatment Reporter: Gastroenterology.
February 27, 2006.
47. Afdhal N, Gish R. Decreased Resistance and Good Safety With Newer Nucleos(t)ides
for Hepatits B. University of Florida/Peer View: Course Director Review. 2006.

48. Afdhal N, Gish R. Nucleos(t)ide Analogues Suppress Hepatitis B Virus, Reverse
Disease in Multiple Patient Populations. University of Florida/Peer View: Course Direc-
tor Review. 2006.

Curriculum Vitae


49. Gish RG, Di Bisceglie AM. In-Depth and Timely Response to Pressing Educational
Needs. Advanced Certificate Program in the Management of Chronic Hepatitis B: Mem-
bers Update. 2006;1(7):2.
50. Gish RG. HBV Review based on the proceedings from our satellite symposium at
AASLD 2006. CME activity for Projects in Knowledge.
51. Gish RG, Newer Nucleos(t)ide Analogues Suppress Hepatitis B Virus, Reverse Disease
in Multiple Patient Populations. PeerView Press. February 15, 2006.
52. Gish RG. Selecting Antiviral Therapy for a Treatment-Naive Patient with Hepatitis B
Posting 3. Practical Guidelines for Managing HBV in Special Patient Populations. August
16, 2006. CME activity for Projects in Knowledge.
53. Dusheiko GM, Gish RG, Keeffe EB, Perrillo RP. Latest Findings in HBV Manage-
ment. CCO Independent Conference Coverage of the 2005 Annual Meeting of the
American Association for the Study of Liver Diseases. San Francisco, CA. November
11-15, 2005. Slideset for Clinical Care Options, posted February 1, 2006.
54. Gish RG. Assessing Antiviral Treatment Effect: Recognizing Primary and Secondary
Treatment FailurePosting 9. Practical Guidelines for Managing HBV in Special Patient
Populations. February 14, 2007. CME activity for Projects in Knowledge.
55. Gish RG. Managing HBV Infection During PregnancyPosting 7. Practical Guidelines
for Managing HBV in Special Patient Populations. January 4, 2007. CME activity for Pro-
jects in Knowledge.
56. Gish RG. Postoperative Management of Patients with Hepatocellular Carcinoma
Posting 12. Practical Guidelines for Managing HBV in Special Patient Populations. May
11, 2007. CME activity for Projects in Knowledge.
57. Gish RG, expert commentary. Expert Insight Into: Provider Knowledge and Practice
Regarding Hepatitis B Screening in Chinese-Speaking Patients. Advanced Certificate
Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other
Diverse Communities. October 10, 2007. CME activity for Projects in Knowledge.
58. Gish RG, expert commentary. Expert Insight Into: Why We Should Routinely Screen
Asian-American Adults for Hepatitis B: A Cross-Sectional Study of Asians in California.
Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treat-
ment in Asian and Other Diverse Communities. December 20, 2007. CME activity for
Projects in Knowledge.
59. Gish RG, expert commentary. Expert Insight Into: A Randomized Controlled Trial of
Lamivudine to Treat Acute Hepatitis B. Advanced Certificate Program III: Bridging Cul-
tural Differences to Improve HBV Treatment in Asian and Other Diverse Communities.
January 28, 2008. CME activity for Projects in Knowledge.
60. DL Veenstra, DE Spackman, A Bisceglie, KV Kowdley, Gish RG. Evaluating anti-viral
effectiveness analysis. Alimentary Pharmacology & Therapeutics, p1240-1252.
Curriculum Vitae


61. Gish RG, Lau GKK. Case Study: Managing Genotype B HBV Infection in an Asian
Patient. TX Reporter Newsletter. Advanced Certificate Program III: Bridging Cultural Dif-
ferences to Improve HBV Treatment in Asian and Other Diverse Communities. Novem-
ber 29, 2007. CME activity for Projects in Knowledge.
62. Gish R, Jacobson I, Pockros P. Improving HBV Treatment: Early Screening and
Sustained Control for Improved Outcomes. Clinical Roundtable Monograph. Gastroen-
terology and Hepatology. January 2008.
63. Gish RG, Kim RW. Case Study: Managing Confounding Herbal Hepatotoxicity and
Familial Hepatocellular Carcinoma Risk in an HBeAg-Negative Vietnamese Immigrant.
TX Reporter Newsletter. Advanced Certificate Program III: Bridging Cultural Differences
to Improve HBV Treatment in Asian and Other Diverse Communities. February 27, 2008.
CME activity for Projects in Knowledge.
64. Gish RG. Update on Hepatitis C Virus: epidemiology, natural history and treatment.
Saint Marys Regional Medical Center. July 24, 2008. 2 AMA Physicians Recognition
Award Category 1 Credits.
65. Gish RG, Terry Baker, Misha Cohen, Stewart Cooper, Randy Dietrich, Gregory T.
Everson, Sylvia Flesner, Peter Hauser, Randy Horwitz, David W. Indest, Jessica Irwin,
Julia Jernberg, Joyce S. Kobayashi, Douglas R. LaBrecque, Lark Lands, Shri K. Mishra,
Sharon D. Montes, Julie Nelligan, J. Lyn Patrick, Bharathi Ravi, Aparna Roy, Lorren
Sandt, Kathleen B. Schwarz, Tina M. St. John, Amy E. Smith, Diana L. Sylvestre, Norah
Terrault, Sivarama Prasad Vinjamury, Qing Cai Zhang, Susan L. Zickmund. Hepatitis C
Choices, 4
th
Edition Diverse Viewpoints and Choices for Your Hepatitis C Journey.
Caring Ambassordors Program. 2008.
66. Gish RG, Al B. Benson III, Morris Sherman, Barbara Sigler Morgan. Cases in Point:
Risk Factors, Surveillance Strategies and Treatment Options for HCC. Gastroenterolo-
gy and Hepatology. Volume 5, Issue 1, Supplement 3. January 2009
67. Gish RG. Hepatocellular Carcinoma Screening in Patients with Hepatitis C Cirrhosis.
Medscape CME. 2009.
68. Gish RG. Hepatitis B treatment: Current best practices, avaoiding resistance.
Cleveland Clinic Journal of Medicine. Supplement to Cleveland Clinic Journal of Medi-
cine. Supplement 3, Volume 76. May 2009.
69. Gish RG, Update in Hepatocellular Carcinoma - The Latest Information on Pathogene-
sis, Screening and Treatment (Course HCC01.07). The Advanced Certificate Program
in Heptocellular Carcinoma Projects in Knowledge, Feb.2010.
70. Gish RG, Hepatitis B Testing and Vaccination Among Vietnamese- and Cambodian-
Americans (Part 2 of Series) (Course HBV5.03), Advanced Certificate V, Bridging cultur-
al Differences to Improve HBV Treatment in Saian and Other Diverse Communities, Pro-
ject of Knowledge, March 2010.
71. Robert Gish, USA Co-author White Letter A Plan of Action for Liver Disease in Viet
Nam March 2010
Curriculum Vitae


72. Wong, Robert, Robert Gish, A Clinical Assessment of Wilson Disease in Patients With
Concurrent Liver Disease" JCG9314 Accepted for publication. March 2010
73. Robert Gish. Staying the Course: Patient Adherence Strategies in the Era of New
Frontline HBV Therapies Barriers to Treatment, Adherence in Asian Americans. Clin-
ical Care Options CME/CE Certified Treatment Update. 2010.
74. Robert Gish, The Secret Epidemic: Hepatitis C Affects Between Four and Six Million
Americans, , Bottom Lines Daily Health News, www.bottomlinesecrets.com, Feb, 7,
2006
75. Robert Gish, New Drug for Hepatitis C, Bottom Lines Daily Health News,
www.bottomlinesecrets.com, May 19, 2011
76. Robert Gish, Hepatocellular Carcinoma: Locoregional and Targeted Therapies,
Gastroenterology Clinics of North America, June 7, 2011

77. Robert Gish, 35
th
Annual CAPA Conference, September 22- 25, 2011

78. Gish, Robert., Learn About Hepatitis and Liver Diseases, www.BenhGan.org.; 2011.

79. Robert Gish, AASLD Annual Meeting, November 2011

80. Robert Gish, Best Practice in Advanced Liver Disease, Chicago, Illinois,
August 13, 2011.

81. Robert G. Gish, Risk Assessment and Clinical Management of Patients with CHB,
Fullerton, CA Speaker, August 15, 2011

82. Robert Gish, The Pacific Health Foundation Presents: Fourteenth Annual Liver
Symposium, Speaker, San Jose, CA, September 17, 2011

83. Robert Gish, Viral Hepatitis and Hepatocellular Carcinoma Symposium, La Jolla,
CA, October 2011

84. Robert Gish, Moores Cancer Center, San Diego, CA. November 2011.

85. Robert Gish, Center for Biomedical Continuing Education, HCC Local CME Speaker
Program, 2011 2012.

86. Robert Gish, University of Nevada, School of Medicine Grand Rounds, 2011 2012

87. Robert Gish, Chronic HBV, Clinics in Liver Disease (Accepted for Publication),
May 2012.

88. Speaker, Hepatitis Hot Topics GRS (?) (Short notice). Scripps Mercy Hospital San
Diego, February 22, 2013.

89. International Liver Cancer Association Meeting, Washington, DC 2013

Curriculum Vitae


90. Speaker, Treatment of Viral Hepatitis Circa 2013. Advances in Gastroenterology and
Hepatology, San Diego Omni Hotel, San Diego, CA. March 2, 2013.

91. Wide Spread Hepatitis B screening and treatment in Vietnam CME meetings in Ha Noi
and HCMC, March 3-5, 2013.

92. Current Insights in to the Management of Hepatic Encephalopathy, Hepatology Centers
of Educational Expertise, San Diego, CA; May 28, 2013.

93. Speaker, Current Insights into the Management of Hepatic Encephalopathy. The Chronic
Liver Disease Foundation, 2013 Hepatology Centers of Educational Expertise Lecture
Series. Ruths Chris Steak House, San Diego, CA. May 28, 2013.

94. Speaker. Hepatitis D and E: The Forgotten Viruses. UCSD AntiViral Research Center,
San Diego, CA. June 21, 2013.

95. HCV Update. Sponsored by Duke University School of Medicine & the Chronic Liver
Disease Institute. Phoenix, AZ. January 20, 2014.

96. Speaker & Educator, Viral Hepatitis Action Plan Webinar, Office of HIV/AIDS and
Infectious Disease Policy, Department of Health and Human Services, December 13,
2013.

97. Speaker, Surveillance for Hepatocellular Carcinoma in the At-Risk Population in
association with Bayer Healthcare and Onyx Pharmaceuticals. Philadelphia, PA.
January 14, 2014.

98. Instructor, State of the Art Therapy for HCV, University of Washington, University of
Alabama Birmingham, IAS-USA online training module, Funded by a grant from the Cen-
ters for Disease Control and Prevention. March 15, 2014.
http://hepatitisc.uw.edu/browse/all/lectures#page/featured/lectures/state-art-therapy
Curriculum Vitae

FEDERAL AND STATE LEGAL HEARINGS

October 28th, 1997: Senate Interim Hearing, Public Safety Subcommittee on Prison
Construction and Operation (Senator Polanco, Chairman).

June 9th, 1998: Advisory Group on Hepatitis C, for the California Assembly Health
Committee on merits of Senate Bill 694 introduced by Senator Polanco (Public education
and screening for hepatitis C virus)

April 14, 2000: Coalition Members, Deparment of Health and Human Services (DHHS) Task
Forced On Hepatitis C.

May 22, 2000: Coalition Members, Senate Bill 1256 (Polanco).

June 6th, 2000: Advisory Group on Hepatitis C for the California Assembly Health
Committee on merits of Senate Bill 1256 introduced by Senator Polanco (Public education
and screening for hepatitis C virus)

May 4, 2001. CASG HCV/Civacir protocol re: NIAID Collaborative Antiviral Study Group
(CASG) clinical trial A Randomized Open-label, Phase I/II Study to Evaluate the Safety and
Pharmacokinetics of Hepatitis C Immune Globulin (Human) Civacir in Liver Transplant
Recipients

2002: Center for Policy Reform Senate Bill AB 2529 (Hep C prevention education for
prisoners).

March 26, 2014: Liver Capitol Hill Day in association with the American Association for the
Study of Liver Diseases, Washington, D.C.

EDUCATIONAL EVENTS

X550 Dinner Program with Temecula-Area Group of Heptologists, Temecula, CA. October,
2011.

Facilitator, Academic Health Centers & Health Reform: Re-establishing the Social
Contract, University of California, San Diego Department of Medicine Grand Rounds, Feb-
ruary 8, 2012.

EASL, The International Liver Congress 2013, 48
th
Annual Meeting of the European
Association for the Study of the Liver. Amsterdam, Netherlands. 24 hours. April 26, 2013

Tools in Waitlisted Patient Management, Xyn Management, May 2013.

Grand Rounds, Internal Medicine Residents & Fellows, Penn State University Medical
Center, Hershey, PA, October 18, 2013.

Facilitator, HBV Task Force, St Josephs Medical Center, Phoenix, AZ March 19, 2014.
Curriculum Vitae

SPECIAL COURSES ATTENDED

Therapeutic Biliary Endoscopy. Kees Huibregtse, M.D., Academic Medical Center.
Amsterdam, Netherlands, April 9-June 6, 1987.

Liver Transplantation Strategies. Baylor Medical Center, May 1988.

Endoscopic Ultrasound: Lok Tio M.D., and Therapeutic Biliary Endoscopy: Kees
Huibregtse, M.D. Academic Medical Center, Amsterdam, Netherlands, June 1-30, 1989.

AASLD Annual Postgraduate Course and Research Meeting, Chicago, Illinois, 1984-
present.

DDW Annual Postgraduate Course and Research Meeting. Various 1985, 1988, 1991,
1992, 1993, 1994.
Laparoscopy and Liver Biopsy. Under the direction of Lennox Jeffers, M.D., University of
Miami, Miami, Florida, 1992.
Liver Transplantation and Viral Hepatitis. NIH, AASLD Symposium, Reston, Virginia, March
25, 1993.
The Psychiatric Effects of Interferon: Theories and Therapeutic Approaches, Integrated
Therapeutics, Short Hills, Virginia, May 31, 1996.
Liver Transplantation for Alcoholic Liver Disease, ASTP/AASLD Forum, Bethesda, Maryland,
December 3, 1996.
Liver Transplantation for Alcoholic Liver Disease, The National Institute of Diabetes and
Digestive and Kidney Diseases, Washington, DC, December 6, 1996.
International Hepatology Symposium, Beijing, China August 8-16, 1997.
Testing for Hepatitis C: New Technologies for Optimal Therapy. Trevose, PA. November 14,
2001; December 13, 2001; December 17, 2001.
HCV Side Effects Consensus Conference. San Francisco, CA. May 18, 2002.
Controversies in Hepatitis C Therapy. Boston, MA. November 3, 2002.
AASLD Annual Meeting and Postgraduate Course, Boston, MA October 24-28, 2003.
Evolving Concepts in Liver Allocation in the MELD/PELD Era. Washington DC, December 8,
2003.
New Directions in the Treatment of Hepatitis B. Chicago, IL, March 2004.
1
st
Internation Conference of Armenian Hepatological Forum-participated as Moderator of
event. Yerevan, Armenia, September 2011.
Armenian Hepatological Forum. Yerevan, Armenia. September 2011.
Curriculum Vitae

SPECIAL COURSES ATTENDED: Continued

Attendee, PBC: Past, Present & Future, The Royal College of Physicians, London, United
Kingdom, April 8. 2014.

Attendee, Towards HCV elimination in Georgia: epidemiology, care and treatment options,
and evidence based control strategies. International Liver Congress 2014, European Asso-
ciation for the Study of the Liver, London. United Kingdom, April 9, 2014.

Attendee, Hepatitis Delta International Network, International Liver Congress 2014,
European Association for the Study of the Liver, London. United Kingdom, April 9, 2014.

COMMUNITY SERVICE and MEDIA APPEARANCES

Hepatitis B Prevention and Transplantation. Viacom Cable Channel 6, City Lights. June, 1992.
Hepatitis B Prevention and Transplantation. Nationally televised program hosted by Dr. Dean
Edell. June, 1992.
The Three H's: Headaches, High Blood Pressure, and Hepatitis B. Presentation to the Liver
Transplant Recipient Support Group, California Pacific Medical Center. San Francisco,
California. July 8, 1992,

Organ Donation. Kaiser Permanente Medical Center. Walnut Creek, California. November 10,
1993.

Organ Transplantation. BBC television. Nightline.

Hepatitis B. Glamour Magazine, 1994.

Hepatic Hotline. Moderator, American Liver Foundation patient and community conference on
hepatitis, St. Mary's Hospital. San Francisco, California. October 29, 1994.

Liver Disease. Liver Disease Support Group. Modesto, California. January 22, 1995.

Viral Hepatitis: Vaccination and Prevention. San Francisco Veteran's Administration Medical
Center. San Francisco, California. October 17, 1995.

Your Liver, Your Life. Public Education workshop. American Liver Foundation, San
Francisco, California. October 7, 1995.

Liver Disease, Liver Transplantation and Organ Donation. Moderator, Public Round Table
Forum, American Liver Foundation. San Francisco, California. October 25, 1995.
Chronic Hepatitis. Public questions and answer period. Eureka, California. December 13,
1995.
Evaluation of Patients with Elevated Liver Enzymes and Viral Hepatitis. Shasta Community
Health. Redding, California. May 14, 1996.
Curriculum Vitae

COMMUNITY SERVICE and MEDIA APPEARANCES: Continued

Recurrent Disease after Liver Transplantation. American Liver Foundation, San Francisco,
California. May 18, 1996.
Future Careers in Organ Transplantation. National Youth Leadership Conference. August 2,
1996.
Treatment of Chronic Viral Hepatitis in the Department of Corrections. Chowchilla State
Prison. August 3, 1996.
Organ Transplantation and its Psychosocial Implications. Chico Support Group. Chico,
California. September 13, 1996.
Treatment of Chronic Viral Hepatitis in the Department of Corrections. Crescent City,
California. September 18, 1996.
Hepatitis C in the Correction System. Folsom State Prison. Folsom, California. October 8,
1996.
Hepatitis A-Z. North Coast Society of Health System Pharmacists. Santa Rosa, California.
January 22, 1997.
Patient Support Group Lectures. John Muir Hospital. Walnut Creek, California. January 30,
1997.
Patient Support Group Lectures. Roseville Liver Transplant at Sutter-Roseville Hospital.
February 9, 1997.
Nutrition for the Liver. Support Group Lecture. Sutter General Hospital. Sacramento,
California. February 19, 1997.
Patient Support Group Lecture. Sacramento Support Group. Sacramento, California. March
1, 1997.
HVC Support Group. Sutter General Hospital., Sacramento, California. March 19, 1997.
Hepatitis C Results. National Morning-Drive Radio Tour. March 27, 1997.
The ABC's of Hepatitis. East County (Contra Costa) Times. May 6, 1997.
Dialogue on Digestive Health Awareness. DDW Telephone Program. May 15, 1997.
Gastroesophageal Reflux Disease.CBS Radio News Show: Diagnosis and Management.
December 20, 1997.
Hepatitis C: An Epidemic in the Prison System. National Radio News Show: 14 Radio
Interviews between October 23-24, 1997.

Curriculum Vitae


Hepatitis C: Setting up and continuing support groups, ALF effort, San Francisco, California,
5/6/98.
Hepatitis C: New treatment options. American Liver Foundation North California Chapter
newsletter, San Francisco, California. June 13, 1998.
Patient Support Group Lecture. San Francisco Veterans Administration Hospital. April 14,
1998.
Hepatitis C Increasing public awareness. Radio America interview with 19 national radio
shows. June 10, 1998.
Hepatitis C screening of inmates proposed. Interview with the Riverside Press-Enterprise.
June 13, 1998.
Alternatives in the treatment of chronic hepatitis C infection. American Liver Foundation, Liver
Lifeline. June, 1998
National Youth Leadership Conference: Forum on Medicine. Berkeley, California. July 16,
1998.
The silent epidemic: Hepatitis C. San Jose, California. August 21, 1998
Updates in research, treatment, and understanding Hepatitis C. Yuba-Sutter Hepatitis C
Support Group Meeting. November, 1999.
I Will Survive. Sacramento Area Support Group. Sacramento, CA. March 15, 2000.
Hepatitis Central guest speaker, questions and answers on line. San Francisco, California.
January 27, 2000.
Is Hepatitis an Epidemic? What are current treatments? KSUF Radio Interviews, San
Francisco, California. April 22, 2000.
Dark to dawn: A lesson in living: Liver Transplant patient Wendy Marx. San Francisco
Examiner. San Francisco, California. May 7, 2000.
China Digest Interview. June 2008.
Hepatitis: Cases of disease rising, and it could get worse. Santa Barbara News. Santa
Barbara, CA. January 18, 2001.
Hepatitis Neighborhood Town Hall hosted chat sessions. San Francisco, California. March 7,
2001.
HCV Advocate Medical Writers Circle. Online community service. 9/2001-current
Galileo High School Students discussion on cirrhosis and liver failure. December 13, 2001.
Curriculum Vitae


Herbal Medicine and HCV. KRON news. February 1, 2002.
Hepatitis C education: The Need at the Professional Level. The First inter-county California
Statewide HSC Task Force Conference. Sacramento, California. March 13, 2002
Managing Treatment Outcomes for HCV-Related Anemia. AdvancMed. May 29, 2002
2002 Laguna Development Meeting for Clinicians Companion VI. Secaucus, NJ. August 2002.
Advances in the Care of Patients with Autoimmune Liver Disease. AXCAN Scandipharm.
Honolulu, HI. September 17, 2002.
Liver Transplant Symposium. September 25, 2002.
Hepatitis C Community Health Update. San Francisco, CA. October 24, 2002.
Alameda County Health Care Services Agency. Oakland, CA. November 14, 2002.
Hepatitis B providers event. NICOS Chinese Health Coalition. May 28, 2003.
HCV Workshop. San Francisco, California. June, 2004.
AWARE Talk Radio. Interview with Dr. Robert Gish. November 9, 2004.
The Q&A Series Liver Cancer., American Liver Foundation. 2006.
Liver Disease Hepatitis B & C. KCBS Radio. 2007.
CPMC & San Francisco Hep B Program 1 in 10 Hepatitis B in the API/Chinese
Community. Imperial Palace Restaurant. San Francisco, CA. May 4, 2008.
The 4
th
Annual Asian Heritage Street Celebration. Japantown. San Francisco, CA. May 17,
2008.
CP#384 event launching on the West side of the City. Picture and comments listed. Ming
Pao News Reporting. November 27, 2008.
HBV Free Physicians Honor Roll 2009 2010
Vietnamese Federation of San Diego, San Diego, October 2011.
Consult to the Commission on Viral Hepatitis. State of Nevada Department of Business
and Industry Athletic Commission. April 8, 2010.
Robert Gish takes the helm of hepatitis B prevention. San Francisco Examiner
Newspaper. Article by: Andrea Koskey. May 27, 2010.
A National Strategy for Viral Hepatitis Control. AASLD 2010
Facilitator, La Jolla High School Organ Tour, University of California, La Jolla, CA, 2011.

Curriculum Vitae


Free Screening for Diabetes and Hep B, UCSD 2011
Hepatitis Screening Education with Asian Pacific Health Foundation, Wesley First United
Methodist Church, San Diego, CA May 29, 2011.

Hepatitis B: Current Epidemiology, UCSD May 19, 2011
Spring Community Health Fair, Wesley First United Methodist Church, May 22, 2011

FAIR Foundation Support Group, Rancho Mirage, CA, June 27, 2011

Clinical Care Options, Bringing into Focus: A Practical Guide to Using Virologic and
Serologic Tests in the Management of Hepatitis B June 2011
Community Health Outreach; Hep B & C Screening, San Diego, June 26, 2011
Hepatitis Screening Education with Asian Pacific Health Foundation, Chinese Evangelical
Church, San Diego, CA July 31, 2011.

Update on the Treatment of Liver Cancer, CancerCare Teleconference, August 18, 2011
World Hepatitis Day 2011, San Francisco, CA, August 2011
UDW 2
nd
Annual San Diego County Health and Resource Fair (hosted by Skaggs School of
Pharmacy and the Asian Pacific Health Foundation), San Diego, CA August 2011.
Domino liver transplants treats two rare diseases, Donate Life, features Allan Hemming,
MD and Robert Gish, MD. CBS 8, KPBS, NBC-SanDiego, 10News, The La Jolla Light, Fox
5, 760AM and BioPortfolio, September 2011
Hepatitis Screening Education with Asian Pacific Health Foundation, Tzu Chi, San Diego,
CA September 11, 2011.

Hepatitis Screening Education with Asian Pacific Health Foundation, Hzi Fang Temple, San
Diego, CA September 25, 2011.
HBV Chinese Community Event held at the office of the Asian Pacific Health Foundation.
October 2011.
Health Fair for the Vietnamese Federation of San Diego, San Diego, presented topic:
Updates on Hepatitis B, October 2011.
Hepatitis Screening Education with Asian Pacific Health Foundation, Vietnamese Federa-
tion, San Diego, CA October 14, 2011.

Hepatitis Screening Education with Asian Pacific Health Foundation, La Jolla Country Day,
San Diego, CA November 6, 2011.
Curriculum Vitae


Hepatitis Screening Education with Asian Pacific Health Foundation, Middlebrook Middle
School, San Diego, CA , December 3, 2011.

Asian Journal-Los Angeles, San Francisco, Las Vegas, New York, November 2011.
Facilitator, La Jolla High School Organ Tour, University of California, La Jolla, CA, 2012
Participant: Buddhist Tzu Chi Foundation San Diego Service Center: Lunar New Year
Blessing Ceremony, San Diego, CA, January 2012.
Facilitator, Vietnamese Federation of Sa Diego in conjunction with the Vietnamese Elderly
Associaton and the Vietnamese Veterans Association, San Diego, CA January 14, 2012.
Event Organizer, 2
nd
Annual Symposium, 2012 Controversies in Inflammatory Bowel
Disease, San Diego, CA January 28, 2012.
Event Organizer, Hepatitis Free San Diego Introductory Meeting, Skaggs School of
Pharmacy, Sponsored by Merck Co, La Jolla, CA January 31, 2012.

Bottom Line Personal (Home of Americas Top Experts in Everything), Everyone born
between 1945 and 1965 should be tested for Hepatitis C, Volume 33, Number 3, February
1, 2012.
The Doctors TV program, Topic: Nail Salon Dangers, featuring Robert Gish, MD.
February 2012.
Facilitator, Asian Pacific Health Foundation Training Session: Handling and Disposal of
Supplies and Barriers Study Surveys, Asian Pacific Health Foundation, San Diego, CA
February 14, 2012.
Hepatitis Screening Education with Asian Pacific Health Foundation, Wesley First United
Methodist Church, San Diego, CA April 4, 2012.
Hepatitis Screening Education with Asian Pacific Health Foundation, Thai Temple (New
Year), San Diego, CA April 19, 2012.
Hepatitis Screening Education with Asian Pacific Health Foundation, Taiwanese American
Community Center, San Diego, CA May 19, 2012
Hepatitis Screening Education with Asian Pacific Health Foundation, Vietnamese Federa-
tion, San Diego, CA June 10, 2012.

Hepatitis Free San Diego, Family Health Day Hepatitis B and C screening Organized by the
Tzu-Chi, St. Peters Church, Fallbrook, CA; June 29, 2012.

Hepatitis Free San Diego, Participant, 2012 Annual Convention of the Vietnamese American
Medical Association, Orlando, FL; August 5, 2012.
Curriculum Vitae


Hepatitis Free San Diego Community Outreach, Union of Homecare Workers (UDW), Joan
Kroc Community Center, San Diego, CA; August 25, 2012.

Hepatitis Free San Diego Hepatitis B and C pilot run Wesley First Methodist Church, San
Diego, CA; August 27-29, 2012.

Hepatitis Free San Diego Hepatitis C screening at the UCSD HERE Initiative (Health + Education
+ Research = Empowerment), Jacobs Center, San Diego, CA; September 8, 2012.

Hepatitis B Screening with Dr. Julio Gutierrez, Asian Pacific Health Foundation targeting
Laotian and Cambodians in East San Diego, Colina Park, San Diego, CA; December 16,
2012.

Facilitator, La Jolla High School Organ Tour, University of California, La Jolla, CA, 2013.

Hepatitis B Screening, Asian Pacific Health Foundation, Good Shepherd Church, San
Diego, CA; January 12, 2013.

Feature Article, A Hep B Free San Diego, Discoveries Magazine, Innovations in Research,
Health Care and Education Volume 3 / 2012.

Tzu-Chi Family Health Day, Asian Pacific Health Foundation, Asian Hepatitis B Screening
for Asians, Saint Peters Church, Fallbrook, CA.; January 13, 2013.

Hepatitis B Screening with Dr. Julio Gutierrez, Asian Pacific Health Foundation, Our Lady of
Sacred Heart Church, San Diego, CA; January 20, 2013.

Hepatitis B Screening with Dr. Julio Gutierrez, Asian Pacific Health Foundation, Coolidge
Park, San Diego, CA; January 27, 2013.

32nd Annual Advanced Nephrology: Nephrology for the Consultant, San Diego, CA; January
31, 2013 February 02, 2013.

National AIDS Treatment Advocacy Project, Sexual Transmission of HCV Among Monoga-
mous Heterosexual Couples: The HCV Partners Study, Abstract by: Norah A. Terrault,
Jennifer L. Dodge, Edward L. Murphy, John E. Tavis, Alexi Kiss, T.R. Levin, Robert Gish,
Michael Busch, Arthur L. Reingold, Miriam J. Alter, (Center for Disease Control and Preven-
tion); February 22, 2013.

Liver Cancer Webinar: Liver Cancer and Hepatitis B: What You Need to Know, Presented
by the Hepatitis B Foundation, Doylestown, PA; March 6, 2013.

Successful Domino Liver Transplantation From A Patient With Methylamalonic Acidemia,
First Ever Report, American Association for the Study of Liver Diseases (AASLD); March 8,
2013.

Curriculum Vitae


Hepatitis B Consultative Meeting: National Viral Hepatitis Task Force (NVHTF) and Viral
Hepatitis Foundation (VHF) a public private partnership to formulate a Road Map for Viral
Hepatitis Control and Prevention in the Philippines, Manila Philippines; March 11, 2013.

Hepatitis B and C screenings: presented by Asian Pacific Health Foundation San Diego
Chinese School, San Diego, CA; March 16, 2013.

Robert Gish, Baby Boomers & Hepatitis C Test, UCSD Online Content, March 2013.

Hepatitis Screening Education with Asian Pacific Health Foundation, San Diego Chinese
School, San Diego, CA March 16, 2013

Hepatitis B and C screenings: presented by Asian Pacific Health Foundation Health Fair:
Wesley First United Methodist Church, San Diego, CA; March 17, 2013.

Hepatitis B Screening, Asian Pacific Health Foundation with Dr. Binh Tran, Nhu Lai Temple,
San Diego, CA, March 19, 2013.

Hepatitis Screening Education with Asian Pacific Health Foundation Vietnamese Federation
of San Diego, San Diego, CA. April 14, 2013

Gish RG, Alain, Litwin, An Evolving Therapeutic Landscape for Chronic Hepatitis C Virus:
Optimizing the Linkage to Care. MD Magazine, Peers & Perspectives Special Issue. May
2013.

International Conference on Continuous Renal Replacement Therapies (CRRT) 2013,
Advances in Critical Care, San Diego, CA; May 4-7, 2013.

Hepatitis B screening, Asian Cultural Festival, Naval Training Center Liberty Station, San
Diego, CA; May 11, 2013.

Attendant, Representing Coalition for the Eradication of Viral Hepatitis in Asia Pacific
(CEVHAP) and National Viral Hepatitis Roundtable (NVHR) Organizations, Viral Hepatitis
Action Coalition, Atlanta, GA.; May 17, 2013.

Hepatitis B screening with Dr. Binh Tran, Asian Pacific Health Foundation, Nhu Lai Temple ,
San Diego, CA May 19. 2013.

Current Insights in to the Management of Hepatic Encephalopathy, Hepatology Centers of
Educational Expertise, San Diego, CA, May 28, 201

Hepatitis Screening Education with Asian Pacific Health Foundation, Mabuhay Filippino-
American Festival, National City, CA. June 8, 2013.

Speaker. Hepatitis D and E: The Forgotten Viruses. UCSD AntiViral Research Center, San
Diego, CA. June 21, 2013.

Curriculum Vitae


Hepatitis B and C screenings with Yi Liu, PhD: presented by Asian Pacific Health Founda-
tion, Zion Market, San Diego, CA; June 29, 2013.

Guest Speaker, PBS Television, PBS radio and NPR; Hepatitis B Prevalent in San Diego's
AsianCommunities, Global update, July 1, 2013.

Hepatitis B and C screenings with Yi Liu, PhD: presented by Asian Pacific Health Founda-
tion, Zion Market, San Diego, CA; June 29, 2013.

Health Fair & Hepatitis B Screening in association with Binh Tran & Asian Pacific Health
Foundation; San Diego Lantern Festival; San Diego CA, July 20-21, 2013.

Health Fair & Hepatitis B Screening in association with Binh Tran & Asian Pacific Health
Foundation; Vietnamese Catholic Center; July 27, 2013.

Hepatitis Screening Education with Asian Pacific Health Foundation, Tzu Chi Foundation,
San Diego, CA, October 19, 2013.

Hepatitis Screening Education with Asian Pacific Health Foundation Nov 2 Health Wellness
Fair at Paradise Valley Hospital, San Diego, CA, November 2, 2013.

Hepatitis B Special Interest Group: SIG Business Meeting, Washington D.C., November 3,
2013.

Sponsor & Supervisor, Hepatitis B Screening, Asian Pacific Health Foundation with Dr. Binh
Tran, Tet Festival, San Diego, CA; February 1, 2014.

Asian Pacific Health Foundation with Dr. Binh Tran, Spring Health Fair at Vietnamese
Federation, San Diego, CA; February 9, 2014

Hepatitis B screening and Bone densitometry Asian Pacific Health Foundation with Dr. Binh
Tran, Living Water Church, San Diego, CA; March 9, 2014.

Liver Capitol Hill Day in association with the American Association for the Study of Liver
Diseases, Washington, D.C., March 26, 2014.

Video Interview, HBV treatment and reactivation, Center for Liver Disease (CLD) Journal,
European Association for the Study of the Liver, London, United Kingdom, April 10, 2014.

Public Service Announcement for National Viral Hepatitis Testing Day. Produced by CBS
local affiliate KPIX-TV and KBCW-TV, San Francisco for national distribution, April 18, 2014.

Curriculum Vitae

INTERNATIONAL COMMUNITY PROGRAMS

Robert Gish, Nguyen Tien Duc, Bui Duy Tam. Detection, Prevention, Control and Treatment
of Viral Hepatitis, Liver Cancer and Other Liver Disease in Viet Nam. February 11, 2010.

Robert Gish, Huy Trinh. Overview of US Medical Schools and comparison to the Viet Nam
and University of Ha Noi programs Ha Noi Medical University, Ha Noi, Viet Nam 8 30 10

Robert Gish, Yerevan, Armenia Yerevan Hepatology Days, Aug 31 Sep 4, 2011

Mohamed Kohla, Mohamed El-Warraky, Sayed Solaiman, Robert Gish, Management of a
Case of Obscure Lower GI Bleeding by Transjugular Intrahepatic Portosystemic Shunt
(TIPS): A Case Report. Poster for Asian Pacific Digestive Week (APDW 2012), Bangkok,
Thailand; December 5-8, 2012

Mohamed Kohla, Mohamed El-Warraky, Robert Gish, Unilateral Sensori-neural Hearing
Loss Induced by Pegylated Interferon 2a: A Case Report. Poster, Asian Pacific Digestive
Week (APDW 2012), Bangkok, Thailand; December 5-8, 2012

Robert De man and Robert G Gish, et al (INCOMPLETE AUTHORS), Abstract A-533-
0019-01294 entitled: Impact of Entecavir Versus Lamivudine on Hepatic Covalently Closed-
Circular DNA and Total Hepatic HBV DNA in Nucleoside-Nave HBeAg Positive Chronic
Hepatitis B Patients. Both ePoster and Paper poster, International Liver Congress 2013
(ILC), Amsterdam, Netherlands; April 26, 2013.

Robert Gish, Binh Tran, John Fontanesi, Lilly Nguyen Co-Author, Cost Efficiency Analysis
of Point-of-Care versus Standard of Care Tests for Hepatitis B in Asian Americans in San
Diego Count. Asian Pacific Health Foundation, UCSD. Summer 2013.

Robert Gish, Binh Tran, John Fontanesi, Thuy Nguyen, Co-Authors. Cost-Effectiveness of
Hepatitis C Screening: Point of Care (POC) vs. Standard of Care Tests. Hepatitis Free San
Diego, UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, Summer 2013.

Robert Gish, Binh Tran, John Fontanesi, Xuan Phan. Co-Authors Viral Hepatitis: Early
Identification and Linkage to Care for Persons with Chronic HBV and HCV infections Hepati-
tis Free San Diego. UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences,
Summer 2013.

Participant, Hepatitis B Prevention PLAN for HCMC University of Health, San Francisco-
HCMC Sister City Committee & International Liver Foundation for Viet Nam. Hepatobiliary
Hospital. Bach Mai, Hanoi, Viet Nam. 2013 Present

Curriculum Vitae

INTERNET SITE and PUBLICATIONS

HealthLink (www.healthlink.com): 1998 New and Evolving Therapies for Hepatitis C.
Sponsored by the Canadian Digestive Disease Week Forum, Banff, Canada.
Sapient (www.sapient.com): 1997-1998 Hepatitis C: Diagnosis Treatment and Management.
Thrive: The Cutting Edge: New Therapies for Hepatitis B and C. 1998.
CPMC (www.cpmc.org): Liver Disease and Liver transplant program.
Contributor, Blog on Liver Transplantation for UCSD, Blog website:
http://ucsdhealthsciences.tumblr.com/; September 2011.
Speaker, Liver Cancer and Hepatitis B - What You Need to Know, 2013 Liver Cancer
Webinar Series, Hepatitis B Foundation, March 6, 2013.
Curriculum Vitae

INVITED LECTURES NATIONAL AND INTERNATIONAL

Effect of t-Butyl hydroperoxide on calcium transport, USC-UCLA Colloquium on Oxygen,
USC Medical School, Los Angeles, California, 7/8/87.
Liver transplantation in the United States: Lichtenberg Hospital, Netherlands, 6/12/89;
Gronengen University, Gronengen, 6/14/89; Dizkzigt, Rotterdam University, 6/16/89;
Amsterdam Medical Center, 6/18/89.
Liver transplantation state of the art, Division of Gastroenterology, University of California at
Irvine, Irvine, California, 4/5/89.
Liver transplantation for malignancy, and The use of databases in the management of a liver
transplant program, in Spanish, Associacion Andaluza de Cirujanos, Cordoba, Spain,
12/13/90.
Acute and chronic liver disease, Straub Clinic, Honolulu, Hawaii, 1/30/91.
FK506: a new immunosuppressant, University of Florida at Gainesville, Gainesville, Florida,
1/21/92.
Gallstones, Utah Academy of Family Physicians, Centerville, Utah, 2/29/92.
Liver cancer, Sixth International Conference on Health Problems Related to the Chinese in
North America, San Francisco, California, 6/19/92.
Liver transplantation for patients with alcoholism and endstage liver disease, American
Society of Addiction Medicine, Los Angeles, California, 5/1/93.
Liver transplantation for alcoholic liver disease, University of Nebraska, Omaha, Nebraska,
4/29/94.
Hepatitis B issues related to liver transplantation, University of Alabama, Birmingham,
Alabama, 9/23/94.
Hepatitis C current diagnostic techniques, World Congress of Gastroenterology, Los
Angeles, California, 10/1/94.
Medical aspects of liver transplantation, University California at Davis, Sacramento,
California, 10/11/94.
Therapeutic options in decompensated hepatitis B, American Association for the Study of
Liver Disease, Chicago, Illinois, 11/4/94.
HCV workup meeting, Tufts University School of Medicine, Boston, Massachusetts, 3/23/96-
3/24/96.

Curriculum Vitae

INVITED LECTURES NATIONAL AND INTERNATIONAL: Continued

Hepatitis A-Z and its relationship to organ transplantation, National Association of Transplant
Coordinators, San Diego, California, 8/5/96.
Combined kidney/liver transplantation roundtable, University of Washington, Seattle,
Washington, 8/9/96.
Hepatitis A through G: an alphabet soup, Hilo, Hawaii, 1/1/97 to 1/4/97.
Consensus conference, University of Pennsylvania Department of Medicine, Philadelphia,
Pennsylvania, 2/97.
Viral hepatitis and liver transplantation, Ochsner Medical Clinic, New Orleans, Louisiana,
3/23/97.
Diagnosis and treatment of chronic hepatitis, Alaska Regional Medical Center, Anchorage,
Alaska, 5/7/97.
Hepatitis B & C, Alaska Public Health Hospital, Anchorage, Alaska, 5/8/97.
Controversies in Liver Transplantation, UCLA Medical Center, Los Angeles, California,
10/21/97
Diagnosis and treatment of elevated liver enzymes, Providence Hospital, Anchorage, Alaska,
5/9/97.
Update on Ribavirin treatment of chronic hepatitis C, Washington, DC, 5/12/97.
The outpatient management of patients with chronic viral hepatitis, Washington, DC, 5/15/97.
Diagnosis and treatment of hepatitis C, Summary of the NIH Conference, St. Louis,
Missouri, 5/16/97.
Hepatitis A through G: an alphabet soup, Honolulu, Hawaii, 5/97.
Diagnosis and treatment of liver cancer, Las Vegas Gastroenterology Group, Las Vegas,
Nevada, 6/2/97.
Post-transplant complications of hepatitis B infection, Hepatitis Awareness Program,
Hong Kong, China, 8/12/97.
Liver transplantation for hepatitis B and C, International Symposium on Hepatology,
Beijing, China, 8/13/97.
Treating relapsers and nonresponders: a clinical Challenge, AASLD Satellite
Symposium, Chicago, Illinois, 11/8/97.

Curriculum Vitae


New and Emerging Therapy for Hepatitis C, Canadian Digestive Disease Week, Banff,
Canada, 3/5/98.
U.S. Combination Trials in NR patients: Review of Preliminary Data, US investigator
meeting, San Puerto Rico, 1/31/98.
Selection of patients for liver transplantation with liver cancer, NIH/AASLD Single Topic
Conference, Saint Louis, Missouri, 3/28/98
Beyond monotherapy: Treatment of Hepatitis C: New options for relapsers and
nonresponders. Satellite symposium, DDW/AALSD New Orleans, Louisiana, 5/17/98
Treatment of Hepatitis C: Poster Review Session, AASLD/DDW, DDW, New Orleans,
Louisiana, 5/17/98
Interferon Treatment for Chronic Hepatitis B: An Update, 8th International Congress on
Infectious Disease, International Society of Infectious Disease, Boston, Massachusetts,
5/14/98
Interferon and ribavirin treatment for chronic hepatitis C: A review of recent data, Cheng Si
Yuan, Conference on Viral Hepatitis, Shenzen, China, 9/14/98
The Therapeutic Standard Strategy for Chronic Hepatitis C, Luncheon Seminar, DDW
Japan 1999
Hepatitis C new therapies, Interferon and Ribavirin Japanese DDW, invited lecture, 9/2000
HCV Research and Prevention, An immunomodulatory approach to HCV therapy HCV
Global Foundation, San Francisco, CA 08/10/00.
Hepatitis C, WFTC World Conference, 09/00.
FTC,DAPD, and L-FMAU Nucleoside Candidates for Treatment of Chronic HBV,
Management of Hepatitis B: 2000 National Institutes of Health, Bethesda, MD 09/09/00.
HCV Research and Prevention, New approaches to HCV therapy HCV Global Foundation,
San Francisco, CA 08/10/01.
Hepatitis B and Liver Transplantation Beijing Friendship University, Beijing, China,
8/30/2001
Interferon and ribavirin treatment for chronic hepatitis C: A review of recent data,
Autoimmune Hepatitis, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis,
Conference of Science and Technology, Conference on Liver Disease, Beijing, China,
8/13/2001

Curriculum Vitae


Hepatitis and liver transplant, current standards of therapy, Barcelona Liver Disease
Symposium, Barcelona Spain, 9/24/2001
Interferon and ribavirin, importance of dosing and compliance Japanese DDW, Osaka and
Tokyo, Japan 10/24/2001
Hepatitis C: 2001, a virus odyssey, New Horizons in Hepatology, UCSD Liver Center 2001,
San Diego, California 9/15/2001
Testing for Hepatitis C: Satellite Symposium. AASLD. Dallas Texas. 11/14/2001
Testing for Hepatitis C: New Technologies for Optimal Therapy. US teleconference. CME
accredited 11/14/2001, 12/3/2001, 12/17/2001.
Managing Hematologic Dysfunction During hepatitis C Therapy. AASLD satellite
symposium. Dallas Texas, 11/5/2001
The workup and evaluation of liver tumors Early AM workshop, AASLD 11/5/2001
CSY China Itl Hepatitis Research Foundation. Hong Kong, China 10/20/2001
Hepatitis C management advances in therapy. William Earl Clark Society. April 30, 2002
Treating Chronic Hepatitis B: Gilead Sciences DDW Interactive Consultants Forum on
Treating Chronic Hepatitis B. San Francisco, CA. 05/19/2002
Management of Hepatitis C NIH/FAES CME Committee. Bethesda, MD. 6/10-6/12/2002.
Earned 13.5 hours CME credit toward the AMA Physicians Recognition Award
Treatment and the HCV Patient including the role of Alternative and Complimentary
Medicine Hepatitis Foundation International. Los Angeles, CA. July 18, 2002
Living Longer, Living Stronger: Maintaining the Quality of Life for Patients with Anemia &
HIV Infection. Institute for Continuing Healthcare Education. Las Vegas, NV. September 4,
2002. Earned CME credit.
Autoimmune hepatitis, PSC and PBC. U-Japan Meeting on Autoimmune Liver Diseases.
Oahu, HI. 9/12-14/2002
Retransplantation of patients with recurrent hepatitis Cupdate. MCAT. San Francisco
Ca. 9/17/2002
Advances in the use of molecular testing for HCV: Diagnosis and treatment. Bayer
Diagnostics. Taipeo, Taiwan. 9/27/02

Curriculum Vitae


Parallel Session XXXIV Primary Biliary Cirrhosis. ILTS Transplant Course. AASLD. Dallas
Texas. 10/27/2002
Cholestatic and Autoimmune Liver Diseases: ILTS Transplant Course. AASLD. Dallas
Texas. 10/27/2002
Hepatitis C: Mechanisms & other treatment issues: ILTS Transplant Course. AASLD.
Dallas Texas. 10/27/2002
Hepatitis C: Treatment: ILTS Transplant Course. AASLD. Dallas Texas. 10/27/2002
Hepatitis B: Treatment: ILTS Transplant Course. AASLD. Dallas Texas. 10/27/2002
106-Optimal Use of Lamivudine before & after liver transplantation? When should
Lamivudine be initiated in patients awaiting liver transplantation?. Liver Transplantation for
Viral Hepatitis. AASLD. 11/01/2002
Point/Counterpoint: Controversies in Hepatitis C Therapy. AASLD Annual Meeting. Boston,
MA. November 3, 2002.
Advances in the management of chronic hepatitis. AASLD. Boston, MA. 11/4/02
Information exchange-conference call. ACG Liver Disease Expert Information Exchange.
ACG Institute for Clinical Research & Education. 12/10/02
Controversies in Transplantation, Beaver Run Resort and Conference Center, University
of Colorado, CME program, Adefovir for the Management of the Transplant Patient. 3/6-8
2003
Treatment of HCV Infection, Managing side-effects during therapy2/3-5 2003
University of Colorado School of Medicine. March 9, 2003
Adefovir treatment of post-transplant HBV.
Hepatitis B and C Are Curable, How to Do It Infectious Diseases Symposium, Emerging
Clinical Issues, Sacramento, CA 5/8-9/2003
Maximizing the Benefits of Antiviral Therapy for HCV, The Advantages of Treating Side
Effects, Orlando, FL 5/20/03
Liver Diseases in Functional-Genomic Era, Third Scientific Meeting of Cheng Si Yuan
(China-International) Hepatitis Research Foundation), Hong Kong-Shanghai International
Liver Congress 2004, 2/14-17/2004
HVC Side-Effect Management Medical Education Program Phone Conference 8/6/2003
HVC Disease Update: Diagnosis and Management, Las Vegas, Nevada, 8/25/2003
Curriculum Vitae


Case Histories in the Management of Patients Chronically-Infected with HBV Hong Kong,
China, 2/17/04.
Surveying the Hepatitis C Landscape, Emerging Treatment Options on the Horizon, Berlin,
Germany, 4/14/04.
Future Alternatives to Ribavirin, Berlin, Germany, 4/14/04.
Liver Diseases, Napa CA, 11/30/04
ACT-HBV-Entecavir Phase III Clinical Trial Results, San Francisco, CA 12/03/04
HBV Hardball-An in-dept Analysis and Fiery Debate on Optimizing Outcomes in the
Treatment of Hepatitis B Virus Nov. 9, 2004, New York.
Face B- Bristol Myers Squibb Hepatitis B Speakers Bureau Conference : Facing a New
Future, Washington, D.C., April 2005
Virologic Response and Safety Outcomes in Therapy-Nave Patients Treated for Chronic
Hepatitis C with Virmadine in Combination with Pegylated Interferon ALFA-2A, DDW
Chicago, IL, May 2005
Entecavir Leads to Sustained Response Off-Treatment in Nucleoside-Nave, HBEAGE(+)
Patients Who Met On-Treatment Response Endpoints at 48 Weeks of Therapy in Phase 3
Study ETV-022, DDW Chicago, IL, May 2005
Entecavir is Well Tolerated for the Treatment of Nucleoside-Nave and Lamivudine-
Refractory Chronic Hepatitis B: Phase 2/3 Safety Results, DDW Chicago, IL May 2005
Opening Remark - Practical Pathways Towards Improved Management of HCV Treatment
Failures, DDW Chicago, IL May 2005
Alanin Aminotrasferease (ALT) Flares are les Frequent with Entecavir than Lamivudine
Treatment Both On- and Off- Treatment in HBeAg(+) Patients, DDW Chicago, IL, May 2005
Entecavir Demonstrates Consistent Responses Among Baseline Subgroups in the
Treatment of Nucleoside-Nave, HBeAg(-) Patients with Chronic Hepatitis B DDW Chicago,
IL, May 2005
Current Diagnostics and Management of HBV Drug Resistant. Saigon, Vietnam. August
29, 2010.
NAT/PCR Role as a Decisions Tool for the Management of Chronic Hepatitis B. Saigon,
Vietnam. August 29, 2010.
Curriculum Vitae


Current Diagnostics and Management of HBV Drug Resistant. Hanoi, Vietman.
September 1, 2010.
NAT/PCR Role as a Decisions Tool for the Management of Chronic Hepatitis B. Hanoi,
Vietnam. September 1, 2010.
New Hepatitis B Treatments: Long-Term Therapy: Balancing the Risk and Benefits as We
Pursue Sustained Viral Clearance. Viral Hepatitis Conference 2010. Melbourne, Australia.
September 6, 2010.
The Shifting Focus of Hepatitis B Supported by the Australian Government Department of
Health and Ageing. Viral Hepatitis Conference 2010. Melbourne, Australia. September 6,
2010.
Delivery of Hepatitis B Care & Management A San Francisco Perspective. Melbourne,
Australia. September 6, 2010.
CHB Treatments, Endpoints & Stopping Rules. New Agents, Better Outcomes. Viral
Hepatitis Conference 2010. Melbourne, Australia. September 7, 2010.
Boceprevir in Practice; MSD Singapore. MSD Hepatitis Advisory Board Meeting, October
2011.
Hepatobiliary Neoplasia Special Interest Group Leadership, Hepatobiliary Neoplasia Special
Interest Group Leadership, San Francisco, CA. November, 2011.
AASLD, The Liver Meeting, San Francisco, CA. November 2011.
Speaker, Advancing Hepatology in New Era: Milestones and Perspectives, 67
TH
Annual
Conference of the Association of Physicians of India, Science City, Kolkata, India, January
12 15, 2012.
Speaker, Asian Pacific Association for the Study of the Liver (ASPASL), Taipei, Taiwan,
February 15, 2012.
Participant, Polaris Group Lunch and Investigator Meeting on: A Randomized, Double-
Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus
Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have
Failed Prior Systemic Therapy, The Intercontinental San Francisco Hotel, , San Francisco,
CA January 19, 2012.
Speaker, Simply Speaking, HBS: An Expert Educators CME Lecture Series, Grand Hyatt,
San Antonio, TX, January 21, 2012.
Facilitator, Guest Lecture Series, M. Bishr Omary, Chair, Department of Molecular &
Integrative Physiology, University of Michigan, Ann Arob, Keratins: Genetic Modifiers of
Liver disease and Required Components of Mallory-Denk Bodies, January 26. 2012.
Curriculum Vitae


Speaker, Nexavar Unresectable Heptocellular Carcinoma , Webcast NAXAVAR Concert
Series sponsored by Onyx and Bayer Pharmaceuticals, February 7, 2012.
Asian Pacific Association for the Study of the Liver. Taipei. February 12-19, 2012
Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP). Taipei, February 19, 2012
Speaker, Gilead GS09620 Protocols Investigators Meeting, St Francis Hotel, San Francis-
co, CA., March 3, 2012.

Speaker, Advanced Curriculum in Chronic HBV Management VII., Presented by Projects in
Knowledge., Tele-Conference, March 5, 2012.

Speaker, Management of Chronic Hepatitis C Infection, One Patient at a Time, Merck March
Talks, Reno, NV, March 15, 2012.

Speaker, Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical
Practice, Merck March Talks, San Diego, CA, March 20 - 21, 2012.

Speaker, American Transplant Congress, Boston, MA, June 2-6, 2012.

Speaker, Coagulopathy in Cirrhosis and Associated Vascular Complications, NEED
NAME OF EVENT, September 29, 2012

Speaker, HBV update, Moderator, Panel Discussion, National Liver Conference 2012, San
Antonio, TX, September 22, 2012.

Speaker, Liver Transplantation, University of Nevada, School of Medicine, Las Vegas, NV,
January 30, 2013.

Presentation on Liver Disease, Digestive Disease Forum. Patient Case Conference, Good
Samaritan Regional Medical Center, 3600 NW Samaritan Drive, Corvallis, OR. February 22,
2013.

Speaker, Hepatitis B World Advocacy Meeting, Philadelphia, PA, March 16, 2013.

Speaker, Part 2: Review of HCV Data from AASLD; Liver Journal Club, NEED CITY,
March 5, 2013.

Speaker, Liver Cancer and Hepatitis B? What You Need to Know, 2013 Liver Cancer
Webinar Series, Hepatitis B Foundation, March 6, 2013.

Moderator & Speaker, National Viral Hepatitis Task Force and Viral Hepatitis Foundation
Convention, Makati, Philippines, March 11-12, 2013.

Curriculum Vitae


Speaker, Chronic Viral Hepatitis: Epidemiology, Who to Screen, How to Screen and
Linkage to Care A Focus on Viral Hepatitis B and C in Viet Nam, Bach Mai Hospital,
Hanoi, Viet Nam, March 15, 2013.

Impact of Entecavir versus Lamivudine on Hepatic Covalently Closed-Circular DNA and
Total Hepatic HBV DNA in Nucleoside-Nave HBeAg Positive Chronic Hepatitis B Patients,
AASLD, Digestive Disease Week. Orange County Convention Center. Orlando, FL. May 18,
2013.

Speaker, World Federation of Chinese Medicine Societies Hepatology Conference.
Western Medicine and the Potential role for TCM in Partnership or the Use of TCM in the
West. Shen Zhen, China. May 31, 2013.

Chronic Hepatitis C Therapy: Current and Future Perspectives. St. Lukes 4th Liver and
2nd Gastroenterology International Symposium. St. Lukes Medical Center, Global City,
Philippines. June 2, 2013.

Clinical Challenge: Management of Chronic Hepatitis B in Special Populations, St. Lukes
4th Liver and 2nd Gastroenterology International Symposium, St. Lukes Medical Center,
Global City, Philippines; June 2, 2013.

Meet the Expert 2: Individualized Therapy in Chronic Hepatitis B. St. Lukes 4th Liver and
2nd Gastroenterology International Symposium. St. Lukes Medical Center, Global City,
Philippines. June 2, 2013.

Speaker, Improvement in Diagnosis and Treatment of HCV Infection. Scientific Symposium
on Hepatitis. Manila, Philippines. June 3, 2013.

Speaker, Summary of the Viral Hepatitis Action Committee Meeting May 16-17 in Atlanta,
GA, CEVHAP General Meeting, Singapore. June 2013.

Speaker, The Histologic Improvement due to the Oral Anti Viral Treatment Treatment in
CHB Patients, 4
th
Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2013), Seoul
120-752,Korea; July 5, 2013.

Speaker, Combination TDF + ETV Therapy in Chronic Hepatitis B Patients with Previous
Treatment Failure, 4
th
Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2013), Seoul
120-752, Korea; July 5, 2013.

Panelist, 4
th
Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2013), Seoul 120-
752,Korea; July 6, 2013.

Robert Gish, Hepatitis A National Viral Hepatitis Roundtable (NVHR), www.nvhr.org;
August 2013.

Curriculum Vitae


Robert Gish, Hepatitis D National Viral Hepatitis Roundtable (NVHR), www.nvhr.org;
August 2013.

Robert Gish, Hepatitis E National Viral Hepatitis Roundtable (NVHR), www.nvhr.org;
August 2013.

Management of Chronic Hepatitis B in Asian Americans, Vietnamese Physicians Associa-
tions of America (VAMA), Seattle, WA; August 8-11, 2013.

Speaker, Viral Hepatitis E The 2
nd
Biannual International Conference of Armenian Hepato-
logical Forum, September 6, 2013.

Chairman, The 2
nd
Biannual International Conference of Armenian Hepatological Forum,
September 6, 2013.
Honored Guest and Meeting with President of the Artsakh Republic President Bako
Sahakyan, (officially Nagorno-Karabakh Republic), Stepanakert, Nagorno-Karabakh Repub-
lic, September 4, 2013.

Chair and Speaker, Global Hepatitis Overview, The 2nd Biennial International Conference
of Armenian Hepatological Forum, Yerevan, Armenia, September 6, 2013.

Speaker, Current Therapy of Hepatitis B. Planning for 2013 and Beyond, Where East
Meets West, Search for a Cure, The 2nd Biennial International Conference of Armenian
Hepatological Forum, Yerevan, Armenia, September 7, 2013.

Speaker, Hepatitis E, The 2nd Biennial International Conference of Armenian Hepatologi-
cal Forum, Yerevan, Armenia, September 7, 2013.

Oral Presentation, Hepatocellular Carcinoma Surveillance: An Inquiry Into Current Practices,
Abstract #ILCA2013-1080, International Liver Cancer Association Seventh Annual Confer-
ence, Washington D.C., September 13-15, 2013.

Impact of Entecavir Versus Lamivudine on Hepatic Covalently Closed-Circular DNA and
Total Hepatic HBV DNA in Nucleoside-Nave HBeAg Positive Chronic Hepatitis B Patients,"
Australian Gastroenterology Week 2013, Melbourne, Australia, October 9, 2013.

Speaker, The Liver Meeting, Hepatitis Delta International Network Meeting, Participant,
Washington, D.C., November 2, 2013.

Moderator, The Liver Meeting, Liver Cancer Roundtable in Association with Caring
Ambassadors, Robert Gish moderator. Washington, D.C., November 5, 2013.

Facilitator, The Liver Meeting, Panel Discussion, HCC Surveillance Protocol Utilizing
Biomarkers, Robert Gish, MD; Facilitator, Walter E. Washington Convention Center, Wash-
ington, D.C. (in association with Wako Life Sciences, Inc.), November 3, 2013.

Curriculum Vitae


Speaker, Complications of Cirrhosis in the Age of Quality Health Measures, Presented by
Salix Pharmaceuticals, Inc. Elements Restaurant, Paradise Valley, AZ; November 14 2013.

Speaker and Partner, International Collaboration on Viral Hepatitis Advocacy, Viral
Hepatitis in the Philippines: Hepatology Society of the Philippines, Launching the National
Viral Hepatitis Task Force, Makati City, Philippines, November 20, 2013.

Speaker, Treatment of HIV-Coinfected Patients in the Era of the DAAs. 3
rd
Annual Asian
Pacific Study of the Liver(APASL) Conference, 21 November 2013. Cebu Philippines.

Speaker, HBV: State of the Art. 3
rd
Annual Asian Pacific Study of the Liver Conference
(APASL). November 22, 2013. Cebu, Philippines.

Speaker, Novel Approaches for the Treatment of Hepatitis B, Viral Hepatitis Grand
Rounds, Perelman School of Medicine, University of Pennsylvania CME; January 15,
2014. Speaker, Viral Hepatitis Grand Rounds from the University of Pennsylvania, Phila-
delphia, PA; January 15, 2014.

Speaker, State of the Art Therapy for HCV, University of Washington, University of Alabama
Birmingham, IAS-USA online training module, Funded by a grant from the Centers for Dis-
ease Control and Prevention. March 15, 2014.
http://hepatitisc.uw.edu/browse/all/lectures#page/featured/lectures/state-art-therapy

Curriculum Vitae

INVITED LECTURES REGIONAL: Continued

1988

Liver transplantation, Sutter-Solano Medical Center, Vallejo, California, 9/23/88.
Occupational liver disease, Western Occupational Health Conference, Monterey,
Liver transplantation: state of the art, Kaweah Delta Hospital, Visalia, California, 10/22/88.
The organization of a liver transplantation program, Scripps Clinic, La Jolla, California,
10/28/88.
Controversies in liver transplantation, University of California at Davis, Davis, California,
11/7/88.
1989
Liver transplantation: a case presentation, Gastroenterology Grand Rounds, Stanford
University, Palo Alto, California, 1/5/89.
Indications and controversies in liver transplantation, Queen of the Valley Hospital, Napa,
Liver transplantation: research opportunities, University of New Mexico, Albuquerque, New
Mexico, 2/1/89.
Update on peptic ulcer disease, Mather Air Force Base, California, 2/6/89.
Treatment of peptic ulcer disease and reflux esophagitis, Mercy General Hospital, Denver,
Colorado, 2/23/89.
Advances in the treatment of liver disease: liver transplantation, Alameda Hospital,
Alameda, California, 2/27/89.
Liver transplantation: indications and timing, House Staff Noon Conference, Santa
Teresa/Kaiser Hospital, San Jose, California, 3/16/89.
Advances in liver transplantation, Medical Grand Rounds, Seton Medical Center, San
Francisco, California and Hawaii, 3/17/89.
Liver transplant symposium, Honolulu and Maui, Hawaii, 4/24/89-4/27/89.
Treatment of gallstone disease, Tri-County Pharmacists Association, Santa Cruz,
Treatment of chronic liver disease, Ukiah Valley Medical Center, Ukiah, California, 9/17/89.
Peptic ulcer disease: an update, Columbia, California, 9/19/89.
Curriculum Vitae


Rounds on liver disease and Peptic ulcer disease, Scenic General Hospital, Modesto,
Diagnosis and treatment of chronic pancreatitis, Peninsula Hospital, Burlingame,
New treatment for PUD, Killeen Hospital Medical Staff, Killeen, Texas, 11/13/89.
Peptic esophagitis: new treatments, Andrews Air Force Base, Tempe, Arizona, 11/17/89.
New treatment for esophagitis and PUD, Regional Conference, Sun Valley, Idaho, 12/2/89.
Omeprazole: proton pump blockers, University of California at Irvine Pharmacy School,
Irvine, California, 12/6/89.
1990
Organ transplantation, Auburn Faith Community Hospital, Auburn, California, 1/3/90.
Management of acid peptic disease, Highland General Hospital, Department of Medicine,
Oakland, California, 1/26/90.
Advances in therapy for acid related disorders, Kaiser Permanente, Roseville, California,
2/20/90.
Advances in therapy for acid related diseases, Brookside Hospital, San Pablo, California,
2/27/90.
Orthotopic liver transplantation state of the art, Tripler Medical Center, Honolulu, Hawaii,
4/18/90.
Liver transplantation for Wilsons disease, Community Hospital, Santa Rosa, California,
4/25/90.
Current advances in the management of gallstones, Dominican Hospital, Santa Cruz,
Management of peptic ulcer disease in the multi-risk patient, Saint Marys Medical Center,
Long Beach, California, 5/11/90.
Liver disease: an update on treatment and liver transplantation, Redding Medial Center,
Redding, California, 5/25/90.

Curriculum Vitae


Advances in the management of liver disease, Western Medical Center, Santa Ana,
California, 6/4/90.
Acid pump inhibitor a new option, Ralph K. Davies Medical Center, San Francisco,
Controversies in ulcer management in the intensive care unit, Good Samaritan Hospital,
San Jose, California, 7/3/90.
Current advances in the treatment of gallstones, Bellwood General Hospital, Bellflower,
Acid pump inhibitora new option, Delta Memorial Hospital, Antioch, California, 8/28/90.
Hepatitis C, Sutter Solano Medical Center, Vallejo, California, 9/4/90.
Hepatitis C, Highland Hospital, Oakland, California, 9/21/90.
Advances in therapy for acid-related disorders, Childrens Hospital, San Francisco,
Management of peptic ulcer in the multi-risk patient, Santa Barbara GI Symposium, Santa
Barbara, California, 10/20/90.
Orthotopic liver transplantation for alcoholic liver disease, American College of
Gastroenterology, San Francisco, California, 10/29/90.
Hepatitis C, Medical Grand Rounds, Seton Medical Center, Daly City, California,
11/16/90.
Liver transplantation, Kaiser Permanente, Sacramento, California, 11/20/90.
1991
Liver transplantation and life after liver transplantation, Ukiah Valley Medical Center,
Ukiah, California, 4/4/91.
Acute and chronic liver failure, Highland Hospital, Oakland, California, 8/16/91.
Endstage liver disease, Mills-Peninsula Hospital, San Mateo and Burlingame, California,
9/10/91.
Management of pancreatic disease, Kaiser Permanente, Richmond, California, 9/16/91.
Multiple organ failure, cytokines, Sequoia Hospital, Redwood City, California, 11/12/91.

Curriculum Vitae


Liver transplantation state of the art, San Jose Medical Center, San Jose, California,
11/14/91.
1992
Gastroenterology and liver disease in the elderly, Internal Medicine Department,
Spokane, Washington, 2/19/92.
Diagnosis and treatment of hepatoma, Asian Health Services Provider Conference,
Asian Health Services, Oakland, California, 3/3/92
Diagnosis and treatment of chronic liver disease, Kaiser Permanente Richmond,
Richmond, California, 3/3/92.
Update on treatment of chronic liver disease, University of Nevada, Reno, Nevada,
4/21/92.
Management of the patient with endstage liver disease, L.D.S. Hospital, Salt Lake City,
Utah, 5/2/92.
Controversies in orthotopic liver transplantation, Central Valley Club, Fresno, California,
7/28/92.
State of the art: chronic hepatitis, Mercy Medical Center, Redding, California, 8/12/92.
Endstage liver disease in liver transplantation, Queens Health Care Plan and
Physicians, Honolulu, Hawaii, 9/28/92.
Hepatitis B infection and treatment, Kuakini Medical Center, Honolulu, Hawaii, 9/28/92.
Patient selection for liver transplantation, Queens Hospital, Honolulu, Hawaii, 9/28/92.
Hepatitis B infection and treatment, Hawaii/Honolulu Gut Club, Honolulu, Hawaii,
9/29/92.
Case presentations, endstage liver disease, Tripler Army Medical Center, Honolulu,
Hawaii, 9/30/92.
Duodenal ulcers current treatment, Lecture Teleconference, California Pacific Medical
Center, 10/21/92.
1992
Chronic hepatitis B, Association of Asian Pacific Community Health Organizations, San
Francisco, California, 10/22/93.

Curriculum Vitae


Hepatitis serology, American Liver Foundation, St. Mary's Medical Center, San
Evaluation of elevated liver tests, Kansas City Southwest Clinical Society, Kansas City,
Missouri, 11/06/92.
Evaluation of abnormal liver tests and Helicobacter Is This A Real Disease, 19th
Annual Gastroenterology Symposium, Enloe Hospital, Chico, California, 11/11/92.
1993
Hepatitis A, B and C: an update, Tahema County Medical Society, Tahema County
Medical Facility, California, 4/26/93.
Interferon and hepatitis, Queen of the Valley Hospital, Napa, California, 7/16/93.
What's new in hepatitis, Mercy Medical Center, Redding, California, 8/31/93.
Chronic hepatitis: what's new, Kaiser Permanete, Napa, California, 9/1/93.
Chronic viral hepatitis, Sequoia Hospital, Redwood City, California, 9/18/93.
Endstage liver disease, University of California at Davis, Family Practice Program,
Merced, California, 9/22/93.
Hepatitis update, Travis Air Force Base Medical Center, Travis, California, 9/24/93.
Medical aspects of liver transplantation, California Pacific Medical Center, San
Metabolic liver disease, University of California at Davis, Family Practice Program,
Chronic hepatitis, Marshall Hospital, Placerville, California, 12/15/93.
The workup and evaluation of patients with chronic liver disease, University of California
at Davis, Family Practice Program, Merced, California, 12/29/93.
1994
Chronic liver disease and viral hepatitis, California Pacific Teleconference, 1/12/94.
Current treatment of viral hepatitis, Highland General Hospital, Oakland, California,
1/15/94
NSAID induced GI injury, Maui Memorial Hospital, Wailuku, Maui, Hawaii, 1/22/94.

Curriculum Vitae


Current diagnosis and treatment of chronic viral hepatitis, St. Francis Medical Center,
Honolulu, Hawaii, 1/24/94.
Treatment of endstage liver disease and portal hypertension, University of Hawaii,
Fulminant liver failure in a kidney transplant recipient, Department of Transplantation,
California Pacific Medical Center, San Francisco, California, 2/25/94.
Diagnosis and treatment of hepatitis C, San Quentin State Prison, San Quentin,
Portal hypertension, part I, University of Nevada, Reno, Washoe Medical Center, Reno,
Nevada, 3/4/94.
1994
Post-liver transplant patient management for nurses, Mercy Medical Center, Redding,
The diagnosis and treatment of chronic hepatitis, Highland General Hospital, Oakland,
Update on hepatitis C, Palomar Medical Center, Escondido, California, 3/24/94.
Alcoholic liver disease, University of California Davis, Medical School, 2nd Year Lecture,
Davis, California, 3/31/94.
Portal hypertension, part II, University of Nevada, Reno, Veterans Hospital, Reno,
Nevada, 4/1/94.
The epidemiology of viral hepatitis, Merced Community Medical Center, Grand Rounds,
Liver cancer update, Merced Community Medical Center, Grand Rounds, Merced,
Histopathology of chronic hepatitis C, St. Mary's Medical Center, Reno, Nevada,
6/30/94.
Hepatocellular carcinoma, University of Nevada, Reno, Nevada, 7/1/94.
Hepatitis C: management in the primary care setting, San Francisco Public Health
Department, Wadell Clinic, San Francisco, California, 7/6/94.
Hepatitis C: diagnosis, management and prognosis, Las Vegas Gut Club, Las Vegas,
Nevada, 7/11/94.
Curriculum Vitae


Update on the diagnosis and treatment of hepatitis C, Rideout Hospital, Marysville,
The diagnosis and treatment of chronic liver diseases, Fremont-Rideout Health Group,
Peachtree Clinic, 7/19/94.
Hepatitis B treatment past, present and future, California Pacific Medical Center,
8/4/94.
Hepatitis C and alpha-Interferon: questions and answers, Tuolumne County Medical
Society, Sonora, California.
Hepatitis C-revisited, Alexian Brothers Hospital, San Jose, California, 9/6/94.
Hepatitis C diagnosis and treatment, Visalia Primary Care Group, Visalia, California,
9/8/94.
Liver disease pathology conference, Fresno Gut Club, Fresno, California, 9/8/94.
Liver transplantation, University of California at Davis, Sacramento, California, 10/11/94.
Reflux disease, Merced Community Medical Center, University of California at Davis
Affiliate, Merced, California, 10/12/94.
Liver enzymes and liver function tests, Kansas City Southwest Clinical Society Annual
Meeting, Kansas City, Missouri, 11/3/94.
Diagnosis and treatment of hepatitis C, San Quentin State Prison, San Quentin,
Update on viral hepatitis: testing, diagnosis, treatment, American College of Osteopathic
Family Physicians, San Francisco, California, 11/17/94.
Hepatitis-grand rounds, St Agnes Medical Center, Fresno, California, 12/13/94.
1995
Liver pathology rounds, Liver Biopsy Conference moderator, St. Mary's Hospital, Reno,
Nevada, 1/6/95, 3/95, 5/95, 7/95, and 9/95.
Hepatitis B and C, Sequoia Hospital, Redwood City, California, 1/17/95.
Liver biopsy diagnosis, Mercy San Juan Hospital, Sacramento, California, 1/24/95.
Basic science of hepatitis, Mercy General Hospital, Sacramento, California, 1/24/95.
Treatment of hepatitis C, Sacramento Gut Club, Sacramento, California, 1/24/95.
Curriculum Vitae


Hepatitis update and histopathology conference, Redding Gut Club, Redding, California,
1/25/95.
Hepatitis diagnosis and treatment, Tracy Prison System, Tracy, California, 1/25/95.
Hepatitis and hemochromatosis, Las Vegas Gut Club, Las Vegas, Nevada, 1/26/95.
New drugs & modern concepts in pharmacotherapy, VA Northern California System of
Clinic, 2/10/95 - 2/12/95, Lake Tahoe and 3/3/95 - 3/5/95, San Francisco, California.
Hepatitis: drugs that cause and drugs that treat, Northern California System of VA
Clinics, Martinez, VA Hospital, N. Lake Tahoe Conference, Incline Village, Nevada,
2/11/95.
Hepatitis C, a silent disease, St. Francis Medical Center, Primary Care conference,
The virology of hepatitis C infection, Kaiser Medical Center, Honolulu, Hawaii, 2/15/95.
The liver in systemic disease, Maui Memorial Hospital, Wailuku, Maui, Hawaii, 2/17/95.
Fulminant liver failure, Sequoia Medical Center, Redwood City, California, 2/28/95.
Hepatitis: drugs that cause and drugs that treat, Northern California System of VA
Clinics, Martinez, VA Hospital, San Francisco, California, 3/2/95.
Fulminant hepatitis: when to refer, UCSF/Fresno, Hanford-Kings County Medical
Society, Hanford, California, 3/18/95.
An educational conference on chronic hepatitis C and B, Northwest R.N. Symposium,
San Francisco, California, 3/23/95.
Hepatitis viruses: the alphabet soup, diagnosis and treatment, Petaluma Valley Hospital,
Petaluma, California, 3/27/95.
Hepatitis C: evaluation of patients, San Joaquin General Hospital, French Camp,
Alcoholic liver disease, University of California at Davis Medical School, 2nd Year
Lecture, Davis, California, 3/31/95.
Hepatitis, Dominican Santa Cruz Hospital, Santa Cruz, California, 6/23/95.
Liver update: alcoholic liver disease, selection criteria for transplantation, Therapeutic
and Diagnostic Pancreaticobiliary Endoscopy Course, California Pacific Medical Center,
San Francisco, California, 7/22/95.
Hepatitis: an alphabet soup, Queen of the Valley Hospital, Napa, California, 8/18/95.
Curriculum Vitae


Evaluation of patients for Wilson's disease, St. Mary's Hospital, San Francisco,
1995
Wilson's disease, GI Conference, St. Mary's Hospital, San Francisco, California, 8/29/95.
Evaluation of acute and chronic liver disease, San Quentin State Prison, San Quentin,
An update on liver transplantation, Wadsworth VA Hospital, Los Angeles, California,
9/1/95.
Recurrent disease after liver transplantation, USC Medical Center, Los Angeles,
Recurrent hepatitis C infection after liver transplantation, Honolulu Regional GI Program,
New forms of viral hepatitis, Honolulu Gut Club, St. Francis Hospital, 10/10/95.
Update on managed care in northern California, Maui, Hawaii, 10/12/95.
Acute and chronic hepatitis: the alphabet soup, Napa State Hospital, Napa, California,
10/20/95.
Hepatitis issues for correctional facilities, San Francisco STD-HIV Prevention Training
Center, 2nd Annual Infectious Disease Conference, California Department of Corrections,
Natoma, California, 11/1/95.
The evaluation of elevated liver enzymes in acute and chronic liver disease, and The
role of medication in the cause of acute and chronic liver disease, 21st GI Symposium,
Chico, California, 11/15/95.
AASLD 1995 review, Sacramento Gut Club, University of California at Davis,
Sacramento, California, 11/15/95.
Workup of elevated liver enzymes, Merced Community Hospital, Merced, California,
11/15/95.
Controversies in chronic liver disease, Sacramento Valley Gut Club, Sacramento,
Controversies in the management of hepatitis, Indian Health Clinic, Trinidad, California,
12/13/95.

Curriculum Vitae


Controversies in the management of chronic hepatitis, Pelican Bay Prison, Pelican Bay,
Autoimmune hepatitis, UCSF, Fresno Valley Gut Club/UCSF, Fresno, California,
12/16/95.
Autoimmune liver disease, Merced Community Hospital, Merced, California, 12/19/95.
1996
Viral hepatitis: the alphabet soup, California Pacific Medical Center Teleconference
Network, San Francisco, California, 1/23/96.
National leadership conference on chronic hepatitis C, University of Medicine and
Dentistry of New Jersey, 1/29/96.
1996

Overview of treatment of hepatitis, Dameron Hospital, Stockton, California, 2/23/96.
Hepatitis A-G: diagnosis, natural history and epidemiology, Dameron Hospital, Stockton,
Evaluation of patients with chronic viral hepatitis B and C, University of California at
Berkeley, Berkeley, California, 2/29/96.
Hepatitis A-G: diagnosis, natural history and epidemiology, Infectious Diseases
Symposium, Sacramento, California, 3/23/96.
Hepatitis A-G: diagnosis and treatment, Medical Grand Rounds, California Pacific
Medical Center, San Francisco, California, 2/27/96.
Hepatitis A-G: prevention, vaccination and therapy, Infectious Diseases Symposium,
Hepatitis A-G: diagnosis and treatment, Sutter Community Hospitals, Sacramento,
Metabolic and autoimmune liver disease, Gastroenterology Club of Las Vegas, Las
Vegas, 4/15/96.
Endstage liver disease and cirrhosis, San Quentin State Prison, San Quentin, California,
5/1/96.
Hepatitis A-G, Sutter Health Conference, Sacramento, California, 5/4/96.

Curriculum Vitae


Primary care for the '90s, University of Nevada School of Medicine, Reno, Nevada, 5/10-
11/96.
Viral hepatitis: the alphabet soup, University of Reno, Reno, Nevada, 5/11/96.
Hepatitis C and Interferon, California Department of Corrections, Las Vegas, Nevada,
5/17/96.
Laboratory tests in hepatitis C in diagnosis and in monitoring therapy, Controversies and
Challenges in Viral Hepatitis C Conference, San Francisco, California, 5/20/96.
Hepatitis A, B and C, San Jose Pharmacy Group, Santa Clara, California, 5/22/96
Liver transplantation III: immunosuppression, Chaired 1996 ASTP Scientific Session,
Dallas, Texas, 5/28/96.
Update on hepatitis C, Santa Rosa Gut Club, Santa Rosa, California, 5/29/96.
The treatment of chronic hepatitis B and C in the prison system of California,
Department of Corrections, Sacramento, California, 5/96.
Overview of hepatitis C, Schering-Plough, 6/5/96.
Point/counterpoint hepatitis C, Ukiah Hospital, Ukiah, California, 6/20/96.
Diagnosis of hepatitis, University of Nevada, Las Vegas, Nevada, 6/27/96.
Hepatitis C lecture, California Pacific Medical Center, San Francisco, California, 7/3/96.
An insider's perspective of a specialist, National Youth Forum on Medicine, San
The diagnosis and treatment of hepatitis A through G, Placerville General Hospital,
Placerville, California, 7/17/96.
1996
Hepatitis A-G: evaluation, diagnosis and prognosis, Mt. Diablo Hospital, Concord,
California, 8/8/96.
Hepatitis diagnosis & treatment, California Women's Facility, Chowchilla, California,
8/15/96.
Chronic hepatitis: an alphabet soup, CPMC Teleconference, produced by Annenberg
Center for Health Sciences, Rancho Mirage, California, 8/17/96.

Curriculum Vitae


Metabolic causes of chronic liver disease, Merced Community Medical Center, Merced,
Molecular diagnosis and treatment of hepatitis C infection, Phoenix Basin
Gastroenterology Club, Phoenix, Arizona, 9/13/96.
Case studies in chronic viral liver disease, Eureka, California, 9/18/96.
Hepatitis A-G: diagnosis, prognosis and treatment, Redding Medical Center, Redding,
Hepatitis A-G: diagnosis and treatment, Merrithview Memorial/Contra Costa Hospital,
9/22/96.
The diagnosis and treatment of chronic hepatitis C infections, Kaiser Permanente, South
Current trends in hepatitis treatment, Marin Consortium's Grand Rounds, Marin General
Hospital, Larkspur, California, 10/1/96.
Viral hepatitis and liver transplantation, Dept. of Internal Medicine, University of Iowa,
Iowa City, Iowa, 10/3/96.
Viral hepatitis and the immune system, Case Conference on Infectious Disease,
University of Iowa, Iowa City, Iowa, 10/3/96.
Chronic viral hepatitis C: immunology, University of Iowa, Iowa City, Iowa, 10/3/96.
Portal hypertension, Merced Community Medical Center, Merced, California, 10/9 &
10/16, 1996.
Evaluation and treatment of helicobacter pylori, Primary Care Physicians, Sacramento,
State-of-the-art Interferon therapy for chronic viral hepatitis, Chronic Viral Hepatitis
(CVH) in the era of Managed Care, AASLD, Chicago, Illinois, 10/17/96.
Should we offer renal transplantation to patients with hepatitis B? What, if any, role is
there for Lamivudine, Grand Rounds, California Pacific Medical Center, San Francisco,
Non-response to treatment with Interferon alfa, Chronic Hepatitis C: Strategies for
Difficult Management Cases Conference, ACG, Seattle, Washington, 10/20/96.
Evaluation and treatment of chronic hepatitis C, Round Table Discussion, American
College of Gastroenterology, Seattle, Washington, 10/20/96.
Hepatitis A-G, Santa Rosa Community Hospital, Santa Rosa, California, 10/23/96.
Curriculum Vitae


Hepatitis A-G: diagnosis and treatment, Veteran's Administration Hospital, Reno,
Nevada, 10/24/96.
1996
Hepatitis A-G: evaluation and treatment, Nevada Academy of Family Physicians, Reno,
Nevada, 10/24/96.
Hepatitis B and C Sacramento Methadone Program, Sacramento, CA 10/30/1996
Hepatitis overview to Stockton prison, Northern California Women's Facility, Stockton,
Hepatitis A-G: the alphabet soup, Lassen Hospital, Susanville, California, 11/12/96.
Hepatitis B & C: liver disease in organ transplant recipients, Advances in
Transplantation, 8th Annual Conference, San Francisco, California, 11/19/96.
Hepatitis C: current diagnosis and treatment, Mad River Hospital, Arcata, California,
11/21/96.Chronic liver disease and hepatitis A-G, St. Joseph's Hospital, Eureka,
Evaluation of the abnormal liver in alcoholism/drug dependency, Academy of Addiction
Psychiatry Meeting, Medical Complications of Substance Abuse, 12/7/96.
Evaluation of the abnormal liver enzymes in alcoholism and drug dependency.
Conference: Medical Complications of substance abuse and treatment of chronic
hepatitis, Academy of Addiction Psychiatry Meeting, Medical Complications of Substance
Abuse, 12/7/96.
Liver transplantation, House Staff Conference, California Pacific Medical Center, San
1997

Hepatitis C update, Santa Rosa Memorial Hospital, Santa Rosa California, 1/16/97
Pharmacological management of chronic viral infections, North Coast Pharmacy
Association, 1/22/97.
Chronic hepatitis A-G: an alphabet soup, San Ramon Regional Medical Center, San
Ramon, California, 1/23/97.
Round table, Sacramento Valley GI Gut Club, Sacramento, California, 1/28/97.
Diagnosis and treatment of hepatitis C, Mill Creek Prison, Ione, California, 1/29/97.

Curriculum Vitae


GI conference, California Pacific Medical AASLD Abstract Review, (AASLD) Meeting
1996, 1/30/97.
Current treatment of hepatitis C, Lake Tahoe, California, 2/5/97.
Elevated liver tests: when is it hepatitis C and what do you do?, Lake Tahoe, California,
2/6/97.
Hepatitis C as a systemic disease, Fresno Gut Club, Fresno, California, 2/27/97.
Diagnosis and treatment of hepatitis A-G, Eden Hospital, Castro Valley, California,
2/28/97.
The role of the primary care physician's diagnosis & treatment of hepatitis, Eden Medical
Center, Castro Valley, California, 2/28/97.
Hepatitis A-G, Northern California Society of Gastroenterology Nurses and Associates,
Larkspur, California, 3/15/97.
Hepatitis C update, Santa Rosa Memorial Hospital Grand Rounds, Santa Rosa,
1997
Hepatitis C: new issues, Sutter North Medical Foundation, Marysville, California,
3/27/97.
Hepatitis A-Z: a review, Grand Rounds, Department of the Air Force, 60th Medical
Operations Squadron (AMC), Travis Air Force Base, Travis, California, 5/2/97.
Hepatitis C casebook development, Laguna Nigel, California, 6/5/97.
Medication-induced chronic liver disease, Merced, California, 6/18/97.
Update on chronic hepatitis B & C, Chinese Hospital, San Francisco, California, 6/25/97.
Hepatitis as a systemic disease, John Muir Medical Center, Walnut Creek, California,
6/26/97.
Hepatitis A-G, who, what, when, GI Nurses of Sacramento, Sacramento, California,
9/4/98.
Hepatitis C, the exploding epidemic, medical management, initial diagnosis, pre- and
post-liver
Transplant management, San Francisco, California, 8/22/97.
Chronic liver disease update, Symposium Moderator, San Francisco, California, 9/9/97.
Curriculum Vitae


New and evolving issues in acute and chronic liver disease: the evaluation of elevated
liver enzymes and liver function tests. Sacramento, California, 9/11/97.
Hepatitis B and C: who and when to treat Alexian Brothers Hospital. San Jose,
Why and how hepatitis B and C should be part of an infectious disease practice, IDSA
Symposium, San Francisco, California, 9/15/97.Chronic liver disease - focus on hepatitis
B and C, Providence Medical Center. Kansas City, Kansas, 10/16/97.
Chronic hepatitis: Case Presentations, Olathe Medical Center, Olathe, Kansas,
10/17/97.
Hepatitis: who, when and where. Resuscitation 5, Redding Medical Center, Redding,
The management of hepatitis C patients in a county medical clinic setting, County of
Sacramento Clinics, Sacramento, California, 11/21/97.
Chronic hepatitis: A - Z, diagnosis and treatment, California Pacific Medical Center.
1998
Liver enzymes and liver function, CPMC GI nurse organization, California Pacific
Medical Center, San Francisco, California, 2/7/98.
AASLD Review, Las Vegas Gut Club, Las Vegas, Nevada, 2/5/98.
AASLD Review, Sacramento Gut Club, Sacramento, California, 2/11/98.
Hepatitis C: an epidemic of awareness, Enloe Hospital, Chico, California, 2/26/98.
New Interferons, Sutter Hospital Roseville, GI Symposium 1998, Sacramento,
Alcohol and Liver Cancer, Mercy Regional Cancer Center, Redding, California, 4/18/98.
1998
Hepatitis C: Third World Disease in a Developed Country, River City Medical Group,
Mercy Hospital Sacramento, Sacramento, California, 4/23/98.
Hepatitis C: Current Evaluation and Management, National Acupuncture and Oriental
Medicine Alliance Annual Meeting, San Francisco, California, 5/2/98.
Chronic hepatitis C: nine years old, San Jose, California 6/8/98.

Curriculum Vitae


Treatment of hepatitis C: new options, North State Practitioners Society, Chico,
Treatment of hepatitis C: Epidemiology and treatment; Applications to the Department of
Corrections, California Department of Corrections, 7/14/98.
Hepatitis C infection in women and minorities, a collaborative approach to research and
intervention, Oakland, California, 7/30/98.
An Epidemic of Awareness: New tests and treatments for hepatitis B and C, Conference:
New Technologies and current trends in infectious disease, Mercy General Hospital,
Sacramento, California 8/8/98.
Treatment of patients with hepatitis C, Sacramento Blood Center, Sacramento,
California 8/6/98.
Combination therapy for relapser and nonresponder patients with hepatitis C, cost
effectiveness of therapy, Hepatitis C Global, Oakland, California 8/24/98.
Combination therapy for, Panel presentation, Hepatitis C Global, Oakland, California
8/24/98.
Hepatitis C update, Alta Bates Medical Center, Berkeley, California 8/26/98.
Hepatitis B: Current treatment options and HIV interactions, Davies Campus of California
Pacific Medical Center, San Francisco, California 9/6/98.
Hepatitis B: Current Treatment Options and HIV Interactions, University of California,
San Francisco, San Francisco, CA 9/14/98.
Update on the Treatment of Hepatitis C, Sacramento Valley Society of Health-System
Pharmacists, Sacramento, CA 10/8/98.
Acute and Chronic Liver Disease, Sacramento, CA 11/3/98.
Hepatitis C, TAP Pharmaceuticals, Carson City, NV 12/3/98.
Hepatitis C: Epidemiology, Diagnosis and New Treatments, San Francisco State
University, San Francisco, CA 12/5/98.
Optimizing Outcomes in Difficult Cases: Relapsers, Boston, MA 10/11/98.
New Treatments for Hepatitis C, Davies Campus of California Pacific Medical Center,
San Francisco, CA 11/20/98.

Curriculum Vitae


1999
An Update on Hepatitis C from AASLD, AMGEN, Las Vegas, NV 1/18/99.
Medications Used for Organ Transplantation, Santa Rosa, CA 1/20/99.
Liver Transplantation: Who, When, and Why, Napa, CA. 02/14/99.
Elevated Liver Enzymes & the Diagnosis of Liver Disease, College of Osteopathic
Medicine, San Francisco, CA 2/16/99.
Hepatitis C Update: New Treatment Options, GUT Conference, Reno, NV 3/4/99.
Interferon/Ribavirin Combination Therapy of Hepatitis C, 67
th
Annual Postgraduate
Convention, San Bernardino, CA 03/99.
1999
Hepatitis B Infection, Sutter Roseville Medical Center, Roseville, CA 4/3/99.
Rebetron, Combination Therapy, Boyes Hot Springs, CA 4/16/99.
Current Approaches to Viral Hepatitis Management, San Francisco, CA 4/17/99.
Hepatitis Update, UNOS Region 5 OPO and Clinical Forum, San Francisco, CA 04/08/99.
Hepatitis C Nineteenth Annual Infectious Diseases Symposium, Sacramento, CA 4/30/99
Hepatology Case Conference, Schering Oncology/Biotech, Fresno, CA 6/3/99
Viral Hepatitis and the Surgeon, California Pacific Medical Center, San Francisco, CA
6/4/99
Hepatitis C Support Group, Sutter General Hospital, Sacramento, CA 6/16/99
Present and future therapies for Hepatitis C, University of California, San Francisco, CA
6/21/99
Whats Your Specialty? San Francisco Medical Forums, National Youth Leadership Forum,
San Francisco, CA 6/30 and 7/14/99.
Hepatitis C, Amgen Medical Education Services, David Grant USAF Medical Center,
Travis Air Force Base, CA 07/02/99
The Best of DDW, Orlando, CA 07/08/99
Hemochromatosis Study, Future of Hepatitis C, UCSF, San Francisco, CA 07/14/99
Curriculum Vitae


Rebetron Medical TAR CE Program, Schering Plough, Stockton, CA 7/7/99
The Best of Liver, The Best of DDW, Phoenix, AZ 07/8/99
Research and Treatment, HCV Global Foundation, Oakland, CA 08/21/99
The Role of the ID Physician in the Treatment of Chronic Hepatitis, Laguna, CA 08/28/99
Viral Hepatitis, Gastroenterology, Liver Transplantation, Sutter Solano Medical Center,
Vallejo, CA 09/14/99
Liver Disease and The Veterans Health Administration: New Advances in the Management
of Hepatitis C, Dover Communications Inc., Scottsdale, AZ 09/17/99
Hepatitis C Overview, American Liver Foundation, Sacramento, CA 10/16/99.
Hepatology for the ID Specialist and Treatment of Hepatitis C, Hepatitis for the New
Millennium, IDSA Annual Conference, Philadelphia, PA 11/18/99
2000
HCV Epidemiology, Virology Symposium, Sacramento, CA 01/29/00
Managing Fulminate, Acute and Chronic Liver Disease, CPSS Liver Disease Symposium,
San Francisco, CA, 02/03/00
Hepatitis C, Sutter Medical Center, Sacramento, CA 02/25/00
Viral Hepatitis: Into the New Millennium, Sutter Medical Center of Santa Rosa, Santa
Rosa, CA 03/07/00
Health Sciences, UC Davis Health System Leadership Council, Sacramento, CA 03/08/00.
Hepatitis C, I will survive Hepatitis C Support Group, Sacramento, CA 03/10/00
Sutter Health Family Practice Residency Program, 03/14/00
Therapy of Viral Hepatitis Including Alternative Therapies Panel, Sutter Roseville Medical
Center, Roseville, CA 04/01/00.
Autoimmune Liver Disease, Sutter Roseville Medical Center, Roseville, CA 04/01/00.
Objective Structured Clinical Exercise University of CA, San Francisco, CA. 04/08/00.
Current Issues Regarding Transmission & Prevention Current Standards for Diagnosis &
Medical Management Hepatitis C: Building a Response to the Northstate Crisis, Red Bluff,
CA 04/28/00
Curriculum Vitae


New Trends in Treatment and Long Term Survival Hepatitis C: Building a Response to the
Northstate Crisis, Red Bluff, CA 04/28/00
Living With Hepatitis C Panel Discussion, Hepatitis C: Building a Response to the
Northstate Crisis, Red Bluff, CA 04/28/00
Hepatitis C Part 2: Liver Transplants and Hepatitis C:, Eden Medical Center, Castro Valley,
CA 05/05/00
Acute Hepatic Failure, Critical Care Training Program, California Pacific Medical Center,
San Francisco, CA 05/11/00
Application of Epidemiology and Biostatistics to Clinical Research, San Diego, CA
05/20/00.
Liver Transplant, Gilead Sciences, Foster City, CA 05/31/00.
New Perspectives in the Diagnosis and Management of Hepatitis C, Bayer Diagnostics
Hepatitis C Satellite Symposium, San Francisco, CA 07/25/00
NYLF/MDs Specialist Seminars, National Youth Leadership Forum, San Francisco, CA
07/27/99
2001
Update of HCV Diagnosis and Management Sutter Community Hospitals, Sacramento, CA
1/26/01.
Portal hypertension management, Merced Community Hospital, Merced California
2/3/2001
Metabolic liver diseases, Merced Community Hospital, Merced California. 4/13/2001
Hepatitis C diagnosis and treatment, Merced Community Hospital, Merced California
6/12/2001
Department of Transplantation Hep-C and HIV Cal Pacific Medical Center 5/14/01
Hepatitis C: Treatment II, Georgia World Congress Center 5/22/01
Current Issues in HIV and Hepatitis C co-infection Institute for Continuing Health Care
Education, CME program, San Francisco CA, 6/27/2001
Liver Transplantation: Update 2001, Feather River Hospital, Paradise, CA 06/25/01
Living Longer, Living Stronger: Maintaining the Quality of Life for Patients with Anemia and
HIV Infection; Current Issues in HIV and Hepatitis C Coinfection, Le Colonial, San Francis-
co, CA 7/16/01
Curriculum Vitae


Hepatitis A, B, C: New Strategies in Management, Dominican Hospital, Santa Cruz, CA
07/20/01
Management of the complex GI patient, Merced Community Hospital, Merced California
8/10/2001

2001
Hepatitis C on the Front Line of Community Health, 5th International HCV Conference,
10/10/2001
Start of the art treatment of viral hepatitis Chico GI Community Lecture, Chico California,
10/8/2001
A comprehensive Overview of hepatitis C Merced Community Physicians, 11/14/2001
Liver Cancer Abstract Review, Post AASLD Review Course Southern California Society of
Gastroenterology, 11/17/2001
Interpretation of liver function tests and new therapies in hepatitis C Sacramento Valley
Society of Health-System Pharmacists, Sacramento California 12/4/2001
12/8/2001
2002
State of the Art Treatment of Viral Hepatitis, Redding CA, 1/24/2002
2/10/2002, 4/6/02, 6/10/02, 8/1/02,10/3/02
Update on Immunosuppressive Therapy
Advances in the treatment of Viral Hepatitis
Diagnosis and Management of Benign and Malignant Liver Tumors
The Ninth Annual Alimentary Update. 2002. Univ. of Nevada School of Medicine. Lake
Tahoe, Nevada. 3/7-9/2002
Therapy of Chronic Viral Hepatitis: An Update. The Medical and Surgical Aspects of
Gastrointestinal Disease A One Day Course. Roseville CA, 4/6/2002
Curriculum Vitae


4/12/2002
Current Issues in HIV and Hepatitis C Coinfection. Institute for Continuing Healthcare
Education. San Mateo, CA. 5/15/02
Managing Treatment Outcomes for HCV - Related Anemia. Advancmed. Santa Barbara,
CA. 5/29/02
Anemia Management in HCV.HCV Regional Advisory Board- Symbiotix. San Francisco,
CA. 5/31/02
CME audio tape/CD Review of the NIH Consensus Conference on Management of Hepatitis
C: 2002. 6/10-12/2002
Hepatitis C. St. Elizabeth Community Hospital CME Meeting. Redding, CA. August 2, 2002
PPIs: Welcome to the Liver; AstraZeneca. San Francisco, CA. 10/08/02
Enloe Medical Center Noon Conference. Chico, Ca. 10/10/02
HCV Provider Training. Alameda County. Oakland, CA. 11/14/02
Updates in the Treatment of Hepatitis B. East Bay Gut Club, Berkeley, CA. 12/12/02
Hepatology Care Conference. Schering Onc/Biotech. San Francisco, CA. 12/19/02
2003
Hepatitis B Therapy advances in Treatment GI gut club, Sacramento, CA. 1/16/2003
Liver Transplant Grand rounds, Department of Surgery faculty, University of California, Los
Angeles 4/8/03
Patients with ESLD and Decompensated Cirrhosis, HCV Summit Meeting, Mandarin Hotel,
Hepatitis B, Sunrise Hospital and Medical Center, Las Vegas, April, 2003
Natural History and Global Epidemiology of HBV Disease, Bayer Diagnostics-sponsored
symposium, EAST 2003, 7/4/03
Trends in Hepatitis Testing and Treatment, Bayer HealthCare, Grand Hyatt, San
Francisco, 6/17/2003
Hepatitis B and C are Curable, Infectious Diseases Symposium, Emerging Clinical Issues,
May, 2003
Curriculum Vitae


Hepatitis C Update, 2003, Community Health Resource Center, June, 2003
Treating and Managing Chronic Viral Hepatitis in Patients Living in the Pacific Rim, The
Lodge at Sonoma, CA July, 2003
NASH July
Managing Treatment Outcomes for Hepatitis C Virus Related Anemia, AdvancMed. August
2003.
Hepatitis C for Schering Oncology in Stockton and Modesto, August, 2003
Update on the Treatment of Hepatitis C, Schering Oncology, August, 2003
Advancing Hepatitis C Education (AHE), Scotts Seafood Grill & Bar, Sacramento, CA,
August,
conferences at Sunrise Hospital Las Vegas Nevada
Portal HTN August
Autoimmune Liver Disease September
Liver Transplant, Galileo High School, San Francisco, CA. September 2003.
From Diagnosis to Treatment: The Full Spectrum of Care in Hepatitis C, Sheraton Boston
Hotel, October 2003.
Hepatitis C Treatment 2003, Sequoia Hospital, October 2003.
Tailoring Hepatitis C Therapy: Treatment Decisions in Select Patient Populations, Boston,
Massachusetts. October 2003
Optimal Clinical Outcomes: Managing Hepatitis Related Challenges, Atlanta, Georgia.
October 2003.
From Diagnosis to Treatment: The Full Spectrum of Care in Hepatitis C, AASLD Satellite
Symposium, Boston, Massachusetts. October 2003.
Molecular Testing in the Diagnosis and Management of Chronic HBV and HCV, Liver and
Digestive Health Medical Clinic and Stanford University Medical Center, October 2003.
Provider Update: Hepatitis C, Alexis Park Resort, Las Vegas. November 2003
Patient Update: Hepatitis C & Liver Transplantation, Alexis Park Resort, Las Vegas.
November 2003.

Curriculum Vitae


2003
Liver Transplant: Complications & When to be Evaluated: The MELD System and Living
Related, Reno Hilton, November 2003.
Issues Related to HCV Treatment in Patients Co-infected with HCV and Management of
Anemia Associated with Combination Therapy for Patients Co-infected with HCV, San
Diego, California. November 2003.
Treatment Options for Patients with HCV, San Bernadino County of Public Health,
November 2003.
Hepatitis B disease November
MELD, Sunrise Hospital and Medical Center, Las Vegas, Nevada. December 2003.
Liver Biopsy Conference, St. Marys Hospital, San Francisco, CA, December 2003.
2004
Recent Advances in Gastroenterology and Hepatology 2004 Squaw Valley, CA January
2004.
Update n Depression Management DDW Faculty Conference Call, San Francisco, CA.
February 2004.
New Directions in the Treatment of Hepatitis B Chicago, IL, March 2004.
Controversies in HBV: What is on the Horizon for Clinical Management of HBV Infections
Rochester, MN, January 2004.
Strength to Thrive Phoenix and Tucson, AZ, March 2004.
Reaching out to Communities San Jose, CA, March 2004.
Hepatitis C: Side Effect Profiles and Current Treatment Paradigms, Las Vegas, NV, June
2004.
Hepatitis C Update and Treatment Options, Chico, CA March 2004.
Hepatitis B, San Jose, CA, March 2004.
Treatment of Hepatitis C, Monterey, CA, June 2004.
Update on the NIH conference on HBV and HCC Las Vegas, NV, June 2004.
Hepatitis C-SFDPH Provide Update, San Francisco, CA, July 2004
Curriculum Vitae


Schering Hepatitis Meeting, Sacramento, CA, October, 2004
Liver Disease: From: Bench to Bedside Boston, MA, October, 2004
What is the Prognosis for HBV?, October, 2004
Diagnostics and New Drugs, Boston, MA, October -November, 2004
10
th
Annual Princeton Workshop, Princeton, NJ, November, 2004
2
nd
Annual UC Davis Conference on Primary Care for Hepatitis C & Other Liver Diseases,
Napa, November 20-21, 2004
Hepatitis B: Evolving Treatment Strategies @ 5
th
International Annual Hot Topics in Lever
Disease Conference, October, 2004
2005
Hepatitis C A Public Health Concern: the Role of Pharmacists, San Rafael, CA July 11,
2005 Sunrise Hospital and Medical Center Continuing Medical Education, Las Vegas, NV,
January May 2005
UNOS Committee Meeting: Liver and Intestine Committee,
University of Florida PeerView CME Medical Accuracy Review, January 2005
Treatment Approaches for Hepatitis B: A Critical Appraisal, San Francisco January, 2005
Drugs and the Live: What the primary care physician should know, Honolulu, HI, January
2005
Treatment of Chronic Viral Hepatitis, San Francisco, January 2005
Reno-Sparks Community Wide Liver Conference, Reno, NV, January 6, 2005
Gastroenterology Case Conference, San Francisco, CA. January 13, 2005.
Liver Diseases: An Update for the Primary Care Provider, Honolulu, HI, January 15, 2005
Improving Outcomes for Asians and Pacific Islanders at Risk for Hepatitis B. Washington
Hospital. Fremont, CA. January 25, 2005.
Gastroenterology Case Conference, San Francisco, CA. January 27, 2005.
HCV Treatment Modalities, Dosage and Duration, South Lake Tahoe, February 2005
Sunrise Hospital & Medical Center: Heavy Metal: Wilsons Disease & Hemochromatosis,
Las Vegas, February 1, 2005
Curriculum Vitae


Gastroenterology Case Conference, San Francisco, CA. March 17, 2005.
Gastroenterology Case Conference, San Francisco, CA. March 24, 2005.
Gastroenterology Case Conference, San Francisco, CA. April 21, 2005.
GI Cancer Board, San Francisco, CA. May 2, 2005.
Recognition & Management of Shock: New Standard of Care, San Francisco, CA. May 6,
2005.
Gastroenterology Case Conference, San Francisco, CA. June 2, 2005.
GI Cancer Board, San Francisco, CA. June 7, 2005.
Gastroenterology Case Conference, San Francisco, CA. June 23, 2005.
Gastroenterology Case Conference, San Francisco, CA. July 7, 2005.
Gastroenterology Case Conference, San Francisco, CA. August 18, 2005.
Gastroenterology Case Conference, San Francisco, CA. August 25, 2005.
Therapy of Hepatitis B AASLD, September 14, 2005
Emerging Treatments for Liver and Complex GI Diseases, Omni Hotel, San Francisco.
September 16-17, 2005.
Gastroenterology Case Conference, San Francisco, CA. September 29, 2005.
Gastroenterology Case Conference. San Francisco, CA. October 10, 2005.
Adult Donor Liver Transplantation, San Francisco, CA. October 21, 2005.
Clinical Case Consults in Chronic Hepatitis B September 26, 2005, October 24, 2005
Hot Topics in Liver Disease St. Lukes Episcopal Hospital. October 7-8, 2005
Update on HBV Sunrise Medical Center, Las Vegas October 18 05
2005
Hepatitis B: Identifying the Issues and Improving Patient Outcomes. University of
Wisconsin Medical School, Office of Continuing Medical Education. San Francisco, CA.
October 20, 2005.
GI Cancer Board, San Francisco, CA. November 1, 2005.
Curriculum Vitae


Treating HCV Maximizing Response and Minimizing Injury. University of Wisconsin
Medical School, Office of Continuing Medical Education. Las Vegas, NV. November 7,
2005.
Where Do We Go From Here? - Emerging Strategies in the Management of HCV
Treatment Failures. AASLD, November 13, 2005
Early Morning Workshops AASLD, November 13-15, 2005.
Entecavir (ETV) Treatment Through 96 Weeks Results in Substantial Virologic and
Biochemical Improvement and HBeAg Seroconversion in HBeAg (+) Chronic Hepatitis B
(CHB) Patients (Study ETV-022). AASLD. San Francisco. 2005.
Presentation at Bricks Restaurant, Reno November 17, 2005.
Treatment Strategies for the HCV Nonresponder. InterMune. Roseville, CA. November
28, 2005.
Expert Council Meeting, ACT-HBV. The Clift Hotel, San Francisco. December 2, 2005.
General Session, ACT-HBV. The Clift Hotel, San Francisco. December 3, 2005.
Primary Care Special Committee ACT-HBV, The Clift Hotel, San Francisco. December 3,
2005.
AASLD Update. Mountain View Hospital. Las Vegas, NV. December 6, 2005.
HBV Resistance Roundtable Meeting The Fairmont Orchid, Kona, HI December 9-10,
2005.
New Date on Hepatitis Drug Development, HEP DART, Kohala Coast, Big Island, Hawaii.
December 11-15, 2005.
A Rising Tide: The Next Wave of Treatment Options in HBV and HCV. AdvancMed. The
Fairmont Orchid. Kona, Hawaii. http://www.advancmed.org/807. December 11, 2005.
Clevudine Advisory Board. Pharmasset. The Fairmont Orchid. Kona, Hawaii. December
12, 2005.
Next Generation of HBV/HCV Inhibitors. HEP DART, The Fairmont Orchid. Kona, Hawaii.
www.ihlpress.com/gaj_120605. December 13, 2005
HCC: Future Therapies, HEP DART, The Fairmont Orchid. Kona, Hawaii. December 13,
2005.
Hepatitis B Treatment: 2005 and beyond: an overview, HEP DART, The Fairmont Orchid.
Kona, Hawaii. www.ihlpress.com/gaj_120605. December 13, 2005.
Curriculum Vitae


2006
Reno-Sparks Community Wide Liver Conference. Saint Marys Regional Medical Center.
Reno, NV. January 19, 2006.
2006 CLDF Steering Committee Meeting Tampa, FL January 20-21, 2006.
Improving Outcomes for Asians and Pacific Islanders at Risk for Hepatitis B, Washington
Hospital. Fremont, CA. January 25, 2005.
GI Grand Rounds. Sunrise Hospital, Las Vegas. February 1, 2006.
Hot Topics in Hepatology: Updates, Strategies and Future Trends Hyatt Regency
Monterey, CA. February 4, 2006.
Reno-Sparks Community Wide Liver Conference. Saint Marys Regional Medical Center.
Reno, NV. February 16, 2006.
Support Group Lecture. Champions of Organ Sharing. A Southern Nevada Transplant
Support Group. March 2006.
MELD Exception Study Group Meeting Westin OHare Hotel. Chicago, IL. March 1-2,
2006.
New and Future Treatments for Hepatitis. Controversies in Transplantation, University of
Colorado School of Medicine. Breckenridge, Colorado. March 3-5, 2006.
COS Shampions of Organ Sharing. Clark County Library. March 14, 2006.
Major Advances in Treating HCV: entering a new era targeted therapy and
immunotherapy, SciClone Pharmaceuticals. Shanghai, China. March 25, 2006.
A Trial of Zadaxin (thymalfasin) with Trans Arterial Chemoembolization (TACE) in the
Treatment of Adult Patients with Unresectable Hepatocellular Carcinoma: A Phase II Trial,
Shanghai-Hong Kong International Liver congress 2006. Shanghai, China. March 26,
2006.
Application of Viral Load Measurement in HCV Patients on Antiviral Therapy, Shanghai-
Hong Kong International Liver Congress 2006. Shanghai, China. March 26, 2006.
Overview of Global and China. Shanghai-Hong Kong International Liver Congress 2006.
Shanghai-China. March 26, 2006.
Management of Chronic Hepatitis B: Entecavir The Global Experience, Shanghai-Hong
Kong International Liver Congress 2006. Shanghai, China. March 26, 2006.
Nucleos(t)ide Analogue as First-line Therapy (Pro), Shanghai-Hong Kong International
Liver Congress 2006. Shanghai, China. March 27, 2006.
Curriculum Vitae


Has Antiviral Therapy Altered the Natural History of HBV, Shanghai-Hong Kong
International Liver Congress 2006. Shanghai, China. March 27, 2006.
Changing paradigm in the Treatment of HBV Infection, Shanghai-Hong Kong International
Medical need for a prophylactic vaccine against HCV, Shanghai-Hong Kong International
Region 5 Meeting. Las Vegas, NV. March 31, 2006.
Hepatitis Alphabet. Fresno-Madera Medical Society 55
th
Annual Yosemite Postgraduate
Institute. Yosemite National Park. March 31-April 2, 2006.
2006
Primary Care Approach to Abnormal Liver Function Tests. Fresno-Madera Medical
Society 55
th
Annual Yosemite Postgraduate Institute. Yosemite National Park. March 31-
April 2, 2006.
A Case Based Approach to the Modern Management of HCV, San Francisco, CA. Meet
the HCV Masters. April 3, 2006.
A Partnership Between Primary Care and Specialty Physicians. Syllabus. 2006.
Management of Hepatitis B Virus. Bethesda, MD. April 6-8, 2006.
Results of a Phase III Randomized Controlled Study Comparing the Survival of Patients
with Unresectable Hepatocellular Carcinoma (HCC) Treated with Nolatrexed (NOL) or
Doxorubicin (DOX), EASL, Vienna. April 27, 2006.
Complication of Cirrhosis, EASL, Vienna. April 27, 2006.
Therapeutic Strategies for Liver Disease: Hepatitis B, Hepatitis C, and Hepatocellular
Carcinoma Treatment Regimens Using Thymalfasin, An Immune System Enhancer.
Austria Center. Vienna. April 27, 2006.
Hepatitis B, C and Liver CA Update, Sunrise Hosptial and Medical Center. Cilis
Restaurant. Las Vegas, NV. May 8, 2006. 1.0 AMA PRA Category Credit.
Cost-effectiveness of Antivirals in HBeAg-positive Chronic Hepatitis B: Impact of
Seroconversion and Viral Suppression. DDW poster. May 2006.
Advanced Certificiate Program II: Management of Chronic Hepatitis B. May 2006.
CLDF Content Development Meeting on HCV Treatment Failures. Hyatt Regency Century
Plaza. Los Angeles, CA. May 19, 2006.
Curriculum Vitae


Refining the HBV Treatment Paradigm. Westin Bonaventure Hotel. Los Angeles, CA.
May 20, 2006.
Scientific Advisory Panel at DDW. Wilshire Grand Hotel. Lost Angeles, CA. May 20,
2006.
International Symposium on HBV. Kyotot International Conference Hall. Kyoto, Japan.
May 27, 2006.
BARACLUDE (entecavir) as a First-Line Treatment Option in Chronic Hepatitis B Patients
and Hypothetical Case Studies. Campagnia Restauarant. Fresno, CA. June 6, 2006.
Whats New in the Treatment of Hepatitis B & C. Double Tree Hotel. Modesto, CA. June
7, 2006.
Idenix/Novartis HCV Clinical Expert Panel. Las Vegas, NV. June 9-10, 2006.
Treating HCV Maximizing Response and Minimizing Injury. Wild Ginger Restaurant.
Seattle, WA. June 12, 2006.
Treatment Strategies for the HCV Nonresponder. Fifth Floor Restaurant. San Francisco,
CA. June 13, 2006.
Chronic Hepatitis B National Advisory Board Meeting. New Haven, CT. June 15-17, 2006.
Reno Sparks Community Wide Liver Conference: Medical & Surgical Aspects of Liver
Transplantation 2006. Reno, NV. June 22, 2006.
Focus on the Virus: A New Paradigm for the Management and Treatment of HBV,
Sheraton Boston Hotel, Boston, MA. October 30, 2006.
The NCSCG Yosemite GI Retreat 2006. Yosemite, CA. November 3-5, 2006.
2007
Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse
Communities Expert Insight Intro: Provider Knowledge and Practice Regarding Hepatitis B
Screening in Chinese-Speaking Patients. Course HBV3:03. 2007.
ESLD and ICU Care Lecture. University of Nevada School of Medicine. February 12,
2007.
New Therapies in Liver Cancer and Hepatitis. Spain, Barcelona. April 12, 2007.
Liver Pathology Rounds. Fresno, CA. April 25, 2007.
Care of Pre and Post Transplant Patients. Medical/Surgical Aspects of Gastrointestinal
Disease A One Day Course. Sutter Roseville Medical Center. Sacramento, CA. April 21,
2007.
Curriculum Vitae


Panel Discussion: Challenges in Therapy of Hep C. Medical/Surgical Aspects of
Gastrointestinal Disease A One Day Course. Sutter Roseville Medical Center.
Sacramento, CA. April 21, 2007.
American Transplant Congress. San Francisco, CA. May 5-9, 2007 (CME Credit)
Molecular Tests for HBV: Genotype, Core and Precore Testing, Quatification Tests. San
Francisco, CA. May 7, 2007.
Molecular Tests for HBV: Genotype, Core and Precore Testing, Quantification Tests.
Seattle, WA. May 9, 2007
Strategies for the Treatment of the HCV Refractory Patient. Seattle, WA. May 9, 2007
Viral Hepatitis. San Jose, CA. May 16, 2007
April 07 Advanced Issues in the Management of Chronic Hepatitis B. San Francisco, CA.
May 17, 2007.
The Next Steps in Viral Eradication for HCV Treatment Failures. Sacramento, CA. May
23, 2007
The Next Steps in Viral Eradication for HCV Treatment Failures. Reno, NV. May 24, 2007
Metabolic Liver Disease. University of Nevada, School of Medicine, Las Vegas. June 11,
2007.
Hepatology in the ICU. CPMC. San Francisco, CA. June 26, 2007.
Vertex Pharmaceuticals Physician Advisory Forum. Chicago, IL. June 30, 2007.
Case 1 - Patient RD: Management of HCV genotypes 2/3. CARES. July 2007.
Case 4 Patient AR: Hematologic Toxicities in Patients Undergoing Treatment for HCV.
CARES. July 2007.
Hepatology in the ICU. CPMC. San Francisco, CA. July 17, 2007.
Evaluation of Abnormal Liver Tests. University of Nevada School of Medicine. July 23,
2007.
April 07 HCP Guide. Las Vegas, NV. July 24, 2007.
April 07 Advanced Issues in the Management of Chronic Hepatitis B. Reno, NV. July 26,
2007.
Curriculum Vitae


Evolving Strategies in the Management of HCV. San Jose, CA. July 31, 2007.
Case 2 Patient FN: Management of HCV Genotype 1. CARES. August 2007.
Case 5 Patient KM: Psychiatric Issues in Patients Undergoing Treatment for HCV.
CARES. August 2007.
2007
Update on Hepatitis. University of Nevada School of Medicine. Las Vegas, NV. August
22, 2007.
Management of CHB in the era of Ptent Antivirals. Workerhill Hotel, Korea. August 29,
2007.
Management of CHB in the era of Ptent Antivirals. Asan Hospital, Korea. August 30,
2007.
Management of CHB in the era of Ptent Antivirals. Samsung Hospital, Korea. August 30,
2007.
HBV Treatment, do we need a compass, roadmap or GPS? (or a seeing eye dog?)
September 1, 2007.
Targeting the RAS/Raf Signaling Pathway: Implications in the Management of
Hepatocellular Carcinoma. Faculty Teleconference. September 6, 2007.
Emerging Data in the Management of HBV. Mortons Steakhouse. San Francisco, CA.
September 6, 2007.
April 07 HCP Guide. Tarpys Roadhouse. Monterey, CA. September 17, 2007.
Liver Pathology Rounds. Community Medical Center. Fresno, CA. September 18, 2007.
HEP B Free 2007 CME. Tommy Toys. San Francisco, CA. September 19, 2007.
Overview of Antiviral Drug Resistance in Chronic Hepatitis B (CHB): Focus on
BARACLUDE (entecavir). Brennans. Houston, TX. September 20, 2007.
HEP B Free 2007 CME with Dr Eddie Cheung. Griffin Room St Lukes Campus.
September 25, 2007.
ILCAs First Annual Conference. Barcelona-Spain. October 5-7, 2007.
Evaluation of a Liver Mass. University of Nevada School of Medicine. October 17, 2007.
Managing the Patient with Advanced Liver Disease. Spencers Spokane, WA. October
26, 2007.
Curriculum Vitae


Optimal Clinical Outcomes: Managing Hepatitis Related Challenges. PlumpJack Caf.
San Francisco, CA. October 29, 2007.
Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment
in Asian and Other Diverse Communities. Projects In Knowledge/AASLD. November
2007.
Hepatitis Medicaid Expansion Project. Expert Working Group Meeting Boston, MA.
November 1, 2007.
Multimodality Approach to the Treatment of HCC: The Emerging Paradigm. AASLD.
Boston, MA. November 4, 2007
Pharmasset/Roche HCV polymerase Clinical Expert Meeting. AASLD. Boston, MA.
November 4, 2007.
Frontiers in Drug Development for Viral Hepatitis. Emory University. December 9-13,
2007.
Fund Raising Study Task Force Conference Call. AASLD. December 18, 2007.
2008
GI Cancer Board, San Francisco, CA. January 1, 2008.
Aug 07 Resistance. BMS. Mitchells Steak House - Columbus, OH. January 8, 2008.
Aug 07 Resistance. BMS. Ohio State University Medical Center - Columbus, OH.
January 9, 2008.
Simply Speaking HBV. The Westin Casuarina. Las Vegas, NV. January 12, 2008.
Drug Induced Liver Disease. University of Nevada School of Medicine. Las Vegas, NV.
January 14, 2008.
Retreatment of Relapsers and Non-Responders. The First Annual Hepatitis C Conference.
Reno, NV. January 18, 2008.
Hepatology in the ICU. CPMC. San Francisco, CA. January 22, 2008.
GI Fellow Teaching. CPMC. San Francisco, CA. January 23, 2008.
Therapeutical strategies and advances on HBV. Shanghai Westin Hotel. Chinese Medical
Association. Shanghai, China. February 2, 2008.
Therapeutical strategies and advances on HBV. Shanghai Hilton Hotel. Chinese Medical
Association. Shanghai, China. February 3, 2008.
Curriculum Vitae


GI Cancer Board, San Francisco, CA. February 5, 2008.
Conquering Contemporary Challenges New Hope with Targeted Therapy for
Hepatocellular Carcinoma. Osake Restaurant. Santa Rosa, CA. February 5, 2008.
GI Fellow Teaching. CPMC. San Francisco, CA. February 6, 2008.
GI Fellow Teaching. CPMC. San Francisco, CA. February 7, 2008.
HBV New Therapies. St Marys Hospital Grand Rounds. San Francisco, CA. February 8,
2008.
Clinical Drug Assessment, A Clinicians View of the Development and Assessment of Drugs
to Treat Hepatitis. Road Map to Drug Discovery, Development and Approval. February 12,
2008.
Session 5: Management of HBV Resistance Case Presentation and Discussion. EASL-
AASLD-APASL-ALEH-IASL Conference: Hepatitis B and C Virus Resistance to Antiviral
Therapies. Paris, France. February 14-16, 2008.
LT, Referral and Indications, pre/post transplant care. Sunrise Hospital. Las Vegas, NV.
February 26, 2008.
American Association for the Study of Liver Disease Update. Saint Marys Regional
Medical Center. Reno, NV. February 28, 2008.
Evolving Treatment Options for Chronic HCV Infection Optimizing Current Treatment
Options. Palms Restaurant. Fresno, CA. March 3, 2008.
GI Cancer Board, San Francisco, CA. March 4, 2008.
HBV Resistance and the Role of Baraclude in CHB. Rice Bowl Restaurant. Sacramento,
CA. March 5, 2008.
Hepatitis B Liver Symposium. Cathedral Hill Hotel. San Francisco, CA. March 15, 2008.
NASH and Fatty Liver. University of Nevada School of Medicine. Las Vegas, NV. March
17, 2008.
Hepatitis C Questions? We have answers. Sunrise Medical Center. Las Vegas, NV.
March 17, 2008.
2008
GI Cancer Board, San Francisco, CA. April 1, 2008.
Healthcare Providers Guide to Chronic Hepatitis B. BMS. Las Vegas, NV. April 14, 2008.
Curriculum Vitae


Portal hypertension and treatment. Renown. Reno, NV. April 17, 2008.
Medical Overview of Hepatitis C. Hepatitis C Community Outreach Event. Las Vegas, NV.
April 19, 2008.
Treatment of Hepatocellular Carcinoma with TACE plus Thymalfasin. Sciclone - New
Therapies in Liver Cancer and Hepatitis. EASL - Milan, Italy. April 24, 2008.
HCV. Silks Restaurant. San Francisco, CA. April 29, 2008.
HCV Update. Schering-Plough. Rhema Restaurant. Fresno, CA. April 30, 2008.
UNOS Regional 5 Meeting. Las Vegas, NV. May 1, 2008.
Overview Slide Presentation. BMS Advisory Board Meeting. Los Angeles, CA. May 3,
2008.
Questions and Answers. BMS Advisory Board Meeting. Los Angeles, CA. May 3, 2008.
GI Cancer Board, San Francisco, CA. May 6, 2008.
Autoimmune liver disease, including PSC and PBC/PBH. Nevada School of Medicine.
Las Vegas, NV. May 13, 2008.
European Association for the Study of Liver Disease Update. Reno Sparks Community
Wide Liver Conference. Beaujulais Bistro. Reno, Nevada. May 15, 2008.
2008 Expert Working Group Meeting. Gilead. San Diego, CA. May 16, 2008.
Editorial Advisory Board DDW Breakfast. Gastroenterology and Hepatology. San Diego,
CA. May 19, 2008.
AASLD Clinical Symposium. DDW-San Diego, CA. May 20, 2008.
An Updated Review of Management Strategies for the HCV Non-Responder. Three Rivers
Pharmaceuticals. Roys Restauarnt. Las Vegas, NV. May 28, 2008.
Alcoholic Hepatitis. Alameda County Medical Center. Oakland, CA. May 30, 2008.
Treatment End Points: Translating Clinical Trials into Clinical Practice. Hong Kong-
Shanghai International Liver Congress BMS Satellite Symposium. Hong Kong, China.
June 14, 2008.
Management of acute liver failure Biological and nonbiological liver support methods.
Hong Kong-Shanghai International Liver. Hong Kong, China. June 14, 2008.
Liver Support System Workshop What Do You Need to Know about Liver Support System
in 2008. Hong Kong-Shanghai International Liver Congress Hong Kong, China. June 14,
2008.
Curriculum Vitae


Nucleic acid testing: role in HBV and HCV management. Hong Kong-Shanghai
International Liver. Hong Kong, China. June 14, 2008.
Combination therapy for CHB: Are we focusing too much on viral suppression rather than
on antiviral ressistance as a sign of efficacy? (Pro). Hong Kong-Shanghai International
Liver. Hong Kong, China. June 15, 2008.
Road map to long term treatment success. Hong Kong-Shanghai International Liver.
Hong Kong, China. June 15, 2008.
IX International Symposium on Viral Hepatitis. Barcelona, Spain. June 20-21, 2008.
2008 Post Conference Update: EASL. Simply Speaking. San Francisco, CA. June 23,
2008.
An Updated Review of Management Strategies for the HCV Non-responder. Three Rivers
Pharmacueticals. Garibaldis Restaurant. Oakland, CA. June 24, 2008.
Strategies for Optimizing Successful Outcomes in the Management of HCV Difficult-to-
Treat Population. Three Rivers Pharmaceuticals. Bricks Restaurant. Reno, Nevada. June
26, 2008.
Keynote Speaker. Hepatitis B Foundation B Informed Patient Conference. St. Vincent
Medical Center. Los Angeles, CA. June 28, 2008.
Ask the Experts Roundtable. Hepatitis B Foundation B Informed Patient Conference.
St. Vincent Medical Center. Los Angeles, CA. June 28, 2008.
GI Cancer Board, San Francisco, CA. July 1, 2008.
New Concepts in the Treatment of HCV. Schering-Plough. July 1, 2008.
HBV. GI Noon Conference. CPMC. San Francisco, CA. July 3, 2008.
HBV Update. APAC Quarterly Meeting. Four Seas Restaurant. July 9, 2008.
How do healthcare providers teach about hepatitis b? With the goals, prevelance, natural
history treatment testing. BMS. E&O Trading. San Francisco, CA. July 15, 2008.
Clinical Implications of HBV Resistance. Ruth Cris Steak House. Honolulu, Hawaii. July
17, 2008.
The Future of Hepatitis B and C. Fourth Annual Liver Update Seminar. Queens
Conference Center. July 19, 2008.

Curriculum Vitae


Updates on the Management & Treatment of Hepatitis B. Fourth Annual Liver Update
Seminar. Queens conference Center. July 19, 2008.
Panel Discussion. Fourth Annual Liver Update Seminar. Queens conference Center.
July 19, 2008.
LFTs. Nevada School of Medicine. Las Vegas, NV. July 23, 2008.
Liver Enzyme Elevation. Renown Nevada School of Medicine. Reno, NV. July 24,
2008.
Update of Hepatitis C Virus: epidemiology, natural history and treatment. Saint Marys
Regional Medical Center. 4
th
Street Bistro. Reno, NV. July 24, 2008.
Management of the Advanced Liver Disease Patient. Roche Pharmaceuticals. Lodi, CA.
August 18, 2008.
Management of the HCV Patient. Schering-Plough. Daily Grill. Fresno, CA. August 19,
2008.
Hepatology in the ICU. CPMC. San Francisco, CA. August 21, 2008.
GI Cancer Board, San Francisco, CA. September 2, 2008.
Clinical Implications of HBV Resistance. BMS. Chicago, IL. September 4, 2008.
Advances in Managing Patients with Hepatitis B. Duke Liver Disease Update and
Symposium. Duke Clinical Research Institute. Durham, North Carolina. September 6,
2008.
Gilead Speaker Training. San Francisco, CA. September 8, 2008.
Hepatology in the ICU. CPMC. San Francisco, CA. September 9, 2008.
Addressing Real World Challenges in the Treatment of Chronic Hepatitis C. Roche. Ruth
Cris Steak House. Kansas City, MO. September 11, 2008.
Management of the Advanced Liver Disease Patient. Roche. University of Kansas.
Kansas City, KS. September 12, 2008.
Clinical Implications of HBV Resistance. BMS. Il Fornaio Restaurant. San Jose, CA.
September 16, 2008.
Treating the Hospitalized Liver Patient. University of Nevada School of Medicine. Las
Vegas, NV. September 22, 2008.
HCV Update. Schering-Plough. Cheese Board Restaurant. Reno, NV. September 22,
2008.
Curriculum Vitae


CME Talk. Renown Nevada School of Medicine. Reno, NV. September 23, 2008.
Current Perspectives on Chronic Liver Disease. CLDF. Scotts Seafood. Sacramento,
CA. September 23, 2008.
2008 Post Conference Update: EASL. HRL Communications. El Paseo Restaurant. Mill
Valley, CA. September 24, 2008.
GI Cancer Board, San Francisco, CA. October 7, 2008.
GI Fellow Teaching. CPMC. San Francisco, CA. October 7, 2008.
Hepatology in the ICU. CPMC. San Francisco, CA. October 9, 2008.
2008 Pegasys Hep B Regional Advisory Board. San Francisco, CA. October 9, 2008.
Biliary Disease Work Up of Jaundice. Nevada School of Medicine. Las Vegas, NV.
October 13, 2008.
Healthcare Provider's Guide to Chronic Hepatitis B. BMS. Del Friscos Restaurant. Las
Vegas, NV. October 14, 2008.
Fatty Liver Evaluation. Renown Nevada School of Medicine. Reno, NV. October 16,
2008.
Update on Liver Cancer from EASL, ILC, and DDW. CME Saint Marys Continuing
Medical Education. 4
th
Street Bistro. Reno, NV. October 16, 2008.
Management of Hepatitis B. Canadian Speaker Tour. On the Fork Restaurant. London,
Ontario. October 21, 2008.
Views on Living Donor Transplants, Hepatocellular Carcinoma Pre and Post Transplant.
Canadian Speaker Tour. London Health Sciences. London, Ontario. October 22, 2008.
Hepatitis B: Implications of Resistance in End Stage Liver Disease and Liver
Transplantation. Canadian Speaker Tour. Toronto General Hospital. October 22, 2008.
Viral Resistance. Canadian Speaker Tour. Toronto Western Hospital. October 23, 2008.
Chronic Hepatitis B. Canadian Speaker Tour. Hotel Intercontinental, Salon Maisonneuve.
Montreal, Quebec. October 23, 2008.
Consequences of Antiviral Resistance. Canadian Speaker Tour. Vancouver Hospital and
Health Sciences Centre. October 24, 2008.
Cases in Point: Risk Factors, Surveillance Strategies and Treatment Options for
Hepacellular Carcinoma. Marriott. San Francisco, CA. November 1, 2008.
Curriculum Vitae


Models for Hepatitis B Screening and Linkage to Care. Gilead Medical Affairs dinner.
Town Hall Restauarnt. San Francisco, CA. November 2, 2008.
Approved Agents for HBV Treatment. Clinical Care Options. Le Meridien. San Francisco,
CA. November 3, 2008.
GI Cancer Board, San Francisco, CA. November 4, 2008.
Approved Agents for HBV Treatment. Clinical Care Options. Le Meridien. San Francisco,
CA. November 4, 2008.
GI Fellow Teaching. CPMC. San Francisco, CA. November 7, 2008.
New Concepts in the Treatment of HCV. Schering-Plough. Plumed Horse Restaurant.
October 10, 2008.
Standard of Care for the Treatment of Hepatitis B & C. Update in Gastroenterology and
Hepatology. Las Vegas Symposium. November 15, 2008.
Hepatitis C. Las Vegas Symposium. November 15, 2008.
Debate Monotherapy is Suitable for HBV. Las Vegas Symposium. November 15, 2008.
GI Cancer Board, San Francisco, CA. December 2, 2008.
HBV Highlights from CCOs Coverage of the 2008 AASLD Meeting, Grand Caf. San
Francisco, CA. December 2, 2008.
CARES Roundtable. Farallon Restaurant. San Francisco, CA. December 4, 2008.
Launching of Hepatitis-B Education and Awareness Campaign. South Seafood
Restaurant. San Francisco, CA. November 25, 2008.
VIREAD: A New Treatment Option for Chronic Hepatitis B in Adults. Gilead. Fifth Floor
Restaurant. San Francisco, CA. December 8, 2008.
GI Fellow Teaching. CPMC. San Francisco, CA. December 9, 2008.
HBV. Nevada School of Medicine. Las Vegas, NV. December 15, 2008.
Chronic Hepatitis B. BMS. Roys Restaurant. Las Vegas, NV. December 15, 2008.
VIREAD: A New Treatment Option for Chronic Hepatitis B in Adults. Gilead. Las Vegas,
NV. December 16, 2008.
Nexavar in the Treatment of Patients With Unresectable HCC. Onyx. Beaujolais Bistro.
Las Vegas, NV. December 18, 2008.

Curriculum Vitae


2009
NASH = Non-alcoholic Fatty Liver Disease. CME Talk. Reno, NV. January 8, 2009.
HBV Screening and Linkage to Care. Simply Speaking. Scottsdale, AZ. January 10,
2009.
Guidelines to Screen for and Treat Chronic Viral Hepatitis B and C Infections. Department
of Medicine. Grand Rounds at CPMC. San Francisco, CA. January 13, 2009.
VIREAD: A First-Line Treatment Option for Chronic Hepatitis B in Adults. Gilead.
Tanglewood Restaurant. San Jose, CA. January 14, 2009.
Nexavar in the Treatment of Patients with Unresectable HCC. Le Papillon Restaurant.
Onyx. San Jose, CA. January 15, 2009.
Speaker Training. 2009 Pegasysm Speaker Training. Estancia. La Jolla, CA. January
16-17, 2009.
Current Management Strategies in CHB. 2
nd
St Lukes International Liver Conference
Scientific Program. Manilla, Philippines. January 19, 2009.
Treatment Approach of a Patient with CHB. 2
nd
St Lukes International Liver Conference
Scientific Program. Manilla, Philippines. January 19, 2009.
Treat to Succeed: A Case by Case Study of Hepatitis B (Discussing current trends and
challenges in the treatment of Chronic Hepatitis B). BMS Edinburgh and Birmingham.
UK and Netherlands Roadshow. January 20, 2009.
challenges in the treatment of Chronic Hepatitis B). BMS Newcastle and Manchester.
UK and Netherlands Roadshow. January 21, 2009.
challenges in the treatment of Chronic Hepatitis B). BMS London. UK and Netherlands
Roadshow. January 22, 2009.
challenges in the treatment of Chronic Hepatitis B). BMS Utrecht. UK and Netherlands
Roadshow. January 23, 2009.
Current Perspectives in the Treatment of Chronic Hepatitis C. Slates Restaurant. Roche.
Frenso, CA. January 28, 2009.
VIREAD: A First-Line Treatment Option for Chronic Hepatitis B in Adults. Gilead. Nola
Restaurant. Palo Alto, CA. February 4, 2009.
CHB Hypothetical Case Studies. BMS. Tommy Toys Restaurant. San Francisco, CA.
February 5, 2009.
Curriculum Vitae


Hepatitis B & C Update. Grand Rounds Talk. Highland Hospital. Oakland, CA. February
6, 2009.
Strategies for Improved Response in the Treatment of Hep B: Patient Case Approach.
Roche. Tanglewood Restaurant. San Jose, CA. February 9, 2009.
Liver Transplant. APASL Meeting. Hong Kong, China. February 12, 2009.
Hepatitis C. APASL Meeting. Hong Kong, China. February 12, 2009.
Chinese American Physicians Association Joint Symposium What Do You Need to Know
about Liver Support System in 2009. APASL Meeting. Hong Kong, China. February 13,
2009.
Long-term treatment goals: Reflections on HBsAg seroconversion. APASL Meeting. Hong
Kong, China. February 13, 2009.
Postgraduate Course V Liver Transplantation. APASL Meeting. Hong Kong, China.
February 13, 2009.
Approach to difficult-to-treat patients. APASL Meeting. Hong Kong, China. February 14,
2009.
Improving Patient Quality of Life: Preventing CHB disease progression with Baraclude.
APASL Meeting. Hong Kong, China. February 14, 2009.
Update on Hepatitis Viral B. Hue College of Medicine and Pharmacy. Hue, Vietnam.
February 18, 2009.
Update on Hepatitis Viral C. Hue College of Medicine and Pharmacy. Hue, Vietnam.
February 18, 2009.
Update on the Treatment of Liver Cancer. Hue College of Medicine and Pharmacy. Hue,
Vietnam. February 18, 2009.
Liver Transplant. Hue College of Medicine and Pharmacy. Hue, Vietnam. February 18,
2009.
Nexavar in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC).
Onyx. Nove Italiano Restaurant. Las Vegas, NV. February 23, 2009.
Onyx. Rapscallion Seafood House. Reno, NV. February 26, 2009.
VIREAD: A First Line Treatment Option for Chronic Hepatitis B in Adults. Oliveto.
Oakland, CA. March 3, 2009.
Be a Hero Dinner. South Seafood Restaurant. San Francisco, CA. March 5, 2009.
Curriculum Vitae


Autoimmune and metabolic diseases: genetic. Nevada School of Medicine. Las Vegas,
NV. March 10, 2009.
Roundtable Discussion. Three Rivers. Ruth Chris Restaurant. Las Vegas, NV. March
10, 2009.
Onyx. Rapscallion Seafood House. Reno, NV. March 12, 2009.
ALF Salute to Excellence. San Francisco, CA. March 14, 2009.
Resistance: Resistance: The Role of Baraclude. BMS. Sasso Restaurant. Boston, MA.
March 16, 2009.
Resistance: The Role of Baraclude. BMS. Jianan Comprehensive Care. Brooklyn, New
York. March 17, 2009.
Onyx. Hyatt at Olive 8. Seattle, WA. March 19, 2009.
Onyx. El Gaucho Restaurant. Seattle, WA. March 19, 2009.
New Therapies for Hepatitis B and Hepatitis C. University of Nevada School of Medicine.
16th Annual Alimentary Update. Harveys Resort. Lake Tahoe, CA. March 27, 2009.
Advances in the Treatment of HCV/HIV Coinfection With Pegasys and Copegus. Roche.
The Grand Caf. San Francisco, CA. March 30, 2009.
Hepatocellular Carcinoma: Current Epidemiology & Management. Good Samaritan
Hospital. CME talk. San Jose, CA. April 1, 2009.
New Paradigm in Treatment of Chronic Hepatitis B. South Bay Gut Club/BMS. Amber
India Restaurant. San Jose, CA. April 1, 2009.
Management of Long Term Sequale of Hepatitis B such as Cirrhosis and Hepatoma.
South Bay Gut Club/BMS. Amber India Restaurant. San Jose, CA. April 1, 2009.
HCV. GLG Roundtable Meeting. Silks Restaurant. San Francisco, CA. April 8, 2009.
Viral hepatitis over view B and C. Renown Medical Center. Reno, NV. April 29, 2009.
Clinical Implications of Hepatitis B Virus Resistance. BMS. Rapscallion Seafood House.
Reno, NV. April 29, 2009.

Curriculum Vitae


2009
Management of Hepatitis B. BMS. Scott's Seafood Restaurant. Sacramento, CA. April
30, 2009.
Wilsons Disease. CPMC. San Francisco, CA. May 2, 2009.
Hepatitis C Fight. Roche. Town Hall Restaurant. San Francisco, CA. May 4, 2009.
Nexavar in the Treatment with Unresectable HCC. Onyx. Scotts Seafood. May 5, 2009.
VIREAD: A First-Line Treatment Option for Chronic Hepatitis B in Adults. Gilead. La Folie
Restaurant. San Francisco, CA. May 6, 2009.
2009 Post Conference Update: EASL. Simply Speaking. El Paseo Restaurant. Mill
Valley, CA. May 13, 2009.
HCC. Renown Medical Center. Reno, NV. May 14, 2009.
HCV and Cryoglobulinemia: How Cool Can You Get. Saint Marys Regional Medical
Center. Reno, NV. May 14, 2009.
Unbranded Professional Programs Program. Gilead. Nove Italiano at The Palms. Las
Vegas, NV. May 19, 2009.
Fatty Liver. Nevada School of Medicine. Las Vegas, NV. May 20, 2009.
Case 6: Patient With HBV Infection: When to Treat and How to Treat. CARES.
McCormick & Kuleto's Restaurant. San Francisco, CA. June 4, 2009.
Nexavar in the Treatment of Patients with Unresectable HCC. Onyx. Renown Hospital.
Reno, NV. June 30, 2009.
Weekly Emergency Medicne Conference. CME talk. Alameda County Medical Center,
Highland Hospital. Oakland, CA. July 1, 2009.
Faculty of John Hopkins University School of Medicine CME Program. Kuleto Trattoria
Restaurant. Burlingame, CA. July 14, 2009.
HCV and Cryoglobulinemia: How Cool Can You Get? Saint Marys Regional Medical
Center. Reno, NV. July 27, 2009.
Chronic Hepatitis B (CHB_: Screening, Diagnosis and Patient Considerations. BMS talk.
Kings Winery Clinic. Fresno, CA. August 5, 2009.
VIREAD An Overview Including Safety and Efficacy. Gilead. Palms Restaurant. Fresno,
CA. August 5, 2009.
Curriculum Vitae


An Updated Review of Management Strategies for the HCV Treatment Failure Patient.
Three Rivers. Gordon Biersch Brewing Company. Las Vegas, NV. August 18, 2009.
Work up of Elevated Liver Tests. Las Vegas, NV. August 19, 2009.
Liver Enzyme Elevation. Renown. Reno, NV. August 20, 2009.
CHB Hypothetical Case Studies. BMS talk. Scotts Seafood. Oakland, CA. August 26,
2009.
GI Journal Club Presentation. University of Alberta. Edmonton, Canada. November 10,
2009.
2010
HCC Diagnosis and Treatement. Sonoma Valley Gut Club. Santa Rosa, CA. January 11,
2010.
State of the Art Liver Transplantation for Hepatocellular Carcinoma: Recurrence of primary
and secondary disease; what is more important? VIVA Restaurant. Los Gatos, CA.
February 25, 2010.
GI Fellow Teaching. CPMC. March 2, 2010.
One Therapy From Day One 5 Year Resistance Update. Oak Brook, IL. March 5, 2010.
Advances in Hepatocellular Carcinoma: 2010 Update. Loyola University. Maywood, IL.
March 6, 2010.
Viral Hepatitis and Hepatocellular Carcinoma. March 6, 2010.
VIREAD Case Vignettes: An Examination of Patient Profiles. Galletto Ristorante.
Modesto, CA. March 10, 2010.
Updates on Viral Hepatitis and Liver Diseases. Hue college of Medicine and Pharmacy.
Vietnam. March 22-23, 2010.
Liver Suport System for the Management of Liver Failure. APASL. Beijing, China. March
25, 2010.
New Concepts in the Treatment of HCV. Plumed Horse Restaurant. Saratoga, CA.
March 29, 2010.
HBV. Kaiser. San Jose, CA. March 31, 2010.
E&O Trading. San Jose, CA. March 31, 2010.
Curriculum Vitae


CHB Resistance: Role of Baraclude in CHB Therapy for Nucleoside-nave Patients.
Northwestern Memorial Hospital. Chicago, IL. April 5, 2010.
The Clinical Implications of Managing Cirrhotics. CLDF. San Francisco, CA. April 12,
2010.
VIREAD Case Vignettes: An Examination of Patient Profiles. Harrahs Steakhouse. Reno,
NV. April 28, 2010.
Overview of HBV and Liver Transplantation: Why is There a Controversy? Sunrise
Symposium: Controversies in Management of HBV after Liver Transplantation. May 2,
2010.
Concurrent Session9: Liver:Allocation Issues. 2010 American Transplant Congress. San
Diego, CA. May 2, 2010.
One Therapy From Day One 5 Year Resistance Update. San Francisco, CA. May 3,
2010.
Chronic Viral Hepatitis: Can we C our way to B cured? CME Talk. St Lukes Grand
Rounds. San Francisco, CA May 5, 2010.

New Advances in the Management of Hepatocellular Carinoma (HCC). Regional Medical
Center of San Jose. May 8, 2010.
Newest Multi-Disciplinary Treatment Modalities for Liver and locally advanced Pancreatic
Cancer. Renown. Reno, NV. May 11, 2010.
2010
VIREAD: An Overview Including Safety and Efficacy. Ritz Carlton Hotel. San Francisco,
CA. May 12, 2010.
Long Term Considerations in Chronic Hep B (CHB) Therapy. Tommy Toys Restaurant.
San Francisco, CA. May 17, 2010.
VIREAD Case Vignettes: An Examination of Patient Profiles. Alexanders Steakhouse.
Cupertino, CA. May 18, 2010.
+Bay Area Non-Doc (BAND). LePapillion Restaurant. San Jose, CA. May 19, 2010.
The Clinical Implications of Managing Cirrhotics. Ruth Chris Steakhouse. San Francisco,
CA. May 25, 2010.
Long-Term Considerations in Chronic Hepatitis B (CHB) Therapy. LePeppillion
Restaurant. San Jose, CA. May 26, 2010.
Curriculum Vitae


Long Term Considerations in Chronic Hep B Therapy Lecture w/HBV Treaters. Ounce
Steakhouse. San Antonio, TX. June 10, 2010.
2010 National Hepatitis B&C Training Program & Treatment Update. Omni Hotel. San
Francisco, CA. June 12, 2010.
Hepatitis C: What is the current diagnostic and treatment paradigm? Community Hospital
of Monterey. Monterey, CA. June 16, 2010.
Coming to your area: Case3: On the Cusp of Change: New Therapeutic Modalities for HCV.
Sienna Restaurant. El Dorado Hills, CA. June 16, 2010.
Chronic Hepatitis B (CHB) Screening, Diagnosis and Patient Considerations.
Pleasanton, CA. June 29, 2010.
Remarks from CPMC. Health Forum. Southeast Asian Community Center. San
Francisco, CA. June 13, 2010.
Hepatitis C: What is the Current Diagnostic and Treatment Paradigm? Community
Hosptial of Monterey. Monterey, CA. June 16, 2010.
Coming to your area: Case 3: On the Cusp of Change: New Therapeutic Modalities for
HCV. El Dorado Hills, CA. June 16, 2010.
Chronic Hepatitis B (CHB)-Screening, Diagnosis and Patient Considerations. Pleasanton,
CA. June 29, 2010.
CHB Hypothetical Case Studies. Las Vegas, NV. July 28, 2010.
Use only the A Team to Beat Hepatitis B. Chinese Hosptial. San Francisco, CA.
August 3, 2010.
Las Vegas, NV. August 17, 2010.
The Clinical Implications of Managing Cirrhotics. San Jose, CA. September 13, 2010.
VIREAD Professional Program. Oakland, CA. September 20, 2010.
Use Only the A Team to Beat Hepatitis B. Saint Francis Memorial Hospital. September
21, 2010.
VIREAD Professional Program. Fresno, CA. September 21, 2010.
HBV Unbranded. San Jose, CA. September 28, 2010.
Risk Assessment and Clinical Management of Patients with CHB. Reno, NV. September
29, 2010.
Curriculum Vitae


Risk Assessment and Clinical Management of Patients with CHB. Sacramento, CA.
September 30, 2010.
Clinical Update 2010: Chronic Liver Disease and Hepatocellular Carcinoma. Sutter
Roseville Medical Center. Roseville, CA. October 2, 2010.
Viral Hepatitis Treatment and HCC. Roseville, CA. October 2, 2010.
Hepatocellular Carcinoma Current Trends in Diagnosis and Management: What all
Healthcare Providers Need to Know. Hartford Hospital Grand Rounds. Hartford, CT.
October 4, 2010.
One Therapy From Day One 5 year Resistance Update. Hartford, CT. October 4, 2010.
Chronic Hepatitis B (CHB) Screening, Diagnosis and Patient Considerations. Hartford,
CT. October 4, 2010.
One Therapy from Day One: Considerations in Long-Term Hepatitis B Management.
Trumbell, CT. October 5, 2010.
HCC Update. Hartford Hospital Grand Rounds. Hartford, CT. October 5, 2010.
VIREAD Professional Program. Kansas University Medical Center. Kansas City, KS.
October 11, 2010.
VIREAD: Examing the Clinical Studies. Kansas City, KS. October 11, 2010.
Managing HBV in the At-Risk Community. San Francisco, CA. October 12, 2010.
Management of Chronic Hepatitis B. Burlingame, CA. October 15, 2010.
Chronic Hepatitis B Hypothetical Case Studies. San Jose, CA. October 18, 2010.
Chronic Hepatitis B Hypothetical Case Studies. Fremont, CA. October 19, 2010.
Hepatitis B & C. Las Vegas, NV. October 25, 2010.
Treat or No Treat: An Educational Case-Based Discussion Considering Evidence and
Expert Insights in Treatment Decisions for CHB. Boston, MA. October 30, 2010.
Viral Hepatitis Treatment and HCC. 2010 Clinical Update: New Advances in the
Management of Hepatocellular Carcinoma. Las Vegas, NV. November 13, 2010.
Addressing Important Factors in HCV Treatment Today: Insulin resistance/Steatosis.
Hexagone. San Diego, CA. November 15, 2010.
HBV and Liver Transplantation. Northwestern. November 19, 2010.
Curriculum Vitae


Hepatitis B and Hepatitis B/HIV Co-Infection. Northwestern. November 20, 2010.
Key Developments in Hepatology. Northwestern. November 20, 2010.
2011
Hepatitis C: The New Dynamic of HCV treatment, UCSD Medical, March 2011

Evaluating Use of Hepatitis B Immunoglobulin in Patients after Liver Transplantation, UCSD
Medical May 2011
Free Screening for Diabetes and Hep B, UCSD 2011
Hepatitis B: Current Epidemiology, UCSD May 19, 2011
International Convention of Vietnamese Physicians, Dentists, and Pharmacists. Toronto,
August 2011.
Salix Best Practice in Advanced Liver Disease Faculty Meeting, Chicago, IL. August 2011.
Diverse Aspects of Hepatitis B, Hepatitis B Outreach Program at Hsi Fang Temple, San
Diego. September 2011
Comparative Effectiveness of Hepatitis C Treatment, Panel Expert, Oregon Health &
Science University, October 2011
Facilitator, CME Roundtable Series, Current Advances in the Management of Cirrhotics,
Palm Restaurant, San Diego, CA October 7, 2011.
DDW 2011
Lecturer. AASLD: The Liver Meeting, San Francisco, CA, November, 2011.
Faculty: 2011 Hepatology Associates Course, San Francisco, CA. Point Counterpoint:
Complex Patient Case Management Issues. November 2011.
Expert Panelist: Comparative Effectiveness of Hepatitis C Treatment, October 2011.
Panelist: 2011 Chronic Liver Disease Foundation (HCEE) HE Webcast Tapings, San
Francisco, CA. November 2011.

Speaker, Tripe Therapy Advanced: Evolution of HCV Treatment: Telaprevir with
PEGASYS/RB; Genetec Speaker Series, Palm Restaurant, San Diego, CA December 20,
2011.

Curriculum Vitae


2012

Vietnamese Federation of San Diego, Event- Vietnamese Elderly Association and the
Vietnamese Veterans Association on the occasion of Lunar New Year; San Diego, CA.
January 14, 2012.

Participant, Effective Teaching Skills for Faculty & Fellows, VA Hospital, Grand Rounds,
Clinical Case Conference, San Diego, CA., January 19, 2012.

Polaris Group; Investigators Meeting in conjunction with the American Society for Clinical
Oncology Gastrointestinal Cancers Symposium, San Francisco, CA. January 19, 2012.

Speaker, Multidisciplinary Strategies for the Management of Hepatic Carcinoma,
Presented by Bayer Healthcare Pharmaceuticals, Onyx Pharmaceuticals, and Abbott
Pharmaceuticals, Mortons Steakhouse, San Francisco, CA, January 20, 2012.

Speaker, Multidisciplinary Strategies for the Management of Hepatocellular Carcinoma:
Paths to Progress, CME Speaker Dinner Series, San Diego, CA. January 21, 2012.

Baldwin Park Lecture for Salix Pharmaceuticals; Los Angeles, CA. January 24, 2012.

CLDF Focus Med Event: San Diego, CA. January 25, 2012.
UCSD Division of Gastroenterology Endowed Jon I. Isenberg Lecture, Keratins: Genetic
Modifiers of Liver Disease and Required Components of Mallory-Denk Bodies, San Diego,
CA. January 26, 2012.
UCSD School of Medicine 2
nd
Annual Symposium-Controversies in Inflammatory Bowel
Disease; San Diego, CA. January 28, 2012.
UCSD Annual Cancer Center Scientific Retreat, Trandisciplinary Research, San Diego,
CA. January 28, 2012.
Hepatitis Free San Diego Introductory Meeting, La Jolla, CA. January 31, 2012
HCC Web Speaker Training (Bayer/Onyx Pharmaceuticals, 2012 Nexavar Concert Series).
Conference Title: Nexavar Unresectable Heptocellular Carcinoma Web Speaker Training,
San Diego, CA. Feb.7, 2012.
Nexavar Concert Series (Bayer Healthcare and Onyx Pharmaceuticals-2012) Conference
Title: Nexavar in the Treatment of Patients with Unresectable Hepatocellular Carcinoma.
Anaheim, CA. February 8, 2012.
Nexavar Concert Series (Bayer Healthcare and Onyx Pharmaceuticals-201 2) Title: Clinical
Consideration in Unresectable Hepatocellular Carcinoma. San Diego, CA. February 9,
2012.
Curriculum Vitae


2012 INCIVEK Professional Speaking Bureau Training Meeting; Santa Monica, CA.
February 11, 2012.
Asian Pacific Health Foundation Training Session: Handling, Disposal of Supplies, Barriers
and Study Surveys. San Diego, CA. February 14, 2012.
Speaker, Metabolic and Autoimmune Liver Disease: What the Primary Care Provide Needs
to Know, Scripps Mercy Hospital Grand Rounds, San Diego, CA, February 14, 2012.
Speaker, HCV Therapeutics, Brio Restaurant, Las Vegas, NV., February 23, 2012.
Speaker, HCV Therapeutics, 888 Seafood Restaurant, Rosemead, CA., February 24,
2012.
Speaker, UCSD AIDS Clinical Rounds, University of California, San Diego., San Diego, CA, March
2, 2012.
Speaker, Clinical Roundtable Discussion: Adult Patients with Chronic Hepatitis B, Ruths
Chris Steak House, Anaheim, CA, March 22, 2012.
Speaker, Variceal Bleeding, University of California, San Diego, GI Division, July 24,
2012.
Management of HCC, Community Liver Event, Redlands, CA; December 6, 2012.

2013

Speaker, Advancing the Standard of Care: Identification, Deciding Whether to Initiate
Therapy, and Contemporary Management Strategies for Patients With Hepatitis C, Roys
Restaurant, Anaheim, CA, January 9, 2013.

Understanding Hyponatremia: Treating Beyond the Primary Diagnosis, Otsuka Pharma-
ceutical America, Palm Springs, CA; January 28, 2013.

Managing HCV Disease, Liver Disease Support Group, Presented by Avella. Specialty
Pharmacy, Valley Hospital Medical Center, Las Vegas, NV. January 30, 2013.

Facilitator, Liver Disease Support Group, Avella Specialty Pharmaceutical Event, Las
Vegas, NV., February 20, 2013.

Speaker, Management of Chronic Hepatitis B in Asian Americans, Vietnamese Physicians
Association of San Diego, San Diego, CA March 1, 2013.

Speaker, HBV, Main Conference, Scripps Clinics 28th Annual New Treatments in Chronic
Liver Disease Conference, La Jolla, CA; March 23, 2013.

Curriculum Vitae


Speaker, Controversy: Warrehouse vs. Treat Now, HBV, Main Conference, Scripps Clinics
28th Annual New Treatments in Chronic Liver Disease Conference, La Jolla, CA; March 23,
2013.

Hepatocellular Carcinoma. Clinical Simulation Center of Las Vegas, University of Nevada,
School of Medicine, Las Vegas, NV. March 27, 2013.

Surveillance for Hepatocellular Carcinoma in the At-Risk Population, Bayer Onyx Oncology
Speaker Program, Phoenix, AZ; May 14, 2013.

Current Insights in to the Management of Hepatic Encephalopathy, Hepatology Centers of
Educational Expertise, San Diego, CA, May 28, 2013.

Chronic Hepatitis C Therapy: Current and Future Perspectives, and Clinical Challenge:
Management of Chronic Hepatitis B in Special Populations, St Lukes, Manila, Philippines;
June 2, 2013

Session Chairman, Transforming Science to Clinical Practice, APASL Liver Week 2013
Singapore: Session Chairman, Singapore, June 6-10, 2013.

Speaker, Treatment of Viral Hepatitis Circa 2013. Advances in Gastroenterology and
Hepatology, San Diego Omni Hotel, San Diego, CA. March 2, 2013.

Speaker, Current Insights into the Management of Hepatic Encephalopathy. The Chronic
Liver Disease Foundation, 2013 Hepatology Centers of Educational Expertise Lecture Se-
ries. Ruths Chris Steak House, San Diego, CA. May 28, 2013.

Guest Speaker, Management of Chronic Hepatitis B in Asian Americans, Hogue Hospital
Gut Club, Laguna Beach, CA; Tuesday, June 18, 2013

Speaker, Hepatitis D and E: The Forgotten Viruses. UCSD AntiViral Research Center, San
Diego, CA. June 21, 2013.

Speaker, Hepatitis D and E: The Forgotten Viruses, AIDS Clinical Rounds San Diego
Providers, June 21, 2013. Speaker, GI Conference & HBV Management, Rady Childrens
Hospital, San Diego, CA, September 12, 2013.

Guest Educator, New and Emerging Strategies to Simplify the Cure of Chronic HCV
Infection, Ruth Chris Steakhouse, Walnut Creek, CA; Sponsored by Rush University Medical
Center & Gilead Sciences, October 24, 2013.

Speaker, Advances in HCV Treatment: The Potential for Hepatitis C Clinical Management
and Treatment in Primary Care and Other Health Care Settings, California Forum on Hepa-
titis C Screening and Treatment, California Endowment Conference Center, Oakland, CA,
November 8, 2013.

Curriculum Vitae


Speaker, Evidence for Baraclude: Clinical Findings, Sponsored by AHM, Magnones
Restaurant, Riverside, CA; November 14 2013.

Speaker, Complications of Cirrhosis in the Age of Quality Health Measures, Paradise Valley,
AZ. November 14, 2013.

2014

Speaker, HCV Update CME , sponsored by Duke University School of Medicine & the
Chronic Liver Disease Foundation. Phoenix, AZ. January 20, 2014.

Speaker, NASH and Fatty Liver, Scripps Health, La Jolla, CA, March 29, 2014 - March
30, 2014

Speaker, HBV update, Scripps Health, La Jolla, CA, March 29, 2014 - March 30, 2014

Speaker, HEV update, Scripps Health, La Jolla, CA, March 29, 2014 - March 30, 2014

Curriculum Vitae

AWARDS, CERTIFICATES AND HONORS

1. Castle Connolly Americas Top Doctors award 2000

2. In appreciation United Network for Organ Sharing certificate in recognition of outstanding
service as an At Large Member on the Liver/Intestine Transplantation Committee,
July 1, 2003- June 30, 2005

3. Outstanding Physician Fundraising Team. Circle of Giving 2007. California Pacific
Medical Center. September 20, 2007.

4. Best Doctors in America 2007-2008. http://www.bestdoctors.com/bd/index.php

5. American Society of Transplantation. Certificate of Appreciation. Nominating Committee.
2008-2009.

6. American Liver Foundation (ALF) Salute to Excellence Honoring Robert Gish.

7. Marin Magazine Best Doctors Issue 2009-2010. February 2010.

8. Certificate of Attendance. 19
th
Conference of the Asian Pacific Association for the Study
of the Liver (APASL). February 13-16, 2009.

9. Certificate of Appreciation. University of Nevada School of Medicine. Department of
Internal Medicine. 2009-2010.

10. Humanitarian of the Year. San Francisco Ho Chi Minh City Sister City Committee. May
27, 2010. http://www.sfexaminer.com/local/Robert-Gish-takes-the-helm-of-hepatitis-B-
prevention-94976469.html

11. Americas Top Doctors for Cancer. 2010.

12. Humanitarian of the Year- 2010

13. Alliance for CME, Outstanding CME Enduring Material, 2010 CaseLine: HCC Program

14. San Diego County Medical Society, 2011 Top Doctors Gastroenterology. Award is
voted by peers within and outside of specialty.

15. Asian Heritage Awards Gala 2011, Presenter, September, 2011

16. $50,000 Grant from Gilead Foundation, Barriers to Hep B Screening. October 2011. (R.
Gish-Full Approver).

17. $100,000 Grant (submitted) from Bristol Myers Squibb, Point of Care HVB. October
2011.

18. 2,000 HCV Kits (received) from Merck, Point of Care HCV For All At-Risk Persons.
October 2011.

Curriculum Vitae

AWARDS, CERTIFICATES AND HONORS: Continued

19. $250,000 Grant (submitted) from Vertex, POC HCV + Operations Cost Savings.
October 2011

20. Americas Top Doctors San Diego. November 2011.

21. Diversity Pioneer Award 2012

22. American Registry, Top Doctor of 2013.

23. San Diegos Top Doctors Annual List, San Diego County Medical Society, 2013.

24. National Top Doctors List, U.S. News & World Report ; 2012-2013.

25. Diversity Pioneer Honoree & Presenter, Asian Heritage Awards, San Diego, CA,
September 14, 2013.

Curriculum Vitae

CONSULTANT / ACKNOWLEDGEMENT AS A CONTRIBUTOR / CME ACTIVITIES

1998 2004

1. Wong J, Bennett W, Koff R, Pauker S. Pretreatment Evaluation of Chronic Hepatitis.
JAMA December 23/30. 1998 Vol 260, No. 24.

2. Louise I. Bertman, Compliance, Noncompliance, and Comparative MMPI-2 Profiles of
Alcohol- Dependent and Non-alcohol Dependent Patients Evaluated for Orthotopic Live
Transplantations. Thesis.

3. Lau G, Carman W, Locarnini S, Okuda K, Lu Z, Williams R. Treatment of Chronic
Hepatitis B Virus Infection: An Asia-Pacific Perspective. Special Report, Journal of
Gastroenterology and Hepatology. (1999) 14, 3-12.

4. Lok AS, Heathcote, EJ, Hoofnagle, JH. Management of Hepatitis B: 2000- summary of a
Workshop. Gastroenterology. 2001;120:1828-1853.

5. McHutchison J and the IHIT Study group (Gish RG). Hepatic HCV RNA before and after
treatment with interferon alone or combined with ribavirin. Hepatology 2002;35:688-693.

6. Pollack, Andrew, F.D.A. Panel Recommends Approval of Hepatitis B Drug. NY Times.
August 7, 2002.

7. AASLD Expert Consensus: Managing Liver Related Challenges. Testing and vaccination
for viral hepatitis. Miami Florida 2003.

8. Christopher Westland, Huiling Yang, William E. Delaney IV, Craig S. Gibbs, Michael D.
Miller, Michael Wulfsohn, John Fry, Carol L. Brosgart, Shelly Xiong, Week 48 Resistance
Surveillance in Two Phase 3 Clinical Studies of Adefovir Dipivoxil for Chronic Hepatitis
B, Acknowledgments include R. Gish.

9. CME Monograph: Side Effect Management in HCV Infection. 2002-2003 with DVC Health
Care Communications. 1) Optimizing Treatment response in HCV Infection by Anemia
Management.

10. CME: Implications & Management of Anemia in Liver Disease. Prevalence and
Characterization of HCV-Associated Cognitive Impairment, CME Monograph Series,
V2, Issue 1, June 2004

11. CME: Hot Topics in Hepatology: Updates, Strategies, and Future Trends, The Institute
for Medical Educations CME Program, September, 2004

12. CME: Chronic Hepatitis B Infection: Re-evaluating Targets for Drug Therapy, CME
Consultants, Inc. BMS Company, September 2004

13. CME: Building New Strategies in Chronic Hepatitis B, BMS & UAB School of Medicine,
October 2004

Curriculum Vitae

CONSULTANT / ACKNOWLEDGEMENT AS A CONTRIBUTOR / CME ACTIVITIES: Contd

14. CME: Implications & Management of Anemia in Liver Disease, CME Monograph
Series, V 2; Issue 2, October 2004

15. CME: Implications & Management of Anemia in Liver Disease Impact of Side Effect
Management and Adherence in HCV-Infected Patients, CME Monograph Series, V2,
Issue 1, November 2004

2005

16. CME: Efficacy and Safety Data on Newer Oral and Injectable Agents for Chronic
Hepatitis B Virus Infection, January 2005

17. CME: Implications & Management of Anemia in Liver Disease Implications &
Management of Anemia in Liver Disease, CME Monograph Series, January 2005

18. CME: Sunrise Hospital & Medical Center, Diet, Nutrition and the Liver. January 2005

19. CME: Treatment of Chronic Viral Hepatitis, HCA Bay Area Healthcare Network,
January 2005

20. CME: Gastroenterology Case Conference, January 13, 2005. 1 Hour CME credit.

21. CME: Gastroenterology Case Conference, January 27, 2005. 1 Hour CME credit.

22. CME : UC Davis , 1
st
Annual Sierra Tahoe Hepatitis C Outreach Conference, February
2005

23. CME: Sunrise Hospital and Medical Center: Heavy Metal: Wilsons Disease and
Hemochromatosis, Las Vegas, February 1, 2005

24. CME: University of Florida College of Medicine & PVI. Efficacy and Safety Data on New
Oral and Injectable Agents for Chronic Hepatitis B Virus Infection, February 2, 2005

25. CME: Implications & Management of Anemia in Liver Disease. Pre-management of
HCV-Infected Patients Before and After Liver Transplantation. V 2, Issue 3;3-13.
February 2005

26. CME: Mayo Clinic College of Medicine. Update in Liver Disease & Transplantation,
Scottsdate, AZ, March 2005

27. CME: Gastroenterology Case Conference, March 17, 2005. 1 Hour CME credit.

28. CME: Gastroenterology Case Conference, March 24, 2005. 1 Hour CME credit.

29. CME: Sunrise Hospital & Medical Center, Should That Patient Die? The Ethics of Liver
Transplantation, April 5, 2005

Curriculum Vitae


30. CME: Gastroenterology Case Conference, April 21, 2005. 1 Hour CME credit.

31. CME: Sunrise Hospital and Medical Center, Hepatitis C and Substance Abuse
Conference April 25, 2005, Las Vegas, NV

32. CME: An Update on Ribavirin Analogues: Meeting the Challenge of Anemia in Hepatitis
C Treatment, Paris, France, April 2005

33. CME: Advanced Certificate Program in the Management of Chronic Hepatitis B
Projects in Knowledge.

34. CME: Practical Pathways Towards Improved Management of HCV Treatment Failures,
DDW, Chicago, IL May 2005

35. CME: GI Cancer Board, May 2, 2005. 1 Hour CME credit.

36. CME: Recognition & Management of Shock: New Standard of Care, May 6, 2005.
One Hour CME credit.

37. CME: Digestive Disease Week 2005 , Chicago, IL May 15 and 16, 2005

38. CME: American Transplant Congress, May 21-25, 2005 Seattle Washington

39. CME: Reno-Sparks Community Wide Liver Conference, May 26, 2005 Reno, Nevada

40. CME: Gastroenterology Case Conference, June 2, 2005. 1 Hour CME credit.

41. CME: GI Cancer Board, June 7, 2005. 1 Hour CME credit.

42. CME: Gastroenterology Case Conference, June 23, 2005. 1 Hour CME credit.

43. CME: Gastroenterology Case Conference, July 7, 2005. 1 Hour CME credit.

44. CME: Expanding Options for Chronic Hepatitis B: New Opportunities to Control
Viremia, University of Florida College of Medicine, PVI, Aug 2. 2005

45. CME: Gastroenterology Case Conference, August 18, 2005. 1 Hour CME credit.

46. CME: Gastroenterology Case Conference, August 25, 2005. 1 Hour CME credit.

47. CME: Advanced Certificate Program in the Management of Chronic Hepatitis B, Vol. 1,
Issue 2, Projects in Knowledge

48. CME: Nucleos(t)ide Analogs in the Treatment of Hepatits B: Update on Recent Data,
Hepatic & Biliary Disorder, PeerView in Session

Curriculum Vitae


49. CME: Emerging Treatments for Liver and Complex GI Diseases San Francisco, CA
Sept 16 to Sept 17, Omni Hotel 6hrs

50. CME: Gastroenterology Case Conference, September 29, 2005. 1 Hour CME credit.

51. CME: Where Do We Go From Here, InterMune, San Francisco, CA

52. CME: Treating HVC with Ribavirin Analogues and Ribavirin-like molecules. Journal of
Antimicrobial Chemotherapy In Press.

53. CME: Hot Topiex in Liver Disease. October 7-8,2005 - 1 credit.

54. CME: Gastroenterology Case Conference, October 10, 2005. 1 Hour CME credit.

55. CME: Adult Donor Liver Transplantation, October 21, 2005. 1 Hour CME credit.

56. CME: ACT HBV San Francisco, CA 10 20 05, San Francisco, Marriott 1.75 Units

57. CME: Clinical Case Consults in Chronic hepatitis B, an interactive teleconference
program, UAB School of Medicine, Sept26, Oct. 24 2005

58. CME: Controversies in Management of HBV: Lessons from Case Studies. October
2005.

59. CME: GI Cancer Board, November 1, 2005. 1 Hour CME credit.

60. CME: Treating HCV Maximizing Response and Minimizing Injury. November 7, 2005
1 credit toward the AMA Physicians Recognition Award.

61. CME: 56
th
Annual Meeting and Postgraduate Course. American Association for the
Study of Liver Diseases, San Francisco, CA. November 11-15, 2005 26 hours.

62. CME: HBV Infection in Clinical Practice. Treatment Reporter: Gastroenterology.

63. CME: Hepatitis B: Identifying the Issues and Improving Patient Outcomes. University
of Wisconsin Medical School, Office of Continuing Medical Education. San Francisco,
CA. October 20, 2005.

64. CME: Treating HCV Maximizing Response and Minimizing Injury. University of
Wisconsin Medical School, Office of Continuing Medical Education. Las Vegas, NV.
November 7, 2005.

65. CME: Presentation at Bricks Restaurant. Reno, NV. November 17, 2005.

66. CME: AASLD Update. Mountain View Hospital. Las Vegas, NV. December 6, 2005.

67. CME: A Rising Tide: The Next Wave of Treatment Options in HBV and HCV. HEP
DART. http://www.advancmed.org/807. December 2006.
Curriculum Vitae


68. CME: Immediately Useful Strategies for Improving Patient Outcomes. TX Reporter
Gastroenterology (Volume 1; Issue 6).

2006

69. CME: Reno-Sparks Community Wide Liver Conference. Saint Marys Regional
Medical Center. Reno, Nevada. January 19, 2006.

70. CME: Improving Outcomes for Asians and Pacific Islanders at Risk for Hepatitis B,
Washington Hospital. Fremont, CA. January 25, 2005.
71. CME: HOT Topics in Hepatology: Updates, Strategies and Future Trends, Hyatt
Regency Monterey, CA. February 4, 2006. 6.5 CME credits.

72. CME: Newer Nucleos(t)ide Analogues Suppress Hepatitis B Virus, Reverse Disease in
Multiple Patient Populations. PeerView Press. February 15, 2006.

73. CME: Treating Hepatitis B With Nucleos(t)ide Analogues: A Review of New Science.
PeerView Press.

74. CME: Course 1 - Current and Evolving Therapeutic Strateies in HBV, Advanced
Certificate Program in the Management of Chronic Hepatitis B. Regional Meeting.
2006.

75. CME: Course 2 - Natural History and Selection of Patients for Treatment of HBV,
Advanced Certificate Program in the Management of Chronic Hepatitis B. Audio
conference. 2006.
76. CME: Course 3 - HBV Treatment: Viral Resistance and Clinical Implications, Advanced
Certificate Program in the Management of Chronic Hepatitis B. Webcast. 2006.

77. CME: Course 4 - Controversies in Management of HBV: Lessons from Case Studies,
Advanced Certificate Program in the Management of Chronic Hepatitis B. CD-ROM.
2006

78. CME: Course 5.1 Diagnosis of Hepatitis B, Advanced Certificate Program in the
Management of Chronic Hepatitis B. TX Reporter 1. 2006

79. CME: Course 5.2 Pretreating Evaluation, Advanced Certificate Program in the
Management of Chronic Hepatitis B. TX Reporter 2. 2006.

80. CME: Course 5.3 Selecting Among Therapeutic Options, Advanced Certificate
Program in the Management of Chronic Hepatitis B. TX Reporter 3. 2006.

81. CME: Course 5.4 Monitoring Therapy, Advanced Certificate Program in the

82. CME: Course 5.5 Natural History and Impact of Therapy, Advanced Certificate
Curriculum Vitae


2006

83. CME: Course 5.6 Management of Chirrhosis and Decompensation, Advanced
Certificate Program in the Management of Chronic Hepatitis B. TX Reporter 6. 2006.

84. CME: Course 5.7 Management of the HBV-Coinfected Patient, Advanced Certificate

85. CME: Course 5.8 A Steady Advance: Latest Findings from Anti-HBV Clinical Trials,
Advanced Certificate Program in the Management of Chronic Hepatitis B. TX Reporter
8. 2006.

86. CME: Course 5.9 Viral Resistance, Advanced Certificate Program in the

87. CME: In-Depth and Timely Response to Pressing Educational Needs. Members
Update Advanced Certificate Program in the Management of Chronic Hepatitis B.
Volume 1, Issue 7. 2006.

88. CME: GI Grand Rounds. Sunrise Hospital, Las Vegas. February 1, 2006.

89. CME: Reno-Sparks Community Wide Liver Conference. Saint Marys Regional
Medical Center. Reno, Nevada. February 16, 2006.

90. CME: Treating Hepatitis B with Nucleos(t)ide Analogues: A Review of New Science.
PeerView in Session, Webcast Lecture. www.peerviewpress.com/t1/idoct05a. March
2006.

91. CME: New and Future Treatments for Hepatitis. Controversies in Transplantation,
University of Colorado School of Medicine. Breckenridge, Colorado. March 3-5, 2006.

92. CME: Application of Viral Load Measurement in HCV Patients on Antiviral Therapy.
Shanghai-Hong Kong Liver Congress. Shanghai, China. March 26, 2006.

93. CME: Nucleos(t)ide Analogue as First-line Therapy (Pro). Shanghai-Hong Kong Liver
Congress. Shanghai, China. March 27, 2006.

94. CME: Changing Paradigm in the Treatment of HBV Infection. Shanghai-Hong Kong
Liver Congress. Shanghai, China. March 28, 2006.

95. CME: Hepatitis Alphabet. Fresno-Madera Medical Society 55
th
Annual Yosemite
Postgraduate Institute. Yosemite National Park. March 31-April 2, 2006.

96. CME: Primary Care Approach to Abnormal Liver Function Tests. Fresno-Madera
Medical Society 55
th
Annual Yosemite Postgraduate Institute. Yosemite National Park.
March 31-April 2, 2006.

Curriculum Vitae


97. CME: A Case Based Approach to the Modern Management of HCV, Meet the HCV
Masters Meeting. San Francisco. April 3, 2006.

98. CME: Hepatitis B, C, and Liver CA Update, Sunrise Hospital and Medical Center. Cilis
Restaurant. Las Vegas, NV. May 8, 2006. 1 AMA PRA Category 1 credit.

99. CME: Refining the HBV Treatment Paradigm. Westin Bonaventure Hotel. Los
Angeles, CA. May 20, 2006.

100. CME: Whats New in the Treatment of Hepatitis B & C. Double Tree Hotel. Modesto,
CA. June 7, 2006.

101. CME: Treating HCV Maximizing Response and Minimizing Injury. Wild Ginger
Restauarant. Seattle, WA. June 12, 2006.

102. CME: A Partnership Between Primary Care and Specialty Physicians. Syllabus. 2006.

103. CME: Reno-Sparks Community Wide Liver Conference: Medical & Surgical Aspects of
Liver Transplantation 2006. Reno, NV. June 22, 2006.

104. CME: The NCSCG Yosemite GI Retreat 2006. Yosemite, CA. November 3-5, 2006. 1
credit.

105. CME: Focus on the Virus: A New Paradigm for the Management and Treatment of
HBV. Sheraton Boston Hotel, Boston , Massachusetts October 30, 2006. 1 credit

2007

106. CME: Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV
Treatment in Asian and Other Diverse Communities. Expert Insight Intro: Provider
Knowledge and Practice Regarding Hepatitis B Screening in Chinese-Speaking
Patients. Course HBV3.03. 2007.

107. CME: Molecular Tests for HBV: Genotype, Core and Precore Testing, Quantification
Tests. Seattle, WA. May 9, 2007

108. CME: Viral Hepatitis. San Jose, CA. May 16 2007

109. CME: Free Hepatitis B Testing Campaign. San Francisco, CA.

110. CME: Educational slide set on Understanding Antiviral Resistance BMS Resistance
Roundtable. 2007.

111. CME: Case 2 Patient FN: Management of HCV Genotype 1. CARES. August 2007.

112. CME: Case 5 Patient KM: Psychiatric Issues in Patients Undergoing Treatment for
HCV. CARES. August 2007.
Curriculum Vitae


113. CME: Case Debates with the Experts: Applying the Updated Practice Guidelines to the
Management of Hepatitis B. 2
nd
International Symposium. Boston, MA. November 3, 2007.
114. CME: Multimodality Approach to the Treatment of HCC: The Emerging Paradigm.
AASLD. Boston, MA. November 4, 2007.

115. CME: Expert Insight Into: Why We Should Routinely Screen Asian American Adults for
Hepatitis B: A Cross-Sectional Study of Asians in California. Bridging Cultural
Differences to Improve HBV Treatment in Asian and Other Diverse Communities.
Course HBV3.08. 2007.

116. CME: San Francisco Hospital to Help Sick in Vietnam. Bay City News in San
Francisco. December 16, 2007.

117. CME: Course 9 - Case Study: Evaluating HBV Infection Status in a Previously
Diagnosed HBeAg-Positive Patient from the Asian and Pacific Islander Community.
HBV TX Reporter NL #2.

2008

118. CME: GI Cancer Board, January 1, 2008. 1 Hour CME credit.

119. CME: GI Cancer Board, February 5, 2008. 1 Hour CME credit.

120. CME: Conquering Contemporary Challenges New Hope with Targeted Therapy for
Hepatocellular Carcinoma. Osake Restaurant. Santa Rosa, CA. February 5, 2008

2008

121. CME: Clinical Drug Assessment, A Clinicians View of the Development and
Assessment of Drugs to Treat Hepatitis. Road Map to Drug Discovery, Development
and Approval. February 12, 2008 1 credit hour.

122. CME: American Association for the Study of Liver Disease Update. Saint Marys
Regional Medical Center. Reno, NV. February 28, 2008. 2 AMA Physician Recognition
Award Category 1 Credits.

123. CME: GI Cancer Board, March 4, 2008. 1 Hour CME credit.

124. CME: GI Cancer Board, April 1, 2008. 1 Hour CME credit.

125. CME: GI Cancer Board, May 6, 2008. 1 Hour CME credit

126. CME: European Association for the Study of Liver Disease Update. Reno Sparks
Community-Wide Liver Conference. Saint Marys Continuing Medical Education. May
15, 2008. CME awarded 2 AMA Physicians Recognition Award Category 1 Credits.

127. CME: AASLD Topic Forum. DDW-San Diego, CA. May 19, 2008.
Curriculum Vitae


128. CME: AASLD Clinical Symposium. DDW-San Diego, CA. May 20, 2008.

129. CME: Alcoholic Hepatitis. Alameda County Medical Center. Oakland, CA. May 30,
2008.

130. CME: American Transplant Congress 2008. Toronto, Canada. May 31, 2008 June
4, 2008. 15 AMA PRA Category 1 credits.

131. CME: Strategies for Optimizing Successful Outcomes in the Management of HCV
Difficult-to-Treat Population. Bricks Restaurant. Reno, Nevada. June 26, 2008.

132. CME: GI Cancer Board, July 1, 2008. 1 Hour CME credit

133. CME: The Future of Hepatitis B and C. Fourth Annual Liver Update Seminar. Queens
Conference Center. Honolulu, Hawaii. July 19, 2008.

134. CME: Evidence-Based Treatment of Intermediate- to Advanced-Stage Hepatocellular
Carcinoma: Improving Outcomes With Modern Therapies.
www.peerviewpress.com/p145. PeerView 2008.

135. CME: Case Study: Managing Drug-Resistant Chronic Hepatitis B Infection. TX
Reporter. 2008.

136. CME: GI Cancer Board, September 2, 2008. 1 Hour CME credit.

137. CME: 6
th
Annual Liver Disease Symposium, The Duke University School of Medicine.
September 5, 2008. 2.00 AMA PRA Category 1 credits.

138. CME: GI Cancer Board, October 7, 2008. 1 Hour CME credit.

139. CME: AASLD, October 31, 2008 to November 4, 2008. 21.5 hours of AMA PRA
Category 1 credits.

140. CME: GI Cancer Board, November 4, 2008. 1 Hour CME credit.

141. CME: Standard of Care for Treatment of Hepatitis B & C, Update in Gastroenterology &
Hepatology Symposium. Renaissance Hotel. Las Vegas, NV. November 15, 2008.

142. CME: Hepatitis C, Update in Gastroenterology & Hepatology Symposium.
Renaissance Hotel. Las Vegas, NV. November 15, 2008.

143. CME: Debate Monotherapy is Suitable for HBV, Update in Gastroenterology &
Hepatology Symposium. Renaissance Hotel. Las Vegas, NV. November 15, 2008.

144. CME: Screening At-Risk Individuals for Hepatitis B: What do the Guidelines Say?
Medscape, Expert Column. Novmeber 2008.
Curriculum Vitae


145. CME: Hepatitis B: Advances in Screening, Diagnosis, and Clinical Management.
Medscape Volume 4. November 2008.
http://www.medscape.com/viewprogram/17750
146. CME: GI Cancer Board, December 2, 2008. 1 Hour CME credit.

147. CME: HBV Highlights from CCOs Coverage of the 2008 AASLD Meeting, Grand Caf.
San Francisco, CA. December 2, 2008.

148. CME: CARES-Roundtable Meeting, Farallon Restaurant. San Francisco, CA.
December 4, 2008.

2009

149. CME: Cases in Point: Risk Factors, Surveillance Strategies and Treatment Options for
HCC. Gastroenterology and Hepatology. Vol 5, Issue 1, Supplement 3. January 2009.
1.0 AMA PRA Category 1 Credit.

150. CME: Nash (Non-alcoholic Fatty Liver Disease). Reno, NV. January 8, 2009. 1 AMA
Physicians Recognition Award Category 1 Credits.

151. CME: Hepatitis B&C Update. Grand Rounds Talk. Highland Hospital. Oakland, CA.
February 6, 2009.

152. CME: Update New Therapies for Hepatitis B and Hepatitis C. 16
th
Annual Alimentary
Update. South Lake Tahoe. March 27, 2009.

153. CME: Hepatocellular Carinoma: Current Epidemiology & Management. CME talk.
Good Samaritan Hospital. San Jose, CA. April 1, 2009.

154. CME: 2010 American Transplant Congress Physician & Physician Assistants.
Institute for the Adavancementof Human Behavior and Amedco. May 1-5, 2010. 15.00
hours.

155. CME: Wilson Disease Symposium. California Pacific Medical Center. San Francisco,
CA. May 2, 2009. 4 CME program hours.

156. CME: HCV and Cryoglobulinemia. Saint Marys Regional Medical Center. Reno, NV.
May 14, 2009. 1 AMA Physicians Recognition Award Category 1 Credits.

157. CME: 2009 American Transplant Congress Physicians. Certificate of Completion
The American Society of transplant Surgeons. May 30, 2009 June 3, 2009. 16 Hours
Awarded.

158. CME: Weekly Emergency Medicne Conference. CME talk. Alameda County Medical
Center, Highland Hospital. Oakland, CA. July 1, 2009.

Curriculum Vitae


159. CME: Faculty of John Hopkins University School of Medicine CME Program. Kuleto
Trattoria Restaurant. Burlingame, CA. July 14, 2009.

160. CME: HCV and Cryoglobulinemia: How Cool Can You Get? Saint Marys Regional
Medical Center. Reno, NV. July 27, 2009. 1 AMA Physicians Recognition Award
Category 1 Credits.

161. CME: Bridging Culturaly Differences to Improve HBV Treatment in Asian and Other
Diverse Communities. Projects in Knowledge. Advanced Certificate Program IV.
2009.

2010

162. CME: Managing Hepatitis B in the Primary Care Setting. PeerView CME. February
2010.

163. CME: Clinical Concepts in Pain and Aging: A Case-Based CME Monograph. John
Hopkins University School of Medicine. Febraury 20, 2010. 1.00 AMA PRA Category 1
credit.

164. CME: Viral Hepatitis and Hepatocellular Carcinoma. March 6, 2010.

165. CME: Advances in Hepatocellular Carcinoma: 2010 Update. Loyola University.
Maywood, IL. March 6, 2010.

166. CME: Clinical roundtable Monograph, moderator A Mulitdisciplinary approach ot the
Management of Hepatolcellular Carcinoma 1.0 AMA PRA Category 1 credits, Mar 2010

167. CME: HBV. Kaiser. San Jose, CA. March 31, 2010.

168. CME: The Clinical Implications of Manging Cirrhotics. CLDF. San Francisco, CA.
April 12, 2010.

169. CME: Chronic Viral Hepatitis: Can we C our way to B cured? ST Lukes Grand
Rounds. San Francisco, CA. May 5, 2010.

170. CME: New Advances in the Management of Hepatocellular Carcinoma (HCC).
Regional Medical Center of San Jose. May 8, 2010.

171. CME: 2010 National Hepatitis B&C Training Program & Treatment Update. Omni
Hotel. San Francisco, CA. June 12, 2010. 7.75 AMA PRA Category 1 Credit.

172. CME: Hepatitis C: What is the current diagnostic and treatment paradigm? Community
Hospital of Monterey. Monterey, CA. June 16, 2010.

173. CME: Coming to your area: Case3: On the Cusp of Change: New Therapeutic
Modalities for HCV. Sienna Restaurant. El Dorado Hills, CA. June 16, 2010.
Curriculum Vitae

CONSULTANT / ACKNOWLEDGEMENT AS A CONTRIBUTOR / CME ACTIVITIES

174. CME: Use only the A Team to beat Hepatitis B. Chinese Hospital. San Francisco,
CA. August 3, 2010.

175. CME: Overview of INCIVEK: Phase III Clinical Trial Data and Prescribing Information,
San Diego, CA. Instructor of Program. August, 2011.

176. CME: HBV Update. Saint Francis Hospital Grand Rounds. San Francisco, CA.
September 21, 2010.
177. CME: Staying the Course: Patient Adherence Strategies in the Era of New Frontline
HBV Therapies Barriers to Treatment, Adherence in Asian Americans. Clinical Care
Options CME/CE Certified Treatment Update. 2010.
178. CME: Expert Insight Into: Perinatal Transmission of Hepatitis B Virus: An Australian
Experience (Part 6 of Series). Bridging Cultural Differneces to Improve HBV Treatment
in Asian and Other Diverse Communities. Advanced Certificate Program V. Projects in
Knowledge. 2010.
179. CME: Clinical Update 2010: Chronic Liver Disease and Hepatocellular Carcinoma.
Sutter Roseville Medical Center. Roseville, CA. October 2, 2010. 4 AMA PRA Catego-
ry 1 credit.
180. ME: Hepatocellular Carcinoma Current Trends in Diagnosis and Management: What all
Healthcare Providers Need to Know. Hartford Hospital Grand Rounds. Hartford, CT.
October 4, 2010. 1 AMA PRA Category 1 credit.

181. CME: HCC Update. Hartford Hospital Grand Rounds. Hartford, CT. October 5, 2010.
182. CME: Managing HBV in the At-Risk Community. San Francisco, CA. October 12,
2010.
183. CME: Treat or No Treat: An Educational Case-Based Discussion Considering Evidence
and Expert Insights in Treatment Decisions for CHB. Boston, MA. October 30, 2010.
184. CME: Clinical Viewpoints, Oct. 2010. Rush University Medical Center, Chicago,
Illinois.

2011
185. CME: " 2011 American Transplant Congress Meeting -Physicians & Transplant
Coordinators April 30- May 4, 2011

186. CME: Hepatitis C: The Expanding Role of the Physician Assistant, Teacher of this
Breakfast Symposium. CME Credit: 1.25 credits. A part of the Education Initiative in
Gastroenterology series.

187. CME: GUTS (Gastroenterology Universal Training Symposium, June 25, 2011. CME
Credits: 8 Hour.

Curriculum Vitae


188. CME: Liver Journal Club at UCSDMC, July 1, 2010-June 30, 2011. CME Credits: 6
AMA PRA Category 1 Credits.
189. CME: Advances in HCV: New Challenges and Hope, Hanford, CA, June 29, 2011, 2
CME Credits, AMA PRA Category 1 Credits

190. CME: University of California San Diego Health System SPA Time Study 2011, June 29,
2011.

191. CME: UCSD GI Division Weekly Conferences (Thursday AM VAMC), July 1, 2010 to
June 30, 2011, CME Credits: 19.5 AMA PR Category 1.5 Credits

192. CME Roundtable Series, 2011 CME Roundtable Series Current Advances in the
Management of Cirrhotics, Palm Springs, CA. October 2011.

193. CME: The Role of the Hepatologist, HCC Los Angeles Dinner, October 2011.
194. CME: Managing a Medical Malpractice Case, CME Credits: 2. October 2011.

195. CME: Coordination of Patient Care, CME Credits: 2. October 2011.

196. CME: 2011 Southern California Chapters 1 & 3 Scientific Meeting. CME Credits: 4.75
AMA PRA Category 1 Credits. October, 2011.

197. CME: GI Conference: Hepatobiliary Case Presentations,CME Credit: 1 AMA PRA
Category 1 Credit. October 2011.

198. CME: 2011 Northern California Chapter Scientific Meeting. American College of
Physicians (ACP)-Internal Medicine. CME credit: 14.75 AMA PRA Category 1 credits.

199. CME: GI Conference-Hepetobiliary, San Diego, October 2011.

200. Xifaxan550 for Reducing the Risk of Overt Hepatic Encephalopathy Recurrence in
Patients (equal or greater than) 18 Years of Age, Temecula, CA. October, 2011.

201. CME: Hepatology Associates Course, San Francisco. CME Credits: 1.0 hr. Teacher of
CME Course to Nephrology Physicians, November 2011.

202. CME: Heptaology Associates Course, AASLD Certified: The Liver Meeting 2011. CME
Credits: 38.5 AMA PRA Category 1 Credits. San Francisco, November 2011.

203. AASLD Annual Meeting, San Francisco, November 2011.

204. CME: General Medicine Practices for Hepatitis B, CME Credits: 1 AMA PRA Category
1 Credit, November, 2011.

Curriculum Vitae


205. CDLF (Chronic Liver Disease Foundation): 2011 Hepatology Centers of Educational
Expertise (HCEE), HE Webcast Tapings, Topic: Point Counterpoint: Complex Patient
Case Management Issues, November, 2011.
206. CME: HCC Dinner Program, Strategies for the Management of Hepatocellular
Carcinoma: Paths to Progress. San Francisco. January 2012

2012

207. CBCE (Center for Biomedical Continuing Education): Multidisciplinary Strategies for the
Management of Hepatocellular Carcinoma: Paths to Progress. January, 2012. CME
Credits: 1.0 AMA PRA Category 1 Credit. San Francisco, CA.

208. CME, Liver Club Journal Meeting with Dr. Zarrinpar, San Diego, CA, January 10, 2012.

209. CME, Liver Club Journal Meeting with Dr. McTigue, San Diego, CA, January 17, 2012.

210. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise
Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; January 18, 2012.

211. CME, Liver Club Journal Meeting with Dr. Shah, San Diego, CA, January 24, 2012.

212. CME, Liver Club Journal Meeting, Roundtable, San Diego, CA, January 31, 2012.

213. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh MD, and Kiarash M.,
Facilitators, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit;
February 1, 2012.

214. CME: UCSD GI Conference, Changing the Management Paradigm in Non-Alcoholic
Steatohepatitis (NASH), VA Hospital, San Diego, CA; February 2, 2012.

215. CME, Liver Club Journal Meeting with Dr. Shah, San Diego, CA, February 7, 2012.

216. CME: CHB Mentorship Hub Program (CHIP), Purdue University & Asian Health
Communications, Roys Restaurant, Anaheim, CA, February 9, 2012.

217. CME, Liver Club Journal Meeting with Dr. Zarrinpar, San Diego, CA, February 14, 2012.

Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; February 15, 2012.

219. CME, Liver Club Journal Meeting with Dr. Kuo, San Diego, CA, February 21, 2012.

220. CME, Liver Club Journal Roundtable, San Diego, CA, February 28, 2012.

221. CME, Liver Club Journal Meeting with Dr. Gish, San Diego, CA, March 6, 2012.

Curriculum Vitae


222. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh MD, and Kiarash M.,
March 7, 2012.

223. CME, Liver Club Journal Meeting with Dr. Nourredin, San Diego, CA, March 13, 2012.

224. CME, Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, March 20, 2012.

Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; March 21, 2012.

226. CME, Liver Club Journal Meeting with Dr. Shah, San Diego, CA, March 27, 2012.

227. CME, Liver Club Journal Meeting with Dr. Patton, San Diego, CA, April 3, 2012.

228. CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh MD & K. Mirkia, MD,
April 4, 2012.

229. CME, Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, April 10, 2012.

230. CME, Liver Club Journal Meeting with Dr. McTigue, San Diego, CA, April 17, 2012.

April 18, 2012.

232. CME, Liver Club Journal Meeting with Dr. Philo, San Diego, CA, April 24, 2012.

233. CME: Liver Club Journal Meeting with Dr. McTigue, San Diego, CA, May 1, 2012.

Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; May 2, 2012.

235. CME: Liver Club Journal Meeting with Dr. Nourredin San Diego, CA, May 8, 2012.

236. CME, Liver Club Journal Meeting with Dr. Loomba, San Diego, CA, May 15, 2012.

237. CME: 2012 Spring Postgraduate Course, American Gastroenterology Association, May
19 20, 2012; 10.75 AMA PRA Category 1 Credits

238. CME: Digestive Disease Week 2012. San Diego, CA. May 19 - 22, 2012. 15 PMA
credits.

239. CME: Liver Club Journal Meeting with Dr. Nourredin, San Diego, CA, June 5, 2012.

Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; June 6, 2012.
Curriculum Vitae


241. CME: Liver Club Journal Meeting with Dr. Kowng, San Diego, CA, June 12, 2012.

242. CME: Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, June 19, 2012.

June 20, 2012.

Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; July 18, 2012.

245. CME: Liver Club Journal Meeting with Dr. Peterson, Hep Series; Basics of Hepato-
pathology, San Diego, CA, July 24, 2012.

Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; August 01, 2012.

247. CME, Liver Club Journal Meeting with Dr. Marie Csete, Hep Series; Anesthesia for Liver
Transplantation, San Diego, CA, July 31, 2012.

248. CME, Liver Club Journal Meeting with Dr. Misel/Kerr, Overview of Immunosuppressant
Management (Induction, Maintenance,& Acute Cellular Rejection), San Diego, CA, Au-
gust 7, 2012.

249. CME: Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, August 14, 2012.

Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; August 15, 2012.

251. CME: Liver Club Journal Meeting with Dr. Kicak, Hep Series; Risk Management, San
Diego, CA, August 21, 2012.

252. CME: Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, August 28, 2012.

253. CME: Liver Club Journal Meeting with Dr. Gish, Hep Series; Management of Hepatitis B,
San Diego, CA, September 4, 2012.

Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; September 5, 2012.

255. CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, September
11, 2012.

256. CME: Liver Club Journal Meeting with Dr. Mendler, Hep Series; Evaluation of the Liver
Transplant Candidate, San Diego, CA, September 18, 2012.

257. CME: HCV Community TeleEcho Clinic, Project Echo., Albuquerque, NM, September
18, 2012; 6 hours.
Curriculum Vitae


258. CME: Liver Club Journal Meeting with Dr. Vodkin & Irine, San Diego, CA, September 25,
2012.

259. CME, Liver Club Journal Meeting with Dr. Loomba, Hep Series; Critical Assessment Of
Medical Literature, San Diego, CA, October 2, 2012.

260. CME: American College of Clinical Pharmacology 2012 Annual Meeting Education
Symposia, October 2012.

Facilitators, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; Oc-
tober 3, 2012.

262. CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, October 9,
2012.

263. CME: Liver Club Journal Meeting with Dr. Kuo, Hep Series; HCV Management in
Cirrhosis and Post-Transplant Population, San Diego, CA, October 16, 2012

Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; October 17, 2012.

265. CME: Liver Club Journal Meeting with Dr. Vodkin & Irine, San Diego, CA, October 23,
2012.

266. CME, Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, October 30, 2012

267. CME: Liver Club Journal Meeting with Dr. Kono, Hep Series; Screening and Manage-
ment of Hepatocellular Carcinoma, San Diego, CA, November 6, 2012.

Facilitators, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; No-
vember 7, 2012.

269. CME: The Liver Meeting, American Association for the Study of Liver Diseases
(AASLD), Boston, MA, 38.5 AMA PRA Category 1 Credits; November 9-13, 2012.

270. CME: Liver Club Journal Meeting with Dr. Desai & Shireena, San Diego, CA, November
13, 2012.

271. CME: Liver Club Journal Meeting with Dr. Patton, Hep Series; Nutritional Assessment
and Management in Chronic Liver Disease, San Diego, CA, November 20, 2012.

Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; November 21, 2012.

273. CME: Liver Club Journal Meeting with Dr. Sohail & Muhammad, San Diego, CA,
November 27, 2012.
Curriculum Vitae


274. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, December 4, 2012.

Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; December 5, 2012.

276. CME: Liver Club Journal Meeting with Dr. Desai & Shireena, San Diego, CA, December
11, 2012.

277. CME: Liver Club Journal Meeting with Dr. Abbas Fehmi, Hep Series; Overview & after
liver transplant management of biliary complications, San Diego, CA, December 18,
2012.

Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; December 19, 2012.

279. CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, January 28,
2013.

280. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, January 15, 2013.

281. CME: Liver Club Journal Meeting with Dr. Sohail & Muhammad, San Diego, CA, January
22, 2013.

282. CME, Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, January 29,
2013.

283. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, February 5, 2013.

284. CME: Liver Club Journal Meeting with Dr. Noureddin & Mazen; San Diego, CA, February
12, 2013.

285. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, February 19, 2013.

286. CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, February
26, 2013.

287. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, March 5, 2013.

288. Asian Pacific Association for the Study of the Liver Conference, Singapore, March 7-10,
2013. 24 hours.

289. CME: Liver Club Journal Meeting with Dr. Desai & Shireena, San Diego, CA, March 12,
2012.

290. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, March 19, 2013

291. CME: Liver Club Journal Meeting with Dr. Sohail & Muhammad, San Diego, CA, March
26, 2013.
Curriculum Vitae


292. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, April 2 2013.

293. CME: Liver Club Journal Meeting with Dr. Vodkin & Irine, San Diego, CA, April 9, 2013.

294. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, April 16, 2013.

295. CME: Liver Club Journal Meeting with Dr. Desai & Shireena, San Diego, CA, April 23,
2012.

296. EASL, The International Liver Congress 2013, 48
th
Annual Meeting of the European
Association for the Study of the Liver. Amsterdam, Netherlands. 24 hours. April 26,
2013.

297. CME, Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, April 30, 2013.

298. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, May 7, 2013

299. CME: Tools in Waitlisted Patient Management, Xyn Management, May 2013.

300. CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, May 14,
2013.

301. CME Digestive Disease Week 2013. Orlando, FL. 1821 May 2013. 15 PMA credits.

302. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, May 21, 2013.

303. CME: Liver Club Journal Meeting with Dr. Vodkin & Irine, San Diego, CA, May 28, 2013

304. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, June 4, 2013.

305. CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, June 11,
2013.

306. CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, June 18, 2013.

307. CME: Liver Club Journal Meeting with DrSohail & Muhammad, San Diego, CA, June 25,
2013.

308. CME: Critical Care Summer Session, Catamaran Hotel, San Diego, CA, 3 Credits, July
25-27, 2013.

309. CME: New and Emerging Strategies to Simplify the Cure of Chronic HCV Infection, Ruth
Chris Steakhouse, Walnut Creek, CA; Sponsored by Rush University Medical Center &
Gilead Sciences; October 24, 2013, 1 credit.

Curriculum Vitae


310. CME: Guest Physician, Educator, GI Tumor Conference, Presented by cCare, St. Agnes
Medical Center, Fresno, CA; November 12, 2013. AMA PRA Category 1 credit

311. CME: HEP DART 2013: Frontiers in Drug Development for Viral Hepatitis 6, sponsored
by Emory University School of Medicine. Kailua-Kona, Hawaii, December 8-12, 2013.

312. CME Hepatitis B and Reducing Perinatal Transmission: An Overview and Discussion of
New Tools, Association of Asian Pacific Community Health Organizations (AAPCHO),
Webinar. December 19, 2013. 2 hours.

313. CME: Hepatitis B and Reducing Perinatal Transmission: An Overview and Discussion of
New Tools Confirmation, Association of Asian Pacific Community Health Organiza-
tions (AAPCHO) Webinair and Meeting. Thu, Dec 19, 2013. 2 hours.

314. CME: State of the Art Therapy for HCV, University of Washington, University of Alabama
Birmingham, IAS-USA online training module, Funded by a grant from the Centers for
Disease Control and Prevention. March 15, 2014

315. CME: New Treatments in Chronic Liver Disease 2014, Scripps Health, La Jolla, CA
March 29, 2014 - March 30, 2014; 8.00 AMA PRA Category 1 credits.

316. CME: International Liver Congress 2014, European Association for the Study of the
Liver, London. United Kingdom, April 9-13, 2014; 20 hours CME accredited credits.

Curriculum Vitae

HISTORICAL PRACTICE ADDRESSES and OUTREACH SITES

ARIZONA

St. Josephs Hospital
Director of Liver Transplantation

350 W Thomas Rd,
Phoenix, AZ 85013

CALIFORNIA

Community Physician's Center
Fresno Liver Clinic
Clovis, California

Enloe Hospital
W. 5th & The Esplanade
Chico, California 95926

Gould Medical Group
6000 Coffee Road
Modesto, CA 95355

Highland Clinic
1411 E. 31st St.
Oakland, California 94602

Liver Clinic
2900 Harris Street
Eureka, California 95501

McHenry Medical Group
1541 Florida Ave. #200
Modesto, California 95355

Merced Liver Clinic
3605 Hospital Rd.
Atwater, California 95301-5173

Oakland East Bay Liver Clinic
Doctors Medical Building
400 - 30
th
Street, Suite 200
Oakland, California 94609-3305

Redding Liver Clinic
2225 Court St
Redding, California 96001

Sacramento Liver Clinic
1020 29 St. 5th fl #580
Sacramento, California 95816-5119

San Luis Obispo Liver Clinic
Pacific Hepatology & Gastroenterology
1250 Peach Street, Suite M
San Luis Obispo, California 93401-2877

Santa Cruz Liver Clinic
1595 Soquel Drive, Suite 350
Santa Cruz, California 95065

Santa Rosa Liver Clinic

Ukiah Liver Clinic
c/o Harold Matossian, M.D.
234 Hospital Drive, A
Ukiah, California 95482

Clinical Professor of Medicine
Medical Director of Center for Hepatobiliary
and Disease and Abdominal
Transplantation (CHAT)
Chief of Hepatology
University of California, School of Medicine

Medical Director, Staff Physician
Stanford, California 94305

Curriculum Vitae

HISTORICAL PRACTICE ADDRESSES and OUTREACH SITES

NEVADA

Desert Gastroenterology
3150 N. Tenaya, Ste. 630
Las Vegas, NV 89128

Digestive Health Associates
5250 Kietzke Lane
Reno, NV 89511

Gastroenterology Consultants
880 Ryland
Reno, NV 89502

Sunrise Liver Clinic
3006 S Maryland Parkway
Las Vegas, Nevada

Curriculum Vitae

RESEARCH SUMMARY

In his historical roles as Co-Director of the Center for Hepatobiliary Disease and Abdominal
Transplantation and Chief of Clinical Hepatology, Dr. Gish was both overseeing and personally
participating in cutting edge research on viral hepatitis, liver transplant, bio-artificial liver, and
liver cancer. He is currently working to expand clinical trials for a variety of antiviral therapies
(including the latest-generation therapies for hepatitis B and for hepatitis C), end-stage liver
disease, autoimmune hepatitis, and new bio-artificial liver systems. He was also directing the
development of a state-of-the-art biorepository to support future scientific investigation. Under
his direction, UCSD researchers are using databases to help uncover associations between
liver cancer and certain cancer biomarkers that may ultimately help to guide treatment decisions
and choice of therapies. He is currently working toward building a multidisciplinary liver cancer
program that will include models of HCC signaling. Dr. Gish has an extensive background in
viral hepatitis clinical trials and liver cancer trials, with a quarter century of experience as a
clinical investigator on many aspects of liver disease, liver transplant and liver cancer.

In addition, Dr. Gish is actively involved, both nationally and internationally, in shaping public
policy that relates to liver transplantation and viral hepatitis screening, vaccination, and
treatment that should ultimately have an impact on liver cancer rates in the region, nationally
and internationally. He recently developed and published a five-year plan for a comprehensive
approach to liver disease in Viet Nam, a country that has a very high prevalence of liver disease
due to the high prevalence of chronic infection with hepatitis B (12%) and C (at least 2%) along
with heavy alcohol consumption by men, but which to date has had no nationwide approach to
the disease and no systematic screening of at-risk individuals. The program that Dr. Gish
developed in collaboration with colleagues in Viet Nam, Australia, and the United States
includes nationwide education for healthcare providers, health educators, and the public;
expansion of nationwide screening for hepatitis B and C followed by HBV vaccination or
treatment of chronic HBV and/or HCV; education about alcoholic liver disease; long-term
surveillance for liver cancer; and reduction of infection transmission related to medical,
commercial, and personal re-use of contaminated needles, syringes, sharp instruments, razors,
and inadequately sterilized medical equipment. The program has already received the full
support of the Vietnamese government and several other countries have now expressed
interest in working with Dr. Gish to develop similar programs. He is currently working on
development of a liver program for Armenia. Dr. Gish has lectured in China, Viet Nam, and a
dozen other countries, and has ongoing long-term research collaborations with colleagues in
Australia, Japan, Viet Nam and China.

In addition, Dr. Gish is currently working in collaboration with the Asian Pacific Health Founda-
tion on development of a major hepatitis B and C screening program in the greater San Diego
area with the goal of ultimately screening at least 10,000 individuals, followed by provision of
vaccination and linkage to care, as appropriate. As part of this program, cutting edge research
on the use of point-of-care rapid results testing for both hepatitis B and C will be carried out. A
unique aspect of this program will be the integration of viral hepatitis screening with broad-
based healthcare screening for other disease states such as metabolic syndrome both of which
are leading causes of liver cancer.

Curriculum Vitae

Dr. Gish is also involved in important research that could help effect changes in public policy on
liver transplant in the United States. His research on the inconsistencies among Regional
Review Boards (RRBs) in the assignment of points for MELD/PELD exception patients has
shown a large, highly significant regional variation in denial rates for appeals by these patients.
This variation gives strong support for replacing the current RRB system with an alternate
system, one important possibility for which would be a national review board that would use
current clinical knowledge, expertise, peer review literature, expert opinion and data to assign
priority on a consistent basis, thus reducing regional inequities and moving toward the goal of
equitable allocation of organs and further compliance with the HHS Final Rule.

Curriculum Vitae

Santa Rosa
Modesto
Merced
Fresno
San Luis Obispo
Las Vegas 1 and 2
Chico
Redding
Santa Cruz
Reno
Ukiah
Role as Director of California Pacifics Liver Disease Management & Transplant Program
Clinic sites established during my tenure at CPMC 1988 to 2010

Curriculum Vitae

Disclosures
(Updated March 2013)

PHARMACEUTICAL COMPANY RELATIONSHIPS

Dr. Robert Gish: Financial Disclosure relative to the pharmaceutical industry up to cur-
rent for the last 2 years. Robert Gish, MD, has a financial interest/relationship or affilia-
tion in the form of:
Grants/Research Support, Bristol-Myers Squibb Company, Gilead, Polairs.

Payments from selected companies are directed to an institutional fund under contract to
UCSD research program. Dr. Gish has performed as Consultant and/or Advisor to (in
the last two years):
Bayer AG, Bristol-Myers Squibb Company, Hoffmann-LaRoche Ltd., Genentech, Gil-
ead Sciences, Onyx, Janssen.

Consultant Payments are made directly to Dr Gish:
Abbott, Hepahope, Merck, Vertex, Arrowhead, Celula, Isis Pharmaceuticals, Benitec,
Tekmira,

Advisory Board: Applied ImmunoGenetics, Arrowhead

Chair Clinical Advisory Board: Arrowhead: Chair of CAB

SPEAKERS BUREAU

These speaker bureau activities focus on HBV, HCV, and liver cancer; specifically, epi-
demiology, diagnosis, and treatment. In addition, program presentations on vaccination
for HBV and management of complications of cirrhosis.

Dr. Gish has an active speakers contract to do promotional talks for BMS, Roche,
Bayer, Bristol-Myers Squibb Company, F. Hoffman-LaRoche Ltd., Gilead Sciences Inc.,
GlaxoSmithKline, Onyx, Merck, Genentech Pharmaceuticals, Salix,

Major Stock Shareholder Hepahope
Minor Stock Shareholder Kinex, Arrowhead (options)

Other Financial Support or Material Support None

Full details of all Research Grant Support See CV
Leadership Position, Other than Employment other than at UCSD None
Expert Testimony for Pharma BMS, ICN
Other Remuneration from Pharma None

DSMB: Tekmira 2011 2013

Robert G. Gish, MD CV - May 2014

Caricato da

Informazioni sul documento

Copyright

Formati disponibili

Condividi questo documento

Condividi o incorpora il documento

Opzioni di condivisione

Hai trovato utile questo documento?

Questo contenuto è inappropriato?

Copyright:

Formati disponibili

Robert G. Gish, MD CV - May 2014

Caricato da

Copyright:

Formati disponibili

Table of Contents

Potrebbero piacerti anche